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Lay summary of thesis  
Acute lower respiratory infection (ALRI) (chest infection), is still causing a large number of 
illness and deaths in young children. Viral ALRI is becoming more and more important 
because of a decreased proportion of bacterial contribution due to available vaccines. The 
global burden of disease due to ALRI related to respiratory syncytial virus (RSV) in young 
children has been recognised. This thesis aims to estimate the absolute contribution of RSV 
in causing ALRI cases, investigate risk factors for RSV associated ALRI, disease burden of 
RSV associated ALRI in children younger than five years old in different regions and in the 
global scale. 
This thesis has used data from systematic reviews of studies published in the last 20 years 
supplemented by 76 unpublished data sets from RSV Global Estimates Network (RSV GEN) 
working group consisting of 45 leading researchers on childhood chest infections.  
The thesis provides evidence that RSV contributed to children presenting with ALRI in a 
causal path and the absolute percentage of RSV resulting in RSV associated ALRI was 
around 90% (80%-95%). Eight risk factors were identified to have significant associations 
with RSV associated ALRI in young children: being born with gestational age <37 weeks, 
low birth weight (<2.5 kg), being male, having siblings, mothers smoking during pregnancy, 
family history of atopy, no breastfeeding and crowding - >7 persons in household. Globally 
in 2015 there were 33.0 (95% CI 20.6-53.2) million episodes of RSV associated ALRI 
occurring in children younger than 5 years old. Among them, 3.0 (95% CI 2.2-4.0) million 
cases were admitted to hospitals. Around 60,000 children died in the hospital settings with 
99% of these deaths occurring in developing countries. The overall mortality from RSV 
associated ALRI was estimated about 131,000. RSV disease burden was particularly higher 
in infants during their early months of life and in developing countries. 
RSV associated ALRI infections are common in young children and cause a substantial 
burden on family care-takers and hospital services worldwide. The population based 
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Acute lower respiratory infection (ALRI) remains as a leading cause of childhood morbidity 
and mortality. With the continued universal vaccination campaign against bacterial 
pathogens, an increase in relative proportion of respiratory viruses contributing to ALRI is 
anticipated. Respiratory syncytial virus (RSV) has been recognised as the most common 
pathogen identified in young children presenting with ALRI as well as an important cause of 
hospital admission. This thesis aims to estimate the aetiological roles and attributable 
fractions of common respiratory viruses among ALRI cases and investigate the risk factors 
for RSV associated ALRI in young children. It also aims to estimate the global and regional 
incidence of RSV associated ALRI in both community and hospital based settings, and the 
possible boundaries for RSV associated ALRI mortality in children younger than five years 
old.  
Methods 
Systematic reviews were carried out separately for the following three research questions: 
aetiological roles of RSV and other common viruses in ALRI cases, risk factors for RSV 
associated ALRI and global/regional burden of RSV associated ALRI, formulating an 
overall picture of epidemiology of RSV associated ALRI in young children. They all focused 
on children younger than five years old. The identified studies were selected according to 
pre-defined inclusion and exclusion criteria. The whole process was conducted following the 
PRISMA guidelines for systematic review and meta-analysis. Unpublished data from RSV 
Global Estimates Network (RSV GEN) were collected from 45 leading researchers on 
paediatric pneumonia (primarily in developing countries). They either reanalysed data from 
their already published work with the pre-defined standardised case definitions or shared 
hitherto unpublished data from ongoing studies. Data from both systematic reviews and RSV 
GEN working group were included into further meta-analysis. Random effects model was 
consistently applied in all meta-analyses.  
Results 
There were 23 studies identified through literature search satisfying the eligibility criteria, 
investigated the viral aetiology of ALRI in young children. Strong evidence was observed 
for RSV in support of its causal contribution in children presenting with ALRI and the 
association was significant measured in odds ratio: 9.79 (4.98-19.27). Thus, the 
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corresponding attributable fraction among the exposed was estimated as 90% (80%-95%), 
which means around 90% of RSV associated ALRI cases were in fact attributed to RSV in a 
causal path.  
In total, 27 studies (including 4 unpublished studies) were included and contributed to the 
analysis. Across these studies, 18 risk factors were described and 8 of them were observed to 
have significant associations with RSV infection: prematurity - gestational age <37 weeks, 
low birth weight (<2.5 kg), being male, having siblings, maternal smoking, history of atopy, 
no breastfeeding and crowding - >7 persons in household.  
Overall, 304 studies met the selection criteria and were included to estimate the global and 
regional burden of RSV associated ALRI in young children. These included 73 published 
articles identified through Chinese language databases and 76 unpublished studies provided 
by RSV GEN working group, mainly from developing countries. It is estimated that in 2015, 
there were 33.0 (95% CI 20.6-53.2) million episodes of RSV associated ALRI occurring in 
children younger than 5 years old across the world. 30.5 (95% CI 19.5-47.9) million of them 
were in developing countries. 3.0 (95% CI 2.2-4.0) million cases were severe enough and 
warranted hospitalisation. Around 60,000 children died in the hospital settings with 99% of 
these deaths occurring in developing countries. The overall mortality from RSV associated 
ALRI was estimated about 131,000.  
Conclusion  
This thesis not only enhanced the epidemiological understanding of RSV in young children, 
but also provided important information for public health decision makers. It incorporated 
both data through systematic reviews of published articles in the past 20 years and more than 
70 unpublished data sets shared by RSV GEN working group. The population based 
incidence, hospitalisation, mortality and risk factor data are essential to assess the various 
severity of illness in a specific age group and region, and inform local public health 
professionals regarding appropriate and prompt cases management, prevention and vaccine 
allocation strategies. National sentinel systems of RSV surveillance gathering structured and 
reasonably representative data are needed. Within the surveillance system, a universal 
definition regarding disease severity in various settings should be developed, and diagnostic 
methods with higher sensitivity and specificity should be applied.  
1 
 
Chapter 1 Introduction  
 Acute lower respiratory infection 
Acute lower respiratory infections (ALRI), which include pneumonia and bronchiolitis, 
decreased from 3.4 million of all-age deaths to 2.8 million during the period from 1990 to 
2010 (Lozano et al., 2012). However, it still remained as the second leading cause of years of 
life lost due to premature mortality (YLL) and global disability-adjusted life year (DALY) in 
2010 and the fourth leading cause of death across all age groups (Murray et al., 2012a, 
Lozano et al., 2012).  
Most of this disease burden occurred in children younger than 5 years old, resulting in a 
substantial burden of childhood morbidity and mortality, particularly within developing 
countries, like Southeast Asia and Africa (Walker et al., 2013). It was estimated that in 2010, 
there were about 120.4 million episodes of ALRI and 14.1 million episodes of severe ALRI 
in children younger than 5 years globally (Rudan et al., 2013). In hospital-based settings, 
globally, 11.9 million new episodes of severe ALRI and 3.0 million of very severe ALRI 
were estimated resulting in hospital admissions in children younger than 5 years in 2010 
(Nair et al., 2013). Among them, around 265,000 deaths occurred in hospital and 99% of 
these deaths were from developing countries. It was also estimated that there were 1.4 
million pneumonia deaths worldwide in this age group in the same year, which decreased to 
936,000 in 2013 (Liu et al., 2015a). ALRI contributed to 6-8% of neonatal deaths (0-27 
days), 20.1% of deaths occurred in post-neonatal period (28-364 days), and 12.4% of 
mortality in young children aged 1-4 years old (Lozano et al., 2012). A high proportion 
(around 81%) of childhood deaths due to pneumonia occurred in children during their first 
two years of life (Walker et al., 2013). Childhood pneumonia was postulated to induce 
several long-term respiratory sequelae. The most common one was restrictive lung disease 
and the risk of major respiratory sequelae was higher in children younger than 2 years 
(Edmond et al., 2012). 
Streptococcus pneumoniae and Haemophilus influenza type b (Hib) have been established as 
the principal aetiological agents of severe pneumonia and pneumonia mortality, especially in 
developing countries. It was estimated that in 2000, there were 14.5 million episodes of 
serious streptococcus pneumococcal disease occurring in children aged 1-59 months 
worldwide (O'Brien et al., 2009). Among them, there were 13.8 million episodes of 
pneumococcal pneumonia, resulting in around 741,000 deaths globally (82,700 deaths in 
HIV-positive children and 658,000 deaths in HIV-negative children). Pneumococcal 
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pneumonia contributed to 95.6% of all pneumococcal cases and 90% of pneumococcal 
deaths. It accounted for 8% of clinical pneumonia and 36% of chest radiography (CXR) 
positive pneumonia according to the meta-analyses results of several trials assessing the 
efficacy of pneumococcal conjugate vaccines against clinical and CXR confirmed 
pneumonia (O'Brien et al., 2009). It was also reported to cause around 18.3% of severe 
pneumonia episodes and 32.7% of all pneumonia deaths in young children (Walker et al., 
2013). Similarly, in 2000, there were around 8.13 million episodes of serious Hib disease 
occurring in children aged 1-59 months globally (Watt et al., 2009). Among all Hib cases, 
there were 7.91 million Hib pneumonia, leading to 292,000 deaths among these young 
children (6,400 in HIV-positive and 286,000 in HIV-negative). It accounted for 5% of 
clinical pneumonia and 21% of pneumonia with radiographic consolidation based on results 
from several vaccine trials assessing the efficacy of Hib vaccine (Watt et al., 2009). Hib also 
contributed to about 4.1% of severe pneumonia cases and 15.7% of pneumonia mortality 
(Walker et al., 2013).  
There are effective interventions available to prevent pneumonia cases caused by 
Streptococcus pneumoniae or Hib, such as pneumococcal conjugate vaccine and Hib 
conjugate vaccine. With the continued widespread of universal vaccination campaign against 
these two bacteria (World Health Organization, 2013b), a substantial reduction in childhood 
morbidity and mortality from bacterial ALRI and an increase in relative proportion of 
respiratory viruses contributing to ALRI are anticipated. Respiratory viruses played a more 
substantial part in causing ALRI deaths in infants compared to the age group of 1-4 years 
(Lozano et al., 2012). Therefore, subsequent research is expected to focus increasingly on 
understanding the role of viral pathogens in the remaining ALRI cases.  
 Respiratory syncytial virus 
1.2.1 Molecular characteristics of RSV  
Respiratory syncytial virus (RSV) has been found to be an important cause of childhood 
ALRI. It is a single-stranded negative-sense RNA enveloped virus and belongs to the family 
Paramyxoviridae and the subfamily Pneumovirinae (Acheson, 2011). It has two antigenic 
groups - subtype A and B. RSV-A is more prevalent than RSV-B (Meng et al., 2014). The 
subtypes contain different nucleotide sequences and amino acids. The RSV virion has two 
different shapes and sizes under electron microscopy: one is a spherical particle with 
diameter of 150-250 nm and the other one is a filament with length up to 10 μm (Bachi and 
Howe, 1973). Both of them are infectious. The virus particles are enveloped by a lipid 
bilayer where the attachment glycoprotein (G) and fusion glycoprotein (F) are inserted 
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(Figure 1). They serve to bind RSV particles to the cell surface components and mediate the 
fusion of virus and cell membranes respectively. Both of them can be observed under 
electron microscopy in the form of spikes around the virion. The F glycoprotein has two 
conformations: functional pre-F in a metastable form and non-functional post-F in a stable 
form (Graham et al., 2015, McLellan et al., 2013). A third small hydrophobic (SH) 
glycoprotein, is expressed on the surface of virus particles. A larger amount of it is produced 
on the surface of infected cells. Inside the virion, the virus nucleocapsid consists of RNA 
genome and nucleoprotein (N). They bind to each other tightly, forming a helical 
morphology. There are other viral proteins incorporated into the nucleocapsid: RNA-
dependent RNA polymerase (L protein), phosphoprotein (P) and 22k protein (M2-1). P 
protein plays a central role in the RSV synthesis, interacting with N, L and 22k proteins. 
Another three non-structural proteins are also encoded by RSV: NS1, NS2 and M2-2. They 
are only expressed in virus-infected cells (not in the virus particles) (Cane, 2006). Among all 
the proteins which make up the RSV virion, only G and F glycoproteins are targeted by 
neutralising antibodies.  
Activated by G glycoprotein, RSV virion binds to the target cell surface glycosaminoglycans 
(GAGs). Then, F protein is triggered and mediates the fusion of membranes from virus and 
target cell on the cell surface in the following process: the highly hydrophobic fusion peptide 
of F protein is exposed and subsequently it is inserted into the host cell membrane; this F 
protein intermediate is refolded, which brings the viral and cell membranes into close 
proximity; a stable structure is formed; lipids of these two membranes are mixed; the fusion 
pore that connects the interior of viral particles and the cytoplasm of target cells is produced. 
This makes the viral nucleocapsids enter into the host cell. Subsequent transcription and 
replication of the viral genome are activated to generate mRNAs followed by translation of 
relevant gene products and antigenome cRNA with opposite polarity but the same full-length 
as the RSV genome respectively. The transcription process requires the coordination of the 
following proteins: N, P, L and 22k proteins, while replication process needs similar proteins 
except from 22k protein. Afterwards, RSV gene products accumulate near the host cell 
membrane and they are assembled into new virions which are then released from the infected 
cells by budding. The matrix protein (M) coordinates this process: it binds to the 
nucleocapsids, which leads them to become transcriptionally inactive before packaging; it 
mediates the association of the nucleocapsid with the newly synthesised viral envelope 




Figure 1: Schematic diagram of RSV virion (Cane, 2006) 
G=attachment glycoprotein: bind virus to cell surface. F=fusion glycoprotein: mediate fusion 
of the viral and cell membranes. SH=small hydrophobic glycoprotein: express on the surface 
of infected cells with low amounts incorporated on the surface of virus particles. 3 non-
structural proteins are produced in infected cells without incorporation in the virus particles.  
However, viral particles with a missing G gene can also bind to the target cells, in spite of 
the attenuated function. Activation of the F glycoprotein is independent of the presence of 
the G glycoprotein. This indicates that alternative factors might exist and mediate binding of 
RSV virion to the host cell surface (Cane, 2006). This remains further investigation. 
1.2.2 Pathogenesis of RSV 
RSV was first discovered in a group of chimpanzees in 1956 and isolated in humans one 
year later (Chanock and Finberg, 1957).  
RSV is transmitted by contact with nasal or oral secretions from infected persons. It infects 
the ciliated epithelial cells of the upper airways at first. Viral replication in the nasopharynx 
produces a high virus load in the upper respiratory tract. In 30-50% of infants, the upper 
airway infection spreads to the lower respiratory tract after 1-3 days (Hall, 2001). This is 
mediated by direct spread of RSV along the respiratory epithelium or aspiration of infected 
nasopharyngeal secretions. The manifestations following RSV infection result from the 
function of direct viral cytotoxicity from viral replication and from the host immune 
response to infection. Immune response to infection includes innate and adaptive immunes. 
The innate immune response triggers the release of cytokines and recruits relevant molecules 
and phagocytic cells to the infection site; while the adaptive immune response consists of 
protective humoral immunity with production of IgG, IgM and IgA antibodies and cellular 
response to clear virus (CD4+ T-helper and CH8+ cytotoxic T lymphocytes) (Cane, 2006). 
Innate immune cells could have an influence on the subsequent adaptive immune response. 
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Crucial factors in response to RSV infection, such as dendritic cells and macrophages, may 
impact on both innate and adaptive immune cells. Therefore, it is important to take into 
account the interaction between innate immune and adaptive immune while assessing the 
role of each one.  
Epithelial cells respond to the RSV infection by producing molecules and proteins that have 
direct effects against RSV, such as defensins, collectins and mucus (Diamond et al., 2000). 
Also, they recruit inflammatory cells and phagocytic cells to enhance the inflammatory 
response, which is achieved by secretion of inflammatory cytokines and chemokines (after 
activation of NF-κB) that increase capillary permeability and recruit inflammatory cells from 
the blood to the site of infection, such as neutrophils, eosinophils and NK cells (McNamara 
and Smyth, 2002). This leads to airway inflammation and bronchoconstriction. The majority 
of inflammatory cells are neutrophils and alveolar macrophages. In response to RSV 
infection, macrophages also play an important role in activating various immune responses, 
for example, interaction with T helper cells and cytotoxic T cells, and producing cytokines 
and phagocytic cells augmenting the immune response. Dendritic cells also activates the 
innate immune response against RSV infection (Cane, 2006). They are antigen-presenting 
cells to activate RSV specific naïve T cells. The sloughing of infected epithelial cells, airway 
inflammation, impaired ciliary beating and mucus accumulation lead to obstruction of 
airways and air trapping, and result in the clinical manifestation of severe bronchiolitis 
associated with RSV infection. This has a particularly significant effect in young infants and 
premature children who have small airways. The pathogenesis process of RSV bronchiolitis 
is shown in Figure 2.  
Even though there are antibodies (limited magnitude and poor durability) and T-cell 
responses produced after a natural RSV infection and there is no antigenic change on RSV 
surface glycoproteins, re-infection with RSV occurs frequently (Meissner, 2016). The 
mechanisms of how RSV evades or inhibits host defences still remain unknown and require 
further research. 
Children inhale droplets containing the virus from infected persons and after 4-6 days of 
incubation, they start to develop respiratory symptoms, such as fever (in about 50% infected 
infants), nasal congestion and rhinorrhea. After the virus spreads to the lower respiratory 
tract, it infects the ciliated epithelial cells of the bronchioles and pneumocytes (Meissner, 










Figure 3: Clinical progression and pathogenesis of RSV (Meissner, 2016)*  
*Reproduced with permission from (EISSNER, H. C. 2016. Viral Bronchiolitis in Children. N 




1.2.3 Epidemiology of RSV 
RSV has been recognised as the most common pathogen identified in young children 
presenting with ALRI as well as an important cause of hospital admission (Nair et al., 2010). 
Globally, 33.8 million new episodes of ALRI which were RSV positive were estimated to 
occur in children younger than 5 years old in 2005. Among them, at least 3.4 million 
episodes represented severe cases which required hospitalisation. It was also estimated that 
RSV attributable in-hospital mortality in children younger than 5 years old was around 
53,000 deaths and up to 199,000 overall deaths in community settings worldwide in 2005, 
with 99% of these occurring in developing countries. A population-based surveillance study 
carried out in 3 counties of the US showed that approximately 2.1 million children younger 
than 5 years old required medical attention every year due to RSV infection (around 10% of 
all under five-year-old children). Among them, around 57,000 children were hospitalised and 
the rest of children were treated in emergency rooms or by paediatric practices (Hall et al., 
2009). A few more studies conducted in US also indicated a very large burden of RSV posed 
in both inpatient and outpatient settings (Stockman et al., 2012, Jain et al., 2015). There is 
also a high burden of RSV disease in HIV infected or exposed children. A hospital-based 
surveillance carried out in 4 provinces from South Africa manifested that the hospitalisation 
rate of RSV associated ALRI in HIV-infected infants less than 6 months was around 67.1 per 
1000 children per year, 50.0 in HIV-exposed but uninfected infants, and 35.1 in infants with 
HIV-unexposed and uninfected (Cohen et al., 2016). The hospitalisation rate ratios for 
infants with HIV infection and HIV-exposed but uninfected were 1.9 (95% CI 1.3-2.7) and 
1.4 (95% CI 1.3-1.6) respectively, compared to infants with HIV-unexposed and uninfected. 
The in-hospital case fatality ratio of RSV associated ALRI among infants with HIV infection 
was around 19%, 2% in infants with HIV-exposed but uninfected, and 0 in infants with HIV-
unexposed and uninfected. The magnitude of RSV incidence or hospitalisation rate varies 
across different study years (months) and geographical areas. Its seasonality pattern will be 
discussed later in detail.  
RSV is known to be more likely to have a severe outcome in children with certain pre-
existing chronic medical conditions, resulting in a higher rate of hospitalisation and a higher 
risk of death. A case control study in southwest Alaska indicated that underlying medical 
conditions, such as prematurity, chronic lung disease and heart disease, were associated with 
an increased risk of RSV hospitalisation (Bulkow et al., 2002). Several other studies also 
confirmed similar results (Hall et al., 2013, Hall et al., 2009). Another systematic review 
reported that the case fatality ratio among children hospitalised with RSV infection was 
higher in children with chronic lung disease, congenital heart disease or prematurity, 
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compared to otherwise healthy children (Welliver et al., 2010). The association between 
RSV illness and other chronic conditions (e.g. Down’s syndrome) is difficult to quantify due 
to the low incidence of RSV disease among this specific population. It was reported that the 
rate of RSV hospitalisation among these high-risk children declined after the implementation 
of RSV immune-prophylaxis in these high-risk populations (Homaira et al., 2014). A 
nationwide database derived study in US – the Kids’ Inpatient Database (KID), indicated 
that the RSV hospitalisation rate in all high-risk infants (chronic lung disease, congenital 
heart disease, congenital airway anomalies, Down syndrome and other conditions), 
decreased from 62.9 per 1000 children per year to 39.1 (37.9% reduction) during the study 
period from 1997 to 2012 (Doucette et al., 2016). The main contribution to rate reduction 
came from infants with chronic lung disease and infants with higher-risk congenital heart 
disease (based on its rate in different ICD-9 codes). Hospitalisation rate among infants with 
the other comorbid conditions were not observed to decline.  
Before this thesis, there had been only one systematic review published over one decade ago 
that assessed the associations between various risk factors and RSV associated ALRI and the 
magnitude of the associations (Simoes, 2003). Male gender, age group of less than 6 months 
during acquisition of RSV, birth during the first half of the RSV season, crowding or having 
siblings, and day care attendance were reported to have significant associations with severe 
RSV associated ALRI; while the roles of race or ethnicity, smoking exposure, low maternal 
education, lack of breastfeeding and malnutrition remained unclear or unknown. However, 
this review was a descriptive study, listing different studies reporting the risk factors of 
interest without carrying out an analysis assessing the overall magnitude of the association 
between each risk factor and RSV associated ALRI. In addition to the risk factors which 
might enhance the risk of obtaining RSV infection, genetic susceptibility to RSV disease is 
also proposed based on several lines of evidence: family studies show that children are at 
higher probability of getting respiratory illness if parents were previously infected in early 
life; aboriginal populations have higher hospitalisation rates of RSV disease; great variations 
of phenotypic traits between laboratory mice of different strains (Cane, 2006). Therefore, 
genetic variation might also affect individual risk to RSV disease, which remains under 
further investigation. 
1.2.4 RSV associated subsequent respiratory morbidity 
Whether or not RSV infection is associated with subsequent wheezing and asthma morbidity 
in young children remains controversial. A randomised double-blind clinical trial carried out 
across multiple centres in Netherlands demonstrated that healthy preterm infants (gestational 
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age of 33-35 weeks), who received monthly monoclonal antibody for RSV prevention 
(palivizumab) during the RSV season, were observed to have less total days of wheezing in 
their first year of life reported by parents, compared to those who received placebo, with a 
relative reduction of 61% and an absolute reduction of 2.7% in the rate of wheezing 
(Blanken et al., 2013). This effect existed in infants with or without a family history of atopy, 
and it persisted even after prophylaxis and outside the RSV season. A reduction of recurrent 
wheezing was also shown in the palivizumab group. The result is consistent with some 
previous observational studies, where an increased rate of asthma and recurrent wheezing 
was identified in early adulthood after they were hospitalised with RSV infection during 
infants (Sigurs et al., 2010). These studies provide some evidence in support of RSV playing 
a role in the pathogenesis of recurrent wheezing. It is hypothesised that RSV infection early 
in life causes direct pulmonary epithelial damage and alterations of the pulmonary 
environment and local immunologic responses. This leads to remodelling of the airway 
which contributes to long-term airway hyper-responsiveness to respiratory viruses (and other 
stimuli) and wheezing. Nevertheless, several other possible mechanisms might exist: there is 
a pre-existing alteration of immune response and pulmonary abnormality in infants which 
predispose them to both subsequent RSV infection and recurrent wheezing; there is a genetic 
tendency to both illnesses. 
Moreover, in another more recent randomised double-blind phase 3 clinical trial, based on 
healthy term Native American infants, infants receiving motavizumab did not present a 
lower rate of medically attended wheezing compared to infants who received placebo after a 
3-year follow up (O'Brien et al., 2015). A similar result was observed in previously healthy 
term infants hospitalised with RSV associated ALRI after a 12-month follow up (Ramilo et 
al., 2014). Therefore, the role of RSV infection in the development of subsequent asthma and 
respiratory morbidity remains unclear. It requires further investigation and the mechanisms 
remain to be clarified. This highlights the importance of understanding the occurrence and 
magnitude of RSV disease in young children in order to estimate its potential impact posed 
in later life.  
1.2.5 Seasonality of RSV 
The seasonality of RSV varies across the world. Seasonal epidemics occur throughout the 
year in tropical and subtropical regions, while RSV outbreaks in temperate regions often 
occur during the winter and spring. Appropriate preparation and management within 
healthcare facilities according to seasonality data is critical to coordinate an appropriate 
response to the rising demand during peak seasons.  
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In temperate regions, annual epidemics of RSV usually occur in the cold and dry winter 
period. The mechanisms are not well elaborated. A retrospective study in Greece 
investigated the relationship between RSV activity and several climate parameters during a 
12-year study period (Sirimi et al., 2016). This study focused on children younger than 15 
years old hospitalised with respiratory tract infection who were tested RSV positive. More 
than 95% of them were infants. The annual epidemic of RSV activity was observed from 
December to April with a peak in February. Statistically significant correlations were found 
between monthly RSV activity and mean monthly relative humidity (positive) as well as 
RSV activity and mean monthly temperature (negative). After multivariable analysis, mean 
monthly temperature remained in a negatively significant association with RSV activity. 
Similar results were observed in other temperate regions. In Netherlands, RSV outbreaks in 
children were observed consistently and positively associated with relative humidity and 
cloud cover as well as negatively associated with minimum temperature throughout the study 
period from 1998 to 2005 (Meerhoff et al., 2009b). Weekly RSV incidence among children 
younger than 2 years old during winter seasons (from 2007 to 2010) in Bologna (Italy) was 
correlated negatively with mean minimum temperature during the same week or with at least 
one-week time lag (Vandini et al., 2013). No correlation was found for the mean relative 
humidity. The weekly RSV detection was also significantly associated with mean PM10 (air 
pollutants) concentration of the week before. The associations between RSV infection rate 
and these meteorological parameters mentioned above could be used to predict RSV 
seasonal pattern in these areas (Tang and Loh, 2014). The negative correlation between RSV 
outbreaks and temperature could be due to the fact that as a lipid-enveloped virus, RSV 
survival decreases as the temperature rises affecting the state of viral proteins and the virus 
genome integrity (Tang, 2009).  
However, the seasonality of RSV in subtropical and tropical regions presents a more 
complicated picture. The associations between RSV infection rate and climate factors are 
variable and inconsistent (Tang and Loh, 2014). A 15-year (1998-2012) retrospective 
epidemiological study conducted in Hong Kong (subtropical area) revealed that RSV was 
predominant in the spring and summer (from April to August) among hospitalised patients 
(Chan et al., 2015). Thus, RSV immune-prophylaxis for children in Hong Kong who are at 
high risk should cover recipients at least during this period. The presence of RSV was 
associated with several meteorological factors: RSV activity was significantly lower with 
mild temperature (20°C) while higher at cold and warm temperatures; high RSV activity was 
also observed during short sunshine duration (4-6 hours); virus activity was lower when 
there was a low level of rainfall (0-50 mm/day). Although there is variation of RSV 
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incidence year by year, the seasonality of RSV in Hong Kong and other subtropical areas is 
still relatively predictable. One article investigated the monthly RSV activity and its 
associations with several meteorological parameters (average monthly minimum temperature, 
average monthly maximum temperature, relative humidity, precipitation) in 7 subtropical 
and tropical areas: Bangladesh, China, Egypt, Guatemala, Kenya, South Africa and Thailand 
(Haynes et al., 2013). The month of onset, peak month, and duration of RSV infection varied 
across different countries, but, in general, were consistent within each country during the 
multiple year surveillance period. However, their associations with climate factors varied 
across both geographical sites and study years. There were one or two annual epidemic 
periods of RSV circulation in each study site. In countries where there is a generally high 
annual precipitation (>14 inches by month), such as in Bangladesh, Guatemala and Thailand, 
the RSV peak was usually observed in wet and warm months during the rainy season (above 
average temperature and relative humidity). In countries where they have moderately hot and 
arid climates (China and Egypt), RSV infection rate was highest in cooler months (below 
average temperature). RSV peaked during autumn in South Africa and there was no clear 
association with weather seasonal patterns observed in the Kenya site. However, these 
observations of correlations between climate parameters and RSV activity are limited to the 
participating surveillance sites and may not be generalisable to other areas. The high RSV 
activity after the precipitation peak was also observed in other study sites with high annual 
precipitation. This might be because during rainy seasons, people tend to stay indoors which 
contributes to indoor crowding and facilitates RSV transmission. This hypothesis was 
discussed in a study in Bangladesh where some evidence of the association between rainfall 
and risk of acute respiratory infection was observed in a 3-month surveillance in young 
children (Murray et al., 2012b). Although the mechanism of the association between 
temperature and RSV activity was well described in temperate areas (as mentioned above), 
there is no conclusive explanation to this in subtropical and tropical regions.  
There have been several possible mechanisms proposed to explain the seasonality of viral 
respiratory tract infection. One article discussed four potential mechanisms and proposed 
that the underlying mechanism is likely to be that the lower temperatures or host chilling 
may activate the viruses in the respiratory tract, which is compatible with the phenomenon 
that the virus arrives simultaneously across different geographical regions (Shaw Stewart, 
2016).  
Understanding RSV seasonality across widespread geographic regions and predicting the 
onset of RSV season based on meteorological parameters in these regions could provide 
evidence-based guidance. It could help to formulate a cost-effective strategy to implement 
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immune-prophylaxis or the targeted delivery of future efficacious and safe RSV vaccines on 
high-risk populations as well as to apply early antiviral treatment to minimise RSV 
transmission. Further monthly continuous surveillance data across large geographical 
locations during a long-term period are needed and would enable improved modelling of the 
associations between climate parameters and RSV activity, and description of the seasonal 
pattern of RSV circulation. 
1.2.6 Clinical specimen and laboratory diagnosis of RSV 
Diagnosis based on clinical features alone will not suffice because the presentation of RSV 
infection is indistinguishable from other viral respiratory infections. Timely diagnosis of the 
associated (or causal) pathogen in cases with respiratory infection is of great public health 
importance. It provides an evidence base for optimal RSV management and treatment. 
Health professionals could implement appropriate infection control measures to reduce child 
morbidity and mortality caused by RSV, and at the same time decrease excessive testing and 
antibiotic use.  
The microbiologic confirmation of RSV infection is based on detection of the virus in 
samples obtained from nasopharyngeal cavity. Most samples come from nasopharyngeal 
aspirate (NPA), nasopharyngeal wash (NPW), nasopharyngeal swab (NPS), oropharyngeal 
swab (OPS), nasal swab, nasal wash or a mix of specimens. Nevertheless, virus detection in 
the nasopharyngeal cavity might also indicate a co-incidental upper respiratory infection. 
Thus, conducting aetiological studies comparing the virus detection in children with ALRI 
with control children might be able to elucidate the percentage of ALRI cases attributable to 
RSV in a causal way. Clinical specimens could also be obtained from the lower respiratory 
tract, such as induced sputum. However, it is difficult to get specimens from this site and it is 
hard to distinguish whether the virus detection is due to prolonged shedding or colonisation 
from infection (Ruuskanen et al., 2011). Using different specimens for RSV diagnosis might 
account for some variations in findings across different studies. Nasal swabs have been 
reported to have a lower sensitivity of detecting RSV compared to NPA, although the results 
were comparable to those for other common respiratory viruses (Heikkinen et al., 2002). 
Another study in adults showed that NPW, NPS and OPS sampling methods shared the same 
sensitivity for RSV identification. However, for detection of any respiratory virus or some 
other specific viruses, such as influenza, rhinovirus and coronavirus, NPW samples had a 
higher sensitivity than NPS, which was more sensitive than OPS (Lieberman et al., 2009).  
There are various laboratory methods with differing sensitivity and specificity available to 
diagnose RSV infection, which include cell culture, antigen-based assays, serology and 
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molecular assays (polymerase chain reaction). Cell culture was the gold standard for the 
respiratory virus identification for many years. Since it has several disadvantages (listed in 
Table 1), molecular assays have now become the new gold standard (Henrickson, 2004, 
Henrickson and Hall, 2007). Table 1 displays the advantages and disadvantages of each 
diagnosis method. This supports one of the selection criteria that studies using serology as 
the only diagnostic test will be excluded, which was applied consistently in the following 
systematic reviews.   
Table 1: Comparison of different diagnosis methods (Henrickson and Hall, 2007) 
 Advantage  Disadvantage  
Cell culture 
Ability to detect coinfections; 
Monitor new mutations (genetic and 
antigenic change); 
Discover unknown viruses; 
High sensitivity (but lower than 
molecular assays); 
Require special specimen handling 
procedures; 
Long assay time (2 to 5 days); 





Easy to perform; 
Easy to interpret; 
Results ready within 2-4 hours; 
Insufficient sensitivity and specificity, 
especially during off-season or in 
special population 




Falsely negative (10-30%); 
Molecular assays 
High sensitivity and specificity; 
Relatively fast diagnosis (2-24 
hours);  
Risk of contamination;  
Not available in most clinical 
laboratories; 
 
There are two different categories of antigen-based assays: immunofluorescence assays (IF) 
and commercially available rapid antigen-detection test (RADT). The former is based on 
microscopic detection of viral proteins via labelled antibodies and the latter one is based on 
macroscopic detection of colour change. IF includes direct immunofluorescent antibody test 
(DFA) and indirect immunofluorescent antibody test (IFA) depending on whether the 
observed signal is from the antibody binding directly on the viral protein or from the 
antibody targeted at the antibody binding viral protein. RADT is easy to use, does not require 
professional laboratory technicians, and the results can be ready within 30 minutes, which 
makes it widely used. RADT for RSV detection has three formats: immunochromatographic 
(ICR) tests, enzyme immunoassays (EIA) and optical immunoassays (OIA) (Prendergast and 
Papenburg, 2013). The principle underlying these three formats is similar. If the patient’s 
clinical specimen contains viral proteins, a macroscopic colour change will be observed. The 
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colour change is incurred by the binding of viral antigen from the sample to the RSV specific 
antibodies in the test. The process of these three formats are displayed respectively in detail 
in Figure 4, Figure 5 and Figure 6. Generally, RADT has been reported to have a lower 
sensitivity compared to PCR or viral culture, but has a consistently comparable specificity 
(Kanwar et al., 2015, Tuttle et al., 2015). There were several other variables which might 
affect the performance of RADT: the age of children, quality of specimens and 
administration of palivizumab. The virus load from nasal secretions decreases with the age 
of children, which lowers its sensitivity. Palivizumab might interfere with the RSV detection 
by RADT (Prendergast and Papenburg, 2013). Therefore, children with a negative RADT 
result should be interpreted with caution and another more sensitive test (PCR) should be 
carried out to confirm those negative cases. In spite of these disadvantages, the feasibility of 
rapid diagnosis of RSV infection at the point of care has shown a few advantages of RADT: 
it can decrease the number of unnecessary tests, limit the use of antibiotics, lead to early 
implementation of infection control measures and decrease the RSV morbidity and mortality 
in infected children (shorter hospital stay). In addition, rapid multiplex point of care antigen 
detection tests for several respiratory viruses are becoming available. 
 
















 Other common respiratory viruses 
RSV is the most commonly identified virus in young children with ALRI, contributing to a 
substantial morbidity and mortality (Nair et al., 2010). However, at least 25 other viruses 
have been described to be associated with community-acquired pneumonia, most notably –
influenza, PIV, hMPV, rhinovirus, bocavirus, adenovirus and coronavirus (Ruuskanen et al., 
2011).  
Influenza, parainfluenza (PIV) and human metapneumovirus (hMPV) are also frequently 
identified in children hospitalised with respiratory infection (Nair et al., 2011, Feikin et al., 
2013, Singleton et al., 2010). Globally 20 million new episodes of influenza associated ALRI 
were estimated to occur in children younger than 5 years in 2008, and around 1 million of 
them were severe enough to warrant hospitalisation (Nair et al., 2011). PIV was the second 
most commonly detected virus after RSV in young Alaskan children hospitalised with 
respiratory infection, and hMPV was associated with a higher severity of respiratory 
infection (Singleton et al., 2010). The hospitalisation rate of hMPV infection among children 
younger than 5 years old from three counties in the US was estimated to be around 1 per 
1000 children per year (Edwards et al., 2013). This was translated into approximately 20,000 
hospitalisation cases with hMPV infection in young children. The hospitalisation rate was 3 
and 2 per 1000 children per year for infants aged 0-5m and 6-11m respectively. Compared to 
children hospitalised without hMPV infection, children with hMPV disease were older, more 
likely to have diagnosis of pneumonia or asthma, more likely to require oxygen 
supplementation and to have a longer length of intensive care unit (ICU) stay. The rates of 
hMPV illness associated with outpatient visits and emergency department visits were 55 and 
13 per 1000 children per year, which meant there were around 1 million outpatient visits and 
263,000 emergency department visits associated with hMPV infection every year. The 
hospitalisation rate of PIV associated acute respiratory illness was estimated as 1 per 1000 
children per year in children less than 5 years old based on New Vaccine Surveillance 
Network (NVSN) (Weinberg et al., 2009). The rates were 3.0 and 1.7 per 1000 children per 
year respectively in younger age groups (0 to 5 months and 6 to 11 months). This was 
projected to around 23,000 hospitalisations associated with PIV infection among young 
children.  
However, their aetiological roles in young children with ALRI remain uncertain and there 
have been no systematic reviews published that investigated this before this thesis. Moreover, 
co-infection of multiple viruses has been commonly described in childhood ALRI, which 
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necessitated the supportive research into other common viruses to have a better estimation of 
RSV disease burden in young children. 
 Clinical significance of this study 
Therefore, it is important to understand the attributable roles of these common respiratory 
viruses to ALRI. This thesis aims to conduct a thorough review to identify available case 
control studies investigating the potential roles of respiratory viruses in the aetiology of 
ALRI in children younger than five years old. The high incidence of RSV infection as well 
as its potentially severe outcome, make it important to identify and prioritise children at high 
risk of developing RSV associated ALRI. There have been no recent comprehensive 
systematic reviews exploring studies in the recent years which investigated the risk factors 
for RSV associated ALRI in young children. Understanding children at increased risk will 
provide an evidence basis to inform policy makers about prevention strategies and priority 
for vaccine allocation. Moreover, the global and regional burden of RSV disease in the 
younger age groups, especially in neonates and children in their first six months of life, has 
not yet been reported. Prompt and up-to-date estimates of key parameters of RSV 
epidemiology, such as incidence pattern and mortality by age and in different geographical 
settings, is critical to inform prevention and management strategies. Resource allocation and 
political support for the introduction of prevention strategies will also depend on good-
quality local epidemiological data. Therefore, it is necessary and important to study the 
epidemiology of RSV associated ALRI in young children to better inform national and 
international policy making. This thesis aims to focus on children younger than five years 
old since this is the age group where most RSV cases occur and this represents a large 





 Aim   
To estimate the epidemiology (incidence, mortality, risk factors etc.) of RSV associated 
ALRI in children younger than 5 years old. 
1.5.1 Specific objectives 
 Investigate the aetiological role and attributable fraction of common respiratory 
viruses among ALRI cases (including RSV) in young chidlren 
 Investigate the risk factors for RSV associated ALRI in children younger than 5 
years old 
 Estimate the incidence rate and number of new cases of RSV associated (severe) 
ALRI in children younger than 5 years old in community settings, stratified by 
different regions and age groups 
 Estimate the number of hospitalised cases of RSV associated ALRI in children 
younger than 5 years old in hospital settings, stratified by different regions and age 
groups, using two different approaches: 
 A hospitalisation rate-based approach using hospital-based studies with a 
clear and well defined denominator population reporting hospitalisation rate; 
 A proportion-based approach using hospital-based studies without a clear 
and defined denominator population reporting proportion of hospitalised 
ALRI cases which are RSV positive coupled to population-based estimates 
of ALRI hospitalisation rates 
 Estimate the hospitalisation rate and number of cases of RSV associated very severe 
ALRI, cases with hypoxemia, cases requiring ICU admission or mechanical 
ventilation in children younger than 5 years old in hospital settings 
 Estimate in-hospital case fatality ratio and mortality from episodes of RSV 
associated hospitalised ALRI in children younger than 5 years old in hospital 
settings, stratified by different regions and age groups 
 Estimate number of deaths in community from episodes of RSV associated ALRI in 
children younger than 5 years old 




 Overall methods 
 Literature search  
Systematic reviews were carried out separately for the following three research questions: 
aetiological roles of common viruses in ALRI, risk factor of RSV associated ALRI and 
global burden of RSV associated ALRI. They all focused on children younger than five years 
of age, formulating an overall picture of epidemiology of RSV associated ALRI in young 
children. The searches were conducted across several databases based in different languages 
(English, Spanish and Chinese): Medline (Ovid), Embase, Global Health, LILACS, 
CINAHL, Web of Science, WHOLIS, IndMed, grey literature (SIGLE), and three Chinese 
language based databases: China National Knowledge Infrastructure (CNKI), Wanfang data 
and Chongqing VIP. Another researcher was involved in the process of each systematic 
review (except the three Chinese language databases), according to PRISMA guidelines for 
systematic review and meta-analysis (Moher, 2009), and carried out the search 
independently. According to each research question, a search strategy with key words was 
developed and the search was performed by two investigators separately. After obtaining all 
records from the literature search, duplicate articles were removed (same articles identified 
in different databases or different articles reporting data with overlapped study period from 
the same study site). Titles and abstracts of non-overlapping articles were read to select 
studies reporting data of interest. The selection process was based on pre-defined eligibility 
criteria (inclusion and exclusion criteria). Afterwards, full texts of relevant studies were 
obtained, reviewed and assessed for qualification. This whole process was displayed in a 
PRISMA flow diagram (Moher, 2009) showing the number of studies assessed in each step 
and reasons for any exclusion. The PRISMA contained four major steps: identification, 
screening, eligibility and inclusion. The list of included articles was compared between two 
independent investigators and the discrepancies between them were discussed. Any 
discordance or uncertainties regarding relevance or inclusion were arbitrated by the 
supervisors for this thesis: Prof Harry Campbell and Dr Harish Nair. The author’s first 
language is Chinese (Mandarin) and second language is English with limited proficiency in 
Spanish, which makes literature search in databases containing several languages feasible. 
Google translate was used for articles written in other languages when this was necessary 
(during full-text review stage). 
After the list of included studies was agreed on, relevant data as well as the characteristics of 
the studies were extracted by each investigator using a standardised data extraction template, 
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which was designed on Microsoft Excel (Microsoft Office 2007). Similarly, the process was 
carried out independently. The information and data were compared and cross-verified by 
two investigators before inclusion in further analysis.   
 Unpublished data collection  
In order to collect unpublished data across the world, especially from developing countries, 
my supervisors, Dr Harish Nair and Prof Harry Campbell established RSV Global Estimates 
Network (RSV GEN). The working group consisted of 45 leading researchers on paediatric 
pneumonia identified through extensive consultations with subject experts or publication 
track record. Common case definitions were formulated and a standard approach for data 
collection, analysis and interpretation was agreed on with collaborators. They either 
reanalysed data from their already published work with these standardised case definitions or 
shared hitherto unpublished data from on-going studies.  
Two data collection templates designed on Microsoft Excel (Microsoft Office 2007) were 
sent out by Dr Harish Nair. One included nine sheets covering the main features of the study 
site and results about RSV positive cases: site description, RSV incidence, gender analysis, 
RSV proportion, morbidity and mortality (all) by month, morbidity and mortality in children 
with gestational age 32-36 weeks by month, morbidity and mortality in children with 
gestational age <32 weeks by month, risk factors for mortality and risk factors for morbidity. 
The details within each sheet were listed in the Appendices - A1. If the study site had 
number of RSV associated ALRI cases for at least 12 continuous months as well as a clear 
and well-defined denominator of the population at risk (in hospital or in community settings), 
variables necessary to calculate an incidence rate or hospitalisation rate of RSV associated 
ALRI were provided (in this case, the “RSV proportion” sheet was left empty). If the study 
site did not have a clear and well-defined catchment area with population number, proportion 
data were collected instead: proportion of hospitalised ALRI cases with RSV positive (“RSV 
incidence” sheet was left empty). The data were also required to have a study period of at 
least 12 continuous months. Overall, the number of RSV associated ALRI cases (including 
severe and very severe cases) and mortality data were collected as well as other details 
(proportion of eligible ALRI cases being tested, RSV subtype data, proportion of cases with 
hypoxemia etc.). If an aetiological study exploring the association between certain risk 
factors and RSV associated ALRI was also available, the data were collected as well. 
Another data collection template including site description, verbal autopsy confirmed 
pneumonia deaths and RSV seasonality data (number of RSV positive cases and number of 
submitted specimen for laboratory testing) was circulated to collect relevant data to build a 
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model to estimate RSV mortality in the community. These data were required to cover a 
minimum continuous period of 36 months. More details were available in Appendices - A2. 
Another three documents were also sent out to assist the data collection process: the first 
contained definitions for a few variables: case definition of ALRI (including severe and very 
severe cases) in community and hospital settings respectively, definition of hypoxemia, and 
definition of primary endpoint pneumonia (PEP); the second contained guidelines for 
populating the RSV data collection template (first excel document); the third one contained 
guidance notes for populating the mortality data template (second excel document).  
Data from unpublished studies provided by RSV GEN collaborators were reviewed for 
quality and inconsistencies. Data across different sheets were compared and checked. A few 
Skype meetings were arranged with local researchers or principal investigators if there were 
a number of queries. Email communications were established with study sites to request 
missing data in the data collection templates, clarify inconsistencies and double check 
selected details. Studies were included only after the data were cleaned. Then the data from 
all included unpublished studies were extracted into a standardised data extraction form (the 
same as the one used for collecting data from published articles). Afterwards, all information 
and data from both published articles identified through the systematic search and 
unpublished studies provided by RSV GEN collaborators were combined and included in a 
further analysis. This method resulted in a substantial contribution from unpublished studies, 
especially in finer age bands (infants, children in the first six months of life or neonates), 
which supplemented the lack of these data from published literature significantly.   
Two RSV GEN conferences were arranged to gather all collaborators and stakeholders to 
discuss the possibility of collecting unpublished data, availability of RSV data from their 
study sites, ways of collecting unpublished data (standardised case definitions), issues raised 
in the data collection process, results of interim analysis and suggestions proposed for further 
analysis. The first conference was held from 4th to 6th November in 2013 in Edinburgh. Over 
45 investigators from across the world participated in the meeting and agreed to share their 
data to contribute to the estimation. The second was on 22nd - 24th June 2015 in Edinburgh. 
Interim results were presented, feedback from working group was collected and further plans 
to share data on other common respiratory viruses (PIV and hMPV) were discussed.      
Overall, 76 unpublished studies met the selection criteria. The data were collected and 
included in further assessment and analysis. Another 8 unpublished studies were excluded 
for the following reasons: less than 50 ALRI cases were enrolled (reporting proportion), 
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serology was used as the only diagnostic test, proportion data were only provided in 
outpatients, less than one year of study period, and unclear study design.  
 Definitions  
2.3.1 Definition of ALRI  
RSV associated ALRI was used as the primary outcome of interest (Nair et al., 2010), which 
includes clinical pneumonia and bronchiolitis. This was to recognise their common 
manifestations in young children with viral ALRI (Wagner, 2009), and the limitations of the 
WHO case definition to reliably differentiate bronchiolitis from pneumonia (World Health 
Organization, 2013a). Data from community-based studies with active ascertainment (health 
care workers visited house-to-house to identify cases) were included. ALRI was defined as 
cough or difficulty in breathing with age-related tachypnoea (WHO Integrated Management 
of Childhood Illness (IMCI) case definition cut-offs: respiratory rate >60 breaths per min in 
children aged <2 months, >50 breaths per min in children aged 2-11 months, and >40 breaths 
per min in children aged 12-59 months). Severe ALRI was defined as cough or difficulty in 
breathing with lower chest wall indrawing for children aged 2-59 months; or an increased 
respiratory rate (>60 breaths per min) or chest wall indrawing for children aged less than 2 
months. Very severe ALRI was defined as a child with cough or difficulty in breathing and 
with at least one WHO IMCI danger sign (cyanosis, difficulty in breastfeeding or drinking, 
vomiting everything, convulsions, lethargy, unconsciousness or head nodding) (World 
Health Organization, 2005). Very severe ALRI was considered as a subgroup of severe 
ALRI, which was considered to be a subgroup of ALRI. Data from hospital-based studies 
with passive ascertainment (parents or carers seek help in hospitals) were included. In this 
case, only children with a physician confirmed diagnosis of ALRI that were hospitalised or 
recommended hospitalisation were included. Thus, this group comprised children with ALRI 
or ARI severe enough to require hospital admission. Very severe ALRI was defined as 
hospitalised ALRI with one danger sign (cyanosis, difficulty in breastfeeding or drinking, 
vomiting everything, convulsions, lethargy, unconsciousness or head nodding), or 
hypoxemia (see case definition below; proxies for hypoxemia included – the child receiving 
mechanical ventilation or ICU admission). Very severe ALRI was considered to be a 
subgroup of hospitalised ALRI.  
2.3.2 Definition of hypoxemia  
Hypoxemia was defined variably depending on altitude and age group. For areas at altitude 
≤2500m, oxygen saturation (at sea level in room air) lower than 90% (measured by pulse 
oximetry) in children aged 1-59 months and lower than 88% in neonates was classified as 
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hypoxemia. For areas with altitude above 2500m, oxygen saturation lower than 87% in 
children aged 1-59 months and lower than 85% for neonates was classified as hypoxemia.  
2.3.3 Definition of regions 
Countries were classified into 6 WHO regions or 4 regions according to World Bank income 
levels (World Bank, 2016, World Health Organization, 2016c). Countries were also 
categorised as “developing” or “industrialised” according to the “Levels & trends in child 
mortality - report 2014” by UNICEF (United Nations Children's Fund, 2014). The child 
population estimates by region for 2015 were provided from the UNICEF report (personal 
communication). The UNICEF report provided population numbers of children under five 
years old and of infants. Population number in children of 0-5 months of age was generated 
by dividing the number of infants evenly; same approach for children in the age group of 6-
11 months.  
 Statistical analysis 
2.4.1 Data standardisation  
Relevant data from the included studies (published articles and unpublished studies) were 
extracted into a standardised template. Data were standardised and reported using a common 
parameter (in odds ratio or rate) and unit. If summary data were not available, they were 
calculated from the original input data provided in the studies (or in the supplemental 
documents) if possible. An odds ratio or rate with 95% confidence intervals were extracted 
or calculated from included studies. The rate was reported in the unit of per 1000 children 
per year. When there was a proportion of ALRI cases which were not tested for pathogen, 
the number of RSV associated ALRI cases was scaled up according to this proportion. This 
is based on the assumption that ALRI cases which were not tested have a similar rate of RSV 
detection.  
2.4.2 Handling of zero values 
Whenever there was no cases or deaths reported in the studies, it led to odds ratio calculation 
or rate calculation of zero. Combining such data into a subsequent meta-analysis can be 
problematic. Therefore, a continuity correction of a constant number 0.00005 was applied to 
replace zero cells. This allowed further calculation not to be zero (but close to zero enough) 




Using STATA (version 11.2), meta-analyses of outcome of interest (attributable fractions of 
common respiratory viruses, associations between risk factors and RSV associated ALRI, 
incidence rate, hospitalisation rate, in-hospital CFR, proportion etc.) were carried out 
separately, and were reported as pooled estimates with corresponding 95% CIs based on 
random effects model (DerSimonian-Laird method) (Borenstein et al., 2009). Significant 
heterogeneity was assumed among included studies (Dersimonian and Laird, 1986) since 
they differed substantially in study settings, study designs, case ascertainment methods, 
population under study, socioeconomic status of underlying population, clinical specimens 
submitted for laboratory testing and diagnostic tests. Subgroup meta-analysis was also 
carried out to estimate the outcome in different regions (by World Bank income level, by 
WHO region, developing or industrialised countries), in different age groups (children in the 
first six months, infants or children aged 0-59 months) and in other categories of interest.  
2.4.3.1 Fixed effect and random effects models 
Under the fixed effect model, there is only one common effect size for all included studies 
and all observed dispersion of effects are due to sampling error (within-study variance), 
which would be zero if the studies had infinitely large sample sizes. Under the random 
effects model, there is a distribution of true effect sizes for underlying included studies and 
the differences of observed effects are due to both sampling error (within-study variance) 
and true variation in effect sizes across studies (between-study variance) (Borenstein et al., 
2009). The summary effect under the fixed effect model represents our estimate of this 
common effect size while under the random effects model it represents the mean of the 
distribution of true effect sizes.  
Study weights are assigned to each study with the goal of minimizing the variance: within-
study error in the fixed effect model and both within-study error and between-study variance 
under the random effects model. They are reflected in the size of box (area) as shown in the 
forests plots in Appendices. The random-effects will distribute the study weights more 
evenly (more balanced): a large study has less influence on the summary effect (relatively 
less weight); a small study has more impact than it would have under the fixed-effect model 
(relatively more weight). Confidence intervals for the summary effect will tend to be wider 
under the random effects model since it incorporates both within-study variance and 
between-study variance (larger variance and standard error) (Borenstein et al., 2009). The 
power for meta-analysis under the fixed effect model is related to the total number of 
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subjects across all included studies while under the random effects model, it is driven by 
both the total number of subjects enrolled and number of studies included in the analysis.  
The selection of a computational model should be based on the understanding of the 
underlying distribution, the context and the characteristics of the included studies, as well as 
the goal in performing the analysis (Borenstein et al., 2009). Since this series of studies were 
conducted by different researchers, in different study settings with different methods applied, 
it suggests that they have differed in certain ways that would have impacted on the outcome. 
Moreover, the goal of carrying out meta-analyses is mostly to generalise the result to a range 
of other scenarios. This function is limited under the assumption of fixed effect model. Since 
studies were identified from the literature review of published articles and unpublished 
datasets across different settings, the random effects model was selected, and it has been 
used consistently in the following chapters.  
2.4.3.2 Quantify heterogeneity across studies 
The observed dispersion in effect sizes across studies includes both random error and true 
variance (dispersion in true effect sizes). There were three ways to isolate and quantify the 
heterogeneity of true effects across the included studies: Q statistic (weighted sum of squared 
deviations on a standardised scale) with a statistical test based on Q (p-value), between-study 
variance of the true effects (T2) and between-study standard deviation (T), and the proportion 
of total observed variation due to true heterogeneity (real differences in effect sizes) (I2) 
(Borenstein et al., 2009). The Q method serves as a test of significance and depends on the 
number of studies and magnitude of effect (just as the significance test in a primary study). 
Thus, a non-significant p-value result should not be interpreted as that the included studies 
share a common effect size. There is a possibility that a substantial amount of dispersion 
exists but it is not successfully identified due to the low statistical power of the test 
(imprecise studies or small number of studies included). The T2 and T method measures the 
absolute value of the true variation of the true effects. The I2 method indicates the ratio of 
these true differences to the total observed variance and it ranges from 0% to 100%. It is 
particularly useful to quantify the heterogeneity across studies using different effect size 
indexes to measure the outcome (e.g. odds ratio in one study while mean difference in 
another study). The latter two parameters are calculated based on Q statistic and are 
independent from number of studies. They each serve to define and quantify the 
heterogeneity of underlying true effect sizes across included studies from different aspects. I2 
and p-value are selected to display in the forest plots of the following meta-analyses to 
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indicate the heterogeneity between studies. The 25%, 50% and 75% cut-off values of I2 are 
considered to have low, moderate and high heterogeneity respectively (Higgins et al., 2003).  
2.4.3.3 Subgroup analysis  
Subgroup meta-analysis means a meta-analysis is performed stratified by one (or several) 
group membership. The analysis is based on groups of studies rather than groups of subjects, 
but they share the same logic of test and calculation process. Fixed effect model means that 
all studies within a subgroup share a common effect size while the random effects model 
indicates that there is a distribution of true effect sizes within each subgroup. Similarly, 
random effects model has been used in the following chapters due to significant 
heterogeneity within subgroups were expected. The group membership of interest in this 
thesis is WHO regions, regions stratified by World Bank income level, developing or 
industrialised regions.  
2.4.3.4 Sensitivity analysis  
Sensitivity analyses were used, if necessary, to exclude or include certain studies, to explore 
how results might have changed if different study inclusion rules had been used: younger age 
group was focused on, exclusion of studies with less than one-year study period, exclusion of 
“low quality” studies, exclusion of studies using specific (different) case definitions, 
inclusion of studies focusing on aboriginal population and exclusion of studies with small 
sample size. The roles of different study selection criteria were assessed in these sensitivity 
analyses.  
2.4.3.5 Forest plot 
The results of each meta-analysis, subgroup analysis and sensitivity analysis were shown in 
the visual figures (forest plots). In the forest plots, each study as well as the summary effect 
are depicted as a point estimate (a square or a diamond) bounded by its confidence interval 
(horizontal line). The location of the squares (or diamonds) indicates the direction and 
magnitude of the point estimate. A vertical line of x=1 was depicted if the effect size was 
measured in odds ratios. This is to show whether the confidence interval of odds ratio from 
each study (and the summary effect) is significant. The test for heterogeneity of true effect 
sizes cross studies was carried out and reported in the same figure. They were summarised in 
the parameters of I2 and p-value. In subgroup analysis, the forest plots showed similar results, 




2.4.3.6 Commands used in STATA 
All meta-analyses were carried out based on the command “metan” in STATA. This 
program was used to pool statistics of interest into one summary value, such as associations 
(odds ratio), one-dimensional continuous measures (incidence rate) or binomial measures 
(proportion), with assumption of approximation to the normal distributions. However, for 
proportion data, their confidence intervals may contain inadmissible statistics on assumption 
of normal distribution based on the asymptotic variance, especially when the values are at 
the margins. “Metaprop” is a newly developed statistical STATA program adapted from 
“metan” and it is implemented to perform meta-analyses of proportions (Nyaga et al., 2014). 
“Metaprop” carries out procedures which are specific to binomial data (proportions) and 
allows computation of exact binomial or score statistic based 95% confidence intervals for 
the individual studies. It also incorporates Freeman-tukey double arcsine transformation to 
compute the pooled estimate or uses the binomial distribution to model the within-study 
variance. The latter one is only available in STATA 13 and later versions. “Metaprop” has 
two advantages which are the limitations of conducting meta-analyses based on “metan” 
command: margin values or close to boundary values of proportion are capable to be 
included (no need for continuity correction); admissible confidence intervals (0-1) are 
computed for individual studies as well as summary effect. Therefore, by using “metaprop”, 
no studies with 0% or 100% proportions were excluded from the meta-analysis. On the 
contrary, a continuity correction of a constant number is applied to the boundary values to 
retain them in meta-analyses while using the “metan” command, just as what was mentioned 
previously in terms of handling zero values. Moreover, study specific and pooled confidence 
intervals are always within admissible values from “metaprop” program. However, when the 
sample size is large and the proportion is not around the extremes, the meta-analysis results 
performed relying on “metan” and “metaprop” commands are similar. Considering that in 
most included studies, the sample size is large and the proportion data (except a few CFR 
values) are not the extremes, it was considered appropriate to carry out the meta-analyses 
based on “metan” command. Furthermore, this program requires a lower level of statistical 
expertise, involves faster computation, and there is statistical software (STATA or R) 







 Aetiological role of common 
respiratory viruses in ALRI in children 
younger than five years old  
 Methods  
3.1.1 Literature search  
3.1.1.1 Search strategy and selection criteria 
A systematic review was performed according to the PRISMA guidelines. Tailored search 
strategies with corresponding search terms were used to search six databases: Medline, 
Embase, Global Health, LILACS, China National Knowledge Infrastructure (CNKI), 
Wanfang Data and Chongqing VIP databases (Appendices - A3). The table of contents of 
specialist journals – the “Influenza and other Respiratory Viruses” and “Pediatric Infectious 
Diseases Journal”, and the reference lists of relevant papers were further hand searched for 
eligible articles. All searches were limited to between January 1st, 1990 and April 4th, 2014, 
and no publication status or language restrictions were applied. Eligible studies were 
observational studies that reported proportions of at least a specific virus of interest in both 
children with ALRI and children in control group. Table 2 shows the selection criteria in 
more detail. Data from included studies were extracted using a standardised data extraction 
form designed on Microsoft Excel (Microsoft Office 2007). 
Table 2: Selection criteria applied in the systematic review of aetiological role of 
common respiratory viruses in ALRI 
Inclusion criteria: 
 Published from Jan 1st, 1990 and Apr 4th, 2014 (Mar 19th for three Chinese databases) 
 Study design - observational studies (case-control or cohort)  
 Provide data for children younger than 5 years 
 Case group should be children with a diagnosis of clinical pneumonia or low respiratory infection 
 Control group should be children without ALRI (children with upper respiratory infection, 
children without any respiratory symptoms or healthy children) 
 Respiratory specimens were collected and diagnostic tests were conducted using valid laboratory 
methods  
 Report results on virus-specific proportions respectively in case group and control group 
Exclusion criteria: 
 Definitions used for ALRI or clinical pneumonia, not clearly stated or inconsistently applied 
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Following PRISMA guidelines, another researcher (Kenneth McLean, BMedSci) conducted 
an independent search in English language databases (Medline, Embase, Global Health and 
LILACS) and extracted data using the same standardised data extraction template. Any 
discordance and/or uncertainties regarding to relevance or inclusion were arbitrated by my 
supervisor for this thesis (Prof. Harry Campbell and Dr Harish Nair). 
3.1.2 Unpublished data collection  
For this review, no unpublished data were collected. However, for some studies which didn’t 
provide complete data in the published articles, the first author was contacted and relevant 
data were requested. 
3.1.3 Definition of case group and control group 
“ALRI”, was used as an equivalent to clinical pneumonia as the case definition, which 
included both pneumonia and bronchiolitis. This was to recognise this common 
manifestation in young children with viral ALRI (Wagner, 2009), and the limits of the WHO 
case definition to reliably differentiate these (World Health Organization, 2013a), as 
explained and detailed in the Chapter 2 - Methods. The case group was defined as children 
with ALRI, which was characterized as cough or dyspnoea with age-related tachypnoea, 
while severe ALRI was defined as those with cough or dyspnoea with indrawing of the lower 
chest wall (in community-based studies), or an acute respiratory infection severe enough to 
necessitate hospitalisation (in hospital-based studies). The control group was defined as 
asymptomatic children (children without any respiratory symptoms), healthy children 
(children without any respiratory symptoms and any other symptoms) or children with upper 
respiratory tract infection (URTI) (children with respiratory symptoms). 
Study sites were classified as from developing or industrialised regions according to the 
“Levels & trends in child mortality - report 2014” by UNICEF (United Nations Children's 
Fund, 2014).  
3.1.4 Statistical analysis 
Relevant data from all included studies were extracted: proportion of viruses reported in both 
case group and control group. Data were summarised in a standardised way: crude odds 
ratios (ORs) with accompanying 95% confidence intervals (95% CIs), to facilitate 
interpretation and comparison. A continuity correction of a constant 0.0005 was applied if a 
virus was detected in one group, but not the other arm of the study (Sweeting et al., 2004). 
This allowed calculation of an OR for these instances, and enabled inclusion of these studies 
within subsequent meta-analyses. Furthermore, matched (mOR) and adjusted (aOR) odds 
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ratios were also extracted, where possible. These were used preferentially in subsequent 
calculations and analyses (than crude ORs). 
Using STATA (version 11.2) (StataCorp, 2009), a meta-analysis of virus-specific ORs was 
performed and pooled estimates with corresponding 95% CIs were reported using the 
random effects model (DerSimonian-Laird method) since significant heterogeneity between 
included studies were expected in several aspects: study setting, study population, 
methodology applied and analysis plan (Borenstein et al., 2009). This was discussed in 
Chapter 2 - Methods. The virus-specific attributable fraction among the exposed (AFE) was 
used to explore the etiological role of each virus in ALRI patients. This estimates the 
percentage of (severe) ALRI cases which can be attributed to each virus, in absolute terms, 
and was calculated as AFE = 100 * (OR-1)/OR with 95% CIs. Its 95% CIs were generated 
accordingly from the 95% CIs of the OR. Thus, the percentage of all ALRI cases caused by a 
given virus can be calculated as overall percentage of ALRI cases positive for that virus 
multiplied by AFE (adjusted percentage (%a) = crude percentage (%c) * AFE), as used in 
previous work (Singleton et al., 2010). Analysis of subtypes of virus was carried out in the 
same way if data were available. Meta-estimate of OR and corresponding AFE would be 
presented in the same table. 
The final estimate was based on studies using hospitalised ALRI as the case group and using 
asymptomatic or healthy children as the control group. Afterwards, two sensitivity analyses 
were carried out to include data from studies using a different definition for case group or 
control group: outpatient ALRI cases and symptomatic controls (URTI) respectively. These 
data were added to generate an overall meta-estimate and the results were presented in the 
same table in comparison to the previous estimate (final estimate). A sensitivity analysis 
excluding studies with less than a one-year study period was carried out. Across studies 
included for the final estimate, subgroup meta-analysis was performed to explore the 





Overall, 3,619 records were identified through literature search, of which only 23 studies 
fulfilled the strict eligibility criteria (Adegbola et al., 1994, Banerji et al., 2009, Berkley et al., 
2010, Bigogo et al., 2013, Dare et al., 2007, Fry et al., 2007, Hammitt et al., 2012a, Hasan et 
al., 2014, Mathisen et al., 2010, Singleton et al., 2010, Xie, 2010, Zhao et al., 2013, Ou et al., 
2009a, Edwards et al., 2013, Iwane et al., 2011, Jansen et al., 2011, Longtin et al., 2008, Prill 
et al., 2012, Rhedin et al., 2014, Yoshida et al., 2013, Wolf et al., 2010, Fry et al., 2011, 
Feikin et al., 2013). Fifty-six studies were reviewed in full texts but excluded for a variety of 
reasons including: no data specific from children under 5 years old (n=10), not fulfilling the 
definitions for cases or controls (n=5), no applicable data reported for cases and controls 
(n=32) and other reasons (n=9). A list of these fifty-six studies with reasons for exclusion is 
available in Appendices - A4. This selection process is shown in more details in Figure 7. In 
the end, 23 studies were included into following analysis and discussion. Among them, two 
were identified from Chinese databases (Ou et al., 2009a, Xie, 2010). Two articles (Berkley 
et al., 2010, Mathisen et al., 2010) provided different definitions for case group or control 
group but didn’t report the data separately, thus the first authors were contacted and data 
stratified by different definitions were provided. Overall eight viruses were reported. They 
are respiratory syncytial virus (RSV), influenza (IFV), parainfluenza (PIV), human 
metapneumovirus (hMPV), adenovirus (AdV), rhinovirus (RV), bocavirus (BoV), and 
coronavirus (CoV). Data regarding to subtypes of RSV (RSV-A and RSV-B), IFV (IFV-A, 
IFV-B and IFV-C), PIV (PIV-1, PIV-2, PIV-3 and PIV-4) and CoV (HKU1, NL63, 229E 
and OC43) were also available and meta-analysis result was presented if possible.  
All included studies were case-control studies and were primarily conducted within 
developing countries (n = 14). Most of the studies have been conducted since 2003 (n=20). 
Among these 23 studies, 4 non-overlapped papers were from one research group in Thailand 
(Dare et al., 2007, Fry et al., 2007, Hasan et al., 2014, Fry et al., 2011) and provided data for 
several viruses (RV, CoV, BoV etc.). More features of these 23 studies are available in Table 
3.  
Definitions of cases and controls were pre-defined to select the qualified studies: the 
definition for the case group was children identified with ALRI, and the definition for the 
control group was children without respiratory symptoms or children with URTI; however, 
some variations of the included studies were still present. Of the case definitions employed, 
most used ALRI/ARI (n=13), while others used (severe) pneumonia (n=8), SARI (n=1) or 
bronchiolitis (n=1). Of the case ascertainment used, all articles reported children hospitalised 
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with ALRI in the case group. Among them, three studies also provided data on children from 
outpatient settings or community based settings separately (Mathisen et al., 2010, Bigogo et 
al., 2013, Feikin et al., 2013). Regarding the definitions of the control group, all studies 
included children who didn’t have any respiratory symptoms, among which 10 were 
considered otherwise “healthy”, and 2 studies (Hammitt et al., 2012a, Mathisen et al., 2010) 
also included children with URTI as another control group and reported the result separately. 
20 control groups were ascertained in hospital-based outpatient/clinic sites while 3 were 
identified in community (Mathisen et al., 2010, Singleton et al., 2010, Banerji et al., 2009).  
Regarding sampling methods of clinical specimens and diagnosis tests, most studies used 
nasopharyngeal swab (NPS) (n=10), nasopharyngeal aspirate (NPA) (n=6) and 
nasopharyngeal wash (NPW) (n=1) as specimens. Five studies used mixed specimens 
including NPA, NPS, lung aspirate and oropharyngeal swab (OPS). All studies used 
polymerase chain reaction (PCR) as the diagnostic testing except one study from Gambia 
(Adegbola et al., 1994), in which case indirect immunofluorescence (IFA) was applied.  
Meta-analyses of virus-specific ORs were reported as well as the corresponding attributable 
fractions among the exposed (AFE). The final estimate was based on studies using children 
hospitalised with ALRI as the case group and using children without any respiratory 
symptoms (or healthy children) as the control group (23 studies totally). Forest plots of the 
final estimate for each virus (with its subtypes) are available in Appendices - A5. Table 4 
presents the final result for eight viruses and their subtypes as well as two sensitivity 
analyses in which case, data from studies using symptomatic controls (URTI) (Hammitt et al., 
2012a, Mathisen et al., 2010) and studies using ALRI cases from outpatients setting (Bigogo 
et al., 2013, Feikin et al., 2013, Mathisen et al., 2010) were added respectively to carry out 
another two rounds of meta-analysis. From Table 4, RSV, IFV, PIV, hMPV and RV were 
significantly more common in children hospitalised with ALRI than asymptomatic controls 
(significant ORs: 9.79 (4.98-19.27) from 13 studies, 5.10 (3.19-8.14) from 10 studies, 3.37 
(1.59-7.15) from 11 studies, 3.76 (2.45-5.78) from 10 studies and 1.43 (1.03-1.97) from 11 
studies respectively). Thus, these viruses had statistically significant positive AFEs (90%, 
80%, 70%, 73% and 30% respectively), which show clear associations between these viruses 
and ALRI hospitalisation in children younger than five years old. About subtypes of these 
viruses, only IFV-A had a significant OR (5.97 (3.29-10.81)) based on 8 studies, which 
means IFV-A was more commonly identified in hospitalised ALRI cases than children 
without respiratory symptoms. There was only one study providing data for subtypes of RSV, 
IFV-C and PIV-4 thus analysis was not carried out. In comparison, the other subtypes didn’t 
have significant associations with hospitalised ALRI. Moreover, AdV, BoV and CoV with 
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their subtypes were also frequently detected in control children, and so did not have 
significant ORs or positive AFEs, which means their roles in ALRI hospitalisation remained 
uncertain. 
Two sensitivity analyses were performed to investigate the effect of inclusion of 
symptomatic (URTI) controls, and of outpatient ALRI cases respectively (Table 4). After 
data from outpatient cases were included, little impact on the associations was observed. 
However, this does not necessarily indicate similarity between the associations of inpatient 
and outpatient ALRI patients. Instead, since only three included articles had ALRI cases 
from outpatients setting and reported the data separately, the sample size might be too small 
to detect any significantly different results. In comparison, the inclusion of symptomatic 
controls had a more substantial influence, which reduced the strength of association with 
every virus, except AdV and CoV-NL63. Similarly, since only two studies provided data 
using symptomatic control group (URTI), the result might not be representative due to very 
small change in sample size (low power).   
Table 5 displays the final estimate (hospitalised ALRI in comparison to 
asymptomatic/healthy children) in the developing country region and industrialised country 
region respectively. Due to limited data points available for subtypes of each virus, meta-
analysis result is missing for all of them (except PIV-3 where there were three studies). For 
RSV, PIV, hMPV and RV, the magnitude of association between hospitalised ALRI and 
virus appeared to be stronger in industrialised region than developing countries; while for 
IFV, the other way around. The strength of associations in both regions is quite similar for 
viruses of AdV, BoV and CoV. There is no single pattern of virus detection depending on 



















There were eight studies with less than one year of study period (Iwane et al., 2011, Jansen 
et al., 2011, Longtin et al., 2008, Prill et al., 2012, Rhedin et al., 2014, Wolf et al., 2010, 
Edwards et al., 2013, Yoshida et al., 2013). Since most viruses have a seasonality pattern 
(Chan et al., 2015), it might have an effect on the presentation of viruses (detection and virus 
load), thus these eight studies were excluded in a sensitivity analysis to investigate whether 
the results would be substantially different (Table 6). Meta-analyses of virus-specific ORs 
and corresponding AFEs were similar to previous results after studies with less than one-year 
study period were excluded. Significant associations were also identified for RSV, IFV (inc. 
IFV-A), PIV, hMPV and RV, which means for studies conducted at least 12 consecutive 
months, there were similar and clear associations between these five viruses and ALRI 
hospitalisation in young children. 
 
56 full-text articles excluded:                                
10 without separate data for children 
under 5 years old;                                                                            
5 without appropriate definitions for 
cases/controls;                                          
32 with no relevant data;                                            
2 with a low internal/external validity;                       
5 without a case-control study design;                         
2 with criteria including co-morbidities;                                 
23 studies included 
3,613 records identified 
through database search 
6 record identified 
through other sources 
3,619 total records 
identified 
329 duplicates removed 
3,290 records 
screened 
79 full-text articles 
assessed for 
eligibility 
3,210 records excluded as not 
relevant to the topic 
1 with no full text published 
Figure 7: Flow diagram of selection of studies of aetiological role of common 
respiratory viruses in ALRI 
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Banjul, The Gambia; 
Periurban; 
Nov 90 - Oct 92 (Adegbola et 
al., 1994) 
3 - 59 M 
NPA, LA; 
IFA, cell culture 
Yes 
119; Passive (IP); 
NS 
P (NS) 
52; Passive (H) 
Matched (Age, area) 
Healthy (No RS 
or malnutrition) 
Baffin Island, Canada; R; 
Jan 02 - Mar 03 (Banerji et al., 
2009) 








119; Active (C); 
Matched (Age) 
Healthy 
(>2W no RS) 
Kenya; R; 
Jan 07 - Dec 07 (Berkley et al., 
2010) 
0 - 59 M NPS; RT-PCR No 




56; Passive (H); 
Same age group 
Healthy (no RS) 
Lwak and Kibera, Kenya; R; 
Mar 07 - Feb 11 (Bigogo et al., 
2013) 




538/ 899ⱡ; Passive 
(IP, OP); 36.9% 
SARI 
(WHO) 
193/109; Passive (H); 
Matched (Age) 
AS 
(>2W no RS) 
Sa Kaeo, Thailand; R; 
Sep 04 - Aug 05 (Dare et al., 
2007) 
0 - 59 M NPS; RT-PCR No 
365; Passive (IP); 
50.5%* 
P (CXR) 
85; Passive (H); 
Same number in 
age/month 
AS 
(>3D no RS) 
Multicentre, USA; U; 
Nov (03 - 09) - May (03 - 09) 
(Edwards et al., 2013)¶ 
0 - 59 M NPS; RT-PCR No 
3490; Passive (IP); 
NS 
ARI (NS) 
770; Passive (H); 
Same age, area, study 
period 
Healthy 
(>2W no RS) 
Asembo, Kenya; R; 
Jan 09 - Feb 10 (Feikin et al., 
2013) 




166/33**; Active (C), 
Passive (IP, OP); NS 
SP 
(WHO) 
93; Passive (H); 
Same age group 
AS 
(>2W no RS) 
Sa Kaeo, Thailand; R; 
Sep 04 - Aug 05 (Fry et al., 
2007) 
0 - 59 M NPS; RT-PCR No 
369; Passive (IP); 
51%* 
P (CXR) 
85; Passive (H); 
Same number in 
age/month 
AS 
(>3D no RS) 
Sa Kaeo, Thailand; R; 
Sep 04 - Aug 05 (Fry et al., 
2011) 
0 - 59 M NPS; RT-PCR No 




85; Passive (H); 
Same number in 
age/month 
AS 
(>3D no RS) 
Kilifi District, Kenya; R; 
Jan 10 - Dec 10 (Hammitt et al., 
1 - 59 M 
NPS, OPS§, IS§; 
mRT-PCR 
Yes 




142/227; Passive (H); 























Sa Kaeo and Nakhon Phanom, 
Thailand; R; Jan 05 - Dec 07 
(Hasan et al., 2014) 
0 - 59 M NPS; RT-PCR No 




589; Passive (H); 
Same age group 
AS 
(>3D no RS) 
Multicentre, USA; U; 
Dec 03/Oct 04 - Apr 04/Apr 05 
(Iwane et al., 2011)¶ 
0 - 59 M NPS; RT-PCR No 
1515; Passive (IP); 
83% 
ARI (NS) 
790; Passive (H); 
Same age, area, study 
period 
AS 
(>2W no RS) 
Amsterdam, The Netherlands; 
U; 
Nov (07-09) - Apr (07-09) 
(Jansen et al., 2011)¶ 
0 - 23 M NPW; mPCR No 
100; Passive (IP); 
NS 
ARI (NS) 
59; Passive (H); 
Same age group 
AS 
(>1W no RS) 
Quebec, Canada; U; 
Dec 02 - Apr 03 (Longtin et al., 
2008)¶ 
0 - 35 M NPA; qPCR No 
225; Passive (IP); 
NS 
ARI (NS) 
100; Passive (H); 
Same study period 
AS (no RS) 
Bhaktapur, Nepal; U; 
Mar 06 - Jul 07 (Mathisen et 
al., 2010) 
2 - 35 M NPA; mRT-PCR No 
29/671**; Passive (IP, 
OP); NS 
P (WHO) 
29/665; Active (C); 
Matched (age) 
AS/URTI 
(No ab >2D) 
Yuedong, China; U; 
Jan 07 - Dec 07 (Ou et al., 
2009a) 
0 - 59 M NPA; mRT-PCR No 




83; Passive (H); 
Same age group 
Healthy 
(>2W no RS) 
Multicentre, USA; U; 
Dec 03/Oct 04 - Apr 04/Apr 05 
(Prill et al., 2012)¶ 
0 - 59 M NPS; RT-qPCR No 
1481; Passive (IP); 
82% 
ARI (NS) 
742; Passive (H); 
Same area, study period 
AS 
(>2W no RS) 
Stockholm, Sweden; U; 
Sep 11 - Jan 12 (Rhedin et al., 
2014)¶ 
0 - 59 M NPA; qPCR No 
209; Passive (IP); 
NS 
ARI (NS) 
209; Passive (H); 
Matched (Age, Time) 
AS 
(>1W no RS) 
YK Delta, Alaska, USA; R; 
Oct 06 - Sep 07 (Singleton et al., 
2010) 
0 - 35 M NPS; sRT-PCR No 




381; Active (C); 
Same age group, 
unmatched 
Healthy 
(>2W no RS) 
Beersheba, Israel; U; 
Nov (01-05) - May (01-05) 
0 - 59 M 
NPW; RT-PCR, 
DFA, cell culture 
No 
1017; Passive (IP); 
37% 
P (WHO) 
136; Passive (H); 
Same study period 




















(Wolf et al., 2010)¶ 
Shantou, China; U; 
Jun 07 - May 08 (Xie, 2010) 
0 - 24 M NPA; mRT-PCR No 
271; Passive (IP); 
NS 
B (NS) 
82; Passive (H); 
NS 
Healthy (no RS) 
Nha Trang, Vietnam; U; 
Jun 08 - Aug 08  (Yoshida et al., 
2013)¶ 
0 - 59 M NPS; mPCR No 




350; Passive (H); 
Same age group 
Healthy (No RS, 
No ab >1M) 
Shanghai, China; U; 
Oct 09 - Aug 12 (Zhao et al., 
2013) 












U=urban. R=rural. NPA=nasopharyngeal aspirate. NPS=nasopharyngeal swab. NPW=nasopharyngeal wash. OPS=oropharyngeal swab. IS=induced 
sputum. LA=lung aspirate. IF=immunofluorescence (IFA=indirect; DFA=direct). ELISA=enzyme-linked immunosorbent assay. PCR=polymerase chain 
reaction (m=multiplex; RT=reverse transcription; s=singleplex; q=quantitative/real time). (S) P=(Severe) Pneumonia. ALRI=acute lower respiratory 
infection. B=bronchiolitis. NS=not stated. RS=respiratory symptoms. ab=antibiotics. Pro=proportion of eligible cases tested. CXR=chest radiography. 
SCDC=Shanghai Centre for Disease Control. IP=inpatient. OP=outpatient. H=hospital. C=community. D=days. W=weeks. M=months. 
AS=asymptomatic. *For whole study (all ages). **Recruitment of IP/OP. §Cases only. ‡Controls only. ⱡRecruitment in the respective Lwak/Kibera site. 
¶There were 8 studies which were conducted for less than 12 consecutive months.  
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Table 4: The meta-analyses of the OR and AFE of each virus and its subtypes within the 23 included studies  
Virus 
Meta Analyses* Sensitivity Analyses* 
(hospitalised cases vs. asymptomatic control) Inclusion of symptomatic (URTI) controls Inclusion of outpatient (OP) cases 
ns OR (95% CI) AFE (95% CI) ns OR (95% CI) AFE (95% CI) ns OR (95% CI) AFE (95% CI) 
RSV 13 9.79 (4.98 to 19.27) 90% (80 to 95) 13 8.60 (4.83 to 15.33) 88% (79 to 93) 14 9.59 (5.26 to 17.49) 90% (81 to 94) 
 
A 1 - - 1 - - 1 - - 
B 1 - - 1 - - 1 - - 
IFV 10 5.10 (3.19 to 8.14) 80% (69 to 88) 10 3.39 (1.64 to 7.02) 71% (39 to 86) 10 5.54 (3.56 to 8.62) 82% (72 to 88) 
 
A 8 5.97 (3.29 to 10.81) 83% (70 to 91) 8 3.99 (1.68 to 9.49) 75% (40 to 89) 9 6.07 (3.35 to 10.98) 84% (70 to 91) 
B 9 2.70 (0.97 to 7.53) 63% (-3 to 87) 9 2.70 (0.97 to 7.54) 63% (-3 to 87) 9 3.36 (1.48 to 7.65) 70% (32 to 87) 
C 1 - - 1 - - 1 - - 
PIV 11 3.37 (1.59 to 7.15) 70% (37 to 86) 11 3.14 (1.25 to 7.85) 68% (20 to 87) 11 4.07 (1.91 to 8.67) 75% (48 to 88) 
 
1 6 2.52 (0.79 to 8.07) 60% (-27 to 88) 6 2.10 (0.64 to 6.88) 52% (-56 to 85) 6 3.10 (1.21 to 7.94) 68% (17 to 87) 
2 7 2.22 (0.80 to 6.16) 55% (-25 to 84) 7 1.18 (0.33 to 4.27) 15% (-203 to 77) 7 2.34 (0.94 to 5.83) 57% (-6 to 83) 
3 8 2.19 (0.97 to 4.97) 54% (-3 to 80) 8 2.05 (0.77 to 5.43) 51% (-30 to 82) 8 4.14 (1.24 to 13.82) 76% (19 to 93) 
4 1 - - 1 - - 1 - - 
hMPV 10 3.76 (2.45 to 5.78) 73% (59 to 83) 10 3.61 (2.38 to 5.46) 72% (58 to 82) 11 3.84 (2.51 to 5.88) 74% (60 to 83) 
AdV 10 1.13 (0.71 to 1.80) 12% (-41 to 44) 10 1.16 (0.76 to 1.77) 14% (-32 to 44) 10 1.13 (0.71 to 1.80) 12% (-41 to 44) 
RV 11 1.43 (1.03 to 1.97) ⱡ 30% (3 to 49) 11 1.41 (1.03 to 1.93) 29% (3 to 48) 11 1.43 (1.03 to 1.97) 30% (3 to 49) 
BoV 8 1.20 (0.36 to 3.98) 17% (-178 to 75) 8 1.20 (0.36 to 3.98) 17% (-178 to 75) 8 1.20 (0.36 to 3.98) 17% (-178 to 75) 
CoV 8 1.03 (0.80 to 1.33) 3% (-25 to 25) 8 0.94 (0.74 to 1.19) -6% (-35 to 16) 8 1.03 (0.80 to 1.33) 3% (-25 to 25) 
 
HKU1 4 0.61 (0.34 to 1.09) -64% (-194 to 8) 4 0.61 (0.34 to 1.09) -64% (-194 to 8) 4 0.61 (0.34 to 1.09) -64% (-194 to 8) 
NL63 5 0.68 (0.38 to 1.24) -47% (-163 to 19) 5 0.71 (0.41 to 1.25) -41% (-144 to 20) 5 0.68 (0.38 to 1.24) -47% (-163 to 19) 
229E 4 1.47 (0.58 to 3.72) 32% (-72 to 73) 4 1.42 (0.46 to 4.43) 30% (-117 to 77) 4 1.47 (0.58 to 3.72) 32% (-72 to 73) 
OC43 5 0.91 (0.32 to 2.64) -10% (-213 to 62) 5 0.84 (0.39 to 1.80) -19% (-156 to 44) 5 0.91 (0.32 to 2.64) -10% (-218 to 62) 
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ns=number of studies. 95% CI=95% confidence interval. RSV=respiratory syncytial virus. IFV=influenza. PIV=parainfluenza. hMPV=human 
metapneumovirus. AdV=adenovirus. RV=rhinovirus. BoV=bocavirus. CoV=coronavirus. OR=odds ratio. AFE=attributable fraction among the exposed. 
*From the random-effects model. ⱡThe OR=1.40 (1.02 to 1.92) and AFE=28% (2 to 48) when studies testing all other enterovirus are excluded.  
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Table 5: The meta-analyses of the OR and AFE of each virus and its subtypes within the 23 included studies by region 
Virus 
Meta Analyses globally* Meta Analyses stratified by region* 
(hospitalised cases vs. asymptomatic control) Developing region Industrialised region 
ns OR (95% CI) AFE (95% CI) ns OR (95% CI) AFE (95% CI) ns OR (95% CI) AFE (95% CI) 
RSV 13 9.79 (4.98 to 19.27) 90% (80 to 95) 9 8.72 (3.66 to 20.80) 89% (73 to 95) 4 13.93 (3.38 to 57.47) 93% (70 to 98) 
 
A 1 - - 1 - - 0 - - 
B 1 - - 1 - - 0 - - 
IFV 10 5.10 (3.19 to 8.14) 80% (69 to 88) 7 5.78 (3.32 to 10.06) 83% (70 to 90) 3 3.50 (1.15 to 10.69) 71% (13 to 91) 
 
A 8 5.97 (3.29 to 10.81) 83% (70 to 91) 6 6.78 (3.46 to 13.27) 85% (71 to 92) 2 - - 
B 9 2.70 (0.97 to 7.53) 63% (-3 to 87) 7 2.70 (0.97 to 7.54) 63% (-3 to 87) 2 - - 
C 1 - - 1 - - 0 - - 
PIV 11 3.37 (1.59 to 7.15) 70% (37 to 86) 7 2.41 (0.99 to 5.90) 59% (-1 to 83) 4 6.75 (3.60 to 12.64) 85% (72 to 92) 
 
1 6 2.52 (0.79 to 8.07) 60% (-27 to 88) 5 1.87 (0.50 to 7.01) 47% (-100 to 86) 1 - - 
2 7 2.22 (0.80 to 6.16) 55% (-25 to 84) 6 2.22 (0.80 to 6.15) 55% (-25 to 84) 1 - - 
3 8 2.19 (0.97 to 4.97) 54% (-3 to 80) 5 2.50 (0.87 to 7.21) 60% (-15 to 86) 3 22.9 (0 to 2.19e+23) 96% (NA to 100) 
4 1 - - 1 - - 0 - - 
hMPV 10 3.76 (2.45 to 5.78) 73% (59 to 83) 4 3.53 (0.52 to 23.83) 72% (-92 to 96) 6 4.15 (2.88 to 5.98) 76% (65 to 83) 
AdV 10 1.13 (0.71 to 1.80) 12% (-41 to 44) 6 1.19 (0.66 to 2.16) 16% (-52 to 54) 4 1.09 (0.46 to 2.61) 8% (-117 to 62) 
RV 11 1.43 (1.03 to 1.97) 30% (3 to 49) 6 1.15 (0.83 to 1.60) 13% (-20 to 38) 5 1.88 (1.04 to 3.40) 47% (4 to 71) 
BoV 8 1.20 (0.36 to 3.98) 17% (-178 to 75) 5 1.25 (0.27 to 5.82) 20% (-270 to 83) 3 1.15 (0.13 to 9.77) 13% (-669 to 90) 
CoV 8 1.03 (0.80 to 1.33) 3% (-25 to 25) 4 1.06 (0.59 to 1.88) 6% (-69 to 47) 4 1.03 (0.88 to 1.37) 3% (-30 to 27) 
 
HKU1 4 0.61 (0.34 to 1.09) -64% (-194 to 8) 2 - - 2 - - 
NL63 5 0.68 (0.38 to 1.24) -47% (-163 to 19) 3 0.23 (0.01 to 3.78) -335% (-9900 to 74) 2 - - 
229E 4 1.47 (0.58 to 3.72) 32% (-72 to 73) 3 1.14 (0.34 to 3.80) 12% (-194 to 74) 1 - - 
OC43 5 0.91 (0.32 to 2.64) -10% (-213 to 62) 3 0.65 (0.10 to 4.27) -54% (-900 to 77) 2 - - 
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ns=number of studies. NA=not applicable. 95% CI=95% confidence interval. RSV=respiratory syncytial virus. IFV=influenza. PIV=parainfluenza. 
hMPV=human metapneumovirus. AdV=adenovirus. RV=rhinovirus. BoV=bocavirus. CoV=coronavirus. OR=odds ratio. AFE=attributable fraction among 
the exposed. *From the random-effects model.  
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Table 6: The meta-analyses of the OR and AFE of each virus and its subtypes within the 15 included studies (after excluding articles with 
less than one-year study period) 
Virus 
Meta Analyses* Sensitivity Analyses* 
(hospitalised cases vs. asymptomatic control) Inclusion of symptomatic (URTI) controls Inclusion of outpatient (OP) cases 
ns OR (95% CI) AFE (95% CI) ns OR (95% CI) AFE (95% CI) ns OR (95% CI) AFE (95% CI) 
RSV 10 8.37 (3.92 to 17.91) 88% (74 to 94) 10 7.14 (3.84 to 13.29) 86% (74% to 92%) 11 8.40 (4.34 to 16.25) 88% (77 to 94) 
 
A 1 - - 1 - - 1 - - 
B 1 - - 1 - - 1 - - 
IFV 8 5.43 (3.14 to 9.38) 82% (68 to 89) 8 3.45 (1.45 to 8.18) 71% (31 to 88) 8 6.00 (3.61 to 9.96) 83% (72 to 90) 
 
A 6 5.88 (2.83 to 12.22) 83% (65 to 92) 6 3.68 (1.16 to 11.68) 73% (14 to 91) 7 6.04 (2.91 to 12.52) 83% (66 to 92) 
B 7 2.76 (0.91 to 8.33) 64% (-10 to 88) 7 2.76 (0.91 to 8.34) 64% (-10 to 88) 7 3.48 (1.48 to 8.23) 71% (32 to 88) 
C 1 - - 1 - - 1 - - 
PIV 8 2.90 (1.30 to 6.45) 66% (23 to 84) 8 2.61 (1.00 to 6.84) 62% (0 to 85) 8 3.61 (1.61 to 8.07) 72% (38 to 88) 
 
1 5 1.87 (0.50 to 7.01) 47% (-100 to 86) 5 1.56 (0.44 to 5.58) 36% (-127 to 82) 5 2.59 (0.91 to 7.36) 61% (-10 to 86) 
2 5 2.22 (0.80 to 6.16) 55% (-25 to 84) 5 1.27 (0.27 to 5.86) 21% (-270 to 83) 5 2.34 (0.94 to 5.83) 57% (-6 to 83) 
3 6 2.42 (0.90 to 6.49) 59% (-11 to 85) 6 2.18 (0.73 to 6.52) 54% (-37 to 85) 6 4.19 (1.17 to 14.94) 76% (15 to 93) 
4 1 - - 1 - - 1 - - 
hMPV 6 3.24 (1.18 to 8.88) 69% (15 to 89) 6 2.93 (1.26 to 6.81) 66% (21 to 85) 7 3.69 (1.53 to 8.92) 73% (35 to 89) 
AdV 7 0.95 (0.56 to 1.63) -5% (-79 to 39) 7 1.00 (0.61 to 1.63) 0% (-64 to 39) 7 0.96 (0.56 to 1.64) -4% (-79 to 39) 
RV 7 1.36 (0.92 to 2.02)ⱡ 26% (-9 to 50) 7 1.34 (0.92 to 1.93) 25% (-8 to 48) 7 1.36 (0.92 to 2.01) 26% (-9 to 50) 
BoV 4 1.51 (0.24 to 9.63) 34% (-317 to 90) 4 1.51 (0.24 to 9.63) 34% (-317 to 90) 4 1.51 (0.24 to 9.63) 34% (-317 to 90) 
CoV 4 1.09 (0.68 to 1.76) 8% (-47 to 43) 4 0.83 (0.57 to 1.22) -20% (-75 to 18) 4 1.09 (0.68 to 1.76) 8% (-47 to 43) 
 
HKU1 2 0.08 (0.00 to 1.24) -1150% (-EV to 19) 2 0.08 (0.00 to 1.24) -1150% (-EV to 19) 2 0.08 (0.00 to 1.24) -1150% (-EV to 19) 
NL63 3 0.23 (0.01 to 3.78) -335% (-9900 to 74) 3 0.68 (0.17 to 2.83) -47% (-488 to 65) 3 0.23 (0.01 to 3.78) -335% (-9900 to 74) 
229E 3 1.14 (0.34 to 3.80) 12% (-194 to 74) 3 1.10 (0.26 to 4.67) 9% (-285 to 79) 3 1.14 (0.34 to 3.80) 12% (-194 to 74) 
OC43 3 0.65 (0.10 to 4.27) -54% (-900 to 77) 3 0.54 (0.16 to 1.84) -85% (-525 to 46) 3 0.65 (0.10 to 4.27) -54% (-900 to 77) 
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ns=number of studies. 95% CI=95% confidence interval. EV=extreme value. RSV=respiratory syncytial virus. IFV=influenza. PIV=parainfluenza. 
hMPV=human metapneumovirus. AdV=adenovirus. RV=rhinovirus. BoV=bocavirus. CoV=coronavirus. OR=odds ratio. AFE=attributable fraction among 
the exposed. *From the random-effects model. ⱡThe OR=1.26 (0.95 to 1.67) and AFE=21% (-5 to 40) when studies testing all enterovirus are excluded.
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 Discussion   
This is the first systematic review to evaluate and summarise the published literature on the 
viral aetiology of ALRI in young children. The aim was to summarise good quality studies 
with relevant data on the absolute effects of the viral exposure and hence to inform causal 
inference in ALRI aetiological studies which report viral respiratory data. This review 
summarises data from 18,592 cases of ALRI in young children reported across 23 studies. 
Stronger evidence was demonstrated (defined here as a statistically significant OR > 3) for 
four viruses in support of a causal attribution when a virus is identified in young children 
presenting with ALRI: RSV (OR 9.79; AFE 90%), IFV (OR 5.10; AFE 80%), PIV (OR 3.37; 
AFE 70%) and hMPV (OR 3.76; AFE 73%). There was less strong evidence (defined here as 
a statistically significant OR 1-3) for RV (OR 1.43; AFE 30%). Therefore, this indicates the 
potential approach for substantive reductions in the number of ALRI cases was young 
children to be vaccinated against these viruses. There was no statistically significant 
difference of viral identification for the other respiratory viruses studied: AdV, BoV, CoV as 
well as subtypes of all viruses (except IFV-A) between ALRI cases and controls. After 
studies with more than one-year study period were focused on, similar associations were 
observed. This clarifies the potential problem that the seasonality of viruses has an impact on 
their presence and the proportion of them being detected in cases. 
These findings support the roles of RSV, IFV, PIV and hMPV as important causes of ALRI 
in young children. They should inform the results of studies which seek to estimate the 
global / regional / national burden of disease due to these viruses, and disease burden 
estimates should take into account the AFE estimates that this review reports – thus the true 
global burden of RSV / IFV / PIV / hMPV associated pneumonia may be 90% / 80% / 70% / 
73% of the values reported in recent publications. Applying these estimates to the burden of 
severe (hospitalised) pneumonia in 2010 (Rudan et al., 2013), we estimate that the likely true 
burden of RSV and influenza associated ALRI for that year would be about 2.9 (95% CI 1.5-
5.5) million and 0.8 (95% CI 0.3-2.2) million respectively. The AFE estimate for RSV (90%) 
would be applied to the estimation of global burden of RSV associated ALRI in young 
children which was presented in the Chapter 5. There is considerable international attention 
on RSV and IFV pneumonia in young children at this time when novel vaccine strategies are 
under development, being evaluated and prioritised and more accurate disease burden 
estimates (using these results) would help inform future policies and interventions. 
There were several methodological issues affecting the results: ascertainment of case group 
and control group, definition of cases and controls, clinical specimen and confounding. All 
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23 studies used passive hospital-based case ascertainment recruiting inpatients which met the 
selection criteria. Three of them also included cases from outpatients setting or community. 
Several previous studies have shown that children in developing countries, particularly those 
residing in rural areas, have in general, limited access to healthcare (Macfarlane, 2000), and 
health care seeking behaviour is often delayed or absent (Tinuade, 2010). This potentially 
introduced a selection bias. Children who didn’t make it to the hospitals might have a 
different severity of pneumonia and might have a different presence of viruses (as well as 
virus load). For control group, only three studies used community based controls (Singleton 
et al., 2010, Mathisen et al., 2010, Banerji et al., 2009) and the others recruited controls in 
hospital/clinic. Hospital ascertained controls may not reflect the general population, and may 
have other health conditions potentially affecting their viral carriage, especially those with 
URTI. The ideal control group for these studies would be a random sample of an age and sex 
matched child population from the same area of residence during the same time. Studies, 
however, recruited controls who were either selected as healthy (asymptomatic) and so 
biased in favour of those not exposed to the respiratory virus (yielding a falsely high OR) or 
those who were selected to have respiratory symptoms and so biased in favour of those who 
had been exposed to the respiratory virus (yielding a falsely low OR). Consistent with this 
interpretation, odds ratios (of ALRI given viral identification) were found (in Table 4) to be 
consistently greater where the control group was “healthy” and asymptomatic in comparison 
to inclusion of symptomatic (URTI) controls except for AdV and CoV-NL63, in which case, 
their results were slightly higher than ones from asymptomatic control group. Table 6 also 
showed the same results where studies with less than one year of study period were excluded. 
We consider that the value of the OR from a population-based control group would lie 
between these two values as described above. 
With regards to case definition, seven of the included studies (Mathisen et al., 2010, Banerji 
et al., 2009, Dare et al., 2007, Fry et al., 2007, Hammitt et al., 2012a, Wolf et al., 2010, 
Feikin et al., 2013) employed the WHO case definition for pneumonia (World Health 
Organization, 2005) and this standardised approach enhanced the comparability of results 
between these studies. These criteria have high sensitivity for pneumonia (Scott, 2008), but 
lower specificity when overlapped with other conditions (Graham, 2008), particularly 
malaria (World Health Organization, 1991) and wheezing disorders. This tends to inflate the 
number of “cases”/denominator and may contribute to a relatively low level of detection of 
pathogenic viruses.  
All included studies obtained upper respiratory tract specimens (i.e. described as 
nasopharyngeal secretions, nasopharyngeal wash samples, nasopharyngeal aspirate samples, 
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oropharyngeal samples). Although their differing sensitivities could result in some 
heterogeneity, they are broadly comparable and have common flaws. As viruses identified 
could be from a coincidental upper airways infection, the sole use of these specimens is not 
sufficient to provide evidence of the cause of ALRI, but can only provide supportive 
evidence for causality. Lung aspiration is considered the gold-standard sampling technique 
given it is directly obtained from the infection site (Hammitt et al., 2012b), which would 
indicate aetiological significance in ALRI cases (high specificity). However, its invasive 
nature and rate of complications limit its use. All studies used polymerase chain reaction 
(PCR) to diagnose viruses from these upper respiratory tract specimens (one study used IFA). 
The high sensitivity of PCR is important for accurate assessment of aetiological contribution. 
There were several potential confounding factors which could have distorted the observed 
associations. Only three studies calculated appropriately adjusted ORs to account for 
confounding effects from age (Hasan et al., 2014), or age and season (Hammitt et al., 2012a, 
Feikin et al., 2013). Instead, matching of cases and controls was more commonly used – 
performed by age (Adegbola et al., 1994, Bigogo et al., 2013, Mathisen et al., 2010, Banerji 
et al., 2009), or age and month (Hammitt et al., 2012a, Rhedin et al., 2014). Nevertheless, 
despite the use of matching, no studies maintained this pairing to allow OR calculation. 
While all studies were conducted on young children under 5 years, six (Banerji et al., 2009, 
Singleton et al., 2010, Mathisen et al., 2010, Xie, 2010, Jansen et al., 2011, Longtin et al., 
2008) were further restricted. As age is an ALRI risk factor (Rudan, 2008), this could 
potentially affect the viral profile detected, introducing further heterogeneity. However, due 
to the limited data points obtained in narrower age bands, sensitivity analysis of associations 
between ALRI and viruses was not carried out.   
In addition, multiple aetiological agents may often be identified in young children with 
ALRI, making the individual contribution of each agent difficult to define. Many of the 
included studies did not provide virological data that excludes co-infections, so viruses 
detected in these cases could conceivably fulfil any etiological role. The high rates of viral 
co-infection detection may overstate the individual contribution (if the rate of co-infection in 
case group is higher than what is in control group).  
Moreover, the small sample size (Adegbola et al., 1994, Mathisen et al., 2010, Jansen et al., 
2011), undoubtedly contributed to the imprecise 95% CIs of the outcome. This may have 
also led to the non-detection of statistically significant associations between ALRI and virus 
as in some case and/or control groups due to low power of studies. Two studies (Banerji et 
al., 2009, Singleton et al., 2010) included children from aboriginal community in USA or 
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Canada and were found to have high ALRI incidence. The viral associations observed in 
these two studies may not be generalizable to other populations in USA/Canada.  
The use of the AFE allows quantification of the excess percentage of ALRI cases due to 
exposure of a specific virus in absolute terms. However, it assumes that the observed 
association between the virus (and/or related factors) and ALRI is causal, and, in practice, 
this will undoubtedly have led to extreme estimations. Furthermore, strict interpretation 
would entail construal of negative values as indicative of the percentage of ALRI prevented 
by viral exposure, which is biologically implausible. In these cases, the negative AFE value 
should be interpreted carefully and the role of this virus in both cases and controls should be 
explored in-depth to see whether there is an alternative explanation or there are other factors 
influencing the detection of this virus.  
Any viruses detected in asymptomatic children could be from an infection with symptoms 
but they were not recognised, an infection without any symptoms (persistent or reactivation 
of latent infection), a nascent infection (symptoms haven’t been developed), or they were 
persistent from a previous infection (remnants of a past infection) (Jartti, 2008). These could 
explain ‘pathogenic’ viruses (such as AdV) being identified commonly in asymptomatic 
children. Therefore, some viruses are detectable for weeks before symptoms of ALRI 
(during incubation period) and after being infected with ALRI (Lessler, 2009, Jartti, 2008) 
and so the studies only assessing asymptomatic status without considering past or future 
history may yield false positive findings (Hammitt et al., 2012a, Adegbola et al., 1994, 
Longtin et al., 2008, Wolf et al., 2010, Berkley et al., 2010).  
A virus (or any pathogen) can be considered to be associated with ALRI when detected with 
a significantly higher frequency in cases than controls without respiratory symptom 
(asymptomatic). The following evidence provides support for a causal relationship: the 
magnitude of the association is strong (significant);  the association is consistently observed 
across studies in various settings, population and study periods; there is a known biologic 
mechanism underneath the association (Hill, 1965). According to Bradford Hill criteria, this 
evidence, while necessary, is insufficient for proof of a causal role between a virus and ALRI. 
Another essential criterion required for the determination of causality is the establishment of 
a temporal sequence of exposure and outcome (Hennekens et al., 1987). As exposure is 
investigated after the outcome in case-control studies, these cannot provide this temporal 
evidence. Therefore, there is a rationale for the conduct of birth cohort studies with routine 
surveillance of children to track the circulation and course of respiratory viral infections. 
Moreover, using passive immune-prophylaxis (e.g. palivizumab for RSV) in randomised 
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controlled trials might be able to provide experimental evidence of the virus as a causal 
pathogen for ALRI and the strength of the effect. Also, “vaccine-probe studies” could in 
theory potentially be used (in future, once effective vaccines are available) to test the causal 
relationship (Feikin, 2014). These would allow conclusive assessment of the burden of ALRI 
attributable to each virus (consequence of a disease from pathogen infection). 
Furthermore, other alternative explanations must first be refuted before causality can be 
concluded. Firstly, the virus could be an “innocent bystander” which is more prevalent in 
patients with ALRI, but has no causal role. Such an effect may be observed due to 
immunocompromised status from the true causal infection, or nosocomial infections. 
Secondly, the virus may be a risk factor for ALRI development, but not itself the primary 
cause. It has been well established that viral infections predispose to subsequent bacterial 
infection, although the exact mechanisms are still debated (Peltola, 2004). Indeed, influenza 
and RSV epidemics are commonly observed to precede those of bacterial pneumonia 
(Hament, 1999, Hartshorn, 2010). Furthermore, there has been lethal synergism observed in 
viral-bacterial super-infections (Bosch, 2013). Viral and bacterial interaction have several 
possible mechanisms: virus infection might destruct respiratory epithelium via altering the 
mucosal surfaces, resulting in the epithelium more susceptible to bacterial colonisation; cells 
with virus infected could present a decreased expression of antimicrobial peptides (beta-
defensins) which increases the possibility that bacteria escape the natural defence; viral 
neuraminidase (NA) activity would remove sialic acids which cover the bacterial receptors 
and increase the possibility of bacterial adherence; virus could also upregulate the expression 
of several receptors which are needed for bacterial adherence; virus infection could lead to 
immunosuppressed status which is favourable for bacterial invasion. Thirdly, the virus may 
be necessary to cause ALRI, but is not sufficient to do so without the concurrent presence of 
one or more other causal factors. There are numerous risk factors that have been associated 
with ALRI, both host and environment (Rudan, 2008). These, singularly or in combination, 
may provide the opportunity for the respiratory virus to cause ALRI. Fourthly, the virus may 
be the direct and sole cause of ALRI, with causality yet to be confirmed. Finally, the virus 
may be the joint cause of ALRI along with other concurrent viral respiratory infections. 
Considerations of the causal role of these viruses are further complicated by the fact that a 
recent respiratory virus infection may have caused temporary immuno-suppression leading 
to a subsequent viral or bacterial infection even though the initial infection can no longer be 
detected (and other mechanisms through which respiratory viruses predisposed to the 
following infection). Influenza viral infections leading to subsequent pneumococcal or 
staphylococcal respiratory infections have been well described (Hament, 1999). This may 
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result in an under-estimation of the burden of disease associated with respiratory viral 
infection. 
Notwithstanding these limitations, this review provides clear evidence in favour of the causal 
role of RSV, IFV, PIV, hMPV and to a lesser extent for RV in children with ALRI and 
presents a first estimate of the proportion of ALRI cases that can be attributed to the viral 
exposure. Aetiological studies which simply report rates of viral identification as causal 
should make an attempt to interpret their findings in terms of the proportion of ALRI cases 




 Risk factors for RSV associated 
ALRI in children younger than five years old  
 Methods  
4.1.1 Literature search  
4.1.1.1 Search strategy and selection criteria  
A systematic review was conducted according to the PRISMA guidelines. The search was 
performed across the following four electronic databases: Medline, Embase, Global Health 
and LILACS. The search strategy with search terms for each database are listed in 
Appendices - A6. The reference lists of relevant papers were hand searched for eligible 
articles. All searches were limited to between January 1995 and July 2015. No restrictions to 
publication status or language were used. Table 7 provides the selection criteria in details. 
Eligible studies should be observational studies (or randomised controlled trials with placebo 
arm only) that assessed the relationship between RSV associated ALRI cases and risk factors 
of interest. Data were extracted using standardised data extraction template designed on 
Microsoft Excel (Microsoft Office 2007). 
Table 7: Selection criteria applied in the systematic review of risk factors for RSV 
associated ALRI 
Inclusion criteria: 
 Published from January 1995 to July 2015 
 Study design - observational studies (case-control or cohort) or randomised controlled trials 
(placebo arm) 
 Sample size: at least 50 children under investigation 
 Provide data for children younger than 5 years 
 Case group should be children with a diagnosis of ALRI and laboratory confirmed RSV illness 
 Control group should be children without any respiratory symptoms or healthy children 
 Report associations between socio-demographic risk factors and RSV associated ALRI  
 Report results of risk factors based on univariable or multivariable analysis 
Exclusion criteria: 
 Definitions used for ALRI or risk factors, not clearly stated or inconsistently applied 
 Focus on risk factors solely among high-risk study population (e.g. preterm babies, children with 
congenital heart disease, chronic lung disease or immunosuppression etc.) 




 Methods for analysis not clearly reported 
Conforming to the guidelines of PRISMA, another investigator (Evelyn Balsells, MPH) also 
conducted an independent literature search and extracted the data. Any discordance or 
uncertainties regarding relevance or inclusion were arbitrated by my supervisors for this 
thesis (Prof. Harry Campbell and Dr Harish Nair). 
The protocol of this review was published in PROSPERO database with registration number: 
CRD42015017923.  
4.1.2 Unpublished data collection   
As described in the Chapter 2 - Methods, unpublished studies with relevant data regarding to 
associations between risk factors and RSV associated ALRI were collected from RSV GEN 
investigators. Overall, four unpublished studies with data on risk factors met selection 
criteria. Their data were summarised in the same data extraction form and combined with the 
data from published articles (Rasmussen, unpublished; Rath, unpublished; Singleton, 
unpublished; Zar, unpublished).  
4.1.3 Definition of risk factor and outcome 
RSV associated ALRI was used as the outcome of interest, which was detailed in the 
Methods Chapter. The case group - ALRI was defined as cough or dyspnoea with age-related 
tachypnoea, while severe ALRI was defined as cough or dyspnoea with lower chest wall 
indrawing (community-based) or an acute respiratory infection severe enough to warrant 
hospital admission (hospital-based). The control group was defined as children without 
respiratory symptoms or healthy children (without any respiratory symptoms or other 
symptoms).  
The definitions for some of the risk factors varied substantially across the included studies. 
Where there were several slightly different definitions regarding to one certain risk factor 
(which may result in differing strengths of association between this risk factor and the 
outcome), these studies were pooled into one meta-analysis (where possible) and then 
conducted a sensitivity analysis to focus on the effect of the risk factor with a certain 
definition. The definitions of risk factors included in the final meta-analysis were listed in 





Table 8: Definitions of risk factors for RSV associated ALRI included in meta-analysis 
Risk factor Definition 
Prematurity 
Gestational age <37 weeks 
Gestational age <33 weeks 
Low birth weight Birth weight <2.5 kg 
Gender Male 
Siblings Mention of siblings or other children living in the household 
Maternal smoking Maternal smoking during pregnancy 
History of atopy Positive family history of asthma or atopy 
Low parental education 
No parent having bachelor’s degree 
Education of primary caretaker: 1-7 years or no schooling 
<12 years’ maternal education 
<11 years’ maternal education 
Passive smoking Smokers in the household 
Daycare centre 
attendance 
Attendance at daycare centre 
Indoor air pollution Use of biomass fuels for cooking or a description of indoor smoke 
No breastfeeding No breastfeeding 
Crowding >7 persons in household 
Multiple births Twins or triplets 
HIV Confirmed presence of HIV infection in child 
Lack of plumbed water Lack of plumbed water in the household 
The Alaskan native population in America was considered to share some epidemiological 
features to populations in developing countries with similar socioeconomic and demographic 
risk factors for respiratory infections in both populations (Bulkow et al., 2012), thus were 
classified as in a developing country setting. Other study sites were classified as from 
developing or industrialised settings according to the “Levels & trends in child mortality - 
report 2014” by UNICEF (United Nations Children's Fund, 2014).  
4.1.4 Quality assessment  
The quality of each study was assessed by using a modified GRADE scoring system (Guyatt 
et al., 2008) focusing on the following seven aspects: study design, quality of control group, 
sample size, analysis method, bias, confounding factors and geographical spread of studies 
(Table 9). Each criterion was categorised into three or four groups with an order of scores 
(from 0 to 2). The overall score for each study was calculated after assigning corresponding 
score for every criterion as listed in the table. Studies with cumulative score ≤lower quartile 
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(25th percentile) of all scores were considered to have “low quality” and they were excluded 
in the final estimate.  
Table 9: Modified GRADE scoring system used to assess the quality of included 
studies of risk factors for RSV associated ALRI 
Criteria Categorisation  Score 
Design 
Cohort study +2 point 
Case control study +1 points 
Cross sectional study 0.5 points 
Randomised control trial 
(placebo arm) 
0 points 
Quality of control group 
Good (matched to cases) +2 points 
Average (not matched, but some 
descriptions about control) 
+1 point 
Poor (no further details) 0 point 
Sample size 
>500 subjects  +2 points 
300-500 subjects +1 point 
<300 subjects 0 point 
Analysis method 
Only multivariable +2 points 
Part of analyses were based on 
multivariable  
+1 point 
Only univariable 0 point 
Bias  
Good attempt to avoid bias 
(selection bias etc.) 
+2 points 
Some attempt to avoid bias 
(selection bias) 
+1 point 
No attempt to avoid bias 0 point 
Confounding factors 
All accounted for (analysis of 
each risk factor has taken into 
account of the other risk factors 
investigated in the same study) 
+2 points 
Some accounted for (analyses of 
some risk factors have taken 
into account of the other risk 
factors investigated in the same 
study) 
+1 point 
Not accounted for  0 point 
Geographical spread of 
studies 










4.1.5 Statistical analysis 
Data about the risk summary measure (odds ratio and relative risk) with 95% CI for risk 
factors of interest were extracted as provided (univariable and multivariable analysis), from 
included studies (published articles and unpublished studies). If such summary data were not 
reported, data reported in the paper were used (where feasible) to calculate one.  
Using STATA (version 11.2) (StataCorp, 2009), a meta-analysis of risk factor specific odds 
ratios was conducted based on random effects model (DerSimonian-Laird method) since 
significant heterogeneity was expected (Borenstein et al., 2009), as discussed in the Chapter 
2 - Methods. And pooled estimates with corresponding 95% CIs were reported. In the first 
instance, only results from studies reporting data based on multivariable analysis would be 
presented since they involved adjustment of other risk factors investigated in the same study 
and represented a more accurate result for the risk factor of interest. Thereafter, data from 
studies reporting ORs using univariable analysis were included. Due to limited studies 
reporting the results based on multivariable analysis and due to the fact that there was no 
access to original datasets from included studies to run one, the final estimate was based on 
meta-analysis of both studies using multivariable analysis and studies using univariable 
analysis. The final estimate didn’t include those “low quality” studies according to modified 
GRADE scoring system. However, a sensitivity analysis including “low quality” studies was 
run afterwards in comparison to the previous final estimate and to show whether the result 
from sensitivity analysis would differ substantially when these “low-quality” studies were 
included. Subgroup analysis was carried out in developing and industrialised countries 




 Overall result  
Overall, 2,690 published articles were identified through literature search, of which only 23 
studies (Boyce et al., 2000, Bulkow et al., 2002, Choudhuri et al., 2006, Cilla et al., 2006, 
Gouyon et al., 2013, Grimwood et al., 2008, Houben et al., 2011, Madhi et al., 2006, Nielsen 
et al., 2003, Okiro et al., 2008, Paynter et al., 2014, Reeve et al., 2006, Rietveld et al., 2006, 
Rossi et al., 2007, Smith et al., 2011, Stensballe et al., 2006, Von Linstow et al., 2008, 
Weber et al., 1999, Weigl et al., 2001, Madhi et al., 2000, Moyes et al., 2013, Bruden et al., 
2015, Hennessy et al., 2008) fulfilled the strict eligibility criteria. The 165 articles which 
were reviewed in full texts but then got excluded were listed in Appendices - A7 with 
corresponding reasons. After including an additional 4 unpublished studies (Rasmussen, 
unpublished; Rath, unpublished; Singleton, unpublished; Zar, unpublished) provided by RSV 
GEN collaborators, 27 studies in total were included in the following analysis. The selection 
process conducted to include studies is shown in Figure 8. Three studies provided data of 
risk factors for RSV associated ALRI from community-based studies (Okiro et al., 2008) 
(Rasmussen, unpublished; Zar, unpublished), three studies reported data for RSV associated 
(hospitalised) ALRI from both outpatient and inpatient settings in hospitals (Houben et al., 
2011, Smith et al., 2011) (Rath, unpublished) and 21 studies provided data for RSV 
associated hospitalised ALRI. Fourteen studies were from industrialised countries and 
thirteen studies were from developing countries. Map of locations of these 27 study sites was 
displayed in Figure 9. Table 11 shows main features of the 27 included studies.  
According to the modified GRADE scoring system, the quality scores of included studies 
varied from 2.5 to 11 with 25th percentile score of 6.25 (Table 12). There were 7 studies 
which had scores ≤6.25 (Bruden et al., 2015, Hennessy et al., 2008, Madhi et al., 2006, 
Madhi et al., 2000, Okiro et al., 2008, Weigl et al., 2001) (Rath, unpublished). As described 
in the Methods, these “low quality” with scores ≤6.25 were excluded in the final estimate.  
Definitions for each risk factor varied across included studies. Table 10 shows all risk factors 
with all definitions used in the included studies. Apart from the ones already listed in Table 8, 
which were included in meta-analysis, there were also several other risk factors in which 
case there were no enough studies (<3 studies) reporting their roles in RSV associated ALRI 
thus were not included in the meta-analysis. Moreover, Table 10 also lists other definitions 
for a certain risk factor which were not displayed in Table 8 because these definitions were 
substantially different from the others. Therefore, they were not included to the existing 
meta-analysis of this certain risk factor; and since there were insufficient studies reporting 
data using these different definitions, thus a separate meta-analysis could not be done. Table 
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13 presents the final results for 12 risk factors with meta-estimate ORs after excluding “low-
quality” studies (20 studies in total). The table displays meta-estimates from studies using 
multivariable analysis only (if possible) as well as meta-estimates from all studies (using 
both multivariable analysis and univariable analysis). The final estimate was based on 
exclusion of “low quality” studies and inclusion of studies using multivariable analysis and 
univariable analysis (Table 13). The corresponding forest plots of the final estimate were 
available in Appendices - A8. A sensitivity analysis was run later to include those seven 
“low-quality” studies to explore whether these studies influenced the overall result 






Table 10: List of all various definitions of risk factors for RSV associated ALRI among 
the included studies 
Risk factor Definition 
Prematurity 
Gestational age <37 weeks (±1 week) 
Gestational age <33 weeks 
Low birth weight Birth weight <2.5 kg (or <3.0 kg) 
No/lack of exclusive 
breastfeeding 
No breastfeeding  
No or <3 months breastfeeding  
No breastfeeding for first 14 days 
Lack of exclusive breastfeeding 
Multiple births Twins or triplets 
Gender Male 
History of atopy Positive family history of asthma or atopy 
Low parental education 
No parent having bachelor’s degree 
Education of primary caretaker: 1-7 years or no schooling 
<12 years’ maternal education 
<11 years’ maternal education 
Siblings Mention of siblings or other children living in the household 
Passive smoking Smokers in the household 
Maternal smoking Maternal smoking during pregnancy 
Daycare centre 
attendance 
Attendance at daycare centre 
Crowding 
>7 persons in household 
≥10 persons in household 
≥2 persons per room  
≥3 siblings less than 6 years old sleeping in same room  
>7 persons sleeping per room 
An increase of 20% of households >1.5 persons/room 
Malnutrition 
Weight for age ≤2 standard deviations (SD) 
Growth ≤median measures (weight for age) 
Indoor air pollution Use of biomass fuels for cooking or a description of indoor smoke 
HIV Confirmed presence of HIV infection in child 
Previous illness Previous history of ALRI/RSV  
Altitude  High altitude 
Lack of plumbed water 
Lack of plumbed water in the household, low in-home water service or 






 2,690 records identified 
through database search 
5 records identified 
through other sources 
892 duplicates removed 
1,803 records screened 
1,615 records excluded due 
to not relevant to topic 
188 full-text articles 
assessed for eligibility 
27 studies included 
165 full-text articles excluded:                  
9 reporting data in high-risk 
children;                                          
5 only reporting p-value;                   
13 using children with RSV 
negative respiratory infections as 
control group;                               
131 articles had no relevant data;        
7 no full-texts 
Figure 8: Flow diagram of selection of studies of risk factors for RSV associated ALRI 




Figure 9: Location of 27 included studies of risk factors for RSV associated ALRI 
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Table 11: Characteristics of 27 included studies of risk factors for RSV associated ALRI 











Hvidovre, Denmark (Von 
Linstow et al., 2008) 




<1y IP ARI 217 NPS; PCR PR, BF, S, PS, MS 
Denmark (Stensballe et 
al., 2006) 
1997 - 2003 Case control <18m IP ARI 15380 RSV database 
M, HOA, DCA, S, 
MS 
Utrecht, Netherlands 
(Houben et al., 2011) 
Jan 2006 - Dec 2008 
Prospective 
birth cohort 
<1y IP, OP ALRI 298 
Nasal/throat 
swab; PCR 
BF, M, HOA, PE, 
DCA, MS 
Colorado, USA 
(Choudhuri et al., 2006) 




San Marcos, Guatemala 
(Smith et al., 2011) 
Oct 2002 - Dec 2004 
Randomised 
controlled trial 
<18m IP, OP ARI NA NA; IF IAP 
Kilifi, Kenya (Okiro et 
al., 2008) 
May 2003 - Apr 
2007 
Birth cohort <4y C ALRI 469 NPW; DFA 
MB, PE, MA, C, S, 
PS 
Soweto, South Africa 
(Madhi et al., 2006) 




<6y IP ALRI 39836 NPA; IF PR, HIV 
South-western 
Netherlands (Rietveld et 
al., 2006) 
Oct 1996 - Apr 1999 
Retrospective 
cohort 
<2y IP ARI NA 
NPA; 
DFA/culture 
PR, LBW, M 
9 perinatal networks, 
France (Gouyon et al., 
2013) 





<1y IP B 498 NPA; IF PR 
Kiel, Germany (Weigl et 
al., 2001) 
Jul 1996 - Jun 1999 Cross sectional <2y IP ARI NA NPA; PCR PR 
Bohol, Philippines Jul 2000 - Dec 2004 Retrospective <5y IP ALRI 10913 NA; M, PE, MA, S 
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(Paynter et al., 2014) cohort PCR/culture 
Townsville, Australia 
(Reeve et al., 2006) 
Jan 1997 - Jun 2004 Case control <3y IP ALRI 750 NPA; DFA PR, LBW, M, S 
Tennessee, USA (Boyce et 
al., 2000) 
Jul 1989 - Jun 1993 
Retrospective 
cohort 
<1y IP ARI 3553 NA PR, M, PE, S, MS 
2 Danish counties, 
Denmark (Nielsen et al., 
2003) 
1990 - 1994 Case control <2y IP ALRI 7632 NPA; DFA PR, LBW, S, MS 
Basque Country, Spain 
(Cilla et al., 2006) 
Jul 1996 - Jun 2000 Case control <2y IP ALRI 14343 NPA; IF PR, LBW, MB, M, 
Wellington Hospital, New 
Zealand (Grimwood et 
al., 2008) 
June/July - October, 
2003-2005 
Case control <2y IP B 11411 NPA; DFA PR, MB, M, MS 
Alaska, USA (Bulkow et 
al., 2002) 
Oct 1993 - Sep 1996 Case control <3y IP ALRI 542 NPA; IF BF, PE, C, S, S 
3 hospitals in western 
region, Gambia (Weber 
et al., 1999) 
1993 - 1995 Case control <5y IP ALRI 641 NPA; IF 
HOA, M, C, S, PS, 
M, LPW, IAP 
Italy (Rossi et al., 2007) 
Oct - Apr, 2000 - 
2004 
Case control ≤4y IP ALRI 437 Nasal sample; IF 
PR, LBW, BF, M, 
HOA, PI, S, PS 
Alaska, USA (Singleton, 
unpublished) 




Apr 2012 - Mar 
2014 
Case control <5y C ALRI 93 NPS; PCR 















Soweto, South Africa 
(Madhi et al., 2000) 
MAR 1997 - Mar 
1998 
Cross sectional 2-23m IP ALRI 24000 NPA; DFA HIV 
3 sites, South Africa 
(Moyes et al., 2013) 
Jan 2010 - Dec 2011 Cross sectional <5y IP ALRI 835060 NPA; PCR HIV 
Alaska, USA (Bruden et 
al., 2015) 
1995 – 2012 Cross sectional <1y IP ALRI NA 
NPA; 
DFA/culture 
C, IAP, LPW 
Alaska, USA (Hennessy 
et al., 2008) 




Paarl, South Africa (Zar, 
unpublished) 




<3y C ALRI 159 NPS; RT-PCR 
PR, LBW, BF, M, 
HOA, PE, S, PS, 
MS, DCA, MA, C, 
IAP, PI 
Berlin, Germany (Rath, 
unpublished) 




<5y IP, OP ALRI 666 
NPS/NPA; RT-
PCR 
PR, LBW, M, C 
Case ascertainment: IP=inpatient; OP=outpatient; C=community. Case definition: ALRI=acute lower respiratory infection; ARI=acute respiratory 
infection; P=pneumonia; B=bronchiolitis. RSV detection: NPA=nasopharyngeal aspirate; NPS=nasopharyngeal swab; NPW=nasopharyngeal wash; 
PCR=polymerase chain reaction; IF=immunofluorescence; DFA=direct fluorescent antibody test; IFA=indirect fluorescent antibody test. Risk factors 
included: PR=prematurity; LBW=low birth weight; BF=no/lack of exclusive breastfeeding; MB=multiple births; M=male; HOA=history of atopy; PE=low 
parental education; S=siblings; PS=passive smoking; MS=maternal smoking; DCA=daycare centre attendance; MA=malnutrition; C=crowding; 
IAP=indoor air pollution; PI=previous illness; HIV=human immunodeficiency virus; LPW=lack of plumbed water. NA=not available. 
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et al., 2006) 
1 2 2 2 1 1 2 11 
(Paynter et 
al., 2014) 
2 1 2 2 1 2 1 11 
(Rietveld et 
al., 2006) 
2 1 2 2 0 1 2 10 
(Reeve et 
al., 2006) 
1 2 2 1 2 1 1 10 
(Nielsen et 
al., 2003) 
1 2 2 1 2 1 1 10 
(Choudhuri 
et al., 2006) 
0.5 1 2 2 0 2 2 9.5 
(Boyce et 
al., 2000) 
2 1 2 1 0 1 2 9 
(Bulkow et 
al., 2002) 
1 2 2 1 1 1 1 9 
(Weber et 
al., 1999) 




2 2 0 0 2 1 2 9 
(Houben et 
al., 2011) 
2 1 0 1 2 1 1 8 
(Smith et 
al., 2011) 
0 1 2 2 1 1 1 8 
(Gouyon et 
al., 2013) 
2 1 1 0 1 1 2 8 
(Grimwood 
et al., 2008) 









2 2 0 1 1 1 0 7 
(Cilla et al., 
2006) 
1 1 2 1 1 1 0 7 
(Rossi et al., 
2007) 



























1 2 0 2 0 1 1 7 
(Moyes et 
al., 2013) 
0.5 0 2 2 0 1 1 6.5 
(Okiro et 
al., 2008) 




2 1 2 0 0 0 1 6 
(Bruden et 
al., 2015) 
0.5 0 2 1 0 1 1 5.5 
(Madhi et 
al., 2006) 
2 1 2 0 0 0 0 5 
(Weigl et 
al., 2001) 
0.5 1 2 0 0 0 1 4.5 
(Hennessy 
et al., 2008) 
0.5 0 2 0 0 0 1 3.5 
(Madhi et 
al., 2000) 
0.5 0 2 0 0 0 0 2.5 




 Results by each risk factor 
For each risk factor, the definitions applied and the characteristics of the included studies 
(region of study setting, case ascertainment approach, analysis method) as well as the overall 
meta-estimate are presented in the following section.  
Prematurity (gestational age <37 weeks) 
Three different definitions were applied among the thirteen included studies. One study (Von 
Linstow et al., 2008) used gestational age <38 weeks as the definition for prematurity, three 
studies (Boyce et al., 2000, Madhi et al., 2006, Rossi et al., 2007) used gestational age <36 
weeks and nine studies used gestational age <37 weeks (Cilla et al., 2006, Grimwood et al., 
2008, Nielsen et al., 2003, Reeve et al., 2006, Rietveld et al., 2006, Weigl et al., 2001) (Rath, 
unpublished; Singleton, unpublished; Zar, unpublished). Only studies using gestational age 
<37 weeks to define prematurity were included in meta-analysis. Among these nine studies, 
two (Cilla et al., 2006) (Singleton unpublished) reported the associations based on 
multivariable analysis and the others used univariable analysis. Two studies (Singleton, 
unpublished; Zar, unpublished) were based on settings categorised as developing countries, 
while the rest were from industrialised countries. One study (Zar, unpublished) was 
community-based, another (Rath, unpublished) included both outpatients and inpatients in 
the case group and the other seven studies used hospitalised children as cases. Two studies 
(Weigl et al., 2001) (Rath, unpublished) were considered to be “low-quality” studies 
according to GRADE scoring system. After excluding these two studies, the odds ratio meta-
estimate was 1.96 (95% CI 1.44-2.67) based on seven studies. Alternatively, if all studies 
irrespective of quality scores (nine studies) were included the meta-estimate was 1.47 (95% 
CI 0.98-2.21).  
Prematurity (gestational age <33 weeks) 
This risk factor was considered as a subgroup (more severe case) of children with 
prematurity. Eight studies reported relevant data. Three hospital-based studies (Boyce et al., 
2000, Nielsen et al., 2003, Rietveld et al., 2006) from industrialised countries reported 
significant associations between prematurity (gestational age <33 weeks) and RSV 
associated ALRI using multivariable analysis. The overall odds ratio meta-estimate was 2.68 
(95% CI 2.02-3.55). Five additional studies (Gouyon et al., 2013, Madhi et al., 2006, Rossi 
et al., 2007) (Rath unpublished; Zar, unpublished), two of which were from developing 
countries (Madhi et al., 2006) (Zar, unpublished), reported odds ratios using univariable 
analysis. The inclusion of these studies resulted in the odds ratio meta-estimate of 2.74 (95% 
CI 1.59-4.71) based on eight studies. Two studies (Madhi et al., 2006) (Rath, unpublished) 
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were considered to have “low quality”. After excluding them, the final odds ratio meta-
estimate was 2.79 (95% CI 2.19-3.55) from six studies. 
Low birth weight 
Seven studies in total were included. Six of them used birth weight <2.5 kg to define low 
birth weight (Cilla et al., 2006, Reeve et al., 2006, Rietveld et al., 2006, Rossi et al., 2007) 
(Rath, unpublished; Zar, unpublished). One study (Nielsen et al., 2003) from Denmark used 
a definition of <3.0 kg, thus it was not included in the meta-analysis. Two hospital-based 
studies (Cilla et al., 2006, Rietveld et al., 2006) from industrialised countries reported 
significant associations between low birth weight (<2.5 kg) and RSV associated ALRI using 
multivariable analysis. Four additional studies (Reeve et al., 2006, Rossi et al., 2007) (Rath, 
unpublished; Zar, unpublished), one of which (Zar, unpublished) was from a developing 
country setting, reported odds ratios based on univariable analysis. When studies using 
univariable analysis were combined with studies using multivariable analysis, the overall 
meta-estimate of odds ratio was 1.37 (95% CI 0.85-2.21) in these 6 studies. After excluding 
one study with “low quality” (Rath, unpublished), the final meta-estimate was 1.91 (95% CI 
1.45-2.53) based on five studies.  
Male sex 
There were 13 studies reporting associating between being male and RSV associated ALRI. 
Five hospital-based studies (Boyce et al., 2000, Grimwood et al., 2008, Paynter et al., 2014, 
Rietveld et al., 2006, Stensballe et al., 2006) and one community-based study (Rasmussen, 
unpublished), reported associations using multivariable analysis. Two of them reported non-
significant associations (Grimwood et al., 2008) (Rasmussen, unpublished) and in the other 
four studies significant associations were reported. The overall odds ratio meta-estimate was 
1.32 (95% CI 1.24-1.40) for these six studies. Seven additional studies (Cilla et al., 2006, 
Houben et al., 2011, Reeve et al., 2006, Rossi et al., 2007, Weber et al., 1999) (Rath, 
unpublished; Zar, unpublished), two of which were from developing countries, reported the 
odds ratios using univariable analysis. Two studies (Houben et al., 2011) (Rath, unpublished) 
recruited cases from hospital inpatients and outpatients and another one (Zar, unpublished) 
identified cases based on active community ascertainment. The inclusion of these seven 
studies did not alter the odds ratio meta-estimate substantially, which was estimated as 1.21 
(95% CI 1.12-1.32) from thirteen studies totally. After excluding one “low-quality” study 






Twelve studies were included. Six hospital-based studies (Boyce et al., 2000, Nielsen et al., 
2003, Paynter et al., 2014, Reeve et al., 2006, Stensballe et al., 2006, Von Linstow et al., 
2008), one of which was from a developing country (Paynter et al., 2014), reported 
associations between siblings (mention of siblings or other children living in the house) and 
RSV associated ALRI using multivariable analysis. Only one of them reported a non-
significant association (Nielsen et al., 2003). The overall odds ratio meta-estimate was 1.53 
(95% CI 1.20-1.95). Six additional studies (Bulkow et al., 2002, Okiro et al., 2008, Rossi et 
al., 2007, Weber et al., 1999) (Rasmussen, unpublished; Zar, unpublished), one of which was 
from an industrialised country (Rossi et al., 2007), reported odds ratios for siblings and RSV 
associated ALRI using univariable analysis. Three studies (Okiro et al., 2008) (Rasmussen, 
unpublished; Zar, unpublished) were based on active community ascertainment. The 
inclusion of these six studies did not have any substantial effect on the odds ratio meta-
estimate, which was 1.62 (95% CI 1.34-1.95) based on overall twelve studies. One study 
(Okiro et al., 2008) was denoted as “low quality”. Therefore, the final estimate was based on 
eleven studies after excluding this study and the meta-estimate was 1.60 (95% CI 1.32-1.95).  
Maternal smoking 
There were seven studies identified from the literature search and unpublished data 
collection network. Four hospital-based studies (Boyce et al., 2000, Grimwood et al., 2008, 
Nielsen et al., 2003, Stensballe et al., 2006), all of which were from industrialised countries, 
reported associations between maternal smoking during pregnancy (active) and hospitalised 
RSV associated ALRI using multivariable analysis. Only one of them reported a non-
significant association (Grimwood et al., 2008). The overall odds ratio meta-estimate was 
1.34 (95% CI 1.26-1.42). Three additional studies (Houben et al., 2011, Von Linstow et al., 
2008) (Zar, unpublished) reported data using univariable analysis: two community-based 
studies from the Netherlands and South Africa (Houben et al., 2011) (Zar, unpublished) 
reporting non-significant odds ratios and one hospital-based study from Denmark (Von 
Linstow et al., 2008) reporting a significant odds ratio. The inclusion of these three studies 
resulted in a similar meta-estimate of odds ratio - 1.36 (95% CI 1.24-1.50) based on seven 
studies totally. There were no studies considered to be of “low quality” thus no sensitivity 
analysis was carried out for this risk factor. However, there was no studies reporting the 
association between prenatal passive tobacco smoke exposure and RSV associated ALRI, 
which required further investigation.  
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Table 13: Meta-estimate of odds ratio for 12 risk factors after excluding studies with 
quality score ≤6.25 (i.e. “low-quality”) 
Risk factor* 





No. of studies 
Meta-estimate OR 
(95% CI) 
No breastfeeding 1 - 3 2.24 (1.56-3.20) 
Prematurity 
(gestational age <37 
weeks) 
2 - 7 1.96 (1.44-2.67) 
Crowding (>7 
persons in household) 
1 - 3 1.94 (1.29-2.93) 
Low birth weight 2 - 5 1.91 (1.45-2.53) 
Daycare centre 
attendance 
2 - 3 1.61 (0.98-2.64) 
Siblings 6 1.53 (1.20-1.95) 11 1.60 (1.32-1.95) 
History of atopy 1 - 5 1.47 (1.16-1.87) 
Low parental 
education 
4 1.23 (0.73-2.09) 6 1.40 (0.94-2.08) 
Maternal smoking 4 1.34 (1.26-1.42) 7 1.36 (1.24-1.50) 
Passive smoking 4 1.40 (0.65-3.00) 8 1.29 (0.96-1.73) 
Being male 6 1.32 (1.24-1.40) 12 1.23 (1.13-1.33) 
Indoor air pollution 4 0.69 (0.35-1.37) 5 0.81 (0.42-1.57) 
 *Only listing risk factors where meta-estimate is available, and the list of risk factors is 
ordered based on meta-estimate of studies using multivariable and univariable analysis from 
high to low. 
 
History of atopy 
Overall, five studies were available reporting the association between history of atopy 
(positive family history of asthma or atopy) and RSV associated ALRI. One hospital-based 
study (Stensballe et al., 2006) from Denmark reported a significant association between 
history of atopy and hospitalised RSV associated ALRI using multivariable analysis. Four 
additional studies (Houben et al., 2011, Rossi et al., 2007, Weber et al., 1999) (Zar, 
unpublished), two of which were from developing countries (Weber et al., 1999) (Zar, 
unpublished), reported the odds ratios using univariable analysis. One study (Houben et al., 
2011) was based on both inpatient and outpatient settings in hospital and another one (Zar, 
unpublished) was a community-based study. The overall odds ratio meta-estimate was 1.47 




Low parental education 
Definitions of low parental education varied among the included studies. Four studies 
(Boyce et al., 2000, Houben et al., 2011, Paynter et al., 2014) (Rasmussen, unpublished), two 
of which were from developing countries (Paynter et al., 2014) (Rasmussen, unpublished), 
reported associations between low parental education (no parent having bachelor’s degree in 
an industrialised country, <11 or <12 years maternal education, primary or no schooling) and 
RSV associated ALRI using multivariable analysis. Additionally, two studies reported 
significant associations. One study (Houben et al., 2011) identified cases from both inpatient 
and outpatient settings in hospital. One study (Rasmussen, unpublished) was a community-
based study and used active ascertainment method. The overall odds ratio meta-estimate was 
1.23 (95% CI 0.73-2.09). Three additional studies (Bulkow et al., 2002, Okiro et al., 2008) 
(Zar, unpublished) from developing countries reported odds ratios for low parental education 
(≤12 grade or primary or no schooling) and RSV associated ALRI based on univariable 
analysis. Two studies (Okiro et al., 2008) (Zar, unpublished) used active community 
ascertainment to identify cases. The inclusion of these three studies resulted in a slightly 
higher odds ratio meta-estimate of 1.77 (95% CI 0.91-3.46) (seven studies in total). After 
excluding one “low-quality” study (Okiro et al., 2008), the meta-estimate was 1.40 (95% CI 
0.94-2.08) based on six studies.  
Passive smoking 
Nine studies were included and reported relevant data for associations between postnatal 
passive smoking (smokers in the house) and RSV associated ALRI. Three hospital-based 
studies and one community-based study reported the associations using multivariable 
analysis with the meta-estimate 1.40 (95% CI 0.65-3.00) (Von Linstow et al., 2008, Weber et 
al., 1999) (Rasmussen, unpublished; Singleton, unpublished). Only one study from Denmark 
(Von Linstow et al., 2008) reported a significant association. Five additional studies (Bulkow 
et al., 2002, Okiro et al., 2008, Reeve et al., 2006, Rossi et al., 2007) (Zar, unpublished), two 
of which were from industrialised countries (Reeve et al., 2006, Rossi et al., 2007), reported 
odds ratios for passive smoking and RSV associated ALRI based on univariable analysis. 
Two of them reported significant associations (Bulkow et al., 2002, Reeve et al., 2006). Two 
studies (Okiro et al., 2008) (Zar, unpublished) identified cases based on active community 
ascertainment. After combining all studies (studies using multivariable and studies using 
univariable analysis), the meta-estimate of odds ratio was 1.23 (95% CI 0.95-1.60) based on 
nine studies. One study (Okiro et al., 2008) was “low quality”. After excluding this study, 
the final meta-estimate was 1.29 (95% CI 0.96-1.73) and there were eight studies in total. 
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Daycare centre attendance 
Three studies were identified. One hospital-based study (Stensballe et al., 2006) from 
Denmark reported a significant association between daycare centre attendance and 
hospitalised RSV associated ALRI using multivariable analysis (1.40 (95% CI 1.15-1.70)). 
One study (Houben et al., 2011) from the Netherlands, which had cases from both inpatient 
and outpatient settings in hospital, reported a non-significant association between daycare 
centre attendance and RSV associated ALRI using multivariable analysis (5.80 (95% CI 
0.76-44.4)). One community-based study (Zar, unpublished) from South Africa also reported 
a non-significant association using univariable analysis. Overall, the odds ratio meta-
estimate was 1.61 (95% CI 0.98-2.64). All studies were of “good quality” and were included 
in the final analysis. 
Indoor air pollution 
Overall, six studies were included reporting the associations between indoor air pollution 
(woodstove in household) and RSV associated ALRI. Three hospital-based studies (Bruden 
et al., 2015, Weber et al., 1999) (Singleton, unpublished) from Alaska and Gambia reported 
associations using multivariable or univariable analysis. Another study (Smith et al., 2011) 
from Guatemala, which was based on both inpatient and outpatient settings in hospital, 
reported a non-significant association using multivariable analysis (0.76 (95% CI 0.42-1.16)). 
A further two studies (Rasmussen, unpublished; Zar, unpublished) from Pakistan and South 
Africa identified cases using active community ascertainment and also reported non-
significant associations using univariable analysis. Overall, the meta-estimate of odds ratio 
was 0.86 (95% CI 0.57-1.31) based on six studies. One study (Bruden et al., 2015) was 
considered as having “low quality”, thus after excluding this study, the final meta-estimate 
was 0.81 (0.42-1.57) from five studies. 
No breastfeeding 
Three hospital-based studies (Bulkow et al., 2002) (Singleton, unpublished; Zar, unpublished) 
from developing countries reported associations between no breastfeeding and RSV 
associated ALRI. Only one of them (Bulkow et al., 2002) reported a significant association 
based on univariable analysis. All of these three studies had “good quality” and the overall 
meta-estimate of odds ratio was 2.24 (95% CI 1.56-3.20). Another four studies (Houben et 
al., 2011, Rossi et al., 2007, Von Linstow et al., 2008) (Zar, unpublished), three from 
industrialised countries, reported odds ratios for lack of breastfeeding (no breastfeeding for 
first 14 days, <3 months breastfeeding or lack of exclusive breastfeeding) and RSV 
associated ALRI. Only one study (Von Linstow et al., 2008) reported a significant odds ratio 
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based on multivariable analysis. One study (Houben et al., 2011) was based on both inpatient 
and outpatient settings in hospital and another one (Zar, unpublished) was community-based. 
Since these four studies used substantially different definitions for breastfeeding and there 
were no enough studies for each category of different definitions, meta-analysis was not 
carried out.  
Crowding  
Included studies used varied definitions for crowding. Four studies (Bulkow et al., 2002) 
(Rath, unpublished; Singleton, unpublished; Zar, unpublished) reported associations between 
crowding (>7 persons in household) and RSV associated ALRI. One study (Rath, 
unpublished) from Germany only had 5 children with crowding exposed (5 in case group and 
0 in control group). The prevalence of crowding is too small to generate a reliable estimate; 
thus this study was not included in analysis. One of them (Singleton, unpublished) reported 
the association using multivariate analysis. One study (Zar, unpublished) was community-
based and the other two were hospital-based. These three studies all had “good quality”. 
Overall, the meta-estimate of the odds ratios was 1.94 (95% CI 1.29-2.93) for these three 
studies. Other studies used substantially different case definitions and, for these, they were 
not included in the meta-analysis. Two studies (Bruden et al., 2015, Bulkow et al., 2002) 
from Alaska presented significant associations between crowding (defined as ≥2 
persons/room in household and an increase of 20% of households >1.5 persons/room) and 
hospitalised RSV associated ALRI. One hospital-based study (Weber et al., 1999) from 
Gambia also reported a significant association using the definition of ≥10 people living in 
the household. Two community-based studies from Kenya (Okiro et al., 2008) and Pakistan 
(Rasmussen, unpublished) reported non-significant associations with definitions of ≥3 
siblings/room or >7 persons/room. These definitions were considerably different from each 
other and there were no sufficient studies reporting data for each category, thus a separate 
meta-analysis was not done. 
Multiple births 
Only one study (Grimwood et al., 2008) from New Zealand reported a non-significant 
association between multiple births (twins or triplets) and hospitalised RSV associated ALRI 
using multivariable analysis. Two additional studies reported non-significant odds ratios 
using univariable analysis. One study from Spain (Cilla et al., 2006) presented the 
association for multiple births and hospitalised RSV associated ALRI whilst another study 
from Kenya (Okiro et al., 2008) was based on active community-based case ascertainment. 
After these three studies were combined, the odds ratio meta-estimate was 1.41 (95% CI 
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0.98-2.03). However, one study (Okiro et al., 2008) was considered as “low-quality” and 
thus no meta-estimate was available after excluding this study (no meta-estimates results 
shown in Table 13).  
HIV 
Three hospital-based studies (Madhi et al., 2006, Madhi et al., 2000, Moyes et al., 2013) 
from South Africa reported significant associations between HIV (confirmed presence of 
HIV infection in child) and RSV associated ALRI. One of them reported an age-adjusted 
association and provided data for two years separately (Moyes et al., 2013). The overall 
meta-estimate of odds ratio was 3.74 (95% CI 2.47-5.66) for these three studies. Two of 
them (Madhi et al., 2006, Madhi et al., 2000) were considered to be of “low quality”. Thus 
no meta-estimate was available after these two “low-quality” studies were excluded (no 
meta-estimates results shown in Table 13).  
Malnutrition  
Only three studies were included. Two community-based studies from Kenya (Okiro et al., 
2008) and South Africa (Zar, unpublished) reported non-significant associations between 
malnutrition (weight for age ≤2 standard deviations) and RSV associated ALRI using 
univariable analysis (1.28 (95% CI 0.75-2.21) and 1 (95% CI 0.4-2.9)). Another hospital-
based study (Paynter et al., 2014) from the Philippines reported a significant association 
between measures less than or equal to median growth (weight for age) and hospitalised 
RSV associated ALRI using multivariable analysis (1.34 (95% CI 1.02-1.76)). This 
definition is substantially different from what was used in the previous two studies (weight 
for age ≤2 standard deviations), thus meta-analysis could not be done (no meta-estimates 
results shown in Table 13).  
Altitude  
Only one hospital-based study (Choudhuri et al., 2006), from Colorado, reported a 
significant association between high altitude and hospitalised RSV associated ALRI using 
multivariable analysis, stratified by age and control group (no meta-estimates results shown). 
The odds ratio of RSV associated hospitalised ALRI among infants at high altitude (>2500 
m) compared to moderate altitude (1500-2500 m) was 1.30 while it was 1.22 when compared 
to low altitude (<1500 m). Also, the odds ratio among children aged 1-4 years old in high 
altitude was 1.80 when compared to moderate altitude and 1.62 when compared to low 




Previous respiratory illness 
One hospital-based study (Rossi et al., 2007) from Italy reported a significant association 
between no previous RSV infections and hospitalised RSV associated ALRI using 
univariable analysis (1.85 (95% CI 1.02-3.36)). Another community-based study from South 
Africa (Zar, unpublished) reported a significant association between previous history of 
ALRI and RSV associated ALRI using univariable analysis (3.9 (95% CI 1.2-12.5)). These 
two studies reported completely different results, although one referred to previous RSV 
infection and another one to previous ALRI infection (aetiology not specified). No further 
details were provided from both studies. They were based on hospital and community 
settings respectively, which might have influenced the result in some unknown way. More 
investigation about the role of this risk factor was required (no meta-estimates results shown 
in Table 13).   
Lack of plumbed water (available within the household) 
Two hospital-based studies (Bruden et al., 2015, Hennessy et al., 2008) from Alaska reported 
significant associations between lack of plumbed water or low proportion in-home water 
service (<80%) and hospitalised RSV associated ALRI (1.45 (95% CI 1.19-1.78) and 2.81 
(95% CI 2.42-3.26)) respectively. However, both studies were considered to be of “low-
quality”. Another study from Gambia (Weber et al., 1999) reported “tap in compound” 
compared to other water sources and the adjusted OR was 1.75 (95% CI 0.85-3.60). This 
number was converted to be comparable (0.57 (95% CI (0.28-1.18)) to those two studies 




Table 14: Meta-estimate of odds ratio for risk factors including data from all studies 
(irrespective of quality scores) 
Risk factor* 





No. of studies 
Meta-estimate OR 
(95% CI) 
HIV 2 - 3 3.74 (2.47-5.66) 
No breastfeeding 1 - 3 2.24 (1.56-3.20) 
Crowding (>7 
persons in household) 
1 - 3 1.94 (1.29-2.93) 
Low parental 
education 
4 1.23 (0.73-2.09) 7 1.77 (0.91-3.46) 
Siblings 6 1.53 (1.20-1.95) 12 1.62 (1.34-1.95) 
Daycare centre 
attendance 
2 - 3 1.61 (0.98-2.64) 
History of atopy 1 - 5 1.47 (1.16-1.87) 
Prematurity 
(gestational age <37 
weeks) 
2 - 9 1.47 (0.98-2.21) 
Lack of plumbed 
water 
2 - 3 1.46 (0.76-2.79) 
Multiple births 1 - 3 1.41 (0.98-2.03) 
Low birth weight 2 - 6 1.37 (0.85-2.21) 
Maternal smoking 4 1.34 (1.26-1.42) 7 1.36 (1.24-1.50) 
Passive smoking 4 1.40 (0.65-3.00) 9 1.23 (0.95-1.60) 
Being male 6 1.32 (1.24-1.40) 13 1.21 (1.12-1.32) 
Indoor air pollution 4 0.69 (0.35-1.37) 6 0.86 (0.57-1.31) 
*Only listing risk factors where meta-estimate is available, and the list of risk factors is 
ordered based on meta-estimate of studies using multivariable and univariable analysis from 





Table 15: Comparison of meta-estimates after excluding or including “low quality” 
studies (with quality score ≤6.25) 
Risk factor* 
Final estimate 






No. of studies 
Meta-estimate OR 
(95% CI) 
HIV 1 - 3 3.74 (2.47-5.66) 
No breastfeeding 3 2.24 (1.56-3.20) 3 2.24 (1.56-3.20) 
Crowding (>7 
persons in household) 
3 1.94 (1.29-2.93) 3 1.94 (1.29-2.93) 
Low parental 
education 
6 1.40 (0.94-2.08) 7 1.77 (0.91-3.46) 
Siblings 11 1.60 (1.32-1.95) 12 1.62 (1.34-1.95) 
Daycare centre 
attendance 
3 1.61 (0.98-2.64) 3 1.61 (0.98-2.64) 
History of atopy 5 1.47 (1.16-1.87) 5 1.47 (1.16-1.87) 
Prematurity 
(gestational age <37 
weeks) 
7 1.96 (1.44-2.67) 9 1.47 (0.98-2.21) 
Lack of plumbed 
water 
1 - 3 1.46 (0.76-2.79) 
Multiple births 2 - 3 1.41 (0.98-2.03) 
Low birth weight 5 1.91 (1.45-2.53) 6 1.37 (0.85-2.21) 
Maternal smoking 7 1.36 (1.24-1.50) 7 1.36 (1.24-1.50) 
Passive smoking 8 1.29 (0.96-1.73) 9 1.23 (0.95-1.60) 
Being male 12 1.23 (1.13-1.33) 13 1.21 (1.12-1.32) 
Indoor air pollution 5 0.81 (0.42-1.57) 6 0.86 (0.57-1.31) 
*Only listing risk factors where meta-estimate is available, and the list of risk factors is 





Table 16: Meta-estimate of odds ratio for risk factors in developing and industrialised 
regions (irrespective of quality scores) 
Risk factor 





No. of studies 
Meta-estimate OR 
(95% CI) 
HIV 3 3.74 (2.47-5.66) 0 - 
No breastfeeding 3 2.24 (1.56-3.20) 0 - 
Crowding (>7 
persons in household) 
3 1.94 (1.29-2.93) 0 - 
Low parental 
education 
5 2.49 (1.12-5.54) 2 - 
Siblings 6 1.65 (1.37-1.98) 6 1.56 (1.20-2.01) 
Daycare centre 
attendance 
1 - 2 - 
History of atopy 2 - 3 1.42 (1.12-1.80) 
Prematurity 
(gestational age <37 
weeks) 
2 - 7 1.60 (1.04-2.44) 
Lack of plumbed 
water 
3 1.46 (0.76-2.79) 0 - 
Multiple births 1 - 2 - 
Low birth weight 1 - 5 1.52 (0.93-2.49) 
Maternal smoking 1 - 6 1.37 (1.24-1.52) 
Passive smoking 6 1.16 (0.91-1.46) 3 1.46 (0.74-2.86) 
Being male 4 1.20 (0.93-1.55) 9 1.21 (1.11-1.33) 





 Discussion  
This study presents the most up-to-date and comprehensive report of the strength of 
association between various socio-demographic risk factors and RSV associated ALRI in 
children younger than five years old. After excluding “low-quality” studies, the final results 
for a total of 18 putative risk factors were described and the meta-estimates were presented if 
possible. Among them, eight risk factors (prematurity, low birth weight, being male, siblings, 
maternal smoking, history of atopy, no breastfeeding and crowding - >7 persons in 
household) were observed to be significantly associated with RSV associated ALRI. 
Children born with prematurity of gestational age <37 weeks were estimated to have higher 
odds (1.96 (1.44-2.67)) of RSV associated ALRI than children born without prematurity. 
Children with low birth weight (<2.5 kg) were at an increased risk (1.91 (1.45-2.53)). Gender 
(being males) also played as a risk factor for RSV associated ALRI (1.23 (1.13-1.33)). 
Having siblings represented an increased risk of outcome (1.60 (1.32-1.95)). Maternal 
smoking during pregnancy also was observed to have a positive OR with RSV associated 
ALRI (1.36 (1.24-1.50)). Positive family history of asthma or atopy similarly had significant 
association with outcome of interest (1.47 (1.16-1.87)). No breastfeeding tended to increase 
the risk by 1.24 (2.24 (1.56-3.20)). Living in a household with more than 7 persons also 
increased the association (1.94 (1.29-2.93)). Other risk factors (low parental education, 
passive smoking, daycare centre attendance, indoor air pollution, HIV, multiple births, 
malnutrition, higher altitude, previous illness and lack of plumbed water in the household) 
were also observed to have an association with RSV associated ALRI. Six out of eighteen 
risk factors did not have meta-estimates available due to insufficient data points (e.g. HIV, 
multiple births). Moreover, for some of these risk factors, which had several different 
definitions (e.g. lack of breastfeeding, crowding), meta-analysis could not be performed to 
generate a separate odds ratio meta-estimate as the case definitions were substantially 
different and there were no sufficient studies available for this specific different definition. 
Therefore, the associations between these risk factors (and certain definitions of some risk 
factors) and RSV associated ALRI require further study.   
There was considerable variation regarding to study design among the 27 included studies 
(including “low-quality” studies). Nine (Boyce et al., 2000, Gouyon et al., 2013, Houben et 
al., 2011, Madhi et al., 2006, Okiro et al., 2008, Paynter et al., 2014, Rietveld et al., 2006, 
Von Linstow et al., 2008) (Rath, unpublished) were cohort studies; eleven (Bulkow et al., 
2002, Cilla et al., 2006, Grimwood et al., 2008, Nielsen et al., 2003, Reeve et al., 2006, Rossi 
et al., 2007, Stensballe et al., 2006, Weber et al., 1999) (Rasmussen, unpublished; Singleton, 
unpublished; Zar, unpublished) were case control studies; six (Choudhuri et al., 2006, Weigl 
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et al., 2001, Madhi et al., 2000, Moyes et al., 2013, Bruden et al., 2015, Hennessy et al., 
2008) were cross sectional studies; and one (Smith et al., 2011) was a randomised controlled 
trial with placebo arm only. Most studies used questionnaires or interviews (of caretakers or 
parents) to gather information on various risk factors, which could be a source of several 
biases, such as response bias (a proportion of participants failed to provide needed 
information and thus excluded in further analysis), recall bias (participants from both groups 
might provide information of the past in a non-comparable manner), interviewer bias 
(investigators might elicit or interpret the information differentially) and misclassification 
bias (misclassification of cases or controls). Other potential biases also existed. For example, 
there could be follow-up bias in cohort studies. Among eleven case control studies, only 
seven (Bulkow et al., 2002, Nielsen et al., 2003, Reeve et al., 2006, Stensballe et al., 2006, 
Weber et al., 1999) (Rasmussen, unpublished; Zar, unpublished) selected a control group 
matched by date of birth and/or sex and/or location of residence. For the remaining four 
studies, which did not use matched control groups, substantial bias in the selection of 
controls might exist.   
Among these 27 studies, 14 were based on settings considered as industrialised regions while 
the rest 13 were based on developing settings. Meta-estimates for each risk factor by regions 
were presented in Table 16. For most risk factors, the result was absent for at least one 
region due to insufficient data points (one or two studies only) or no studies providing 
relevant data, which remained the comparison of strength of associations between risk 
factors and RSV associated ALRI in different regions unavailable. Whether the magnitude of 
reported association varies across regions remains unknown.  
Considering the limited data points from multivariable analysis contributed to estimates, 
estimates from studies using univariable analysis were also considered to produce the final 
estimate. However, there were substantial differences with regards to the number of 
confounders adjusted in each study. Seven studies (Grimwood et al., 2008, Paynter et al., 
2014, Choudhuri et al., 2006, Rietveld et al., 2006, Smith et al., 2011, Stensballe et al., 2006) 
(Singleton, unpublished) used multivariable analysis to adjust for all other risk factors 
investigated in the same study. Some also adjusted for age at third dose of pneumococcal 
conjugate vaccine, age at risk and weight for age z-score at first vaccination (Paynter et al., 
2014), or population distribution of education level, households that were living below 
poverty level and race (Choudhuri et al., 2006). One study reported age adjusted relative risk 
(Moyes et al., 2013). Four studies (Madhi et al., 2006, Madhi et al., 2000, Moyes et al., 2013, 
Von Linstow et al., 2008) also reported concurrent bacteraemia or coinfection with other 
viruses. Another seven studies used univariable analysis, and twelve studies reported the 
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results for some risk factors by using multivariable analysis while other studies only used 
univariable analysis. For those risk factors where meta-estimate was based on univariable 
analysis, nothing was done to account for potential confounding factors (including those 
investigated in the same study), which might hide the real association between the risk 
factors and RSV associated ALRI. Moreover, the exposure of a few risk factors is related to 
one another (e.g. prematurity and low birth weight, crowding and having sibling in the 
household). Analysing data only focusing on one single risk factor without taking into 
consideration other confounders or other related aspects might produce misleading estimate. 
Inclusion of the results from univariable analysis to those based on multivariable analysis 
might not be ideal, which requires further investigation. 
The quality score of each study obtained from modified GRADE scoring system varied from 
2.5 to 11 with a mean of 7.6. There were seven studies with “low quality” (quality score 
≤6.25). Most of the studies were not designed as case-control studies, did not avoid/consider 
biases within the research, did not take into account of potential confounders or reported 
estimates using univariable analysis. A sensitivity analysis was carried out to include these 
“low-quality” studies for each risk factor. The meta-estimate OR from sensitivity analysis 
did not differ substantially from the analysis where only studies with quality scores >6.25 
were included (Table 15). Besides, this quality assessment tool did not address all aspects 
related to quality of study since only seven of them were looked into: study design, quality of 
control group, sample size, analysis method, bias, confounding factors and geographical 
spread of studies. More detailed and appropriate quality assessment tools should be applied 
to evaluate the quality of included studies and studies with higher quality would be needed to 
generate more reliable results. In this review, selection criteria were not based on the quality 
of studies, which means, all studies irrelevant of quality scores were included in the analysis 
and were discussed, but only studies with “good quality” were included to generate the final 
estimate for each risk factor. 
It is noteworthy that there was substantial heterogeneity in the definitions for a specific risk 
factor across the included studies, which limited the analysis. For example, six studies used a 
definition of birthweight <2.5 kg to define low birth weight, while one study (Nielsen et al., 
2003) used a higher threshold - birthweight <3.0 kg, and was therefore excluded from the 
meta-analysis. Nine studies defined prematurity as gestational age <37 weeks, while three 
studies (Boyce et al., 2000, Rossi et al., 2007, Madhi et al., 2006) used gestational age <36 
weeks and another one (Von Linstow et al., 2008) used <38 weeks. After excluding “low-
quality” studies and these four studies using different definitions of prematurity, the meta-
estimate of the association between prematurity (gestational age <37 weeks) and RSV 
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associated ALRI was 1.96 (95% CI 1.44-2.67), which was slightly higher than the alternative 
estimate 1.47 (95% CI 0.98-2.21) when all studies irrespective of quality scores were 
included. Only one study (Zar, unpublished) reported that prematurity was determined using 
ultrasonography. Seven studies defined low parental education using five different 
definitions - no parent having bachelor’s degree (Houben et al., 2011), 1-7 years of education 
or no schooling for primary caretaker (Okiro et al., 2008) (Zar, unpublished), 1-5 years of 
education or no schooling for parents (Rasmussen, unpublished), <12 years maternal 
education (Boyce et al., 2000, Bulkow et al., 2002) and <10 years maternal education 
(Paynter et al., 2014). Since there were insufficient studies in each category, a subgroup 
meta-analysis was not conducted. Similarly crowding was defined using substantially 
different definitions in the included studies: >7 persons living in household (Bulkow et al., 
2002) (Singleton, unpublished; Zar, unpublished), ≥10 persons in household (Weber et al., 
1999), ≥2 persons per room (Bulkow et al., 2002) (Zar, unpublished), ≥3 siblings less than 6 
years old sleeping in the same room (Okiro et al., 2008), >7 persons sleeping per room 
(Rasmussen, unpublished), an increase of 20% in number of households >1.5 persons/room 
(Bruden et al., 2015). Therefore, once again, a subgroup meta-analysis was not carried out in 
this instance except for the definition of >7 persons living in household (3 studies reported 
this). The substantial variability in definitions used for the same risk factor require that 
standardised definitions should be proposed for future studies, which will improve the 
comparability of these studies. Alternatively, if those standardised definitions are not 
compatible for different study setting/regions, more studies referring to a specific definition 
of a risk factor should be carried out and a separate meta-analysis should be conducted.  
Moreover, participants with various age groups were included in each study. Only six studies 
included children younger than five years old (Madhi et al., 2006, Paynter et al., 2014, 
Weber et al., 1999, Moyes et al., 2013) (Rath, unpublished), and 21 studies included children 
in younger age bands (eg, 0-11months, 0-18 months, 0-23 months). Fourteen studies focused 
on children younger than two years old, and among them, six studies included only infants 
(children aged 0-11 months) (Boyce et al., 2000, Gouyon et al., 2013, Houben et al., 2011, 
Von Linstow et al., 2008, Bruden et al., 2015, Hennessy et al., 2008). Since data from 
different age groups were pooled together into one analysis, and RSV is predominantly an 
infection in children younger than 2 years (Nair et al., 2010), the association between these 
risk factors and RSV associated ALRI in children aged 0-59 months may have been 
overestimated, where actually children with a younger age group were (partially) involved.  
Another limitation is that we did not have access to individual patient data on risk factors for 
RSV associated ALRI. Further research should focus on obtaining individual patient data 
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from previous studies or ongoing studies, such as multi-centre Pneumonia Etiology Research 
for Child Health (PERCH) project. With these patient level data, we could have a better 
understanding about the role of each risk factor in RSV associated ALRI (particularly with 
regard to the lack of independence of prematurity and low birth weight as well as crowding 
and presence of siblings) and adjust for possible confounders (investigated in the same study) 
in a pooled analysis.  
Table 17 displays results after studies conducted among children younger than two years old 
(14 studies) were focused on. Meta-estimate results were missing for most risk factors due to 
insufficient data points available. The magnitude of association between prematurity 
(gestational age <37 weeks) and RSV associated ALRI was slightly higher in children under 
two years compared to the association in children under five years (also for being male), 
while for the rest risk factors the associations were pretty similar.  
Furthermore, the sample size of each study varied considerably. Only studies with a sample 
size greater than 50 were included, as specified in the eligibility criteria. However, among 
the 27 included studies, the sample size varied from 68 (Singleton, unpublished) to 835060 
(Moyes et al., 2013). This is reflected in the wide confidence intervals of the ORs for some 
studies with small sample size, indicating less precise estimates. Studies with larger sample 
sizes with more statistical powerful results were required.  
Another limitation is that we did not have access to individual patient data on risk factors for 
RSV associated ALRI. Further research should focus on obtaining individual patient data 
from previous studies or ongoing studies, such as multi-centre Pneumonia Etiology Research 
for Child Health (PERCH) project. With these patient level data, we could have a better 
understanding about the role of each risk factor in RSV associated ALRI (particularly with 
regard to the lack of independence of prematurity and low birth weight as well as crowding 
and presence of siblings) and adjust for possible confounders (investigated in the same study) 
in a pooled analysis.  
Table 17: Comparison of associations with risk factors in children younger than five 
years and children younger than two years respectively (after excluding “low quality” 
studies) 
Risk factor* 









No breastfeeding 3 2.24 (1.56-3.20) 0 - 
Prematurity 
(gestational age <37 
weeks) 




persons in household) 
3 1.94 (1.29-2.93) 0 - 
Low birth weight 5 1.91 (1.45-2.53) 2 - 
Daycare centre 
attendance 
3 1.61 (0.98-2.64) 2 - 
Siblings 11 1.60 (1.32-1.95) 4 1.51 (1.09-2.08) 
History of atopy 5 1.47 (1.16-1.87) 2 - 
Low parental 
education 
6 1.40 (0.94-2.08) 2 - 
Maternal smoking 7 1.36 (1.24-1.50) 6 1.37 (1.24-1.52) 
Passive smoking 8 1.29 (0.96-1.73) 1 - 
Being male 12 1.23 (1.13-1.33) 6 1.28 (1.19-1.38) 
Indoor air pollution 5 0.81 (0.42-1.57) 1 - 
*the list of risk factors is ordered based on meta-estimate of studies in children under five 
years old from high to low. 
 
Compared to the previous review (Simoes, 2003) conducted over one decade ago, this 
review presented an overview of a larger number and more recent studies investigating more 
risk factors associated with RSV and summarised the findings using meta-analysis (rather 
than descriptive methods). Both reviews shared similar results for some risk factors, such as 
being male, crowding/siblings and day care attendance. Also, more evidence for some risk 
factors which had an unclear role with regard to RSV in previous review were provided 
(passive smoking, low parental education). In addition, more risk factors associated with 
RSV which were not available in previous review due to insufficient evidence were 
identified (prematurity, low birth weight, maternal smoking, history of atopy, indoor air 
pollution, no breastfeeding). However, age of acquisition of RSV as well as birth during the 
first half of RSV season, race/ethnicity, which were investigated in previous review, were 
not evaluated in this review because no recent relevant studies were found or they didn’t 
meet the selection criteria (such as, studies were done in children with prematurity). In 
previous review, the majority of RSV hospitalisation cases occurred within first year of life. 
This review didn’t specifically look into age of acquisition of RSV as a risk factor, however, 
the following Chapter 5 of disease burden of RSV showed that incidence rate of RSV 
associated ALRI is high in infants. Birth during the first half of RSV season was also 
assumed to be a risk factor for RSV associated ALRI (development and hospitalisation) 
probably due to low maternal antibody level (not exposed to RSV yet). Hospitalisation rate 
due to RSV was observed higher in Hispanic infants, American Indian/Alaskan Native and 
Inuit infants, and Japanese infants without further details/explanation. More studies are 
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needed to update/verify the roles of these risk factors. Moreover, several risk factors which 
were mentioned in some studies were not included in the search strategy (then in the 
analysis), such as, sibling’s death, parent’s nationality, parent’s occupation, their roles also 
remained unknown (Weber et al., 1999). A more comprehensive research of all possible risk 
factors on RSV associated ALRI should be carried out.  
In this systematic review, asymptomatic children (children without respiratory symptoms) or 
healthy children (children do not have respiratory symptoms or any other symptoms) were 
chosen as the control group. This is clearly stated in the selection criteria. RSV negative 
ALRI cases, which means that ALRI cases were positive for other pathogens, were not used 
as a control group. This is because ALRI cases (RSV negative) might share similar socio-
demographic risk factors with RSV associated ALRI cases, which would conceal the real 
roles of RSV. This is explained in details in the next paragraph.  
The definitions of some risk factors were similar or the same as those reported in a review 
(Jackson et al., 2013) investigating risk factors for severe ALRI (for which aetiology was not 
further specified), which indicates that pneumonia and RSV associated ALRI do share a few 
socio-demographic risk factors which are amenable to public health interventions, such as 
maternal smoking, passive smoking and no breastfeeding. This supported the selection 
criteria – only children without any respiratory symptoms or healthy children should be 
included in control group and children with ALRI (RSV negative) should not be used as a 
control. Table 18 compares the strength of association of risk factors discussed in both 
reviews. The strength of association between risk factors and severe ALRI was generally 
slightly stronger than the corresponding ones in RSV associated ALRI. Several risk factors 
were only investigated for severe ALRI, such as incomplete immunization, vitamin D 
deficiency, anaemia, zinc deficiency, birth interval, birth order, and vitamin A deficiency 
(one study), while some risk factors were only explored for RSV associated ALRI (siblings, 
history of atopy, multiple births, high altitude (one study), and lack of plumbed water in the 
household (one study)). On the other hand, since pneumonia and RSV associated ALRI share 
some risk factors and this review is investigating the roles of risk factors in ALRI cases 
which are positive for RSV, whether the (significant) associations between risk factors and 
outcome of interest were partially due to ALRI and to what extent remains unknown. 
Therefore, when interpreting the results, we should state it clearly that the results reflect the 
association between risk factors and RSV associated ALRI.  
The Integrated Global Action Plan for the Prevention and Control of Pneumonia and 
Diarrhoea (GAPPD) highlighted several proven effective interventions in order to achieve 
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maximum benefit of coordinated management of both major preventable causes of child 
death (UNICEF and Organization, 2013). Some of them were covered by this review: 
exclusive breastfeeding for 6 months, safe drinking-water and sanitation, reduce household 
air pollution, HIV prevention. Also several other interventions were proposed: adequate 
complementary feeding, vitamin A supplementation, handwashing with soap, vaccination etc. 
Since RSV associated ALRI shared common risk factors with pneumonia. Interventions 
which are aimed to decrease pneumonia occurrence might also contribute to a reduction of 
RSV associated ALRI. Moreover, there were several risk factors associated with both RSV 
associated ALRI and pneumonia which were not covered by GAPPD: maternal smoking 
during pregnancy, passive smoking, low parental education etc. Their roles should be 
evaluated with more substantial studies and if verified, should be incorporated into this 
integrated key intervention framework. This integrated approach should be implemented 
effectively with priority and slight adjustment in national level (and community level) 
depending on the circumstances of this area. All sectors including governments, health 
workers, education professionals, NGOs, financial sponsors should be engaged in this 
process to maximise the benefit from this strategy.  
Table 18: Summary of risk factors for RSV associated ALRI and severe ALRI 
Risk factor* 
RSV associated ALRI 










Vitamin D deficiency 0 - 3 7.3 (2.5-21.5) 
HIV 1 - 2 4.6 (2.2-9.7) 
Anaemia 0 - 5 3.9 (2.4-6.3) 
Daycare centre attendance 3 1.61 (0.98-2.64) 3 3.7 (0.7-20.2) 
Malnutrition (weight for 
age ≤2 standard 
deviations) 
2 - 10 3.2 (1.6-6.4) 
Low birth weight 5 1.91 (1.45-2.53) 4 3.2 (1.0-9.9) 
Maternal smoking 7 1.36 (1.24-1.50) 3 2.7 (1.0-7.8) 
Passive smoking 8 1.29 (0.96-1.73) 4 2.4 (1.0-5.8) 
No breastfeeding 3 2.24 (1.56-3.20) 6 2.3 (1.4-3.9) 
Lack of exclusive 
breastfeeding 
2 - 10 2.3 (1.4-3.9) 
Crowding (≥2 persons/room 
in household) 
2 - 4 2.2 (1.8-2.7) 
Birth order 0 - 3 2.1 (1.2-4.4) 
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Crowding (>7 persons in 
household) 
3 1.94 (1.29-2.93) 3 1.9 (1.5-2.5) 
Prematurity (gestational 
age <37 weeks) 
7 1.96 (1.44-2.67) 5 1.9 (1.3-2.8) 
Incomplete immunization 0 - 5 1.8 (1.3-2.5) 
Previous respiratory illness 2 - 5 1.7 (0.8-3.4) 
Low parental education 6 1.40 (0.94-2.08) 6 1.6 (1.0-2.6) 
Indoor air pollution 5 0.81 (0.42-1.57) 5 1.6 (1.1-2.3) 
Being male 12 1.23 (1.13-1.33) 6 1.5 (1.0-2.3) 
Birth interval 0 - 2 1.4 (0.9-2.2) 
Zinc deficiency 0 - 2 0.5 (0.3-0.9) 
Multiple births 2 - 0 - 
Siblings 11 1.60 (1.32-1.95) 0 - 
History of atopy 5 1.47 (1.16-1.87) 0 - 
*Only listing risk factors where meta-estimate is available. The list of risk factors is ordered 
based on meta-estimate of severe ALRI from high to low. 
Together with estimates for the prevalence of these risk factors across countries, evidence 
generated from this study examining the strength of association between risk factors and 
RSV associated ALRI as well as the incidence rate of RSV associated ALRI globally and 
regionally (from Chapter 5), the national incidence estimates of RSV associated ALRI could 
be modelled.  
Further research on this topic should identify, seek access to, and analyse additional 
unpublished RSV datasets to further improve the precision of these estimates. Individual 
patient data should be obtained to explore the role of each risk factor with consideration of 
potential confounders. Such analysis should include, where possible, investigation of 
possible association with risk factors which have been reported to show association with (all 
cause) ALRI: incomplete immunization, vitamin D deficiency, anaemia, zinc deficiency, 
birth interval, birth order, and vitamin A deficiency. Also, this should involve those risk 
factors with unclear associations due to limited data available so far. Risk factors with 
various definitions should also be investigated: either a standard definition should be 
proposed and used consistently or more studies of each category of the definitions would be 




 Global burden of RSV associated 
ALRI in children younger than five years old 
 Methods  
5.1.1 Literature search 
5.1.1.1 Search strategy and selection criteria 
A systematic review was conducted across the following 9 electronic databases: Medline 
(Ovid), Embase, Global Health, CINAHL, Web of Science, WHOLIS, LILACS, IndMed and 
grey literature (SIGLE). In order to follow the guidelines from PRISMA for systematic 
review and meta-analysis, the literature search was also carried out independently by another 
researcher (Evelyn Balsells, MPH) and data were extracted. Three Chinese databases: China 
National Knowledge Infrastructure (CNKI), Wanfang data and Chongqing VIP were also 
searched to identify studies published in Chinese language (Mandarin) because most of them 
were not searchable in PubMed. This is feasible because the author’s first language is 
Chinese (Mandarin).  
The reference lists of identified records were further hand searched for more eligible articles. 
No publication status or language restrictions were applied. Search strategies including 
search terms for each database were displayed in Appendices - A9. Table 19 shows selection 
criteria in detail. Any discordance or uncertainties regarding relevance or inclusion were 
arbitrated by my supervisors for this thesis (Prof. Harry Campbell and Dr Harish Nair). Data 
were extracted using a standardised data extraction template designed on Microsoft Excel 
(Microsoft Office 2007). 
5.1.2 Unpublished data collection  
As introduced in the Chapter 2 - Methods, RSV GEN research group consists of leading 
researchers in paediatric pneumonia from all over the world, mainly in developing countries. 
This network has provided substantial unpublished data contributing to the estimate of global 
burden of RSV associated ALRI. Overall, 76 unpublished studies were collected and were 
combined with qualified published papers identified through literature search. All 
unpublished data were cross-checked with local researchers if there were any inconsistencies 




Table 19: Selection criteria applied in the systematic review of global burden estimate 
Inclusion criteria: 
 Studies published from Jan 1995 to Aug 2015 
 Report data for children younger than 5 years 
 Use case definition of ALRI (e.g. pneumonia, bronchiolitis) or ARI/ALRI involving 
hospitalisation with evidence of RSV infection 
 At least 12 consecutive months of study period (except for CFR studies) 
 Report data for at least the first year of life 
 Provide clear and well-defined catchment denominators or estimates of the population at risk 
(for studies reporting incidence or hospitalisation rate) 
Exclusion criteria: 
 Investigate RSV as a co-infection rather than primary outcome 
 Case definition not clearly defined or not consistently applied 
 Studies using serology as the only diagnosis test 
 Number of hospitalised ALRI cases which were tested was less than 50 (for proportion 
studies) 
 Studies providing duplicate data as in unpublished studies  
 
5.1.3 Definitions 
5.1.3.1 Definition of ALRI 
As described in the Chapter 2 - Methods, ALRI, which includes clinical pneumonia and 
bronchiolitis, was used as the case definition to recognise the fact that they are common in 
children with viral ALRI and WHO definitions of cases could not distinguish bronchiolitis 
from pneumonia reliably. ALRI cases include all severe ALRI cases, which in turn include 
all very severe ALRI cases. In community-based settings, cases were identified by active 
ascertainment (health workers visiting house-to-house to diagnose cases). ALRI was defined 
as cough or difficulty in breathing and fast breathing with age (IMCI cut-offs: respiratory 
rate >60 breaths per min in children aged <2 months, >50 breaths per min in children aged 2-
11 months, >40 breaths per min in children aged 12-59 months), while severe ALRI cases 
was defined as cough or difficulty in breathing with lower chest wall indrawing for children 
aged 2-59 months; an increased respiratory rate (>60 breaths/min) or chest wall indrawing 
for children aged <2 months. Severe ALRI with at least one WHO IMCI danger sign (World 
Health Organization, 2005) (cyanosis, difficulty in breastfeeding or drinking, vomiting 
everything, convulsions, lethargy, unconsciousness or head nodding) was defined as very 
severe ALRI. In hospital-based settings, cases were identified by passive ascertainment 
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(carers seek help in hospitals), only children hospitalised with ALRI or ARI were included 
(physician confirmed diagnosis). Among them, there were severe cases, which included 
hospitalised ALRI cases with chest wall indrawing and very severe hospitalised ALRI cases, 
which normally had hypoxemia or at least one WHO IMCI danger sign, required mechanical 
ventilation or ICU admission. The definitions were classified into three categories: WHO 
definition applied by a health worker (coded as I), physician’s assessment (coded as II), 
severe acute respiratory illness (SARI) definition (coded as III), with or without other 
features contributing to case definition, such as wheeze (coded as W+/-), crepitation (coded 
as C+/-), fever (coded as F+/-), tachypnea (coded as T+/-), X-ray confirmation (coded as 
XR), chest wall indrawing (coded as CWI+/-), hypoxemia (coded as O2+/-), danger signs 
(coded as DS+/-), mechanical ventilation (coded as MV+/-), intensive care unit (ICU) 
admission (coded as ICU+/-).  
5.1.3.2 Definition of hypoxemia  
Hypoxemia was defined by altitude and age group. For areas at altitude ≤2500m, oxygen 
saturation (at sea level in room air) lower than 90% (measured by pulse oximetry) in children 
aged 1-59 months and lower than 88% in neonates was regarded as hypoxemic. For areas 
with altitude above 2500m, if oxygen saturation was lower than 87% in children aged 1-59 
months and lower than 85% for neonates, they would be classified as having hypoxemia.  
5.1.3.3 Definition of RSV season 
A modification of the definition for RSV season was used – at least 10 specimens were 
analysed and any month of a year with RSV detected in more than 5% of the submitted 
respiratory specimens were deemed to be within the RSV season.  
5.1.3.4 Definition of region category  
Countries were separated into 6 WHO regions or 4 regions according to World Bank income 
levels (World Health Organization, 2016c, World Bank, 2016). Countries were categorised 
as developing or industrialised region according to the “Levels & trends in child mortality - 
report 2014” by UNICEF (United Nations Children's Fund, 2014). The child population 
number in 2015 by region and by age group (0-11m and 0-59m) were provided by UNICEF 
report (personal communication). Child population in narrower age bands within infants (0-
5m and 6-11m) were obtained by dividing the population in infants evenly.  
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5.1.4 Statistical analysis 
5.1.4.1 Data scale-up to estimate number of cases 
In studies reporting number of RSV associated ALRI cases (both in community and in 
hospital) where only a proportion of eligible ALRI cases were tested for pathogen, the 
number of cases was scaled up according to the proportion of ALRI cases which were tested 
for RSV, on assumption that among the untested ALRI cases, the proportion of RSV 
detection would be the same as in those tested ALRI cases: overall RSV cases = reported 
RSV cases/proportion of ALRI cases tested for virus. This is an exception in very severe 
cases (in community or in hospital settings). 
5.1.4.2 Data imputation across age groups 
Few studies reported RSV data for the full age range (0-59 months). Data imputation was 
used on the basis of the approach adopted by Nair where necessary (Nair et al., 2010). For 
community-based studies reporting incidence rate, relative to an incidence of 1.0 for RSV 
associated ALRI in the 0-11 months age group, an incidence rate ratio of 1.01 was calculated 
for children aged 0-5 months (based on 9 studies), 0.90 for children aged 0-23 months (8 
studies), 0.84 for children aged 0-35m (6 studies) and 0.57 for those younger than 5 years (6 
studies), by taking the median of the incidence rate ratios of studies reporting incidence for 
these age ranges; for severe RSV associated ALRI, an incidence rate ratio of 1.26 was 
calculated for children aged 0-5 months (based on 7 studies), whereas for those younger than 
2 years, 3 years and 5 years, the ratios were 0.64 (7 studies), 0.56 (4 studies)  and 0.34 (4 
studies). For hospital-based studies reporting hospitalisation rate, relative to children 
younger than 1 year, the median hospitalisation rate ratio for children aged 0-5 months was 
1.32 (based on 27 studies), for those younger than 2 years, 3 years and 5 years, the median 
rate ratios were estimated as 0.63 (38 studies), 0.44 (23 studies) and 0.27 (34 studies); for 
studies reporting hospitalisation rate in cases with chest wall indrawing, the median rate ratio 
was 1.33 (6 studies) and 0.27 (6 studies) for children aged 0-5 months and 0-59 months, 
compared to infants. Figure 10, Figure 11 and Figure 12 summarise the overall approach and 
the associated rationale for the decisions adopted.  
5.1.4.3 Deal with zero data 
Whenever there are no hospital deaths, combining such data to meta-analysis of in-hospital 
CFR can be problematic, so continuity correction of a constant of 0.00005 was used. This 
allowed calculation of CFR for these instances, and enabled inclusion of these studies within 




Using STATA (version 11.2) (StataCorp, 2009), meta-analyses of incidence rate 
(community-based studies), hospitalisation rate, in-hospital CFR, and proportion data 
(hospital-based studies) were conducted separately based on random effects model 
(DerSimonian-Laird method) since significant heterogeneity was assumed among included 
studies (Dersimonian and Laird, 1986, Borenstein et al., 2009). They differed in various 
aspects, such as geographical distribution, study setting, ascertainment method, clinical 
specimen and diagnosis test. The pooled estimates with corresponding 95% CIs were 
reported. Studies conducted in indigenous populations from industrialised countries 
(Australia and USA) were excluded in the final estimate because they reported substantially 
different data (higher) compared to other areas within these two industrialised countries and 
might not be representative. The studies comprised those in the aboriginal population in 
Townsville Australia, Alaska and Indian Native populations in America, and Navajo and 
White Mountain Apache populations in America. These studies were included in a later 
sensitivity analysis. Studies using criteria of fever, wheeze exclusion or SARI to define the 
cases were excluded in another sensitivity analysis. Subgroup meta-analysis was carried out 
in different regions (WHO region, region by World Bank income level or 
developing/industrialised region) and in different age groups (large age bands such as 0-11m, 
0-59m; narrower exclusive age bands such as 0-5m, 6-11m, 12-59m). 
5.1.4.5 Estimate of RSV associated ALRI cases  
For community-based or outpatient-based (industrialised countries only) studies reporting 
incidence rate where catchment was well defined and denominator population were available, 
the meta-estimate of incidence rate of RSV associated ALRI was reported by WHO regions, 
World Bank income regions as well as for industrialised and developing countries 
respectively. Age and region specific population number in 2015 was applied to the 
corresponding meta-estimate of incidence rate to produce the number of new cases of RSV 
associated ALRI in community. The approach was summarised in Figure 10.  
For hospital-based studies reporting hospitalisation rate where denominator population were 
provided, similarly, the data were analysed in different regions and in different age groups. 
Then the region and age specific population number in 2015 was applied to the 
corresponding meta-estimate of hospitalisation rate to generate the number of new episodes 
of RSV associated hospitalised ALRI in 2015. The global number of cases was summed 
from regional estimates and the number of cases for children aged 0-59m was summed from 
estimates in narrower exclusive age bands (0-5m, 6-11m and 12-59m). This represents the 
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first approach to estimate number of RSV associated ALRI cases admitted in hospitals. In a 
parallel second approach based on proportion data – the proportion of hospitalised ALRI 
cases which are RSV positive, extracted from hospital-based studies where population 
denominator was not available, the number of hospitalised ALRI cases in 2015 was 
combined with the respective meta-analysis result of proportion data to produce the number 
of new cases of RSV associated hospitalised ALRI. The number of hospitalised ALRI cases 
in 2015 was provided by my supervisor, Dr Harish Nair (personal communication), who 
developed the estimates for 2010, and whose team updated these estimates for 2015 after 
incorporating novel data. This represents the second approach to obtain the number of new 
cases of RSV associated ALRI which required hospital admission. These two approaches 
were summarised in Figure 11. They represent two independent approaches to estimate the 
same outcome of interest. They used completely different data from different studies as input 
data and were based on different assumptions. The final estimate was based on the approach 
which used studies reporting hospitalisation rate (the first approach) since these were 
population-based studies and were designed to estimate the burden of RSV associated ALRI 
in hospital settings with well-defined catchment area.  
5.1.4.6 Estimate of RSV associated ALRI mortality  
This process was shown in Figure 12 where the approach to generate RSV associated ALRI 
mortality in hospital and in community was summarised respectively. To estimate number of 
in-hospital deaths from RSV associated ALRI, the age and region specific meta-estimate of 
hospitalisation rate and meta-estimate of in-hospital case fatality ratio (CFR) with their 
confidence intervals were used.  
For each age-group and region, and summing across regions and age-groups, the number of 
in-hospital deaths was estimated as the product of the hospitalisation rate, population in 2015 
and the in-hospital CFR. Estimates of hospitalisation rates and in-hospital CFR were 
obtained from meta-analyses (random effects method in STATA) and population data from 
UNICEF. The CFR analysis was based on studies which reported data for all three exclusive 
age bands: 0-5m, 6-11m and 12-59m. Uncertainty intervals for the in-hospital deaths were 
obtained via Monte Carlo simulation. The estimates and standard errors for each meta-
estimate of hospitalisation rate and in-hospital CFR were used to define log-normal 
distributions. 10,000 independent samples were drawn from each of these log-normal 
distributions. In-hospital deaths (output variable) was calculated as: hospitalisation 
rate*population in 2015*in-hospital CFR for each of the 10,000 samples to obtain samples 
from the posterior distribution for this hospital deaths. This analysis was repeated for each 
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outcome. The median of this distribution was used to obtain the point estimate of in-hospital 
deaths and the 2.5th and 97.5th centiles were reported as the lower and upper confidence 
limits for the point estimate (95% uncertainty interval). The simulation process was carried 
out in R (version 3.0.2). The R codes used to generate these estimates by Monte Carlo 
simulation were shown in Appendices - A10. The global estimate of in-hospital mortality 
was generated from samples formulating regional estimates (developing countries and 
industrialised countries). For children aged 0-59m, the estimate was produced based on 
samples in narrower age bands: 0-5m, 6-11m and 12-59m.  
Access to health services is known to be limited in developing countries, thus RSV 
associated ALRI mortality in community was calculated for these countries. All excess 
mortality from ALRI in children younger than 5 years within the RSV season was assumed 
to be due to RSV and that non-RSV mortality was equal within and between RSV epidemic 
months. The duration of RSV season for each calendar year of study was defined by months 
(MonRSV). In each year, the overall number of verbal autopsy confirmed pneumonia deaths 
(TOTAL), and the mean number of pneumonia deaths that occurred during RSV season per 
month (AvgRSV) and outside RSV season per month (AvgOTHER) were calculated. The 
proportion of yearly deaths of pneumonia due to RSV for each year was then calculated as: 
[(AvgRSV – AvgOTHER) × MonRSV]/TOTAL 
Application of this proportion to the estimated under five child deaths attributable to 
pneumonia (Liu et al., 2014) in the same year would provide an estimate of child deaths due 
to RSV in that year. This approach required population-based data for RSV seasonality by 
month and number of monthly pneumonia deaths (verbal autopsy confirmed) for an at least 
3-year period. Then, an average number of RSV deaths if community-based active case 
ascertainment was used was generated. This was compared to the corresponding in-hospital 
mortality (meta-estimate of hospitalisation rate and CFR in developing countries and 
population from this country in the mean study year) and an inflation factor was calculated 
as follows: inflation factor = number of RSV deaths in community/number of RSV deaths in 
hospital. The mean inflation factor was calculated and would be used to extrapolate the in-
hospital mortality from RSV associated ALRI in developing countries, and generate global 
mortality in community. Global mortality from RSV associated ALRI in children under five 
years old in community = in-hospital mortality of RSV associated ALRI from developing 
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 Results  
Overall, 13,387 records were identified through database searching, after removing 
duplicates and excluding studies not relevant to the topic, 880 records remained for full-text 
review. After reviewing the full texts, 225 published articles met the selection criteria. There 
were 3 articles providing 2 data points for different areas in each article, thus in total 228 
studies were included in further analysis. The list of excluded articles during full-text review 
process with corresponding reasons was listed in Appendices – A11. Another 76 unpublished 
studiesU1-76 with appropriate data were collected from RSV GEN (listed in Table 20). Two of 
them provided both community-based incidence rate and hospital-based hospitalisation 
rateU1, U10. Therefore, 304 studies in total were included for further assessment and analysis 
(266 new data points were added compared to previous estimate published in Lancet). The 
selection process was shown in Figure 13. More than 41 million children with relevant data 
were reported. Among all of them, 41 studies were in rural populations, 225 studies in urban 
populations and 38 were in a mixture of both. 225 studies were based in developing 
countries. Among them, 30 studies were either cohort studies or in the demographic 
surveillance site; 1 study had a well-defined catchment area for which the population were 
RSV-ALRI mortality in 
hospital 
Global mortality from RSV-ALRI 
Systematic review and data collection 
RSV-ALRI mortality in 
community 
Define RSV-ALRI 
mortality in community 
Assign all excess in ALRI 
mortality during seasonal 






mortality in hospital 
Figure 12: Approach to estimate mortality from RSV associated ALRI  
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estimated with a healthcare utilisation survey; 25 studies were conducted in hospitals with 
well-defined catchment areas. These 56 studies reported either incidence rate of RSV 
associated ALRI (community-based setting) or hospitalisation rate (hospital-based setting). 
Only 40 studies (11 published articles (Robertson et al., 2004, Ahmed et al., 2012, Chiu et al., 
2010, Fry et al., 2010, Gil-Prieto et al., 2015, Hall et al., 2009, Iwane et al., 2004, Muller-
Pebody et al., 2002, Paramore et al., 2004, Rowlinson et al., 2013, Vicente et al., 2003) with 
12 studies and 28 unpublished studiesU3-5, U8, U11, U15-24, U26-29, U32, U34-37, U39-40, U42, U45) reported 
disease incidence / hospitalisation rate by age group for the full age range (for 0-59m group); 
for the remaining studies data were imputed where necessary. There were 18 population-
based studies reporting incidence rate of RSV associated (severe) ALRI in populations under 
surveillance, 73 studies estimating hospitalisation rate on the basis of hospital discharge 
records or laboratory diagnosis reports and a census-based or defined denominator of 
children at risk, 99 studies reporting RSV mortality in hospital, 199 studies estimating 
proportion of hospitalised ALRI cases that are RSV positive (73 were from Chinese 
language databases). 63 studies reported the incidence rate, hospitalisation rate or in-hospital 
CFR by narrow age bands for the first year of life. Only 37 studies (1 published and 36 
unpublished) reported data specifically for neonates (aged 0-27 days). Not all eligible ALRI 
cases were tested. The list of studies which didn’t have all ALRI cases tested for pathogen 
were listed in Appendices – A12. In these studies, the number of RSV associated ALRI cases 
(except for very severe cases) were scaled up according to the proportion of eligible ALRI 
cases tested for RSV (as described in the Chapter 2 - Methods). Studies reporting rate in 
community and hospital settings as well as in-hospital mortality were mapped in Figure 14, 





Table 20: List of 76 unpublished studies with relevant data 
Study 
number 
Location (reference) Study period Setting Published reference Remarks 
U1 
Kilifi birth cohort, Kenya 
(Nokes and colleagues) 
Jan 2002 - May 
2005 
rural Clin Infect Dis 2008; 46:50-7 
report both community-based rate and hospital-
based rate; data re-analysed using common case 
definitions 
U2 
San Marcos, Guatemala 
(Bruce and colleagues) 
Dec 2002 - Dec 
2004 
rural Lancet 2011; 378(9804): 1717-26 data re-analysed using common case definitions 
U3 
Dhaka, Bangladesh (Brooks 
and colleagues) 
Jan 2005 - Feb 
2008 
urban 
Pediatr Infect Dis J 2010; 29(3): 216-
21 
RSV was tested for the first 4 years of study; 15 
ALRI deaths without information about virus 
U4 
Ballabhgarh, India (Krishnan 
and colleagues) 
Aug 2012 - Aug 
2013 
rural BMC Infect Dis 2015; 15: 462 data re-analysed using common case definitions 
U5 
Bandung, Indonesia (Simoes 
and colleagues) 
1st Feb 1999 - 




Pediatr Infect Dis J 2011; 30(9): 778-
84 
data re-analysed using common case definitions 
U6 
Managua, Nicaragua (Gordon 
and colleagues) 
Sep 2011 - Sep 
2012 
urban 
Pediatr Infect Dis J 2016; 35(2): 152-
6 
data re-analysed using common case definitions 
U7 
Matiari, Pakistan (Ali and 
colleagues) 
Oct 2011 - Jun 
2014 
rural PLoS One 2013; 8(9) data re-analysed using common case definitions 
U8 
Gilgit, Pakistan (Rasmussen 
and colleagues) 
1st Apr 2012 - 
31st Mar 2014 
rural no data are not yet published 
U9 
Puerto Maldonado, Peru 
(Romero and colleagues) 
Jan - Dec 2013 
periurba
n 
no only one very severe case in 12-23m 
U10 
Paarl, South Africa (Zar and 
colleagues) 




i. Thorax 2015; 70(6): 592-4 
ii. Lancet Glob Health 2015; 3(2): 
e95-e103 
report both community-based rate and hospital-
based rate; data re-analysed using common case 
definitions 





Location (reference) Study period Setting Published reference Remarks 
(Wright and colleagues) 1993 outpatients in industrialised countries 
U12 
CEMIC, Buenos Aires, 
Argentina (Echavarria and 
colleagues) 
1st Jun 2008 - 31st 
Dec 2010 
urban 
i. Arch Argent Pediatr 
2011;109(4):296-304 
ii. Pediatr Infect Dis J 2013; 32(3): 
e105-e110 
iii. Medicina 2012; 72(1): 28-32 
another paper is in preparation; data re-analysed 
using common case definitions 
U13 
Buenos Aires, Argentina 
(Polack and colleagues) 
2011 - 2013 
urban 
and rural 
Am J Respir Crit Care Med 2013; 
187(9): 983-90 
data re-analysed using common case definitions 
U14 
Kishoregonj, Bogra, Comilla 
and Barisal, Bangladesh 
(Homaira and colleagues) 
2010 - 2013 
urban 
and rural 
PLoS One 2016; 11(2): e0147982. data re-analysed using common case definitions 
U15 
Belo Horizonte, Brazil 
(Oliveira and colleagues) 
2011 - 2013 urban no data are not yet published 
U16 
Concepcion, Chile (Fasce and 
colleagues) 




no data are not yet published 
U17 
Iquique, Chile (Fasce and 
colleagues) 




no data are not yet published 
U18 
Jingzhou, China (Yu and 
colleagues) 




J Infect Dis 2013; 208 Suppl 3: S184-
8 
data re-analysed using common case definitions 
U19 
Santa Ana, El Salvador (Clara 
and colleagues) 
2008 - 2013 urban 
i. Bull World Health Organ 2012; 
90(10): 756-63 
ii. Influenza Other Respir Viruses 
2016 
data re-analysed using common case definitions 
U20 
Gambia Western Region, 
Gambia (Howie and 
colleagues) 









Location (reference) Study period Setting Published reference Remarks 
U21 
Santa Rosa, Guatemala 
(McCracken and colleagues) 
2008 - 2013 
urban 
and rural 
i.  Infect Dis 2013; 208 Suppl 3: 
S197-206 
ii. Pediatr Infect Dis J 2013; 32(6): 
629-35 
data re-analysed using common case definitions 
U22 
Quetzaltenango, Guatemala 
(McCracken and colleagues) 
2009 - 2013 
urban 
and rural 
i.  Infect Dis 2013; 208 Suppl 3: 
S197-206 
ii. Pediatr Infect Dis J 2013; 32(6): 
629-35 
data re-analysed using common case definitions 
U23 
Ballabhgarh, India (Broor and 
colleagues) 
Jan 2010 - Dec 
2012 
rural J Infect 2015; 70(2): 160-70 data re-analysed using common case definitions 
U24 
Pune, India (Chadha and 
colleagues) 
May 2009 - Apr 
2013 
rural J Infect 2015; 70(2): 160-70 data re-analysed using common case definitions 
U25 
Lombok, Indonesia (Gessner 
and colleagues) 
2000 - 2002 
urban 
and rural 
Epidemiol Infect 2008; 136(10): 
1319-27 
data re-analysed using common case definitions 
U26 
Kilifi hospital study, Kenya 
(Nokes and colleagues) 




JAMA 2010; 303(20): 2051-7 data re-analysed using common case definitions 
U27 
Bondo district, Kenya (Feikin 
and colleagues) 
Jan 2007 - Jun 
2009 
rural J Med Virol 2013; 85(5): 924-32 data re-analysed using common case definitions 
U28 
Manhiça, Mozambique (Bassat 
and colleagues) 
20th Sep 2006 - 
19th Sep 2007 
rural 
Pediatr Infect Dis J 2011; 30(1): 39-
44 
data re-analysed using common case definitions 
U29 
Manhiça, Mozambique (Bassat 
and colleagues) 
1st Jan 2011 - 30th 
Jun 2014 
rural 
Pediatr Infect Dis J 2011; 30(12): 
1032-6 
data re-analysed using common case definitions 
U30 
Utrecht, Netherlands (Bont 
and colleagues) 
2001 - 2010 urban 
i. Pediatr Infect Dis J 2014; 33(1): 
19-23 
ii. Pediatrics 2011; 127(1): 35-41 
healthy term infants; data re-analysed using 
common case definitions 





Location (reference) Study period Setting Published reference Remarks 
and colleagues) and rural common case definitions 
U32 
David City, Panama (Jara and 
colleagues) 
Jan 2011 - Dec 
2013 
urban no data are not yet published 
U33 
Tagbilaran and 6 rural sites, 
Philippines (Lucero and 
colleagues) 




i. Pediatr Infect Dis J 2009; 28(6): 
455-62 
ii. J Clin Microbiol 2013; 51(3): 945-
53 
data re-analysed using common case definitions 
U34 
Gauteng province, South 
Africa (Cohen and colleagues) 
2009 - 2012 urban 
i. J Infect Dis 2013; 208 Suppl 3: 
S217-26 
ii. J Infect Dis 2012; 206 Suppl 1: 
S159-65 
data re-analysed using common case definitions 
U35 
KwaZulu-Natal province, 
South Africa (Cohen and 
colleagues) 
2010 - 2014 
periurba
n 
i. J Infect Dis 2013; 208 Suppl 3: 
S217-26 
ii. J Infect Dis 2012; 206 Suppl 1: 
S159-65 
data re-analysed using common case definitions 
U36 
Klerksdorp site, South Africa 
(Cohen and colleagues) 




i. J Infect Dis 2013; 208 Suppl 3: 
S217-26 
ii. J Infect Dis 2012; 206 Suppl 1: 
S159-65 
data re-analysed using common case definitions 
U37 
Soweto, South Africa (Madhi 
and colleagues) 
Mar 1998 - Oct 
2005 
urban J Clin Virol 2006; 36(3): 215-21 data re-analysed using common case definitions 
U38 
Maela Camp, Tak Province, 
Thailand (Turner and 
colleagues) 
Nov 2007 - Oct 
2010 
rural 
i. PLoS ONE 2012; 7(11): e50100 
ii. BMC Infect Dis 2013; 13(1) 
data re-analysed using common case definitions 
U39 
Sa Kaeo and Nakhon Phanom, 
Thailand (Thamthitiwat and 
colleagues) 
Jan 2008 - Dec 
2011 
rural 
i. Pediatr Infect Dis J 2014; 33(2): 
e45-e52 
ii. J Infect Dis 2013; 208 Suppl 3: 





Location (reference) Study period Setting Published reference Remarks 
S238-45 
U40 
Tone district, Togo (Gessner 
and colleagues) 
Aug 2011 - Dec 
2013 
rural no data are not yet published 
U41 
Alaska, USA (Singleton and 
colleagues) 
Jul 1994 - Jun 
2012 
rural 
i. Pediatr Infect Dis J 2007; 
26(11(Supplement): S46-S50 
ii. J Med Virol 2010; 82(7): 1282-90 
reporte very severe cases from 1994 to 2007; 
hypoxemia data from Oct 2005 to Sep 2007; 
data re-analysed using common case definitions 
U42 
Colorado, USA (Simoes and 
colleagues) 




no ICD-9 codes for hypoxemia 
U43 
Navajo and WMA, USA - 
MEDI (O'Brien and 
colleagues) 
Oct 2004 - Dec 
2010 
rural submitted to journal data re-analysed using common case definitions 
U44 
Navajo and WMA, USA - EPI 
(O'Brien and colleagues) 
Oct 1997 - Mar 
2000 
rural Pediatrics 2002; 110(2 Pt 1): e20 data re-analysed using common case definitions 
U45 
Nha Trang, Vietnam (Yoshida 
and colleagues) 




i. Pediatr Infect Dis J 2010; 29(1): 
75-7 
ii. Eur Respir J 2013; 42(2): 461-9 
subtypes data from 2010 to 2012; another paper 
is in preparation; data re-analysed using 
common case definitions 
U46 
Buenos Aires, Argentina 
(Echavarria and colleagues) 
1st Jun 2008 - 31st 
Dec 2010 
urban 
i. Arch Argent Pediatr 
2011;109(4):296-304 
ii. Pediatr Infect Dis J 2013; 32(3): 
e105-e110 
iii. Medicina 2012; 72(1): 28-32 
another paper is in preparation; data re-analysed 
using common case definitions 
U47 
Buenos Aires, Argentina 
(Gentile and colleagues) 
2001 - 2013 urban 
Arch Argent Pediatr 2014; 112(5): 
397-404 
data re-analysed using common case definitions 
U48 
Takeo and Kampong Cham, 
Cambodia (Goyet and 
colleagues) 
Apr 2007 - Feb 
2010 
urban 
Pediatr Infect Dis J 2013; 32(1): e8-
13 





Location (reference) Study period Setting Published reference Remarks 
U49 
Chillan, Chile (Fasce and 
colleagues) 
2010 - 2013 
urban 
and rural 
no data are not yet published 
U50 
Osorno, Chile (Fasce and 
colleagues) 
2010 - 2013 
urban 
and rural 
no data are not yet published 
U51 
Punta Arenas, Chile (Fasce 
and colleagues) 
2010 - 2013 
urban 
and rural 
no data are not yet published 
U52 
Santiago, Chile (Fasce and 
colleagues) 
2010 - 2013 urban no data are not yet published 
U53 
Valparaiso, Chile (Fasce and 
colleagues) 
2010 - 2013 
urban 
mostly 
no data are not yet published 
U54 China (Yu and colleagues) 




PLoS One 2014; 9(6): e99419 data re-analysed using common case definitions 
U55 Beijing, China (GABRIEL) 
Jan 2011 - Dec 
2012 




Sep 2011 - Oct 
2012 
urban no data are not yet published 
U57 
Phnom Penh, Cambodia 
(GABRIEL) 
Oct 2010 - Jan 
2013 
urban no data are not yet published 
U58 Lucknow, India (GABRIEL) 
















Jul 2010 - May 
2013 
urban no data are not yet published 





Location (reference) Study period Setting Published reference Remarks 
2012 
U62 
Berlin, Germany (Rath and 
colleagues) 
1st Apr 2010 - 
31st Mar 2014 
urban 
i. iagn Microbiol Infect Dis 2015; 
81(3): 171-6 
ii. J Clin Microbiol 2009; 47(6): 
1800-10 
data re-analysed using common case definitions 
U63 
Amman, Jordan (Khuri and 
colleagues) 
Mar 2010 - Mar 
2013 
urban Vaccine 2015; 33(47): 6479-87 data re-analysed using common case definitions 
U64 
Lwak, Kenya (Montgomery 
and colleagues) 
2007 - 2011 rural 
J Infect Dis 2013; 208 Suppl 3: S207-
16 
data re-analysed using common case definitions 
U65 
Rabat, Morocco (Bassat and 
colleagues) 
Nov 2010 - Dec 
2011 
urban 
i. J Trop Pediatr 2014; 60(4): 270-8 
ii. Epidemiol Infect 2016; 144(3): 
516-26 
data re-analysed using common case definitions 
U66 
Kathmandu, Nepal (Basnet 
and colleagues) 
Jan 2006 - Jun 
2008 
urban 
i. Pediatr Infect Dis J 2011; 30(12): 
1032-6 
ii. Pediatrics 2012; 129(4): 701-8 
data re-analysed using common case definitions 
U67 
Karachi, Pakistan (Ali and 
colleagues) 
Aug 2009 - Jul 
2012 
urban PLoS One 2013; 8(9) data re-analysed using common case definitions 
U68 Basse, Gambia (PERCH) 
3rd Nov 2011 - 
2nd Nov 2013 
rural no data are not yet published 
U69 Kilifi, Kenya (PERCH) 
15th Aug 2011 - 
15th Nov 2013 
urban no data are not yet published 
U70 Bamako, Mali (PERCH) 
3rd Jan 2012 - 
14th Jan 2014 
urban no data are not yet published 
U71 
Nakhon Phanom and Sa Kaeo, 
Thailand (PERCH) 
1st Jan 2012 - 31st 
Jan 2014 





Location (reference) Study period Setting Published reference Remarks 
U72 Lusaka, Zambia (PERCH) 
10th Oct 2011 - 
31st Oct 2013 
urban no data are not yet published 
U73 Dhaka, Bangladesh (PERCH) 
1st Jan 2012 - 31st 
Dec 2013 
urban no data are not yet published 
U74 Matlab, Bangladesh (PERCH) 
1st Jan 2012 - 31st 
Dec 2013 
rural no data are not yet published 
U75 
Tacloban, Philippines (Lupisan 
and colleagues) 
May 2008 - Jul 
2012 
rural BMC Infect Dis 2012; 12: 267 data re-analysed using common case definitions 
U76 
Mpumalanga, South Africa 
(Cohen and colleagues) 
Jan 2010 - Dec 
2014 
rural 
i. J Infect Dis 2013; 208 Suppl 3: 
S217-26 
ii. J Infect Dis 2012; 206 Suppl 1: 
S159-65 
data re-analysed using common case definitions 























Figure 13: Flow diagram of selection of studies of global burden of RSV associated 
ALR
13,385 records identified 
through database search 
4 records identified 
through other sources 
4,512 duplicates removed 
8,877 records screened 
882 full-text articles 
assessed for eligibility 
7,995 records excluded 
because not relevant to 
topic 
225 articles included 
657 full-text articles excluded:                  
102 studies had less than 12 months 
surveillance;                                   
103 papers had no data specific to 
children <5 years old;                      
34 had improper case definition;     
192 articles had no relevant data;        
100 used improper methods;                                                    
96 had duplicate data;                      
30 no full-texts or in other language 
199 studies reported hospitalised 
proportion data - 73 were 
Chinese data 
87 studies reported 
incidence/hospitalisation 
data 
99 studies reported in-
hospital CFR data  
76 studies from 










Figure 15: Location of studies reporting proportion data by WHO region 
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5.2.1 Incidence rate of RSV associated ALRI  
In total 18 studies reported community-based or outpatient-based (industrialised countries 
only) incidence rate of RSV associated (severe) ALRI with a well-defined catchment area 
with denominator data. Seven were published articles (Homaira et al., 2012, Broor et al., 
2007, Hasan et al., 2006, Robertson et al., 2004, Sutmoller et al., 1995, Wu et al., 2015, 
Forster et al., 2004) and 11 were unpublished studiesU1-U11 (Table 21). Five of them were 
from urban settings, three from mix areas (both urban and rural) and the rest 10 study sites 
were based in rural areas. All studies from developing countries (16 studies) adopted 
community-based active case ascertainment - ALRI cases sought by health workers during 
regular house-to-house visits. Sixteen of them reported incidence rate of RSV associated 
ALRI and main characteristics of these included studies (location, study period, case 
definition, study denominator, specimen and diagnostic test, incidence rate in children aged 
0-5m/0-11m/0-59m) were summarised in Table 22. Data computed using median rate ratio 
from studies providing data for full age range were highlighted with parentheses. Another 
table containing data in narrower age bands was in Appendices – A13. Similarly, 9 studies 
reporting RSV associated severe ALRI were presented in Table 23. Four studies provided 
data of RSV associated very severe ALRI (Table 24). Data regarding meta-estimate of 
incidence rate as well as number of new cases from different regions were presented in Table 
25. Corresponding forest plots were available in Appendices – A14. Overall, the meta-
estimate of incidence rate of RSV associated ALRI in infants from developing countries was 
88.3 per 1000 children per year, 28.7 for severe cases and 5.8 for very severe cases. For 
children under five years old from developing countries, the meta-estimate for RSV 
associated ALRI was 50.8 per 1000 children per year, 10.2 for RSV associated severe ALRI, 
and 1.4 for RSV associated very severe ALRI. Thus, in 2015, there were 30.5 (95% CI 19.5-
47.9) million new episodes of RSV associated ALRI among children younger than 5 years 
from developing countries (30.0 (95% CI 19.1-47.0) million in low and middle income 
countries). 20.1% of them were severe cases and 2.7% were very severe cases. The incidence 
rate for children aged 0-59m in industrialised countries was estimated as 35.6 per 1000 
children per year based on two studies, which means that 2.5 (95% CI 1.2-5.3) million of 
RSV associated ALRI cases occurred in this region in 2015. Globally there were 33.0 (95% 
CI 20.6-53.2) million of new episodes of RSV associated ALRI among children younger 
than five years old. Among infants, there were 10.9 million new cases of RSV associated 
ALRI in developing countries (10.7 million in low and middle income countries); 0.9 million 
in industrialised countries (1.0 million in high income countries). The meta-estimate result of 
incidence data from developing countries in exclusive finer age bands was shown in Figure 
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16. The incidence rate was high in children at the first two years, especially among infants. A 
sensitivity analysis was carried out to compare the meta-estimate of incidence rate after 
excluding the imputed data (Appendices – A15). No substantial difference was found. 
Table 21: List of 11 unpublished studies reporting incidence rate 
Study number Location (reference) Study period 
U1 Kilifi birth cohort, Kenya (Nokes and colleagues) Jan 2002 - May 2005 
U2 San Marcos, Guatemala (Bruce and colleagues) Dec 2002 - Dec 2004 
U3 Dhaka, Bangladesh (Brooks and colleagues) Jan 2005 - Feb 2008 
U4 Ballabhgarh, India (Krishnan and colleagues) Aug 2012 - Aug 2013 
U5 Bandung, Indonesia (Simoes and colleagues) 1
st Feb 1999 - 26th Apr 2001 
U6 Managua, Nicaragua (Gordon and colleagues) Sep 2011 - Sep 2012 
U7 Matiari, Pakistan (Ali and colleagues) Oct 2011 - Jun 2014 
U8 Gilgit, Pakistan (Rasmussen and colleagues) 1
st Apr 2012 - 31st Mar 2014 
U9 Puerto Maldonado, Peru (Romero and colleagues) Jan - Dec 2013 
U10 Paarl, South Africa (Zar and colleagues) Mar 2012 - Dec 2014 













Incidence of RSV associated ALRI (per 1000 children 
per year)* 
0-5m 6-11m 0-11m 12-23m 24-59m 0-59m 
San Marcos, Peru (rural, Mar 2009 - Sep 






343.8 338.1 340.8 304.3 
 
(194.3) 
Dhaka, Bangladesh (urban, Apr 2009 - 




NPW; RT-PCR 150.0 110.0 (148.5) 120.0 
 
(84.7) 
Kilifi birth cohort, Kenya (rural, Jan 




NPA, nasal wash; 
DFA 
147.0 63.0 105.1 71.0 
 
(59.9) 
Mirzapur, Bangladesh (rural, Oct 1993 - 









Ballabhgarh, India (rural, Oct 2001 - 




NPA; DFA 60.2 18.0 38.0 52.0 
 
(21.7) 
Ibadan, Nigeria (rural, Jun 1999 - May 











San Marcos, Guatemala (rural, Dec 2002 
- Dec 2004) (Bruce and colleagues) 
I, II, DS+/- 
Defined population 
base 
NPA; DFA 107.7 172.4 147.5 124.5 
 
(84.1) 
Rio de Janeiro, Brazil (rural, Jan 1987 - 










Dhaka, Bangladesh (urban, Jan 2005 - 








28.3 36.7 32.2 21.8 9.5 17.5 
Ballabhgarh, India (rural, Aug 2012 - 




NPS; RT-PCR 97.3 76.9 85.5 54.6 10.1 33.4 
Bandung, Indonesia (periurban and 
rural, 1st Feb 1999 - 26th Apr 2001) 






26.6 141.5 87.9 97.3 21.1 65.4 
Managua, Nicaragua (urban, Sep 2011 - 











Gilgit, Pakistan (rural, 1st Apr 2012 - 
















Incidence of RSV associated ALRI (per 1000 children 
per year)* 
0-5m 6-11m 0-11m 12-23m 24-59m 0-59m 
Paarl, South Africa (periurban, Mar 2012 




NPS; RT-PCR 506.7 141.8 331.0 78.6 
 
(188.7) 
Nashville, Tennessee, USA (urban, Jan 










Multicentric, Germany (urban, Nov 1999 









RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. NPA=nasopharyngeal aspirate. NPS=nasopharyngeal swab. 
NPW=nasopharyngeal wash. RT-PCR=reverse transcriptase polymerase chain reaction. IFA=indirect immunofluorescent antibody test. DFA=direct 
immunofluorescent antibody test. ELISA=enzyme-linked immunosorbent assay. I=WHO definition applied by a health worker. II=physician’s assessment. 
T+/-=tachypnea part of case definition or not. W+/-=wheeze part of case definition or not. DS+/-=danger signs part of case definition or not. O2+/-
=hypoxemia part of case definition or not. C+/-=crepitation part of case definition or not. NA=not applicable. #Except for these two studies from hospital 














Incidence of RSV associated severe ALRI (per 1000 
children per year)* 






Kilifi birth cohort, Kenya (rural, Jan 2002 - May 






86.0 47.0 68.5 17.0 
 
(23.3) 
Ballabhgarh, India (rural, Oct 2001 - Mar 2005) 




NPA; DFA 20.1 9.0 14.3 6.5 
 
(4.8) 
Dhaka, Bangladesh (urban, Jan 2005 - Feb 2008) 








5.1 1.4 3.4 0.5 
 
1.0 
Ballabhgarh, India (rural, Aug 2012 - Aug 2013) 




NPS; RT-PCR 53.1 51.3 52.0 32.1 2.3 17.7 
Bandung, Indonesia (periurban and rural, 1st 







(24.1) 35.8 19.1 13.0 3.1 11.2 
Managua, Nicaragua (urban, Sep 2011 - Sep 











Matiari, Pakistan (rural, Oct 2011 - Jun 2014) 




NPS; RT-PCR 19.0 22.2 20.6 3.1 
 
(7.0) 
Paarl, South Africa (periurban, Mar 2012 - Dec 




NPS; RT-PCR 406.7 82.1 253.5 36.9 
 
(86.2) 
Nashville, Tennessee, USA (urban, Jan 1973 - 









RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. OP=outpatient. NPA=nasopharyngeal aspirate. NPS=nasopharyngeal swab. 
NPW=nasopharyngeal wash. RT-PCR=reverse transcriptase polymerase chain reaction. DFA=direct immunofluorescent antibody test. I=WHO 
definition applied by a health worker. II=physician’s assessment. W+/-=wheeze part of case definition or not. DS+/-=danger signs part of case definition 
or not. F+/-=fever part of case definition or not. O2+/-=hypoxemia part of case definition or not. C+/-=crepitation part of case definition or not. NA=not 
applicable. #Except for this study from hospital outpatient settings (high-income countries), the others were active community based. *Data in 













Incidence rate of RSV associated very severe ALRI 







Puerto Maldonado, Peru (periurban, Jan - Dec 












Paarl, South Africa (periurban, Mar 2012 - Dec 




NPS; RT-PCR 26.7 14.9 21.1 2.5 
  
Dhaka, Bangladesh (urban, Jan 2005 - Feb 2008) 




OPS; RT-PCR 1.1 0.5 0.8 
  
0.2 
Ballabhgarh, India (rural, Aug 2012 - Aug 2013) 




NPS; RT-PCR 17.7 6.4 11.1 6.4 
 
3.4 
RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. NPS=nasopharyngeal swab. NPW=nasopharyngeal wash. OPS=oropharyngeal 
swab. RT-PCR=reverse transcriptase polymerase chain reaction. I=WHO definition applied by a health worker. W+/-=wheeze part of case definition or 




Table 25: Summary of incidence rate and number of new cases of RSV associated ALRI 
Region Severity No. 
0-5m 0-11m 0-59m 
Incidence rate 
(per 1000 
children per year) 





children per year) 





children per year) 
Number of new 
cases  
(*10³) 
Developing and industrialised regions 
Developing 
countries 

















3 8.0 (1.0-62.3) 492 (63-3834) 5.8 (0.8-43.9) 713 (95-5400) 1.4 (0.2-11.3) 817 (96-6782) 
Industrialised 
countries 
RSV-ALRI 2 66.1 (33.5-130.4) 448 (227-884) 65.4 (33.2-129.1) 887 (450-1751) 35.6 (16.6-76.2) 2482 (1158-5320) 































3 8.0 (1.0-62.3) 483 (62-3769) 5.8 (0.8-43.9) 713 (95-5400) 1.4 (0.2-11.3) 803 (94-6668) 
High income 
countries 
RSV-ALRI 2 66.1 (33.5-130.4) 517 (262-1020) 65.4 (33.2-129.1) 1024 (519-2020) 35.6 (16.6-76.2) 2841 (1326-6090) 
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Figure 16: Meta-estimate of incidence rate of RSV associated ALRI by finer age bands 
RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. Numbers above 
each bar are number of studies included in meta-analysis for that category. Error bars are 95% 






















































RSV-ALRI severe RSV-ALRI very severe RSV-ALRI
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5.2.2 Hospitalisation rate of RSV associated ALRI  
In total, 37 published studies (Ahmed et al., 2012, Anders et al., 2015, Boyce et al., 2000, 
Chan et al., 1999a, Chiu et al., 2010, Cilla et al., 2009, Dede et al., 2010, Deshpande and 
Northern, 2003, Diez Domingo et al., 2006, Emukule et al., 2014, Eriksson et al., 2002, 
Fjaerli et al., 2004, Forster et al., 2004, Fry et al., 2010, Gil-Prieto et al., 2015, 
Hacimustafaoglu et al., 2013, Hall et al., 2009, Henrickson et al., 2004, Holman et al., 2004, 
Iwane et al., 2004, Jain et al., 2015, Jansen et al., 2007, Ji et al., 2010, Muller-Pebody et al., 
2002, Resch et al., 2002, Robertson et al., 2004, Rowlinson et al., 2013, Stockman et al., 
2012, Suwanjutha et al., 2002, Vicente et al., 2003, Weber et al., 2002, Weigl et al., 2002a, 
Whitehall et al., 2001, Leader and Kohlhase, 2003, Paramore et al., 2004) were identified to 
report hospitalisation rate (two articles provided four studies). 36 unpublished studies from 
RSV GEN were providedU1, U10, U12-45 (Table 26). Overall, 73 studies were included in the 
meta-analysis of hospitalisation rate (Table 27). Data computed using median rate ratios 
from studies providing data for full age range were highlighted with parentheses. A 
sensitivity analysis was carried out to compare the meta-estimate of hospitalisation rate after 
excluding the imputed data (Appendices – A15). All studies adopted passive hospital-based 
or clinic-based case ascertainment (inpatients only) – children with ALRI who have sought 
treatment in hospitals or clinics are enrolled. There were 43 studies from developing 
countries and 30 from industrialised countries. Regarding the study setting, 30 studies were 
based on urban areas, another 25 studies were from study sites with a mix of population 
(both urban and rural) while the remaining 18 studies were from rural areas. The table 
containing data in narrower age bands was in Appendices – A16. Two published articles 
(Holman et al., 2004, Whitehall et al., 2001) and 3 unpublished studiesU41, U43, U44 reported 
data in study sites with aboriginal population (Townsville in Australia, Alaska, Navajo and 
White Mountain Apache in United States). They were from a special group of population, 
and reported relevantly higher rates than other areas from the same country. Thus, they were 
excluded in the final estimate. Three published studies (Ahmed et al., 2012, Chiu et al., 2010, 
Emukule et al., 2014) and four unpublished studiesU15, U18, U19, U20 used different case 
definitions: 2 studies including fever as part of the case definitions, 4 studies using SARI as 
the case definition, 1 study excluding children with wheeze condition. These studies were 
excluded in a sensitivity analysis in order to explore the effects of studies using different 
case definitions on the outcome. The summary of meta-estimate of hospitalisation rate in 
different age groups and in different regions (regions by World Bank income, developing 
and industrialised) was presented in Figure 17 and Table 28, and corresponding number of 
hospitalised cases was shown in Table 29. The forest plots were available in Appendices - 
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A17. Hospitalisation rate was high among children in first year of life and high in upper 
middle income countries. It was estimated that 3.0 (95% CI 2.2-4.0) million new cases of 
RSV associated hospitalised ALRI occurred in children younger than 5 years old in the 
worldwide in 2015, of which 87% were in developing countries. The overall number was 
added up from estimates of exclusive finer age bands in different regions. There were 21 
countries in sub-Saharan Africa with high HIV burden according to UNAIDS Global Plan 
(UNAIDS, 2013). Thirteen studies identified in this review reported hospitalisation rate in 
young children from these African countries, and the number of new episodes of RSV 
associated hospitalised ALRI in children under five was around 0.7 (95% CI 0.6-0.9) million. 
Among 73 studies, 9 also reported hospitalisation rate in RSV associated hospitalised ALRI 
cases with chest wall indrawing. All of them were unpublished studies from developing 
countries (Table 30). The meta-estimate in children younger than 5 years was 4.6 (95% CI 
2.8-7.4) per 1000 children per year in developing countries (no estimate available for 
industrialised countries). This is translated to 2.6 (95% CI 1.6-4.5) million new cases of RSV 
associated hospitalised ALRI which had chest wall indrawing in developing countries (sum 
of estimates from exclusive narrower age bands). Regarding very severe cases in hospital 
settings, 18 studies were available to provide the estimates (Table 31). All of them were 
unpublished studies. Three studies were from industrialised countries while the other 15 
studies were based in developing countries. One study was carried out in an aboriginal 
population and thus excluded in final estimateU41. Adjustment of number of cases according 
to proportion of ALRI cases which were tested and imputation of missing data across age 
groups was not performed among very severe cases since the underlying assumptions might 
not be valid. Among these 18 studies, 8 also provided hospitalisation rate of very severe 
cases which were ICU admitted (Table 32); 4 reported hospitalisation rate in very severe 
cases requiring mechanical ventilation (Table 33). The hospitalisation rates of RSV 
associated very severe ALRI in children aged 0-5m, 6-11m and 12-59m from developing 
countries were estimated as 5.2 (95% CI 2.4-11.0), 3.0 (95% CI 1.2-7.7) and 0.2 (95% CI 
0.1-0.4) per 1000 children per year respectively (Table 34). Therefore, it was estimated that 
in 2015, around 598,000 (95% CI 265,000-1,359,000) new episodes of RSV associated very 
severe ALRI occurred in children under five years old in developing countries (Table 35). 
Among them, about 212,000 (95% CI 102,000-215,000) cases were estimated with ICU 
admission (no estimate for mechanical ventilation). There were no enough studies to produce 
the estimate in industrialised countries.  
Two sensitivity analyses were carried out to include studies with indigenous populations in 
industrialised countries and to exclude studies using different case definitions (fever, wheeze 
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negative or SARI) respectively. From Table 36, after five studies with indigenous 
populations were included, the meta-estimate of RSV associated hospitalised ALRI in 0-59m 
in high income countries was increased from 5.5 to 6.7 per 1000 children per year. Four 
studies were from America, which increased the meta-estimate in Americas region 
substantially (5.1 vs. 7.2). This supports the decision to report the regional/global meta-
estimate after excluding studies with aboriginal population. When 7 studies using different 
case definitions for ALRI were excluded, the meta-estimate stratified by different regions 




Table 26: List of 36 unpublished studies reporting hospitalisation rate 
Study 
number 
Location (reference) Study period 
U1 Kilifi birth cohort, Kenya (Nokes and colleagues) Jan 2002 - May 2005 
U10 Paarl, South Africa (Zar and colleagues) Mar 2012 - Dec 2014 
U12 
CEMIC, Buenos Aires, Argentina (Echavarria and 
colleagues) 
1st Jun 2008 - 31st Dec 
2010 
U13 Buenos Aires, Argentina (Polack and colleagues) 2011 - 2013 
U14 
Kishoregonj, Bogra, Comilla and Barisal, Bangladesh 
(Homaira and colleagues) 
2010 - 2013 
U15 Belo Horizonte, Brazil (Oliveira and colleagues) 2011 - 2013 
U16 Concepcion, Chile (Fasce and colleagues) Jan 2012 - Dec 2013 
U17 Iquique, Chile (Fasce and colleagues) Jan 2012 - Dec 2013 
U18 Jingzhou, China (Yu and colleagues) Jan 2010 - Dec 2012 
U19 Santa Ana, El Salvador (Clara and colleagues) 2008 - 2013 
U20 
Gambia Western Region, Gambia (Howie and 
colleagues) 
Jul 2007 - Jun 2008 
U21 Santa Rosa, Guatemala (McCracken and colleagues) 2008 - 2013 
U22 Quetzaltenango, Guatemala (McCracken and colleagues) 2009 - 2013 
U23 Ballabhgarh, India (Broor and colleagues) Jan 2010 - Dec 2012 
U24 Pune, India (Chadha and colleagues) May 2009 - Apr 2013 
U25 Lombok, Indonesia (Gessner and colleagues) 2000 - 2002 
U26 Kilifi hospital study, Kenya (Nokes and colleagues) Jan 2002 - Dec 2010 
U27 Bondo district, Kenya (Feikin and colleagues) Jan 2007 - Jun 2009 
U28 Manhiça, Mozambique (Bassat and colleagues) 
20th Sep 2006 - 19th Sep 
2007 
U29 Manhiça, Mozambique (Bassat and colleagues) 
1st Jan 2011 - 30th Jun 
2014 
U30 Utrecht, Netherlands (Bont and colleagues) 2001 - 2010 
U31 41 sites in Netherlands (Bont and colleagues) 2008 - 2013 
U32 David City, Panama (Jara and colleagues) Jan 2011 - Dec 2013 
U33 
Tagbilaran and 6 rural sites, Philippines (Lucero and 
colleagues) 
5th Jul 2000 - 31st Dec 
2004 
U34 Gauteng province, South Africa (Cohen and colleagues) 2009 - 2012 
U35 
KwaZulu-Natal province, South Africa (Cohen and 
colleagues) 
2010 - 2014 
U36 Klerksdorp site, South Africa (Cohen and colleagues) Jan 2011 - Dec 2014 
U37 Soweto, South Africa (Madhi and colleagues) Mar 1998 - Oct 2005 
U38 
Maela Camp, Tak Province, Thailand (Turner and 
colleagues) 





Location (reference) Study period 
U39 
Sa Kaeo and Nakhon Phanom, Thailand (Thamthitiwat 
and colleagues) 
Jan 2008 - Dec 2011 
U40 Tone district, Togo (Gessner and colleagues) Aug 2011 - Dec 2013 
U41 Alaska, USA (Singleton and colleagues) Jul 1994 - Jun 2012 
U42 Colorado, USA (Simoes and colleagues) Jan 2008 - Jun 2013 
U43 
Navajo and WMA, USA - MEDI (O'Brien and 
colleagues) 
Oct 2004 - Dec 2010 
U44 Navajo and WMA, USA - EPI (O'Brien and colleagues) Oct 1997 - Mar 2000 
U45 Nha Trang, Vietnam (Yoshida and colleagues) Feb 2007 - Dec 2012 
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Hospitalisation rate of RSV associated ALRI (per 1000 
children per year)* 
0-5m 6-11m 0-11m 12-23m 24-59m 0-59m 
Alice Springs, Australia (urban, 1st Jan 









Suzhou, China (urban, Jan 2007 - Dec 2008) 









Hong Kong, China (urban, 2003 - 2006) 




NPA; DFA, culture 26.8 10.4 18.7 10.1 4.4 13.0 
Sa Kaeo and Nakhom Phanom, Thailand 












Damanhour, Egypt (urban and rural, Jun 











Lørenskog, Norway (periurban, 1993 - 









Valencia, Spain (urban, 2001 - 2002) (Diez 









Gipuzkoa, Spain (urban, Jul 2004 - Jun 




NPA; RT-PCR 39.4 10.8 25.1 3.0 
 
(6.8) 
Bursa, Turkey (urban, 1st Mar 2010 - 28th 









USA (urban and rural, 1997 - 2006) 




NA (32.8) 13.4 (24.8) 5.0 0.8 6.7 
Dadaab and Kakuma, Kenya (rural, Sep 













Gipuzoka, Spain (urban, Jul 1996 - Jun 




NPA; ELISA 36.8 14.2 25.5 3.6 0.5 6.2 
Kiel, Germany (urban, 1996 - 97 to 2000 -

























Hospitalisation rate of RSV associated ALRI (per 1000 
children per year)* 
0-5m 6-11m 0-11m 12-23m 24-59m 0-59m 
Oct 2001) (Forster et al., 2004) estimate 
Shropshire, United Kingdom (urban, 1996 - 









Stockholm, Sweden (urban, 1987 - 1998) 



















England, United Kingdom (urban, Apr 1995 



















Banjul, Fajara and Sibanor, Gambia (urban 










Mpumalanga, South Africa (rural, Apr 2000 













Takhli, Thailand (rural, 1999 - 2000) 










Hong Kong, China (urban, 1993 - 1997) 












Townsville (Queensland), Australia (urban 
and rural, Jan 1997 - Oct 1999)# (Whitehall 









Monroe and Davidson Counties in 
Tennessee, USA (urban and rural, Oct 2000 




nasal and throat 
swab; viral culture, 
RT-PCR 
18.5 7.4 12.9 3.3 0.4 3.5 
Milwaukee, USA (urban, Nov 1996 - Oct 





















Hospitalisation rate of RSV associated ALRI (per 1000 
children per year)* 
0-5m 6-11m 0-11m 12-23m 24-59m 0-59m 
Tennessee, USA (urban, Jul 1989 - Jun 




NA 88.2 30.1 63.0 7.3 
 
(17.0) 
Alaska, USA (rural, Jan 2000 - Dec 2001)# 









USA (urban and rural, Jan 2000 - Dec 2001) 









Nashville, Rochester and Cincinnati, USA 






nasal and throat 
swab; RT-PCR, 
culture 
16.9 5.1 11.1 2.7 0.4 3.0 
Kilifi birth cohort, Kenya (rural, Jan 2002 - 






NPA, nasal wash; 
DFA 
20.0 6.0 11.6 5.4 
 
(3.1) 
CEMIC, Buenos Aires, Argentina (urban, 











Buenos Aires, Argentina (urban and rural, 







NPA; PCR 64.5 33.4 48.9 9.1 
 
(13.2) 
Kishoregonj, Bogra, Comilla and Barisal, 
Bangladesh (urban and rural, 2010 - 2013) 











Belo Horizonte, Brazil (urban, 2011 - 2013) 










7.9 1.3 0.9 2.2 
Concepcion, Chile (urban and rural, Jan 





NPA; IF (11.0) 
 
8.3 1.9 0.3 2.2 
Iquique, Chile (urban and rural, Jan 2012 - 





NPA; IF (30.4) 
 
23.0 3.2 0.5 4.9 
Jingzhou, China (urban and rural, Jan 2010 
















Hospitalisation rate of RSV associated ALRI (per 1000 
children per year)* 
0-5m 6-11m 0-11m 12-23m 24-59m 0-59m 
Santa Ana, El Salvador (urban, 2008 - 2013) 




NPS; IFA (52.5) 
 
39.8 16.2 2.0 12.2 
Gambia Western Region, Gambia (urban 







NPA; PCR (32.2) 17.4 24.4 6.3 1.6 5.7 
Santa Rosa, Guatemala (urban and rural, 









26.4 5.6 0.8 7.1 
Quetzaltenango, Guatemala (urban and 










14.4 3.3 0.4 3.8 
Ballabhgarh, India (rural, Jan 2010 - Dec 




NPS; RT-PCR 6.3 2.0 3.8 1.0 0.1 1.0 
Pune, India (rural, May 2009 - Apr 2013) 




NPS; RT-PCR 12.2 22.1 18.5 11.1 2.2 5.3 
Lombok, Indonesia (urban and rural, 2000 - 




nasal wash; ELISA 14.0 12.3 13.1 2.6 
 
(3.5) 
Kilifi hospital study, Kenya (urban and 






OPS, NPS, nasal 
wash; DFA 
27.2 11.1 19.3 3.4 0.6 4.9 
Bondo district, Kenya (rural, Jan 2007 - Jun 







52.6 25.0 32.0 6.3 7.1 16.5 
Manhiça, Mozambique (rural, 20th Sep 





NPA; RT-PCR 14.5 6.6 11.0 2.8 0.6 3.2 
Manhiça, Mozambique (rural, 1st Jan 2011 





NPA; RT-PCR 4.4 1.9 3.2 1.2 0.4 1.1 
Utrecht, Netherlands (urban, 2001 - 2010) 











41 sites in Netherlands (urban and rural, 


























Hospitalisation rate of RSV associated ALRI (per 1000 
children per year)* 
0-5m 6-11m 0-11m 12-23m 24-59m 0-59m 
2013) (Jara and colleagues) population base RT-PCR 
Tagbilaran and 6 rural sites, Philippines 
(urban and rural, 5th Jul 2000 - 31st Dec 





NPA, nasal swab; 
culture, PCR 
73.1 54.8 62.4 23.1 
 
(16.8) 
Gauteng province, South Africa (urban, 




NPA; PCR (38.9) 
 
29.4 6.8 1.3 7.8 
KwaZulu-Natal province, South Africa 





NPA; PCR (27.5) 
 
20.8 2.6 0.7 5.1 
Klerksdorp site, South Africa (periurban, 










Soweto, South Africa (urban, Mar 1998 - 





NPA; IF 33.1 10.2 20.0 4.0 0.5 4.7 
Paarl, South Africa (periurban, Mar 2012 - 





NPS; RT-PCR 146.7 29.9 91.5 4.9 
 
(24.7) 
Maela Camp, Tak Province, Thailand 






NPA; RT-PCR 135.7 73.1 105.0 61.9 
 
(28.4) 
Sa Kaeo and Nakhon Phanom, Thailand 








NPS; PCR 12.2 18.6 15.4 15.3 6.3 9.8 
Tone district, Togo (rural, Aug 2011 - Dec 






0.4 0.3 0.4 0.2 0.0 0.1 
Alaska, USA (rural, Jul 1994 - Jun 2012) 




NPS; ELISA, DFA, 
culture 
202.0 121.1 161.6 39.8 
 
(43.6) 
Colorado, USA (urban and rural, Jan 2008 - 




nasal wash; PCR (23.8) 
 
18.1 5.8 1.6 5.7 
Navajo and WMA, USA - MEDI (rural, Oct 

















Hospitalisation rate of RSV associated ALRI (per 1000 
children per year)* 
0-5m 6-11m 0-11m 12-23m 24-59m 0-59m 
Navajo and WMA, USA - EPI (rural, Oct 




NPA; ELISA 230.2 158.9 194.4 81.7 
 
(52.5) 
Nha Trang, Vietnam (urban and rural, Feb 






NPS; RT-PCR 9.3 3.8 7.5 4.1 0.8 2.8 
Memphis, Nashville and Salt Lake City, 












Spain (urban, Jan 1997 - Dec 2011) (Gil-






41.4 8.0 2.2 10.7 
Karemo, Kenya (rural, Aug 2009 - Jul 






13.4 14.0 (19.3) 8.1 2.0 5.2 
Ho Chi Minh, Vietnam (urban, Jul 2009 - 









Dong Thap, Vietnam (urban and rural, Aug 



























RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. NPA=nasopharyngeal aspirate. NPS=nasopharyngeal swab. 
NPW=nasopharyngeal wash. OPS=oropharyngeal swab. RT-PCR=reverse transcriptase polymerase chain reaction. IFA=indirect immunofluorescent 
antibody test. DFA=direct immunofluorescent antibody test. ELISA=enzyme-linked immunosorbent assay. IF=immunofluorescence. II=physician’s 
assessment. III=SARI definition. F+/-=fever as part of case definition or not. T+/-=tachypnea part of case definition or not. W+/-=wheeze part of case 
definition or not. C+/-=crepitation part of case definition or not. XR=X-ray confirmed (radiologically confirmed pneumonia). CWI+/-=chest wall indrawing 
part of case definition or not. DS+/-=danger signs part of case definition or not. O2+/-=hypoxemia part of case definition or not. ICU=intensive care unit. 
MV=mechanical ventilation. NA=not applicable. *Data in parentheses are computed hospitalisation rate estimates. #Studies reporting hospitalisation 





Figure 17: Meta-estimate of hospitalisation rate of RSV associated ALRI in finer age bands 
RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. Numbers above each bar are number of studies included in meta-analysis for 
























































High income Upper middle income Lower middle income Low income
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Table 28: Meta-estimate of hospitalisation rate of RSV associated ALRI 
Region 












(per 1000 children per year) 
Low income 5 7.4 (2.4-22.6) 4 3.4 (0.6-19.5) 3 0.4 (0.1-1.7) 
Lower middle income 17 22.9 (17.7-29.7) 9 11.3 (6.1-21.0) 9 1.8 (1.2-2.8) 
Upper middle income 15 23.0 (16.1-32.9) 5 18.5 (9.8-34.7) 7 2.2 (1.3-3.9) 
High income 31 26.3 (22.6-30.5) 8 13.0 (7.2-23.7) 6 1.6 (1.1-2.3) 
       
Developing 43 20.2 (16.7-24.5) 20 11.0 (7.7-15.7) 21 1.5 (1.0-2.1) 
Industrialised 25 27.3 (23.1-32.1) 6 11.5 (5.5-24.2) 4 2.0 (1.3-3.1) 




Table 29: Number of new cases of RSV associated hospitalised ALRI from studies reporting hospitalisation rate 
Region 
0-5m 6-11m 12-59m 0-59m* 
Hospitalised cases  
(*10³) 
Hospitalised cases  
(*10³) 
Hospitalised cases  
(*10³) 
Hospitalised cases  
(*10³) 
Low income 79 (26-240) 36 (6-207) 30 (7-132) 145 (39-580) 
Lower middle income 737 (569-955) 362 (195-674) 451 (288-702) 1551 (1052-2331) 
Upper middle income 407 (284-582) 327 (174-615) 305 (173-538) 1039 (632-1735) 
High income 206 (177-239) 102 (56-185) 100 (69-145) 407 (302-569) 
     
Developing 1243 (1025-1508) 674 (471-963) 693 (482-1003) 2610 (1979-3474) 
Industrialised 185 (157-218) 78 (37-164) 113 (73-176) 376 (267-557) 
     
Global# 1428 (1182-1726) 752 (509-1127) 806 (556-1179) 2986 (2246-4032) 
RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. *number of hospitalised cases in 0-59m is sum of estimates from exclusive finer 





Table 30: List of 9 studies reporting hospitalisation rate of RSV associated ALRI with chest wall indrawing 
Location (reference) Case definition (codes) 
Hospitalisation rate of RSV associated ALRI cases with chest 
wall indrawing (per 1000 children per year)* 
0-5m 6-11m 0-11m 12-23m 24-59m 0-59m 
Gambia Western Region, Gambia (Howie and colleagues) II, CWI+/-, W-, O2+/- (16.4) 17.4 12.4 3.4 1.0 3.4 
Santa Rosa, Guatemala (McCracken and colleagues) II, CWI+/-, DS+/- (34.3) 
 
25.8 5.2 0.8 6.9 
Quetzaltenango, Guatemala (McCracken and colleagues) II, CWI+/-, DS+/- (18.7) 
 
14.1 3.1 0.4 3.7 
Lombok, Indonesia (Gessner and colleagues) II, CWI+ 13.9 12.1 13.0 2.6 
 
(3.5) 
Kilifi hospital study, Kenya (Nokes and colleagues) II, CWI+, O2+/DS+ 22.8 10.3 16.6 3.2 0.5 4.3 
Tagbilaran and 6 rural sites, Philippines (Lucero and colleagues) II, CWI+, DS+/- 69.5 52.1 59.3 20.5 
 
(16.0) 
Soweto, South Africa (Madhi and colleagues) II, CWI+, O2+/- 9.2 3.3 5.8 0.9 0.2 1.3 
Maela Camp, Tak Province, Thailand (Turner and colleagues) II, CWI+, T+ 128.7 70.6 100.3 58.9 
 
(27.1) 
Nha Trang, Vietnam (Yoshida and colleagues) II, CWI+/DS+ 5.4 1.4 3.8 1.1 0.3 1.1 
RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. II=physician’s assessment. T+/-=tachypnea part of case definition or not. W+/-
=wheeze part of case definition or not. CWI+/-=chest wall indrawing part of case definition or not. DS+/-=danger signs part of case definition or not. 
O2+/-=hypoxemia part of case definition or not. *Data in parentheses are computed hospitalisation rate estimates.  
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Table 31: List of 18 studies reporting hospitalisation rate of RSV associated very severe ALRI 
Location (reference) Case definition (codes) 
Hospitalisation rate of RSV associated very severe ALRI 
cases (per 1000 children per year) 
0-5m 6-11m 0-11m 12-23m 24-59m 0-59m 
Buenos Aires, Argentina (Polack and colleagues) 
II, O2+, W+, F+/-, ICU+, 
MV+ 
28.8 12.4 20.6 3.8 
  
Belo Horizonte, Brazil (Oliveira and colleagues) II, F+, O2+, ICU+ 
  
0.6 0.1 0.0 0.1 
Concepcion, Chile (Fasce and colleagues) II, F+/-, ICU+ 
  
0.3 0.2 0.1 0.2 
Iquique, Chile (Fasce and colleagues) II, F+/-, ICU+ 
  
3.4 0.2 0.1 0.7 
Santa Rosa, Guatemala (McCracken and colleagues) II, CWI+/-, DS+ 
  
18.7 4.5 0.7 5.1 
Quetzaltenango, Guatemala (McCracken and colleagues) II, CWI+/-, DS+ 
  
11.1 2.6 0.3 3.0 
Ballabhgarh, India (Broor and colleagues) II, DS+ 3.2 1.1 2.0 0.3 0.1 0.6 
Kilifi hospital study, Kenya (Nokes and colleagues) II, CWI+, O2+/DS+ 3.2 0.6 2.0 0.2 0.1 0.5 
Bondo district, Kenya (Feikin and colleagues) II, O2+/DS+ 14.7 5.9 9.5 5.0 3.9 6.4 
Manhiça, Mozambique (Bassat and colleagues) II, T+ 6.0 3.3 4.7 0.6 0.0 1.1 
Manhiça, Mozambique (Bassat and colleagues) II, T+, O2+ 1.0 0.5 0.7 0.2 0.1 0.2 
41 sites in Netherlands (Bont and colleagues) II, ICU+ 
  
2.8 
   
Tagbilaran and 6 rural sites, Philippines (Lucero and colleagues) II, CWI+, DS+ 5.5 4.2 4.8 1.8 
  
Soweto, South Africa (Madhi and colleagues) II, CWI+, O2+ 9.9 1.6 5.2 0.6 0.0 1.1 
Maela Camp, Tak Province, Thailand (Turner and colleagues) II, CWI+, T+ 44.5 26.8 35.8 24.1 
  
Sa Kaeo and Nakhon Phanom, Thailand (Thamthitiwat and 
colleagues) 
II, F+/-, T+/-, CWI+, O2+ 0.1 0.0 0.0 0.0 0.0 0.0 
Colorado, USA (Simoes and colleagues) II 
  
2.1 0.4 0.2 0.6 
Alaska, USA (Singleton and colleagues)# II, MV+ 9.1 3.1 6.1 0.1 
  
RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. II=physician’s assessment. F+/-=fever as part of case definition or not. T+/-
=tachypnea part of case definition or not. W+/-=wheeze part of case definition or not. CWI+/-=chest wall indrawing part of case definition or not. DS+/-
=danger signs part of case definition or not. O2+/-=hypoxemia part of case definition or not. ICU=intensive care unit. MV=mechanical ventilation. 
#Studies reporting hospitalisation rate in an aboriginal population from a high-income country.  
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Table 32: List of 8 studies reporting hospitalisation rate of RSV associated ALRI with ICU admission 
Location (reference) Case definition (codes) 
Hospitalisation rate of RSV associated ALRI cases with ICU 
admission (per 1000 children per year) 
0-5m 6-11m 0-11m 12-23m 24-59m 0-59m 
Buenos Aires, Argentina (Polack and colleagues) II, O2+, W+, F+/-, ICU+, MV+ 5.6 1.4 3.5 0.2 
  
Belo Horizonte, Brazil (Oliveira and colleagues) II, F+, O2+, ICU+ 
  
0.5 0.1 0.0 0.1 
Concepcion, Chile (Fasce and colleagues) II, F+/-, ICU+ 
  
0.3 0.2 0.1 0.2 
Iquique, Chile (Fasce and colleagues) II, F+/-, ICU+ 
  
3.4 0.2 0.1 0.7 
Kilifi hospital study, Kenya (Nokes and colleagues) II, CWI+, O2+/DS+ 2.2 0.4 1.3 0.2 0.1 0.4 
41 sites in Netherlands (Bont and colleagues) II, ICU+ 
  
2.8 
   
Soweto, South Africa (Madhi and colleagues) II, CWI+, O2+ 0.8 0.1 0.4 0.0 0.0 0.1 
Colorado, USA (Simoes and colleagues) II 
  
2.1 0.4 0.2 0.6 
RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. II=physician’s assessment. F+/-=fever as part of case definition or not. W+/-
=wheeze part of case definition or not. CWI+/-=chest wall indrawing part of case definition or not. DS+/-=danger signs part of case definition or not. 





Table 33: List of 4 studies reporting hospitalisation rate of RSV associated ALRI with mechanical ventilation 
Location (reference) Case definition (codes) 
Hospitalisation rate of RSV associated ALRI cases with 
mechanical ventilation (per 1000 children per year) 
0-5m 6-11m 0-11m 12-23m 24-59m 0-59m 
Buenos Aires, Argentina (Polack and colleagues) II, O2+, W+, F+/-, ICU+, MV+ 2.1 1.6 1.8 0.6 
  
41 sites in Netherlands (Bont and colleagues) II, ICU+ 
  
2.3 
   
Sa Kaeo and Nakhon Phanom, Thailand (Thamthitiwat 
and colleagues) 
II, F+/-, T+/-, CWI+, O2+ 0.1 0.0 0.0 0.0 0.0 0.0 
Colorado, USA (Simoes and colleagues) II 
  
0.8 0.1 0.0 0.2 
RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. II=physician’s assessment. F+/-=fever as part of case definition or not. T+/-
=tachypnea part of case definition or not. W+/-=wheeze part of case definition or not. CWI+/-=chest wall indrawing part of case definition or not. O2+/-




Table 34: Meta-estimate of hospitalisation rate of RSV associated very severe ALRI  
Region 
0-5m 6-11m 12-59m 
No. of 
studies 
Hospitalisation rate (per 1000 
children per year) 
No. of 
studies 
Hospitalisation rate (per 
1000 children per year) 
No. of 
studies 
Hospitalisation rate (per 
1000 children per year) 
Low income 3 4.5 (1.1-19.0) 3 2.2 (0.6-8.6) 3 0.4 (0.0-6.4) 
Lower middle income 3 3.8 (2.7-5.6) 3 1.5 (0.4-5.9) 4 0.4 (0.1-1.3) 
Upper middle income 4 8.4 (3.4-21.1) 4 8.0 (1.8-35.2) 3 0.1 (0.0-0.2) 
High income 0 - 0 - 3 0.2 (0.1-0.3) 
       
Developing 10 5.2 (2.4-11.0) 10 3.0 (1.2-7.7) 12 0.2 (0.1-0.4) 
Industrialised 0 - 0 - 1 - 




Table 35: Number of new cases of RSV associated very severe hospitalised ALRI 
Region 
0-5m 6-11m 12-59m 0-59m* 
Hospitalised cases Hospitalised cases Hospitalised cases Hospitalised cases 
Low income 47774 (11279-202481) 23089 (5852-90973) 33694 (2407-512628) 104557 (19537-806083) 
Lower middle income 123468 (85205-179092) 47265 (11897-189060) 107821 (35104-318448) 278553 (132207-686600) 
Upper middle income 149448 (59850-373090) 142366 (32404-624001) 6932 (1386-29115) 298746 (93641-1026206) 
High income - - 10927 (5785-19926) - 
     
Developing 318188 (149554-677611) 184020 (72008-471435) 95526 (42987-210156) 597733 (264549-1359202)# 
Industrialised - - - - 
*number of hospitalised cases in 0-59m is sum of estimates from exclusive finer age bands (0-5m, 6-11m and 12-59m). #212088 (101602-214723) 




Table 36: Sensitivity analyses of hospitalisation rate to include studies with aboriginal population and exclude studies with different case 
definitions respectively 
Region 
Final estimate in 0-59m 
Sensitivity analysis to include studies with 
aboriginal population 
Sensitivity analysis to exclude studies 
with different case definitions 
No. of 
studies 
Hospitalisation rate (per 
1000 children per year) 
No. of studies 
Hospitalisation rate (per 
1000 children per year) 
No. of studies 
Hospitalisation rate (per 
1000 children per year) 
Low income 5 1.7 (0.6-5.1) 5 1.7 (0.6-5.1) 4 1.2 (0.3-4.5) 
Lower middle income 17 5.1 (3.7-6.9) 17 5.1 (3.7-6.9) 14 4.5 (3.4-6.1) 
Upper middle income 15 6.2 (5.0-7.8) 15 6.2 (5.0-7.8) 13 6.9 (5.3-8.9) 
High income 31 5.5 (4.7-6.3) 36 6.7 (5.9-7.8) 30 5.3 (4.6-6.2) 
       
Developing 43 4.9 (4.1-5.8) 43 4.9 (4.1-5.8) 36 4.6 (3.8-5.6) 





5.2.3 Proportion of RSV associated hospitalised ALRI  
Overall, 168 articles (Al-Shehri et al., 2005, Al-Toum et al., 2006, Assaf-Casals et al., 2015, 
Avendano et al., 2003, Bakir et al., 1998, Balmaks et al., 2014, Banerji et al., 2009, Bdour, 
2001, Bedoya et al., 1996, Bukhari and Elhazmi, 2013, Calvo et al., 2010, Canducci et al., 
2008, Carballal et al., 2000, Cevey-Macherel et al., 2009, Chan et al., 2007, Chan et al., 
1999b, Chen et al., 2005, Chen et al., 2014b, Chung et al., 2007, Do et al., 2011, 
Ekalaksananan et al., 2001, Farzin et al., 2015, Feikin et al., 2013, Ferone et al., 2014, 
Ferronato et al., 2012, Flaherman et al., 2010, Foulongne et al., 2006, Fuller et al., 2013, 
Garcia et al., 2010, Garcia-Garcia et al., 2006, Hamada et al., 2014, Hammitt et al., 2012a, 
Harada et al., 2013, He et al., 2014, Hervas et al., 2012, Huang et al., 2013a, Hussey et al., 
2000, Jansson et al., 2002, Juven et al., 2000, Kaneko et al., 2002, Khamis et al., 2012, 
Kwofie et al., 2012, Lamarao et al., 2012, Loscertales et al., 2002, Macedo et al., 2002, 
Maggi et al., 2007, Mazumdar et al., 2013, Min et al., 2011, Mlinaric-Galinovic et al., 2009a, 
Mlinaric-Galinovic et al., 2009b, Moore et al., 2012, Moriyama et al., 2010, Moura et al., 
2002, Murray et al., 2014, Nascimento-Carvalho et al., 2010, Noyola et al., 2007, Okada et 
al., 2012, Oliveira et al., 2009, Ouedraogo et al., 2014, Pecchini et al., 2008, Pineros et al., 
2013, Pourakbari et al., 2014, Salomao Jr et al., 2011, Santibanez et al., 2012, Singh et al., 
2014, Singleton et al., 1995, Siritantikorn et al., 2002, Sparremberger et al., 2011, Sung et al., 
2009, Suryadevara et al., 2011, Sutmoller et al., 1995, Takeyama et al., 2014, Tallo et al., 
2014, Tang et al., 2008, Teeratakulpisarn et al., 2007, Tran et al., 2013, Tsolia et al., 2003, 
Turkish Neonatal, 2012, Turner et al., 2013, Vagia et al., 2010, Van Leeuwen et al., 2012, 
Videla et al., 1998, Viegas, 2011, Vieira et al., 2007, Wasem et al., 2008, Weigl et al., 2002b, 
Wolf et al., 2006, Wolf et al., 2010, Yeolekar et al., 2008, Yoo et al., 2007, Zhang et al., 
2012b, Zhang et al., 2011, Zuccotti et al., 2011, Cao et al., 2004, Cao et al., 2007, Cao et al., 
2015, Cao et al., 2013, Chang et al., 2010, Che et al., 2004, Chen, 2012, Chen and Chen, 
2009, Chen et al., 2010, Chen et al., 2014a, Ding and Tian, 2014, Ding et al., 2012, Du, 2012, 
Fan et al., 2007, He, 2015, Hu and Wang, 2014, Huang et al., 2013b, Ji et al., 2013, Jiang 
and Lan, 2007, Jiang et al., 2013a, Jiang et al., 2013b, Ju et al., 2012, Lei, 2012, Li et al., 
2013, Liang and Ge, 2014, Liang et al., 2012, Lin et al., 2015, Liu et al., 2013a, Liu et al., 
2015b, Liu et al., 2013b, Lu et al., 2005, Lu et al., 2012, Ma et al., 2005, Miao et al., 2010, 
Ou et al., 2009b, Peng et al., 2009b, Qin et al., 2008, Ru et al., 2013, Sheng et al., 2014, Shi 
et al., 2012, Sun et al., 2004, Tan et al., 2009, Wan et al., 2006, Wang et al., 2015, Wang et 
al., 2011, Wang, 2011, Wang et al., 2012, Xiang et al., 2005, Xiao et al., 2012, Xie et al., 
2013, Xie and Deng, 2011, Xu et al., 2014, Xue et al., 2014, Yang et al., 2009, Yao et al., 
2015, Ye and Yuan, 2004, Ye et al., 2014, Yin, 2014, Yin et al., 2012, Zeng et al., 2008, 
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Zhang et al., 2013a, Zhang et al., 2012a, Zhang et al., 2014a, Zhang and Yu, 2015, Zhang, 
2008, Zhang et al., 2014b, Zhang et al., 2013b, Zhang et al., 2014c, Zhang et al., 2002, Zhao 
et al., 2011, Zhao et al., 2003, Zheng, 2011, Zhu and Hua, 2011, Malekshahi et al., 2010, 
Faghihloo et al., 2014) were identified providing proportion data (proportion of hospitalised 
ALRI cases which are RSV positive) and 73 of them were identified in Chinese language 
based databases. An additional 31 unpublished studies from RSV GEN were providedU46-76 
(Table 37). Overall, 199 studies were included in the meta-analysis (Table 38). All of these 
studies adopted passive hospital-based or clinic-based case ascertainment, and recruited only 
inpatients. Among them, 36 were from industrialised countries while 163 were from 
developing countries. Most studies (178 studies) were based in urban settings, 13 were from 
rural areas and 8 were from districts with mixed populations. Five studies provided 
proportion data in only neonates. One study reported proportion data in Alaska among an 
aboriginal population and therefore was excluded from the final estimate (Singleton et al., 
1995). There were 15 published studies (Avendano et al., 2003, Bakir et al., 1998, Calvo et 
al., 2010, Cevey-Macherel et al., 2009, Feikin et al., 2013, Ferronato et al., 2012, He et al., 
2014, Juven et al., 2000, Mazumdar et al., 2013, Okada et al., 2012, Sparremberger et al., 
2011, Suryadevara et al., 2011, Tallo et al., 2014, Zhang et al., 2012b, Ding et al., 2012) and 
9 unpublished studiesU48, U55-62 which used different definitions (SARI, wheeze exclusion or 
fever inclusion) to define ALRI and thus they were excluded in a further sensitivity analysis 
to explore the influence of these studies. The meta-analysis result was presented by six WHO 
regions because the updated estimate of hospitalisation rate of pneumonia is only available 
by WHO region. After application of the population number in 2015, the number of new 
cases of pneumonia was generated, which was then combined with the corresponding meta-
estimate of the proportion data. The summary of the meta-estimate of the proportion data in 
each region as well as number of hospitalised cases were shown in Table 39. The relevant 
forest plots were available in Appendices – A18. In Africa, 21.3% of hospitalised ALRI 
cases were estimated to be positive with RSV among children younger than 5 years, the 
proportion was 28.6% in Americas, 23.9% in Eastern Mediterranean, 28.3% in Europe, 24.2% 
in South-East Asia, and 22.1% in Western Pacific. After applying the number of hospitalised 
ALRI cases in each WHO region to the corresponding meta-estimate of the proportion data 
respectively, the global number of new episodes of RSV associated hospitalised ALRI in 
children younger than five years was around 2.8 (95% CI 2.3-3.4) million. Compared to the 
estimate of hospitalised cases from studies reporting hospitalisation rate, which is 3.0 (95% 
CI 2.2-4.0) million, both estimates are quite similar and their confidence intervals overlap. 
These two approaches represent two independent methods to estimate number of new cases 
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of RSV associated hospitalised ALRI based on completely different studies (different study 
sites, different underlying population enrolled, different methodologies used etc.). However, 
the substantial similarity between estimates from these two approaches cross check and act 
to broadly replicate the estimate of the number of hospitalised cases. The estimate from the 
first approach which used studies reporting hospitalisation rate will be used in the following 
analysis.  
A sensitivity analysis was carried out to exclude studies with different case definitions which 
were mentioned above. The result was compared to previous estimate and was shown in 
Table 40. In general, the proportion from sensitivity analysis where studies using different 
case definitions were excluded was consistently lower than the meta-estimate where these 
studies were included, however, no substantial difference was identified across regions. 
Another sensitivity analysis to include studies reporting data in aboriginal population was 





Table 37: List of 33 unpublished studies reporting hospital based proportion data 
Study 
number 
Location (reference) Study period 
U46 Buenos Aires, Argentina (Echavarria and colleagues) 
1st Jun 2008 - 31st Dec 
2010 
U47 Buenos Aires, Argentina (Gentile and colleagues) 2001 - 2013 
U48 
Takeo and Kampong Cham, Cambodia (Goyet and 
colleagues) 
Apr 2007 - Feb 2010 
U49 Chillan, Chile (Fasce and colleagues) 2010 - 2013 
U50 Osorno, Chile (Fasce and colleagues) 2010 - 2013 
U51 Punta Arenas, Chile (Fasce and colleagues) 2010 - 2013 
U52 Santiago, Chile (Fasce and colleagues) 2010 - 2013 
U53 Valparaiso, Chile (Fasce and colleagues) 2010 - 2013 
U54 China (Yu and colleagues) Jan 2009 - Sep 2013 
U55 Beijing, China (GABRIEL) Jan 2011 - Dec 2012 
U56 Ulaanbaatar, Mongolia (GABRIEL) Sep 2011 - Oct 2012 
U57 Phnom Penh, Cambodia (GABRIEL) Oct 2010 - Jan 2013 
U58 Lucknow, India (GABRIEL) Jun 2012 - Dec 2013 
U59 Antananarivo, Madagascar (GABRIEL) Dec 2010 - Feb 2013 
U60 Asuncion, Paraguay (GABRIEL) Jul 2010 - May 2013 
U61 Bamako, Mali (GABRIEL) Jul 2011 - Nov 2012 
U62 Berlin, Germany (Rath and colleagues) 
1st Apr 2010 - 31st Mar 
2014 
U63 Amman, Jordan (Khuri and colleagues) Mar 2010 - Mar 2013 
U64 Lwak, Kenya (Montgomery and colleagues) 2007 - 2011 
U65 Rabat, Morocco (Bassat and colleagues) Nov 2010 - Dec 2011 
U66 Kathmandu, Nepal (Basnet and colleagues) Jan 2006 - Jun 2008 
U67 Karachi, Pakistan (Ali and colleagues) Aug 2009 - Jul 2012 
U68 Basse, Gambia (PERCH) 
3rd Nov 2011 - 2nd Nov 
2013 
U69 Kilifi, Kenya (PERCH) 
15th Aug 2011 - 15th Nov 
2013 
U70 Bamako, Mali (PERCH) 
3rd Jan 2012 - 14th Jan 
2014 
U71 Nakhon Phanom and Sa Kaeo, Thailand (PERCH) 
1st Jan 2012 - 31st Jan 
2014 
U72 Lusaka, Zambia (PERCH) 
10th Oct 2011 - 31st Oct 
2013 
U73 Dhaka, Bangladesh (PERCH) 






Location (reference) Study period 
U74 Matlab, Bangladesh (PERCH) 
1st Jan 2012 - 31st Dec 
2013 
U75 Tacloban, Philippines (Lupisan and colleagues) May 2008 - Jul 2012 








Specimen and diagnostic test 
Proportion of RSV associated 
hospitalised ALRI (%) 
0-11m 0-23m 0-35m 0-59m 
Subiaco, Australia (urban, Jan 2000 - Dec 2005) (Moore et al., 
2012) 
II 




Hangzhou, China (urban, Jan 2001 - Dec 2006) (Tang et al., 
2008) 




Lanzhou, China (urban, 1st Jan - 31st Dec 2011) (Huang et al., 
2013a) 
II, F+/-, W+/-, XR throat swab; RT-PCR 19.3 
   
Lanzhou, China (urban, Oct 2004 - Oct 2005) (Zhang et al., 
2011) 
II, F+/-, XR NPA, serum; DFA, ELISA 23.4 
 
20.3 19.2 
Shanghai, China (urban, May 2009 - Jul 2010) (Zhang et al., 
2012b) 




Hong Kong, China (urban, 1st Jan 2004 - 31st Dec 2004) (Chan 
et al., 2007) 




Hong Kong, China (urban, Nov 2005 - Oct 2006) (Sung et al., 
2009) 
II, W+/-, F+/- 
NPA, nasal swab; DFA, RT-
PCR, viral culture    
8.4 
Taiwan, China (urban, Jan 2001 - Dec 2003) (Chen et al., 2005) II NPA; virus culture, IF 26.1 24.3 
 
23.5 
Shizuoka, Japan (urban, 1st Jul 1997 - 30th Jun 2000) (Kaneko 
et al., 2002) 




Tokyo, Japan (urban, Mar 2007 - Jul 2009) (Moriyama et al., 
2010) 




Japan (urban, Apr 2008 - Apr 2009) (Okada et al., 2012) II, F+, XR NPS; RT-PCR 26.9 28.7 
 
26.1 
Nagasaki, Japan (urban, Apr 2009 - Mar 2010) (Harada et al., 
2013) 
II, XR NPS; IF, RT-PCR 
   
55.9 
Seoul, Korea (urban, Jan - Dec 2004) (Yoo et al., 2007) II, W+, XR NPA; RT-PCR 
   
29.5 
Seoul, Korea (urban, Jul 2004 - Jan 2006) (Chung et al., 2007) II, XR, W+ NPA; DFA 
   
20.6 




Kuala Lumpur, Malaysia (urban, Jan 1982 - Dec 1997) (Chan et 
al., 1999b) 







Specimen and diagnostic test 
Proportion of RSV associated 
hospitalised ALRI (%) 
0-11m 0-23m 0-35m 0-59m 
Ho Chi Minh City, Vietnam (urban, Nov 2004 - Jan 2008) (Do et 
al., 2011) 
II, T+, CWI+/-, 
ICU+/- 





Ho Chi Minh City, Vietnam (urban, Apr 2010 - May 2011) (Tran 
et al., 2013) 








Kolkata, India (urban, Apr 2010 - Mar 2011) (Mazumdar et al., 
2013) 
III, CWI+, W+, C+, 
T+ 





Lucknow, India (urban, Jun 2011 - May 2012) (Singh et al., 
2014) 
II, CWI+ NPA; RT-PCR 34.3 
  
25.2 
Khon Kaen, Thailand (urban, Aug 1992 - Nov 1994) 
(Ekalaksananan et al., 2001) 
II, CWI+, XR NPA; virus culture, IF, ELISA 
   
29.0 
Nakhon Sawan, Thailand (rural, Nov 1998 - Feb 2001) 
(Siritantikorn et al., 2002) 
II, CWI+ NPA; IFA 
   
34.2 
Khon Kaen, Thailand (urban, Apr 2002 - Aug 2004) 
(Teeratakulpisarn et al., 2007) 
II, W+, T+ NPA; RT-PCR 67.6 64.7 
  
Tak Province, Thailand (rural, Apr 2009 - Sep 2011) (Turner et 
al., 2013) 
II, CWI+/-, DS+/- NPA; RT-PCR 39.1 
   
Seeb, Oman (urban, Dec 2007 - Dec 2008) (Khamis et al., 2012) II NPA; IF, RT-PCR 
   
21.6 




Amman, Jordan (urban, Sep 2002 - Mar 2004) (Al-Toum et al., 
2006) 
II NPA; DFA 15.6 12.5 
  
Riyadh, Saudi Arabia (urban, Apr 1993 - Mar 1996) (Bakir et 
al., 1998) 
II, F+, W+/-, XR NPA; IFA 
   
28.9 
Riyadh, Saudi Arabia (urban, Jan 2005 - Dec 2010) (Bukhari 
and Elhazmi, 2013) 
II NPA; DFA 48.8 
 
48.4 47.4 
Abha, Saudi Arabia (urban, Oct 1997 - Sep 2001) (Al-Shehri et 
al., 2005) 
II NPA; ELISA, IFA 
   
35.3 
Zagreb County, Croatia (urban, 1994 - 2005) (Mlinaric-
Galinovic et al., 2009b) 
II NPA; DFA, virus isolation 50.9 47.4 
 
45.8 








Specimen and diagnostic test 
Proportion of RSV associated 
hospitalised ALRI (%) 
0-11m 0-23m 0-35m 0-59m 
(Mlinaric-Galinovic et al., 2009a) 




Montpellier, France (urban, 1st Nov 2003 - 31st Oct 2004) 
(Foulongne et al., 2006) 
II NPA; DFA, virus culture 33.8 30.5 29.4 
 
Kiel, Germany (urban, Jul 1996 - Jun 2001) (Weigl et al., 2002b) II NPA; ELISA, RT-PCR 28.2 23.6 
 
19.8 
Germany (urban, Nov 1999 - Oct 2001 and Oct 2002 - Jun 2005) 
(Wasem et al., 2008) 
II NPA; RT-PCR, ELISA 42.8 36.2 34.1 
 
Athens, Greece (urban, 2008 - 2009) (Vagia et al., 2010) II NPA; IF 
   
28.5 
Be'er Sheva, Israel (urban, Nov 2001 - Oct 2002) (Wolf et al., 
2006) 
II nasal wash; DFA 
   
19.6 
Be'er Sheva, Israel (urban, Nov 2001 - Oct 2005) (Wolf et al., 
2010) 
II, XR NPW; DFA, culture 
   
28.0 








Milan, Italy (urban, 1st Dec 2008 - 31st Dec 2009) (Zuccotti et al., 
2011) 
II, W+/- OPS; RT-PCR 52.0 42.6 
 
37.0 
Enschede, Netherlands (urban, 2006 - 2007) (Van Leeuwen et al., 
2012) 








Madrid, Spain (urban, Oct 2000 - Jun 2005) (Garcia-Garcia et 
al., 2006) 








Malmo, Sweden (urban, 1998 - 1999) (Jansson et al., 2002) II NPA; IF 54.5 
   
Lausanne and Geneva, Switzerland (urban, Mar 2003 - Dec 
2005) (Cevey-Macherel et al., 2009) 
II, CWI+, W- 
NPA, serum; RT-PCR, IFA, 
ELISA, serology    
13.1 
Turkey (urban, May 2008 - Sep 2010) (Turkish Neonatal, 2012) II 
NPA, NPS, nasal wash, nasal 
swab; IF  
16.9 
  









Specimen and diagnostic test 
Proportion of RSV associated 
hospitalised ALRI (%) 
0-11m 0-23m 0-35m 0-59m 
(Carballal et al., 2000) 
Buenos Aires, Argentina (urban, 1999 - 2004) (Viegas, 2011) II NPA; RT-PCR, DFA 
   
31.6 
Pelotas, Brazil  (urban, 1st Aug 1997 - 31st Jul 1998) (Macedo et 
al., 2002) 
II, CWI+ NPA; DFA 30.8 
   
Bahia, Brazil (urban, Jan - Dec 1998) (Moura et al., 2002) II NPA; IFA 
   
23.8 
Sao Paulo, Brazil (urban, Mar 1999 - Jun 2000) (Vieira et al., 
2007) 
II, W+, XR 
NPA, nasal swab; IFA, virus 
culture, RT-PCR 
60.9 
   
Sao Paulo, Brazil (urban, Jan 2003 - Dec 2006) (Oliveira et al., 
2009) 
II NPA, nasal swab; RT-PCR 45.4 
  
42.0 
Sao Paulo, Brazil (urban, Jan 2006 - Dec 2007) (Ferronato et al., 
2012) 
II, W- NPA; IFA 63.5 
   
Bahia, Brazil (urban, Sep 2003 - May 2005) (Nascimento-
Carvalho et al., 2010) 
II, XR NPA, serum; IF, ELISA 
   
15.2 
Sao Paulo, Brazil (urban, May 2004 - Sep 2005) (Salomao Jr et 
al., 2011) 
II, T+/-, W+/- NPA; RT-PCR 40.4 34.1 
  
Sao Paulo, Brazil (urban, Feb 2005 - Sep 2006) (Pecchini et al., 
2008) 
II, W+/- NPA; IFA 30.1 
  
28.6 
Sao Paulo, Brazil (urban, Mar 2008 - Aug 2011) (Ferone et al., 
2014) 




Belem, Brazil (urban, Nov 2006 - Oct 2007) (Lamarao et al., 
2012) 




Porto Alegre, Brazil (urban, Sep 2009 - Sep 2010) 
(Sparremberger et al., 2011) 
II, W- NPA; DFA 53.5 
   
Iqaluit, Canada (urban, 28th Jan 2002 - 27th Mar 2003) (Banerji 
et al., 2009) 




British Columbia, Canada (urban, Apr 2008 - Mar 2010) 
(Santibanez et al., 2012) 
II NA 48.1 
   
Medellin, Colombia (urban and rural, Apr 1994 - Apr 1995) 
(Bedoya et al., 1996) 
II NPW; DFA 41.7 
   
Colombia (urban, Apr 2005 - Apr 2006) (Pineros et al., 2013) II NPA; IF 30.1 






Specimen and diagnostic test 
Proportion of RSV associated 
hospitalised ALRI (%) 
0-11m 0-23m 0-35m 0-59m 
San Luis Potosi, Mexico (urban, 1st May 2003 - 30th Apr 2005) 
(Noyola et al., 2007) 
II NPW; DFA 26.9 25.9 24.8 
 
Alaska, USA (rural, 1st Oct 1991 - 30th Sep 1993)# (Singleton et 
al., 1995) 








Dallas, Texas, USA (urban, Jan 2002 - Dec 2007) (Garcia et al., 
2010) 




New York, USA (urban, Oct 2007 - May 2010) (Suryadevara et 
al., 2011) 
II, F+ 




Kumasi, Ghana (urban, Jan 2008 - Dec 2008) (Kwofie et al., 
2012) 





Rarieda, Kenya (rural, 1st Mar 2007 - 28th Feb 2010) (Feikin et 
al., 2013) 
III, DS+/CWI+ NPS, OPS; RT-PCR 
   
22.6 
Kilifi, Kenya (rural, Jan - Dec 2010) (Hammitt et al., 2012a) II, CWI+ NPA, OPS, sputum; RT-PCR 
   
26.5 
Bondo district, Kenya (rural, Aug 2008 - Dec 2010) (Fuller et al., 
2013) 
II, CWI+/DS+/O2+ NPS, OPS; RT-PCR 
   
17.1 
Santiago, Chile (urban, Jan 1989 - Dec 2000) (Avendano et al., 
2003) 




Cape Town, South Africa (urban, Jun 1995 - Aug 1996) (Hussey 
et al., 2000) 




Manhica District, Mozambique (rural, Oct 1998 - May 2000) 
(Loscertales et al., 2002) 
II, CWI+/-, W+/-, 
T+/- 
NPA; ELISA 10.7 
   
Athens, Greece (urban, Feb 1997 - Jun 2000) (Tsolia et al., 2003) II, XR, W+/-, T+/- NPW; DFA 61.5 
   
Buenos Aires, Argentina (urban, May 1991 - Dec 1992) (Videla et 
al., 1998) 






Rio de Janeiro, Brazil (rural, Jan 1987 - Dec 1989) (Sutmoller et 
al., 1995) 
II, T+/-, W+/- NPA; IFA, culture 
   
40.5 
Beijing, China (urban, Feb 2001 - Mar 2003) (Cao et al., 2004) II NPA; virus culture, IFA 44.9 
 
39.0 36.5 








Specimen and diagnostic test 
Proportion of RSV associated 
hospitalised ALRI (%) 
0-11m 0-23m 0-35m 0-59m 
Changsha, China (urban, Sep 2007 - Aug 2008) (Ding et al., 
2012) 
II, F+, T+ NPA; RT-PCR 42.0 
 
37.1 37.0 
Changsha, China (urban, Sep 2007 - Aug 2008) (Xiao et al., 2012) II NPA; RT-PCR 30.1 
 
27.6 27.6 
Changsha, China (urban, Jun 2011 - Jun 2012) (Li et al., 2013) II NPA; DFA 55.1 
 
53.7 53.9 
















Chongqing, China (urban, Apr 2003 - Oct 2007) (Peng et al., 
2009b) 




Chongqing, China (urban, Apr 2008 - Mar 2009) (Du, 2012) II NPA; RT-PCR 31.7 29.3 28.7 
 
Chongqing, China (urban, Feb 2009 - Mar 2011)* (Zhu and Hua, 
2011) 
II NPA; DFA 
    












Fuyang, China (urban, Jan 2003 - Dec 2004)* (Jiang and Lan, 
2007) 
II NPA; DFA 
    
Guangzhou, China (urban, Oct 2009 - Sep 2010) (Xie and Deng, 
2011) 
II NPS; RT-PCR 10.7 
 
8.5 7.5 




Guiyang, China (urban, Jun 2006 - Apr 2011) (Huang et al., 
2013b) 












Hangzhou, Chin (urban, 2001 - 2003)* (Ma et al., 2005) II NPA; DFA 






Specimen and diagnostic test 
Proportion of RSV associated 
hospitalised ALRI (%) 
0-11m 0-23m 0-35m 0-59m 
Jiaxing, China (urban, Dec 2008 - Dec 2009) (Miao et al., 2010) II NPA; RT-PCR, DFA 16.8 15.8 
  
Jiaxing, China (urban, Aug 2010 - Aug 2012) (Zhang et al., 
2013a) 








Kunming, China (urban, Sep 2009 - Sep 2010) (Zheng, 2011) II NPA; RT-PCR 46.2 42.9 40.8 40.2 
Yueqing, China (urban, Jan 2006 - Dec 2010) (Zhang et al., 
2012a) 
II NPA; DFA 32.0 
 
23.2 19.3 
Liaocheng, China (urban, Oct 2007 - Oct 2008) (Chen and Chen, 
2009) 




Linyi, China (urban, Dec 2010 - Dec 2011) (Chen, 2012) II NPA; RT-PCR 33.2 31.5 
  
Nanjing, China (urban, Apr 2006 - Mar 2007) (Qin et al., 2008) II NPA; DFA 28.3 20.9 
 
17.1 








Shanghai, China (urban, May 2001 - Apr 2002) (Zhao et al., 
2003) 




Shanghai, China (urban, Jan - Dec 2000) (Che et al., 2004) II NPA; IF 21.1 
 
19.1 18.6 
Shanghai, China (urban, Oct 2002 - Apr 2004) (Lu et al., 2005) II NPA; DFA 29.8 
 
20.4 19.0 
Shanghai, China (urban, 2003 - 2006) (Zeng et al., 2008) II NPA; DFA 21.4 
 
23.0 21.6 
Shanghai, China (urban, Jan 2009 - Mar 2010) (Zhao et al., 
2011) 




Shanghai, China (urban, Mar 2011 - Feb 2012) (Zhang et al., 
2013b) 




Shangluo, China (urban, May 2011 - May 2012) (Ru et al., 2013) II NPA; IF 43.3 
 
40.6 39.7 
Shantou, China (urban, Jan 2007 - Dec 2007) (Ou et al., 2009b) II NPA; RT-PCR 
   
19.1 
Suzhou, China (urban, Sep 2005 - Oct 2011) (Ji et al., 2013) II NPA; DFA 22.4 
 
18.9 17.1 









Specimen and diagnostic test 
Proportion of RSV associated 
hospitalised ALRI (%) 
0-11m 0-23m 0-35m 0-59m 








Wenzhou, China (urban, Jan 2003 - Jan 2005) (Xiang et al., 
2005) 












Wenzhou, China (urban, Jan 2007 - Dec 2008) (Chang et al., 
2010) 




Wenzhou, China (urban, Feb 2009 - Jan 2010) (Wang et al., 
2011) 
II NPA; DFA 34.1 
 
30.4 28.2 
Wenzhou, China (urban, Jan - Dec 2010)* (Liang et al., 2012) II NPA; IF 
    








Zhongshan, China (urban, Apr 2011 - Mar 2012) (Liu et al., 
2013b) 
II NPS; IF 17.8 
   
Zhuzhou, China (urban, Jan - Dec 2011) (Jiang et al., 2013b) II NPA; DFA 26.7 
 
25.3 22.5 
Buenos Aires, Argentina (urban, 1st Jun 2008 - 31st Dec 2010) 
(Echavarria and colleagues) 
II, ICU+/-, MV+/- NPA; IFA 43.0 36.8 34.8 33.3 
Buenos Aires, Argentina (urban, 2001 - 2013) (Gentile and 
colleagues) 
II, MV+/- NPA; IFA 42.7 40.4 39.8 38.9 
Takeo and Kampong Cham, Cambodia (urban, Apr 2007 - Feb 
2010) (Goyet and colleagues) 
II, F+, T+ NPS, throat swab; RT-PCR 22.6 20.5 20.2 18.8 
Chillan, Chile (urban and rural, 2010 - 2013) (Fasce and 
colleagues) 
II NPA; IF 27.2 
  
23.7 
Osorno, Chile (urban and rural, 2010 - 2013) (Fasce and 
colleagues) 
II NPA; IF 25.4 
  
22.3 
Punta Arenas, Chile (urban and rural, 2010 - 2013) (Fasce and 
colleagues) 








Specimen and diagnostic test 
Proportion of RSV associated 
hospitalised ALRI (%) 
0-11m 0-23m 0-35m 0-59m 
Santiago, Chile (urban, 2010 - 2013) (Fasce and colleagues) II NPA; IF 33.5 
  
28.2 
Valparaiso, Chile (urban mostly, 2010 - 2013) (Fasce and 
colleagues) 
II NPA; IF 20.1 
  
16.0 
China (urban and rural, Jan 2009 - Sep 2013) (Yu and 
colleagues) 
II, XR, W+/-, F+/- NPA, NPS; PCR 27.0 24.9 23.5 21.6 
Beijing, China (urban, Jan 2011 - Dec 2012) (GABRIEL and 
colleagues) 
II, T+, W-, XR NPA, NPS; RT-PCR 73.8 53.8 42.2 33.1 
Ulaanbaatar, Mongolia (urban, Sep 2011 - Oct 2012) (GABRIEL 
and colleagues) 
II, T+, W-, XR NPA, NPS; RT-PCR 21.4 21.5 24.7 22.8 
Phnom Penh, Cambodia (urban, Oct 2010 - Jan 2013) 
(GABRIEL and colleagues) 
II, T+, W-, XR NPA, NPS; RT-PCR 21.8 22.6 22.8 21.7 
Lucknow, India (urban and rural, Jun 2012 - Dec 2013) 
(GABRIEL and colleagues) 
II, T+, W-, XR NPA, NPS; RT-PCR 9.1 6.4 6.2 5.7 
Antananarivo, Madagascar (urban and rural, Dec 2010 - Feb 
2013) (GABRIEL and colleagues) 
II, T+, W-, XR NPA, NPS; RT-PCR 10.9 15.9 15.0 13.2 
Asuncion, Paraguay (urban, Jul 2010 - May 2013) (GABRIEL 
and colleagues) 
II, T+, W-, XR NPA, NPS; RT-PCR 25.6 16.9 14.9 14.3 
Bamako, Mali (urban, Jul 2011 - Nov 2012) (GABRIEL and 
colleagues) 
II, T+, W-, XR NPA, NPS; RT-PCR 43.6 36.4 30.9 26.5 
Berlin, Germany (urban, 1st Apr 2010 - 31st Mar 2014) (Rath 
and colleagues) 
II, F+, ICU+/- NPS, NPA; RT-PCR 38.8 31.2 29.5 27.7 
Tehran, Iran (urban, Mar 2008 - May 2009) (Malekshahi et al., 
2010) 
II throat swab and wash; PCR 20.5 18.9 17.6 17.6 
Iran (urban, Nov 2007 - Apr 2013) (Faghihloo et al., 2014) II throat swab; RT-PCR 24.6 24.7 
  




nasal and throat swab; PCR 55.7 52.5 
  
Lwak, Kenya (rural, 2007 - 2011) (Montgomery and colleagues) II, CWI+/DS+/O2+ NPS, OPS; RT-PCR 32.9 25.9 23.3 21.5 
Rabat, Morocco (urban, Nov 2010 - Dec 2011) (Bassat and 
colleagues) 
II, CWI+, T+ NPA; RT-PCR 29.3 22.3 19.9 17.3 







Specimen and diagnostic test 
Proportion of RSV associated 
hospitalised ALRI (%) 
0-11m 0-23m 0-35m 0-59m 
colleagues) 
Karachi, Pakistan (urban, Aug 2009 - Jul 2012) (Ali and 
colleagues) 
II throat swab; RT-PCR 22.1 21.2 20.5 19.4 
Basse, Gambia (rural, 3rd Nov 2011 - 2nd Nov 2013) (PERCH 
and colleagues) 
II, CWI+, DS+/- NPS, OPS; PCR 25.5 21.9 20.3 19.3 
Kilifi, Kenya (urban, 15th Aug 2011 - 15th Nov 2013) (PERCH 
and colleagues) 
II, CWI+, DS+/- NPS, OPS; PCR 33.7 27.0 25.2 23.7 
Bamako, Mali (urban, 3rd Jan 2012 - 14th Jan 2014) (PERCH 
and colleagues) 
II, CWI+, DS+/- NPS, OPS; PCR 32.0 27.5 26.4 25.4 
Nakhon Phanom and Sa Kaeo, Thailand (rural, 1st Jan 2012 - 
31st Jan 2014) (PERCH and colleagues) 
II, CWI+, DS+/- NPS, OPS; PCR 26.4 26.2 29.1 27.3 
Lusaka, Zambia (urban, 10th Oct 2011 - 31st Oct 2013) (PERCH 
and colleagues) 
II, CWI+, DS+/- NPS, OPS; PCR 20.4 19.6 18.9 18.7 
Dhaka, Bangladesh (urban, 1st Jan 2012 - 31st Dec 2013) 
(PERCH and colleagues) 
II, CWI+, DS+/- NPS, OPS; PCR 21.3 19.9 19.6 18.7 
Matlab, Bangladesh (rural, 1st Jan 2012 - 31st Dec 2013) 
(PERCH and colleagues) 
II, CWI+, DS+/- NPS, OPS; PCR 53.6 39.0 35.8 33.3 
Tacloban, Philippines (rural, May 2008 - Jul 2012) (Lupisan and 
colleagues) 
II, CWI+, DS+/- 
NPS, serum; PCR, virus 
isolation, culture, serology 
21.6 18.9 17.9 17.0 
Mpumalanga, South Africa (rural, Jan 2010 - Dec 2014) (Cohen 
and colleagues) 
II NPA; PCR 25.9 23.2 22.4 21.3 
Nanjing, China (urban, Jan 2013 - Dec 2013) (Zhang et al., 
2014a) 




Guangdong, China (urban, Jul 2010 - Jul 2012) (Xu et al., 2014) II NPA; RT-PCR 6.1 
 
8.8 7.5 
Yanting, China (urban, Jan 2011 - Dec 2012) (He, 2015) II NPA; RT-PCR 56.3 
 
49.0 41.7 
Guiyang, China (urban, Jan 2012 - Dec 2013) (Liang and Ge, 
2014) 








Guangzhou, China (urban, Jun 2012 - Jun 2013) (Chen et al., 
2014a) 








Specimen and diagnostic test 
Proportion of RSV associated 
hospitalised ALRI (%) 
0-11m 0-23m 0-35m 0-59m 
Guangxi, China (urban, Jan 2013 - Dec 2013) (Zhang and Yu, 
2015) 
II NPA; DFA 13.9 
 
13.0 12.5 
Huzhou, China (urban, Jan 2011 - Dec 2013) (Yao et al., 2015)  II NPA; DFA 18.4 
 
17.2 16.8 
Foshan, China (urban, Feb 2012 - Jan 2014) (Zhang et al., 2014b) II NPA; DFA 16.6 15.4 
 
13.0 
Wuhan, China (urban, Jan 2011 - Dec 2012) (Hu and Wang, 
2014) 
II NPA; DFA 20.2 
   
Wenzhou, China (urban, Jan 2013 - Dec 2013) (Ye et al., 2014) II NPA; RT-PCR 42.6 
  
42.4 
Wenzhou, China (urban, Dec 2012 - Nov 2013) (Xue et al., 2014) II NPA; DFA 20.0 
 
16.3 13.0 
Chongqing, China (urban, Feb 2013 - Apr 2014) (Wang et al., 
2015) 
II NPA; DFA 11.7 
 
10.4 9.3 
Ningxia, China (urban, Jan 2010 - Dec 2013) (Ding and Tian, 
2014) 
II NPA; DFA 91.8 82.5 76.8 
 




Nantong, China (urban, Jan 2012 - Mar 2013) (Sheng et al., 
2014) 
II NPA; DFA 39.7 
 
30.8 28.5 
Quanzhou, China (urban, Jan 2012 - Jan 2013) (Lin et al., 2015) II NPS; DFA 37.7 
 
31.0 25.6 
Suzhou, China (urban, Jan 2009 - Dec 2013) (Yin, 2014) II NPS; DFA 18.9 17.6 17.1 15.8 
Changsha, China (urban, Apr 2013 - Mar 2014) (Liu et al., 
2015b) 
II NPA; DFA 50.7 
 
46.4 45.0 
Shenzhen, China (urban, Jul 2007 - Jun 2010) (He et al., 2014) II, F+ NPA; RT-PCR 16.3 15.6 
  
Soma, Japan (urban, Feb 2008 - Aug 2009) (Takeyama et al., 
2014) 




Tokyo, Japan (urban, Apr 2007 - Mar 2012) (Hamada et al., 
2014) 




Baguio, Philippines (urban, Apr 2009 - Dec 2011) (Tallo et al., 
2014) 









Mirzapur, Bangladesh (both, Jun 2006 - Sep 2007)* (Farzin et II nasal wash; RT-PCR 






Specimen and diagnostic test 
Proportion of RSV associated 
hospitalised ALRI (%) 
0-11m 0-23m 0-35m 0-59m 
al., 2015) 
Beirut, Lebanon (urban, Oct 2012 - Mar 2014) (Assaf-Casals et 
al., 2015) 




England, UK (urban, Apr 2007 - Mar 2008) (Murray et al., 2014) II NA 28.0 
   
Tehran, Iran (urban, Jan 2012 - Dec 2012) (Pourakbari et al., 
2014) 
II NPA; RT-PCR 
   
17.2 




Ouagadougou, Burkina Faso (urban, Jul 2010 - Jul 2011) 
(Ouedraogo et al., 2014) 




RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. NPA=nasopharyngeal aspirate. NPS=nasopharyngeal swab. 
NPW=nasopharyngeal wash. OPS=oropharyngeal swab. RT-PCR=reverse transcriptase polymerase chain reaction. IFA=indirect immunofluorescent 
antibody test. DFA=direct immunofluorescent antibody test. ELISA=enzyme-linked immunosorbent assay. IF=immunofluorescence. II=physician’s 
assessment. III=SARI definition. F+/-=fever as part of case definition or not. T+/-=tachypnea part of case definition or not. W+/-=wheeze part of case 
definition or not. C+/-=crepitation part of case definition or not. XR=X-ray confirmed (radiologically confirmed pneumonia). CWI+/-=chest wall indrawing 
part of case definition or not. DS+/-=danger signs part of case definition or not. O2+/-=hypoxemia part of case definition or not. ICU=intensive care unit. 
MV=mechanical ventilation. NA=not applicable. #Studies reporting proportion rate in an aboriginal population from a high-income country. *Five studies 




Table 39: Meta-estimate of proportion data and number of new hospitalised cases 
Region 







Hospitalised cases  
(*10³) 
Africa 9 24.7 (18.7-32.5) 12 21.3 (19.3-23.5) 945 (856-1043) 
Americas 19 37.5 (32.6-43.3) 14 28.6 (24.6-33.2) 176 (152-204) 
Eastern 
Mediterranean 
7 28.9 (20.1-41.5) 8 23.9 (17.8-32.1) 429 (319-577) 
Europe 10 42.3 (34.1-52.5) 9 28.3 (22.3-35.9) 529 (417-671) 
South-East 
Asia 
10 30.8 (21.8-43.7) 8 24.2 (19.0-30.6) 635 (500-805) 
Western 
Pacific 
79 26.9 (24.7-29.4) 45 22.1 (19.5-25.0) 109 (96-123) 
Global#   
  
2823 (2340-3423) 
RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. *number of 
hospitalised cases in 0-59m is generated from meta-estimate of proportion in 0-59m and 






Table 40: Sensitivity analysis of proportion data to exclude studies with different case 
definitions 
Region 
Final estimate in 0-59m 
Sensitivity analysis to exclude studies 
with different case definitions 
No. of 
studies 
Prop (%) No. of studies Prop (%) 
Africa 12 24.7 (18.7-32.5) 9 21.2 (19.1-23.7) 
Americas 14 37.5 (32.6-43.3) 13 29.4 (25.3-34.3) 
Eastern 
Mediterranean 
8 28.9 (20.1-41.5) 7 23.2 (15.7-34.3) 
Europe 9 42.3 (34.1-52.5) 7 30.5 (23.0-40.4) 
South-East Asia 8 30.8 (21.8-43.7) 6 28.1 (23.5-33.5) 





5.2.4 In-hospital CFR from RSV associated ALRI  
There were 44 studies reporting in-hospital CFR from systematic review (one article 
provided two studies) (Avendano et al., 2003, Berner et al., 2001, Bockova et al., 2002, 
Byington et al., 2015, Carballal et al., 2001, Chan et al., 2007, Chan et al., 1999a, Chen et al., 
2005, Chi et al., 2011, Deshpande and Northern, 2003, Do et al., 2011, Duppenthaler et al., 
2003, El Kholy et al., 2013, Eriksson et al., 2002, Fjaerli et al., 2004, Forster et al., 2004, Fry 
et al., 2010, Garcia et al., 2010, Gil-Prieto et al., 2015, Greenberg et al., 2014, Hervas et al., 
2012, Huo et al., 2013, Hussey et al., 2000, Khuri-Bulos et al., 2010, Loscertales et al., 2002, 
Miranda-Novales et al., 1999, Mori et al., 2011, Noyola et al., 2007, Numa, 2000, Pourakbari 
et al., 2014, Resch et al., 2002, Roglic et al., 2009, Rowlinson et al., 2013, Savic et al., 2011, 
Simon et al., 2007, Singleton et al., 2010, Tallo et al., 2014, Tsolia et al., 2003, Videla et al., 
1998, Vieira et al., 2001, Weber et al., 2002, Whitehall et al., 2001, Paramore et al., 2004). 
An additional 55 unpublished studies were also includedU10, U12-13, U15-17, U19-37, U39-45, U47-48, U55-65, 
U67-76 (Table 41). In total, 99 studies contributed to the meta-analysis of in-hospital CFR due 
to RSV associated hospitalised ALRI (Table 42). Similar to studies reporting hospitalisation 
rate, all studies adopted passive hospital-based or clinic-based case ascertainment (inpatients 
only). 69 studies came from developing countries and 30 were from industrialised countries. 
There were 54 studies from urban areas, 25 studies from mixed study settings (urban and 
rural) while 20 studies were based on rural settings. The table containing data in narrower 
age bands was in Appendices – A19. Three published studies (Bockova et al., 2002, 
Singleton et al., 2010, Whitehall et al., 2001) and another three unpublished studiesU41, U43-44 
reported in-hospital mortality among indigenous population in Australia (Townsville) and 
America (Alaska, Navajo and White Mountain Apache). They were excluded in the 
following estimate. There were 4 published studies (Avendano et al., 2003, El Kholy et al., 
2013, Huo et al., 2013, Tallo et al., 2014) and 12 unpublished studiesU15, U19-20, U48, U55-62 using 
SARI, wheeze negative or fever positive as part of the case definitions and these studies 
were excluded in a sensitivity analysis. In order to increase the comparability of in-hospital 
mortality across age groups, studies which provided complete dataset for three exclusive 
non-overlapping age bands (0-5m, 6-11m and 12-59m) were included to carry out the meta-
analysis. There were 43 studies in total which had CFR data in these three age groups. 
Among them, there were no studies carried out among aboriginal population and 10 studies 
used different definitions (as mentioned above). The number of RSV mortality in hospital in 
2015 was based on the Monte Carlo simulation incorporating the meta-estimate of 
hospitalisation rate (Table 28) and the corresponding meta-estimate of in-hospital CFR 
(Table 43) from the same age group and region (as explained in Chapter 2 – Methods). The 
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global estimate was generated from regional samples while the estimate in children aged 0-
59m was produced from samples in three exclusive age groups (0-5m, 6-11m, 12-59m). The 
results were shown in Table 44. Overall, around 60,000 (95% CI 48,000-75,000) children 
younger than 5 years were estimated to die from RSV associated ALRI in hospital in 2015, 
with 99% of these deaths occurring in developing countries (where 89% of the world’s 
population aged younger than 5 years reside). For children in the first six months, the 
number of in-hospital deaths was around 27,000 (95% CI 21,000-36,000), for children aged 
6-11m, the number was about 17,000 (95% CI 11,000-26,000), while for children aged 12-
59m the number of deaths was 15,000 (95% CI 10,000-25,000).  
When considering all studies reporting in-hospital CFR regardless whether or not they 
provided data for the full age range, there were 93 studies totally (exclusion of 6 studies in 
aboriginal population). Another round of meta-analysis was carried out in three age groups: 
0-5m, 6-11m and 12-59m. The results were compared to the previous estimates from 43 
studies which had data for the full age range (Table 45). Meta-estimates in several age 
groups/regions were different substantially (such as in 0-5m from high income countries). A 
different (higher or lower) result would be expected since studies with different study 
settings, population and methodologies were included in each age group analysis, which 
compromised the comparability of estimates across age groups. Thirteen studies reported in-
hospital CFR in young children aged 0-59m from African countries with high HIV burden, 
and the total RSV mortality in hospital was estimated as 15,000 in these countries. Only two 
unpublished studies provided in-hospital CFR stratified by HIV status. In South AfricaU37, 
in-hospital CFR for RSV associated ALRI in young children (0-59m) with HIV positive was 
6.5% compared to 0.6% in children without HIV. For infants, the CFR for RSV associated 
hospitalised ALRI was 7.5% if the infants were HIV positive, while it was 0.8% if infants 
did not have HIV. Similarly, in ZambiaU72, one of the PERCH studies, the RSV mortality in 
hospital was much higher in children with positive HIV than children with negative HIV 
(28.6% vs. 4.2%). These two studies showed consistently that in-hospital CFR of RSV 
associated hospitalised ALRI was much higher in HIV positive children compared to HIV 
negative children. However, the hospitalisation rate is not available stratified by HIV status, 
thus the number of cases or deaths is not available.  
Similar to previous analyses, two sensitivity analyses to include studies reporting data in 
aboriginal population and exclude studies using different case definitions were performed in 
infants and the results were compared (Table 46). In general, the results were similar. The 
meta-estimate after excluding those studies with different definitions of cases was slightly 
lower than the previous estimate where these studies were included. Fifteen studies didn’t 
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include neonates and therefore reported data in children aged 1-59m rather than 0-59m. A 
meta-analysis was run after excluding these 15 studies. The meta-estimate was 1.26% (95% 
CI 0.77-2.09) in developing countries compared to 1.47% (95% CI 0.94-2.30) where these 
studies were included. For those 43 studies which provided data for full age range, there 
were 11 studies with less than 50 RSV positive cases. These studies were excluded in 
another sensitivity analysis. The results were shown in Table 47. After excluding studies 
with small sample size, meta-estimate of in-hospital CFR was similar to previous estimate 
except in the age group of 6-11m from low income region. This is because there were two 
studiesU28, U61 with small sample sizes reporting high in-hospital CFR and they were excluded 
in the sensitivity analysis. The in-hospital mortality data were generated from the estimates 
of developing countries and industrialised countries; thus this didn’t affect the global 
mortality estimate substantially.  
The case definitions applied in studies reporting in-hospital CFR were compared to those 
used in studies providing hospitalisation rate data (Table 48). The percentage of each 
definition as well as each clinical feature in these two groups of studies were measured and 
summarised. Most studies used physician’s assessment as the case definition (around 97%). 
X-ray confirmation, tachypnea, chest wall indrawing, hypoxemia and WHO IMCI danger 
signs were also widely used to define ALRI (around 10%). In general, the percentage of each 
definition code was similar between those two groups of studies. This made combination of 





Table 41: List of 55 unpublished studies reporting in-hospital case fatality ratio 
Study number Location (reference) Study period 
U10 Paarl, South Africa (Zar and colleagues) Mar 2012 – Dec 2014 
U12 
CEMIC, Buenos Aires, Argentina (Echavarria and 
colleagues) 
1st Jun 2008 – 31st Dec 
2010 
U13 Buenos Aires, Argentina (Polack and colleagues) 2011 – 2013 
U15 Belo Horizonte, Brazil (Oliveira and colleagues) 2011 – 2013 
U16 Concepcion, Chile (Fasce and colleagues) Jan 2012 – Dec 2013 
U17 Iquique, Chile (Fasce and colleagues) Jan 2012 – Dec 2013 
U19 Santa Ana, El Salvador (Clara and colleagues) 2008 – 2013 
U20 Western Gambia (Howie and colleagues) Jul 2007 – Jun 2008 
U21 Santa Rosa, Guatemala (McCracken and colleagues) 2008 – 2013 
U22 
Quetzaltenango, Guatemala (McCracken and 
colleagues) 
2009 – 2013 
U23 Ballabhgarh, India (Broor and colleagues) 2010 – 2012 
U24 Pune, India (Chadha and colleagues) May 2009 – Apr 2013 
U25 Lombok, Indonesia (Gessner and colleagues) 2000 – 2002 
U26 Kilifi hospital study, Kenya (Nokes and colleagues) Jan 2002 – Dec 2010 
U27 Bondo district, Kenya (Feikin and colleagues) Jan 2007 – Jun 2009 
U28 Manhiça, Mozambique (Bassat and colleagues) 
20th Sep 2006 – 19th Sep 
2007 
U29 Manhiça, Mozambique (Bassat and colleagues) 1st Jan 2011 – 30th Jun 2014 
U30 Utrecht, Netherlands (Bont and colleagues) 2001 – 2010 
U31 41 sites in Netherlands (Bont and colleagues) 2008 – 2013 
U32 David City, Panama (Jara and colleagues) Jan 2011 – Dec 2013 
U33 
Tagbilaran and 6 rural sites, Philippines (Lucero and 
colleagues) 
5th Jul 2000 – 31st Dec 2004 
U34 
Gauteng province, South Africa (Cohen and 
colleagues) 
2009 – 2012 
U35 
KwaZulu-Natal province, South Africa (Cohen and 
colleagues) 
2010 – 2014 
U36 Klerksdorp site, South Africa (Cohen and colleagues) Jan 2011 – Dec 2014 
U37 Soweto, South Africa (Madhi and colleagues) Mar 1998 – Oct 2005 
U39 
Sa Kaeo and Nakhon Phanom, Thailand 
(Thamthitiwat and colleagues) 
Jan 2008 – Dec 2011 
U40 Tone District, Togo (Gessner and colleagues) Aug 2011 – Dec 2013 
U41 Alaska, USA (Singleton and colleagues) Jul 2001 – Jun 2004 
U42 Colorado, USA (Simoes and colleagues) Jan 2008 – Jun 2013 
U43 Navajo and WMA, USA – MEDI (O’Brien and Oct 2004 – Dec 2010 
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Study number Location (reference) Study period 
colleagues) 
U44 
Navajo and WMA, USA – EPI (O’Brien and 
colleagues) 
Oct 1997 – Mar 2000 
U45 Nha Trang, Vietnam (Yoshida and colleagues) Feb 2007 – Dec 2012 
U47 Buenos Aires, Argentina (Gentile and colleagues) 2001 – 2013 
U48 
Takeo ad Kampong Cham, Cambodia (Goyet and 
colleagues) 
Apr 2007 – Feb 2010 
U55 Beijing, China (GABRIEL and colleagues) Jan 2011 – Dec 2012 
U56 Ulaanbaatar, Mongolia (GABRIEL and colleagues) Sep 2011 – Oct 2012 
U57 Phnom Penh, Cambodia (GABRIEL and colleagues) Oct 2010 – Jan 2013 
U58 Lucknow, India (GABRIEL and colleagues) Jun 2012 – Dec 2013 
U59 
Antananarivo, Madagascar (GABRIEL and 
colleagues) 
Dec 2010 – Feb 2013 
U60 Asuncion, Paraguay (GABRIEL and colleagues) Jul 2010 – May 2013 
U61 Bamako, Mali (GABRIEL and colleagues) Jul 2011 – Nov 2012 
U62 Berlin, Germany (Rath and colleagues) 
1st Apr 2010 – 31st Mar 
2014 
U63 Amman, Jordan (Khuri and colleagues) Mar 2010 – Mar 2013 
U64 Lwak, Kenya (Montgomery and colleagues) 2007 – 2011 
U65 Rabat, Morocco (Bassat and colleagues) Nov 2010 – Dec 2011 
U67 Karachi, Pakistan (Ali and colleagues) Aug 2009 – Jul 2012 
U68 Basse Santa Su, Gambia (PERCH and colleagues) 
3rd Nov 2011 – 2nd Nov 
2013 
U69 Kilifi, Kenya (PERCH and colleagues) 
15th Aug 2011 – 15th Nov 
2013 
U70 Bamako, Mali (PERCH and colleagues) 3rd Jan 2012 – 14th Jan 2014 
U71 
Nakhon Phanom and Sa Kaeo, Thailand (PERCH 
and colleagues) 
1st Jan 2012 – 31st Jan 2014 
U72 Lusaka, Zambia (PERCH and colleagues) 
10th Oct 2011 – 31st Oct 
2013 
U73 Dhaka, Bangladesh (PERCH and colleagues) 1st Jan 2012 – 31st Dec 2013 
U74 Matlab, Bangladesh (PERCH and colleagues) 1st Jan 2012 – 31st Dec 2013 
U75 Tacloban City, Philippines (Lupisan and colleagues) May 2008 – Jul 2012 












In-hospital CFR of RSV associated hospitalised ALRI 
(%) 
0-5m 6-11m 0-11m 0-23m 0-35m 0-59m 
Hong Kong, China (urban, 1st Jan 2004 – 31st Dec 2004) 
(Chan et al., 2007) 
II NPA; DFA 
    
0.0 
 




culture, IF      
0.0 
Ho Chi Minh, Vietnam (urban, Nov 2004 – Jan 2008) (Do et 
al., 2011) 
II, T+, CWI+/-, 
ICU+/- 
nasal swab, throat 
swab, NPA; RT-
PCR 
     
0.0 




ELISA, culture    
0.1 
  
San Luis Potosi, Mexico (urban, 1st May 2003 – 30th Apr 
2005) (Noyola et al., 2007) 
II NPW; DFA 
    
0.0 
 
Alaska, USA (rural, 4th Oct 2005 – 30th Sep 2007)# 
(Singleton et al., 2010) 
II 
NPS, NPW; RT-
PCR     
0.0 
 
Dallas, Texas, USA (urban, Jan 2002 – Dec 2007) (Garcia et 
al., 2010) 
II 
NPA; IF, DFA, 
virus culture    
0.1 
  
Jingzhou, China (urban, Jan – Dec 2011) (Huo et al., 2013) 
III, W+/-, T+/-, 
XR 
NPS, OPS; RT-
PCR      
0.0 
Taiwan, China (urban, 2004 – 2007) (Chi et al., 2011) II NA 
     
0.1 
Sa Kaeo and Nakhom Phanom, Thailand (rural, 1st Jan 
2004 – 31st Dec 2007) (Fry et al., 2010) 
II, XR 
NPS, serum; RT-
PCR, IFA      
0.1 
Damanhour, Egypt (urban and rural, Jun 2009 – Jun 2012) 
(Rowlinson et al., 2013) 
II 
NPS, OPS; RT-
PCR      
0.0 
Lørenskog, Norway (periurban, Feb 1993 – Jan 2000) 
(Fjaerli et al., 2004) 
II NPA; ELISA 
   
0.2 
  
272 institutions, Japan (urban, Aug 2006 – Jul 2008) (Mori 
et al., 2011) 
II NA 
    
1.4 
 
Cairo, Egypt (urban, Feb 2010 – May 2011) (El Kholy et al., 
2013) 
III 
NPS and OPS; 
RT-PCR   
5.0 
   
Amman, Jordan (urban, 18th Jan – 29th Mar 2007) (Khuri- II, F+/- nasal and throat 









In-hospital CFR of RSV associated hospitalised ALRI 
(%) 
0-5m 6-11m 0-11m 0-23m 0-35m 0-59m 
Bulos et al., 2010) swab; RT-PCR 
Croatia (urban, Sep 2003 – Oct 2009) (Roglic et al., 2009) II NPA; DFA 
     
0.2 
Beer-Sheva, Israel (urban, Nov to Mar, 2004 – 2011) 
(Greenberg et al., 2014) 
II, CWI+, XR 
NPW; DFA and 
culture    
0.2 
  
Belgrade, Serbia (urban, Nov 2008 – Mar 2009) (Savic et al., 
2011) 
II NPA; EIA 
  
2.2 
   
Athens, Greece (urban, Feb 1997 – Jun 2000) (Tsolia et al., 
2003) 





   
Stockholm, Sweden (urban, 1987 – 1998) (Eriksson et al., 
2002) 
II NPW; IFA 
  
0.3 
   
Multicentric, Germany (urban, Nov 1999 – Oct 2001) 
(Forster et al., 2004) 
II NPS; PCR 
    
0.7 
 
Shropshire, United Kingdom (urban, Apr 1996 – Mar 1999) 
(Deshpande and Northern, 2003) 
II NA; IF 
   
0.2 
  
Berne, Switzerland (urban, Jul 1997 – Jun 2001) 
(Duppenthaler et al., 2003) 
II NPS; DFA 
     
0.2 
Freiburg, Germany (urban and rural, Apr 1997 – Mar 
1999) (Berner et al., 2001) 
II NPS; IF 
     
0.7 
Germany (urban, 1999 – 2005) (Simon et al., 2007) II 
NPA; ELISA, 
culture, PCR   
0.5 
   
Manhica, Mozambique (rural, Oct 1998 – May 2000)§ 




     
3.4 
Banjul, Fajara and Sibanor, Gambia (urban and rural, Oct 
1993 – Dec 1996) (Weber et al., 2002) 
II NPA; IF 
   
2.0 
  
Hong Kong, China (urban, Jan 1993 – Dec 1997) (Chan et 
al., 1999a) 
II 
NPA, throat swab; 
DFA, virus 
isolation 
     
0.1 
Sydney, Australia (urban, May 1997 – Oct 1999) (Numa, 
2000) 
II NA 
   
0.3 
  
Townsville, Australia (urban and rural, Jan 1997 – Oct II NA; IF, culture 
  
1.1 








In-hospital CFR of RSV associated hospitalised ALRI 
(%) 
0-5m 6-11m 0-11m 0-23m 0-35m 0-59m 
1999)# (Whitehall et al., 2001) 
Navajo and WMA, USA (rural, Oct 1997 – Mar 2000)# 
(Bockova et al., 2002) 
II NPA; ELISA 
   
0.1 
  
Buenos Aires, Argentina (urban, Apr 1993 – Dec 1994) 
(Carballal et al., 2001) 
II NPA; DFA 
     
1.3 
Santiago, Chile (urban, Jan 1989 – Dec 2000) (Avendano et 
al., 2003) 
II, W- NPA; IFA 
   
0.1 
  
Graz, Austria (urban, Nov 1999 – Oct 2000) (Resch et al., 
2002) 
II NPA; ELISA 
  
0.0 
   
Cape Town, South Africa (urban, Jun 1995 – Aug 1996) 
(Hussey et al., 2000) 
II, W+/- NPA; ELISA 
   
2.1 
  
Buenos Aires, Argentina (urban, May 1991 – Dec 1992) 
(Videla et al., 1998) 
II, CWI+/-, XR, 
W+/-, T+/- 
NPA; IFA 
   
0.0 
  
Sao Paulo, Brazil (urban and rural, Mar 1995 – Aug 1996) 
(Vieira et al., 2001) 
II NPA, NPS; IFA 
     
0.0 
Tlaxcala, Mexico (urban and rural, Oct 1994 – Jun 1995) 
(Miranda-Novales et al., 1999) 
II NPS; IFA 
     
0.0 




PCR     
0.4 
 
Buenos Aires, Argentina (urban, 2001 – 2013) (Gentile and 
colleagues)* 
II, MV+/- NPA; IFA 1.9 1.7 1.8 1.8 1.8 1.8 
Takeo ad Kampong Cham, Cambodia (urban, Apr 2007 – 
Feb 2010) (Goyet and colleagues)* 
II, F+, T+ 
NPS, throat swab; 
RT-PCR 
0.0 0.0 0.0 0.0 0.0 0.0 
Beijing, China (urban, Jan 2011 – Dec 2012) (GABRIEL 
and colleagues)* 
II, T+, W-, XR 
NPA, NPS; RT-
PCR 
0.0 0.0 0.0 0.0 0.0 0.0 
Ulaanbaatar, Mongolia (urban, Sep 2011 – Oct 2012) 
(GABRIEL and colleagues)* 
II, T+, W-, XR 
NPA, NPS; RT-
PCR 
0.0 0.0 0.0 0.0 0.0 0.0 
Phnom Penh, Cambodia (urban, Oct 2010 – Jan 2013) 
(GABRIEL and colleagues)* 
II, T+, W-, XR 
NPA, NPS; RT-
PCR 
0.0 0.0 0.0 0.0 0.0 0.0 
Lucknow, India (urban and rural, Jun 2012 – Dec 2013) 
(GABRIEL and colleagues)* 
II, T+, W-, XR 
NPA, NPS; RT-
PCR 








In-hospital CFR of RSV associated hospitalised ALRI 
(%) 
0-5m 6-11m 0-11m 0-23m 0-35m 0-59m 
Antananarivo, Madagascar (urban and rural, Dec 2010 – 
Feb 2013) (GABRIEL and colleagues)* 
II, T+, W-, XR 
NPA, NPS; RT-
PCR 
0.0 0.0 0.0 0.0 0.0 0.0 
Asuncion, Paraguay (urban, Jul 2010 – May 2013) 
(GABRIEL and colleagues)* 
II, T+, W-, XR 
NPA, NPS; RT-
PCR 
0.0 0.0 0.0 0.0 0.0 0.0 
Bamako, Mali (urban, Jul 2011 – Nov 2012) (GABRIEL 
and colleagues)* 
II, T+, W-, XR 
NPA, NPS; RT-
PCR 
0.0 14.3 4.2 3.6 3.3 3.2 
Berlin, Germany (urban, 1st Apr 2010 – 31st Mar 2014) 
(Rath and colleagues)* 
II, F+, ICU+/- 
NPS, NPA; RT-
PCR 
0.0 0.0 0.0 0.0 0.0 0.0 




nasal and throat 
swab; PCR 
0.4 0.4 0.4 0.4 
  






8.3 0.0 4.2 3.8 4.6 4.0 
Rabat, Morocco (urban, Nov 2010 – Dec 2011) (Bassat and 
colleagues)* 
II, CWI+, T+ NPA; RT-PCR 4.5 6.1 5.2 3.8 3.2 2.9 





1.1 0.0 0.7 0.5 0.5 0.9 
Basse Santa Su, Gambia (rural, 3rd Nov 2011 – 2nd Nov 
2013) (PERCH and colleagues)* 
II, CWI+, DS+/- NPS, OPS; PCR 0.0 0.0 0.0 0.0 0.0 0.0 
Kilifi, Kenya (urban, 15th Aug 2011 – 15th Nov 2013) 
(PERCH and colleagues)*§ 
II, CWI+, DS+/- NPS, OPS; PCR 3.4 3.7 3.5 3.6 3.5 4.0 
Bamako, Mali (urban, 3rd Jan 2012 – 14th Jan 2014) 
(PERCH and colleagues)* 
II, CWI+, DS+/- NPS, OPS; PCR 1.7 5.6 2.2 2.7 2.6 2.6 
Nakhon Phanom and Sa Kaeo, Thailand (rural, 1st Jan 2012 
– 31st Jan 2014) (PERCH and colleagues)* 
II, CWI+, DS+/- NPS, OPS; PCR 0.0 0.0 0.0 0.0 0.0 0.0 
Lusaka, Zambia (urban, 10th Oct 2011 – 31st Oct 2013) 
(PERCH and colleagues)*§ 
II, CWI+, DS+/- NPS, OPS; PCR 4.8 8.0 5.7 6.1 5.9 5.8 
Dhaka, Bangladesh (urban, 1st Jan 2012 – 31st Dec 2013) 
(PERCH and colleagues)* 
II, CWI+, DS+/- NPS, OPS; PCR 0.0 0.0 0.0 0.0 0.0 0.0 
Matlab, Bangladesh (rural, 1st Jan 2012 – 31st Dec 2013) 
(PERCH and colleagues)* 
II, CWI+, DS+/- NPS, OPS; PCR 0.0 0.0 0.0 0.0 0.0 0.0 








In-hospital CFR of RSV associated hospitalised ALRI 
(%) 
0-5m 6-11m 0-11m 0-23m 0-35m 0-59m 
(Lupisan and colleagues)* PCR, virus 
isolation, culture, 
serology 
Mpumalanga, South Africa (rural, Jan 2010 – Dec 2014) 
(Cohen and colleagues)*§ 
II NPA; PCR 2.4 4.6 3.2 2.6 2.4 2.2 
CEMIC, Buenos Aires, Argentina (urban, 1st Jun 2008 – 31st 
Dec 2010) (Echavarria and colleagues)* 
II, ICU+/-, 
MV+/- 
NPA; IFA 0.0 0.0 0.0 0.0 0.0 0.0 
Buenos Aires, Argentina (urban and rural, 2011 – 2013) 
(Polack and colleagues) 
II, O2+, W+, 
F+/-, ICU+/-, 
MV+/- 
NPA; PCR 1.4 1.1 1.3 1.1 
  
Belo Horizonte, Brazil (urban, 2011 – 2013) (Oliveira and 
colleagues)* 




1.8 2.0 1.9 1.6 1.4 1.3 
Concepcion, Chile (urban and rural, Jan 2012 – Dec 2013) 
(Fasce and colleagues)* 
II, F+/-, ICU+/- NPA; IF 0.0 0.0 0.0 0.0 0.0 0.5 
Iquique, Chile (urban and rural, Jan 2012 – Dec 2013) 
(Fasce and colleagues)* 
II, F+/-, ICU+/- NPA; IF 0.0 3.3 1.0 0.9 0.9 0.8 
Santa Ana, El Salvador (urban, 2008 – 2013) (Clara and 
colleagues) 





Western Gambia (urban and rural, Jul 2007 – Jun 2008) 
(Howie and colleagues) 




0.0 0.0 0.0 0.0 0.0 
Santa Rosa, Guatemala (urban and rural, 2008 – 2013) 





3.7 1.7 3.1 2.8 2.6 3.0 
Quetzaltenango, Guatemala (urban and rural, 2009 – 2013) 





0.9 1.4 1.0 1.4 1.3 1.3 
Ballabhgarh, India (rural, 2010 – 2012) (Broor and 
colleagues)* 
II, DS+/- NPS; RT-PCR 0.0 0.0 0.0 0.0 0.0 0.0 
Pune, India (rural, May 2009 – Apr 2013) (Chadha and 
colleagues)* 
II NPS; RT-PCR 0.0 0.0 0.0 0.0 0.0 0.0 





3.3 0.7 2.1 1.8 
  








In-hospital CFR of RSV associated hospitalised ALRI 
(%) 
0-5m 6-11m 0-11m 0-23m 0-35m 0-59m 
Dec 2010) (Nokes and colleagues)*§ O2+/DS+ wash; DFA 





0.0 7.7 2.6 1.8 1.6 1.5 
Manhiça, Mozambique (rural, 20th Sep 2006 – 19th Sep 
2007) (Bassat and colleagues)*§ 
II, T+ NPA; RT-PCR 0.0 10.0 2.9 2.3 2.2 2.0 
Manhiça, Mozambique (rural, 1st Jan 2011 – 30th Jun 2014) 
(Bassat and colleagues)*§ 
II, T+, O2+/- NPA; RT-PCR 0.0 0.0 0.0 0.0 0.0 0.0 
Utrecht, Netherlands (urban, 2001 – 2010) (Bont and 
colleagues) 
II 
NPS, NPW; PCR, 
IF 
0.0 0.0 0.0 
   
41 sites in Netherlands (urban and rural, 2008 – 2013) (Bont 
and colleagues) 
II, ICU+/- 
NPS, NPW; PCR, 
IF 
0.0 0.0 0.0 
   
David City, Panama (urban, Jan 2011 – Dec 2013) (Jara 
and colleagues)* 
II 
NPS, OPS; IFA, 
RT-PCR 
0.0 0.0 0.0 0.0 0.0 0.0 
Tagbilaran and 6 rural sites, Philippines (urban and rural, 
5th Jul 2000 – 31st Dec 2004) (Lucero and colleagues) 
II, CWI+, DS+/- 
NPA, nasal swab; 
culture, PCR 
0.8 0.8 0.8 0.6 
  
Gauteng province, South Africa (urban, 2009 – 2012) 
(Cohen and colleagues)*§ 
II NPA; PCR 0.9 0.0 0.6 0.5 0.5 0.5 
KwaZulu-Natal province, South Africa (periurban, 2010 – 
2014) (Cohen and colleagues)*§ 
II NPA; PCR 0.0 0.0 0.0 0.0 0.0 0.0 
Klerksdorp site, South Africa (periurban, Jan 2011 – Dec 
2014) (Cohen and colleagues)*§ 
II NPA; PCR 2.6 0.0 2.0 1.6 1.5 1.5 
Soweto, South Africa (urban, Mar 1998 – Oct 2005) (Madhi 
and colleagues)*§ 
II, CWI+, O2+/- NPA; IF 2.4 1.0 2.0 1.7 1.7 1.6 
Paarl, South Africa (periurban, Mar 2012 – Dec 2014) (Zar 
and colleagues) 
II, CWI+, T+, 
DS+/- 
NPS; RT-PCR 0.0 0.0 0.0 0.0 
  
Sa Kaeo and Nakhon Phanom, Thailand (rural, Jan 2008 – 
Dec 2011) (Thamthitiwat and colleagues)* 
II, F+/-, T+/-, 
CWI+, O2+/- 
NPS; PCR 0.0 0.0 0.0 0.0 0.0 0.0 





0.0 0.0 0.0 0.0 0.0 0.0 
Colorado, USA (urban and rural, Jan 2008 – Jun 2013) 
(Simoes and colleagues)* 








In-hospital CFR of RSV associated hospitalised ALRI 
(%) 
0-5m 6-11m 0-11m 0-23m 0-35m 0-59m 
Navajo and WMA, USA – MEDI (rural, Oct 2004 – Dec 
2010) (O’Brien and colleagues)# 
II, O2+/- NPS; RT-PCR 0.0 0.0 0.0 
   
Navajo and WMA, USA – EPI (rural, Oct 1997 – Mar 2000) 
(O’Brien and colleagues)# 
II, O2+/- NPA; EIA 0.3 0.0 0.2 0.1 
  
Nha Trang, Vietnam (urban and rural, Feb 2007 – Dec 
2012) (Yoshida and colleagues)* 
II, CWI+/DS+ NPS; RT-PCR 0.0 0.0 0.0 0.0 0.0 0.0 
Spain (urban, Jan 1997 – Dec 2011) (Gil-Prieto et al., 2015) II 
   
0.1 0.1 0.1 0.1 








Tehran, Iran (urban, Jan 2012 – Dec 2012) (Pourakbari et 
al., 2014) 
II NPA; RT-PCR 
     
0.0 
USA (urban, 2000, 2003, 2006 and 2009) (Byington et al., 
2015) 
II NA 
   
0.1 
  
USA (urban, 2000 – 2011) (Byington et al., 2015) II NA 
   
0.3 
  
USA (urban, 2000) (Paramore et al., 2004) II NA 
     
0.1 
RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. CFR=case fatality ratio. NPA=nasopharyngeal aspirate. NPS=nasopharyngeal 
swab. NPW=nasopharyngeal wash. OPS=oropharyngeal swab. RT-PCR=reverse transcriptase polymerase chain reaction. IFA=indirect 
immunofluorescent antibody test. DFA=direct immunofluorescent antibody test. ELISA=enzyme-linked immunosorbent assay. IF=immunofluorescence. 
II=physician’s assessment. III=SARI definition. F+/-=fever as part of case definition or not. T+/-=tachypnea part of case definition or not. W+/-=wheeze 
part of case definition or not. C+/-=crepitation part of case definition or not. XR=X-ray confirmed (radiologically confirmed pneumonia). CWI+/-=chest 
wall indrawing part of case definition or not. DS+/-=danger signs part of case definition or not. O2+/-=hypoxemia part of case definition or not. 
ICU=intensive care unit. MV=mechanical ventilation. NA=not applicable. *Studies providing in-hospital CFR for full age range (0-5m, 6-11m and 12-
59m). #Studies reporting in-hospital CFR in an aboriginal population from a high-income country. §Studies sites in sub-Saharan Africa which had high-
HIV burden and reported data in 0-59m.  
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Meta-estimate of in-hospital CFR (%) 
0-5m 6-11m 12-59m 
Low income 9 1.7 (0.4-6.8) 9.3 (3.0-28.7) 4.7 (0.7-33.7) 
Lower middle income 16 2.7 (2.0-3.6) 2.8 (1.8-4.4) 2.7 (1.7-4.3) 
Upper middle income 12 1.8 (1.2-2.6) 2.4 (1.1-5.4) 0.5 (0.1-3.5) 
High income 6 0.2 (0.0-12.8) 0.9 (0.2-4.0) 0.7 (0.1-5.2) 
     
Developing 41 2.2 (1.8-2.7) 2.4 (1.9-3.2) 2.2 (1.6-3.0) 
Industrialised 2 0.0 (0.0-0.1) 0.1 (0.0-0.4) 0.1 (0.0-0.3) 





Table 44: Number of in-hospital deaths of RSV associated ALRI from 43 studies reporting full data in finer age bands 
Region No. of studies 
In-hospital mortality 
0-5m 6-11m 12-59m 0-59m* 
Low income 9 1335 (234-7917) 3376 (413-26619) 1418 (129-16085) 8169 (2225-36928) 
Lower middle income 16 19991 (13499-29474) 10260 (4752-21643) 12268 (6515-23132) 43638 (31446-60431) 
Upper middle income 12 7170 (4227-12259) 7962 (2802-22140) 1487 (186-11709) 17928 (10265-34485) 
High income 6 440 (1-228220) 887 (172-4568) 666 (81-5646) 3280 (673-231067) 
      
Developing 41 27141 (20679-35494) 16460 (10443-25814) 15265 (9456-24967) 59578 (47750-74325) 
Industrialised 2 38 (1-2029) 38 (6-277) 102 (33-322) 237 (78-2202) 
      
Global# 43 27271 (20744-36178) 16513 (10533-26094) 15445 (9547-24902) 59581 (47959-74542) 
RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. CFR=case fatality ratio. *number of in-hospital deaths in 0-59m is sum of 
estimates from exclusive finer age bands (0-5m, 6-11m and 12-59m) based on Monte Carlo Simulation. #Global estimate is sum of regional estimates 





Table 45: Comparison of meta-estimates of in-hospital CFR from 43 studies and all studies  
Region 
0-5m 6-11m 12-59m 
43 studies All studies* 43 studies All studies* 43 studies All studies* 
No. CFR (%) No. CFR (%) No. CFR (%) No. CFR (%) No. CFR (%) No. CFR (%) 
Low income 9 1.7 (0.4-6.8) 9 1.7 (0.4-6.8) 9 9.3 (3.0-28.7) 10 9.3 (3.0-28.7) 9 4.7 (0.7-33.7) 10 4.7 (0.7-33.6) 
Lower middle 
income 
16 2.7 (2.0-3.6) 18 2.8 (2.1-3.6) 16 2.8 (1.8-4.4) 18 2.3 (1.5-3.5) 16 2.7 (1.7-4.3) 16 2.7 (1.7-4.3) 
Upper middle 
income 
12 1.8 (1.2-2.6) 14 1.5 (1.0-2.1) 12 2.4 (1.1-5.4) 14 1.9 (0.9-3.9) 12 0.5 (0.1-3.5) 12 0.5 (0.1-3.5) 
High income 6 0.2 (0.0-12.8) 9 0.8 (0.3-2.1) 6 0.9 (0.2-4.0) 9 1.1 (0.5-2.4) 6 0.7 (0.1-5.2) 7 0.4 (0.1-2.5) 
             
Developing 41 2.2 (1.8-2.7) 46 2.0 (1.7-2.4) 41 2.4 (1.9-3.2) 47 2.0 (1.6-2.6) 41 2.2 (1.6-3.0) 42 2.2 (1.6-3.0) 
Industrialised 2 0.0 (0.0-0.1) 4 0.0 (0.0-0.1) 2 0.1 (0.0-0.4) 4 0.1 (0.0-0.4) 2 0.1 (0.0-0.3) 3 0.1 (0.1-0.1) 





Table 46: Sensitivity analyses of in-hospital CFR to include studies with aboriginal population and exclude studies with different case 
definitions respectively 
Region 
Meta estimate in 0-11m* 
Sensitivity analysis to include studies with 
aboriginal population 
Sensitivity analysis to exclude studies with 
different case definitions 
No. of studies CFR (%) No. of studies CFR (%) No. of studies CFR (%) 
Low income 10 2.7 (1.1-6.4) 10 2.7 (1.1-6.4) 5 2.4 (0.9-6.4) 
Lower middle income 20 3.1 (1.7-5.7) 20 3.1 (1.7-5.7) 17 2.4 (1.9-3.0) 
Upper middle income 15 1.4 (0.9-2.2) 15 1.4 (0.9-2.2) 11 1.4 (0.8-2.4) 
High income 14 0.5 (0.2-1.3) 17 0.4 (0.2-1.2) 13 0.5 (0.2-1.3) 
       
Developing 49 2.3 (1.5-3.4) 49 2.3 (1.5-3.4) 37 2.3 (1.5-3.4) 
Industrialised 10 0.3 (0.1-0.7) 13 0.3 (0.2-0.7) 9 0.3 (0.2-0.7) 






Table 47: Sensitivity analysis of in-hospital CFR to exclude studies with small sample size 
Region 
In-hospital CFR based on 43 studies Sensitivity analysis excluding studies with small sample size 
No. 0-5m 6-11m 12-59m No. 0-5m 6-11m 12-59m 
Low income 9 1.71 (0.43-6.82) 9.25 (2.98-28.68) 4.74 (0.67-33.66) 4 1.71 (0.43-6.83) 5.55 (0.78-39.37) 4.75 (0.67-33.75) 
Lower middle income 16 2.71 (2.02-3.63) 2.81 (1.79-4.41) 2.73 (1.74-4.28) 14 2.71 (2.02-3.63) 2.81 (1.79-4.41) 2.73 (1.74-4.28) 
Upper middle income 12 1.76 (1.20-2.59) 2.43 (1.09-5.41) 0.49 (0.07-3.48) 9 1.76 (1.20-2.59) 2.43 (1.09-5.41) 0.49 (0.07-3.48) 
High income 6 0.21 (0.00-12.79) 0.87 (0.19-4.03) 0.66 (0.08-5.18) 5 0.21 (0.00-14.33) 0.85 (0.17-4.27) 0.66 (0.08-5.40) 
         
Developing 41 2.18 (1.80-2.65) 2.44 (1.85-3.23) 2.20 (1.60-3.02) 30 2.18 (1.80-2.65) 2.28 (1.71-3.04) 2.20 (1.60-3.02) 
Industrialised 2 0.02 (0.00-0.13) 0.05 (0.01-0.38) 0.09 (0.03-0.25) 2 0.02 (0.00-0.13) 0.05 (0.01-0.38) 0.09 (0.03-0.25) 
CFR=case fatality ratio. 
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Table 48: Comparison of case definitions applied in studies reporting hospitalisation 
rate and in-hospital CFR 
Case definition codes 
Percentage among 73 studies 
reporting hospitalisation rate 
(%) 
Percentage among 99 studies 
reporting in-hospital CFR (%) 
II 97.18 96.94 
III 5.63 4.08 
F+ 2.82 3.06 
F+/- 8.45 5.10 
XR 7.04 13.27 
T+ 8.45 14.29 
T+/- 5.63 6.12 
W+ 1.41 1.02 
W+/- 4.23 5.10 
W- 1.41 9.18 
CWI+ 12.68 17.35 
CWI+/- 9.86 8.16 
O2+ 1.41 1.02 
O2+/- 15.49 11.22 
DS+/- 12.68 17.35 
ICU+/- 8.45 9.18 
MV+/- 4.23 4.08 
CFR=case fatality ratio. II=physician’s assessment. III=SARI definition. F+/-=fever as part of 
case definition or not. XR=X-ray confirmed (radiologically confirmed pneumonia). T+/-
=tachypnea part of case definition or not. W+/-=wheeze part of case definition or not. CWI+/-
=chest wall indrawing part of case definition or not. O2+/-=hypoxemia part of case definition 





5.2.5 Burden of RSV associated ALRI in neonates (0-27 days) 
Overall 37 studies reported relevant data for RSV associated ALRI in neonates aged 0-27 
days, including incidence rate in community, hospitalisation rate and in-hospital mortality. 
One was a published article (Vicente et al., 2003) and the other 36 unpublished studiesU2-3, 
U10, U13, U15-17, U21-29, U31-32, U34-36, U38-39, U41-44, U47, U62-65, U67, U75-76 (two studies from U10) were 
provided by RSV GEN. The unavailability of neonatal data from most published articles is 
probably due to insufficient surveillance in narrower age bands (as excluded in the selection 
criteria) or the difficulty of defining RSV cases within this special age group (sepsis like 
episodes). There were 3 studies providing community-based incidence rate of RSV 
associated ALRI for neonates and the meta-estimate was around 40.0 (2.5-635.7) per 1000 
children per year in developing countries (or low and middle income countries). The 
confidence interval of this estimate is wide and it is only based on 3 studies (with small 
sample size). More studies from community based studies are needed to verify the high 
incidence of RSV infection in neonates. Fifteen studies reported hospitalisation rate of RSV 
associated ALRI in neonates from hospital-based studies. One was from industrialised 
countries (another 3 were from aboriginal population and thus excluded in analysis) and the 
remaining 11 studies were from developing countries. Meta-estimate was 15.9 (95% CI 8.8-
28.9) per 1000 children per year in developing countries, 46.4 (95% CI 3.9-549.5) in upper 
middle income countries, 9.3 (95% CI 2.5-35.3) in lower middle income countries. There 
were 29 studies (another 2 studies with data in aboriginal population were excluded) 
reporting in-hospital CFR for neonates. 26 of them were in developing countries and 3 of 
them were from industrialised countries. It was estimated that 5.3% (95% CI 2.8-9.8) of 
RSV associated hospitalised ALRI cases died in hospitals from developing countries, 1.0% 
(95% CI 0.1-7.2) in upper middle income countries, 6.3% (95% CI 3.3-12.1) in lower middle 
income countries, 0 in industrialised countries (and high income countries). If only studies 
which provided data for the full age range were considered, 22 studies from developing 
countries reported the same meta-estimate. The results for narrower age bands including 




5.2.6 RSV associated ALRI mortality in community 
Three studies from developing countries (Argentina, Bangladesh and Indonesia) reported 
number of childhood verbal autopsy confirmed pneumonia deaths in community as well as 
RSV seasonality data for at least 3 continuous years. The number of months of the RSV 
season, average number of pneumonia deaths outside and within RSV season as well as 
proportion of ALRI which were positive for RSV on assumption that any excess deaths 
within RSV season was attributed to RSV, and community-based mortality due to RSV were 
summarised in Table 49 for each site. The inflation factor for each site was calculated by 
comparing community-based RSV mortality to its respective in-hospital mortality (Table 50). 
In-hospital mortality for each site was generated by combining the meta-estimate of 
hospitalisation rate, meta-estimate of in-hospital CFR in the region where this study came 
from (developing region) and population number from mean study year. The mean inflation 
factor was applied to the overall in-hospital mortality in developing countries in order to get 
the community-based mortality for developing countries. Therefore, global mortality due to 
RSV associated ALRI was calculated as: in-hospital mortality in developing 
countries*inflation factor + in-hospital mortality in industrialised countries. For Argentina, 
the number of deaths due to RSV in community was estimated as 1.5 times higher than what 
was estimated in hospital. The adjustment factors for RSV mortality in community compared 
to in-hospital mortality was 2.1 and 2.9 in Bangladesh and Indonesia respectively. The mean 
inflation factor was 2.2. When extrapolated to other developing countries, it yielded a crude 
estimate (for developing countries) of roughly 131043 (95% CI 105539-162720) deaths 
attributable to RSV associated ALRI in young children in 2015. Although data from 
Argentina and Indonesia were for children younger than 2 years only, this limitation was not 
likely to be important since most pneumonia deaths in children occur during the first 2 years 
of life. Overall, the global mortality due to RSV associated ALRI in children younger than 5 
years if active community-based case ascertainment was applied was 131482 (95% CI 
105937-163370) (Table 51). Another 2 scenarios were assumed and corresponding analyses 




Table 49: RSV associated ALRI deaths in community from three studies in developing countries 
Site Study year 
Months of 
















due to RSV 
(%) (e)* 
ALRI deaths 
overall in this 
country (f) 
(Liu et al., 
2015a) 
RSV deaths 




2011 4 6.3 1.8 39 46.2 887 409 
2012 4 8.5 0.9 41 74.4 878 653 
2013 4 3.3 0.9 20 47.5 844 401 
Mean       488 
Multicentre, 
Bangladesh 
2010 9 3.0 2.7 35 8.6 21917 1879 
2011 4 8.8 5.4 78 17.3 20028 3466 
2012 6 9.5 6.3 95 20.0 18759 3752 
Mean       3032 
Lombok, 
Indonesia 
2000 6 73.3 62.3 814 8.1 39257 3183 
2001 6 84.8 48.8 802 26.9 37584 10122 
2002 7 45.0 36.8 499 11.5 36020 4143 
Mean       5816 




Table 50: Calculation of inflation factors - RSV mortality in community compared to RSV mortality in hospital 
Site 
Meta-estimate of hospitalisation 
rate (per 1000 per year) (h)§ 
Meta-estimate of in-
hospital CFR (%) 
(i)§ 
Population in mean 
study period (j) 
RSV deaths in 
hospital overall 
(k)* 





Argentina 4.9 1.9 3407649 320 488 1.5 
Bangladesh 4.9 1.9 15197631 1426 3032 2.1 
Indonesia 4.9 1.9 21639000 2030 5816 2.9 
Mean      2.2 







Table 51: RSV associated ALRI mortality in children younger than five years old in hospital and in community respectively 
 
In-hospital mortality Inflation factor In-community mortality 
Developing 59578 (47750-74325) 2.2 131043 (105539-162720) 
Industrialised 237 (78-2202) 1 237 (78-2202) 
Global* 59581 (47959-74542) 
 
131482 (105937-163370) 
RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. *Global number of RSV associated ALRI mortality is sum of estimates from 
developing countries and industrialised countries. 
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5.2.7 RSV subtypes 
There were 19 studies providing data on RSV-A and RSV-B subtypes. Seven were published 
articles (Bdour, 2001, Carballal et al., 2000, Lamarao et al., 2012, Suryadevara et al., 2011, 
Tran et al., 2013, Vieira et al., 2007, Balmaks et al., 2014) identified from the systematic 
review and 12 unpublished studiesU5, U8, U12, U20, U24, U26, U28-29, U45-46, U65, U75 were provided by 
RSV GEN (Table 52). Two of them were community-based studies and the remaining 17 
studies were from hospital settings. Two studies came from industrialised countries and the 
others were from developing countries. The numbers of cases of each subtype were 
summarised in Table 53. In most cases, RSV-A was substantially more commonly identified 
than RSV-B. Subtype data were also presented in several non-overlapping narrower age 
bands (Table 53). There were 14 studies providing these data. From the table, most RSV 
cases occurred during the first year. Across all age groups, the number of RSV-A cases was 
higher than the number of RSV-B. Two studies reported incidence rate of RSV subtypes and 
another six studies reported hospitalisation rate (all from developing countries). For the latter 
one where meta-analyses were carried out, the hospitalisation rate of RSV-A associated 
ALRI was estimated as 2.4 per 1000 children per year in children aged 0-59m, while it was 
0.7 for RSV-B associated ALRI and 1.4 for RSV unknown subtype associated ALRI. 
Regarding the in-hospital case fatality ratio, nine of the studies provided data for both RSV-
A and RSV-B (Table 54). All of them were from developing countries. In three sites, where 
there was at least one death for each subtype, the in-hospital CFR for RSV-A was higher 
than the one in RSV-B. When meta-analyses were carried out among these studies, in-
hospital CFR from RSV-A associated hospitalised ALRI in children younger than 5 years 
from developing countries was 2.32% (95% CI 1.74-3.10) while it was 1.45% (95% CI 0.76-




Table 52: List of 12 unpublished studies reporting data of RSV subtypes 
Study 
number 
Location (reference) Study period 
U5 Bandung, Indonesia (Simoes and colleagues) 
1st Feb 1999 - 26th Apr 
2001 
U8 Gilgit, Pakistan (Rasmussen and colleagues) 
1st Apr 2012 - 31st Mar 
2014 
U12 
CEMIC, Buenos Aires, Argentina (Echavarria and 
colleagues) 
1st Jun 2008 - 31st Dec 
2010 
U20 
Gambia Western Region, Gambia (Howie and 
colleagues) 
Jul 2007 - Jun 2008 
U24 Pune, India (Chadha and colleagues) May 2009 - Apr 2013 
U26 Kilifi hospital study, Kenya (Nokes and colleagues) Jan 2002 - Dec 2010 
U28 Manhiça, Mozambique (Bassat and colleagues) 
20th Sep 2006 - 19th Sep 
2007 
U29 Manhiça, Mozambique (Bassat and colleagues) 
1st Jan 2011 - 30th Jun 
2014 
U45 Nha Trang, Vietnam (Yoshida and colleagues) Feb 2007 - Dec 2012 
U46 Buenos Aires, Argentina (Echavarria and colleagues) 
1st Jun 2008 - 31st Dec 
2010 
U65 Rabat, Morocco (Bassat and colleagues) Nov 2010 - Dec 2011 




Table 53: List of 19 studies reporting subtypes data for RSV associated ALRI 
Location (reference) 






















































16 16 1 8 8 1 5 5 0 3 3 0 
Pune, India (Chadha 
and colleagues)# 
61 44 22 21 16 7 22 14 9 18 14 6 
Kilifi hospital study, 
Kenya (Nokes and 
colleagues)# 




49 49 0 34 34 0 9 9 0 6 6 0 
Manhiça, 
Mozambique (Bassat 










































Nha Trang, Vietnam 
(Yoshida and 
colleagues)# 
89 61 11 49 37 3 25 16 5 15 8 3 
Ho Chi Minh City, 
Vietnam (Tran et al., 
2013) 
230 165 21 
         
Zarqa, Jordan 
(Bdour, 2001) 
69 69 0 67 67 0 2 2 0 
   
Buenos Aires and 
Santa Fe, Argentina 
(Carballal et al., 
2000) 
352 174 21 
         
Sao Paulo, Brazil 
(Vieira et al., 2007) 
117 86 24 117 86 24 
      
Belem, Brazil 
(Lamarao et al., 
2012) 
243 18 207 
         
New York, USA 
(Suryadevara et al., 
2011) 
76 38 37 





















































358 165 135 262 121 99 63 28 24 33 16 12 
Riga, Latvia 
(Balmaks et al., 
2014) 
88 53 33 
         
RSV=respiratory syncytial virus. ALRI=respiratory syncytial virus. *All RSV included unknown subtypes. #Studies reported incidence rate or 
hospitalisation rate of RSV subtypes associated ALRI.  
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CFR of RSV-B 
(%) 
Buenos Aires, Argentina (Echavarria and colleagues) 0 1 0.0 0 0 NA 
Gambia Western Region, Gambia (Howie and 
colleagues) 
0 16 0.0 0 1 0.0 
Pune, India (Chadha and colleagues) 0 44 0.0 0 22 0.0 
Kilifi hospital study, Kenya (Nokes and colleagues) 23 853 2.7 7 445 1.6 
Manhiça, Mozambique (Bassat and colleagues) 1 49 2.0 0 0 NA 
Manhiça, Mozambique (Bassat and colleagues) 0 59 0.0 0 9 0.0 
Nha Trang, Vietnam (Yoshida and colleagues) 0 61 0.0 0 11 0.0 
Rabat, Morocco (Bassat and colleagues) 4 127 3.1 1 61 1.6 
Tacloban, Philippines (Lupisan and colleagues) 3 165 1.8 1 135 0.7 






5.2.8 RSV cases with hypoxemia 
Twenty-eight studies provided full details of hypoxemia among RSV positive cases 
according to a predefined definition. One was a published article (Rowlinson et al., 2013) 
and the other were unpublished studiesU10, U13, U21, U25, U26-28, U32-33, U37-39, U41-42, U44, U47, U62-63, U65, 
U68-75 (Table 55). Another 18 studies with hypoxemia data were excluded in the further 
analysis for several reasons (Table 56): unknown or unclear definition of hypoxemia, 
impropriate study design, substantially different definitions for hypoxemia, small sample 
size (less than 20 RSV cases). The detailed definitions of hypoxemia applied in each 
included study as well as its data were summarised in Table 57. They were all from hospital-
based settings and reported hospitalisation rate (when catchment area was well defined and 
denominator population was available) or proportion of hospitalised ALRI cases with RSV 
positive (when denominator number was not available). Two unpublished studiesU41, U44 
reported data from aboriginal populations and were excluded in the final meta-analysis 
(being consistent with previous epidemiological analyses). The proportion of RSV cases 
with recorded oxygen saturation data ranged from 27.4% to 100%. Since there were 0-72.6% 
of RSV cases with missing data of oxygen saturation, the estimate of hypoxemia (number of 
cases with hypoxemia, rate of cases with hypoxemia) was substantially underestimated. 
Overall, 21.2% (95% CI 16.7-27.0) of all hospitalised RSV positive cases in children 
younger than 5 years were identified with hypoxemia (Table 58). The proportion was similar 
in children with younger age: 21.6% (95% CI 17.1-27.2) in infants and 20.3% (95% CI 16.1-
25.5) in children younger than two years. There were 13 studies with a well-defined 
denominator population available, thus hospitalisation rate of RSV associated ALRI cases 
with hypoxemia was summarised in Table 59. One studyU44 was conducted in an aboriginal 
population and similarly it was excluded in the final analysis. In developing countries, the 
hospitalisation rate of RSV associated ALRI with hypoxemia for children aged 0-5m was 
estimated as 8.9 (95% CI 4.4-18.0) per 1000 children per year, 3.8 (95% CI 1.9-7.6) for 
children aged 6-11m, and 0.3 (95% CI 0.1-0.8) for children aged 12-59m (Table 60). 
Therefore, 0.9 (95% CI 0.4-1.9) million new cases of RSV associated ALRI with hypoxemia 
were estimated occurring in hospitals from developing countries in 2015 (Table 61). Among 
28 studies with hypoxemia data which met the pre-defined definitions, 25 of them also 
provided in-hospital mortality for RSV cases with hypoxemia. Their in-hospital CFRs were 
compared to the corresponding in-hospital CFR in all RSV cases (irrespective of oxygen 
saturation status) (Table 62). For most study sites, in-hospital mortality in RSV cases which 
had hypoxemia was higher than the mortality in all RSV cases (with or without hypoxemia).  
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Two sensitivity analyses of proportion of hospitalised RSV cases with hypoxemia in infants 
were carried out to exclude studies which did not report mortality data and studies which did 
not provide in-hospital CFR data for full age range respectively. Only three studies (two 
were in aboriginal population) did not report in-hospital CFR and the result did not differ 
much from previous estimate in infants: 21.6% (95% CI 17.1-27.2) vs. 22.1 (95% CI 17.5-
28.0). Similar result was observed after excluding studies that did not report in-hospital 




Table 55: List of 27 unpublished studies reporting data of RSV cases with hypoxemia 
Study number Location (reference) Study period 
U10 Paarl, South Africa (Zar and colleagues) Mar 2012 - Dec 2014 
U13 Buenos Aires, Argentina (Polack and colleagues) 2011 - 2013 
U21 Santa Rosa, Guatemala (McCracken and colleagues) Jan 2008 to Dec 2013 
U25 Lombok, Indonesia (Gessner and colleagues) 2000 - 2002 
U26 Kilifi hospital study, Kenya (Nokes and colleagues) Jan 2002 - Dec 2010 
U27 Bondo district, Kenya (Feikin and colleagues) Jan 2007 - Jun 2009 
U28 Manhiça, Mozambique (Bassat and colleagues) 
20th Sep 2006 - 19th Sep 
2007 
U32 David City, Panama (Jara and colleagues) Jan 2011 - Dec 2013 
U33 
Tagbilaran and 6 rural sites, Philippines (Lucero and 
colleagues) 
5th Jul 2000 - 31st Dec 2004 
U37 Soweto, South Africa (Madhi and colleagues) Mar 1998 - Oct 2005 
U38 
Maela Camp, Tak Province, Thailand (Turner and 
colleagues) 
Nov 2007 - Oct 2010 
U39 
Sa Kaeo and Nakhon Phanom, Thailand 
(Thamthitiwat and colleagues) 
Jan 2008 - Dec 2011 
U41 Alaska, USA (Singleton and colleagues) Oct 2005 - Sep 2007 
U42 Colorado, USA (Simoes and colleagues) Jan 2008 - Jun 2013 
U44 
Navajo and WMA, USA - EPI (O'Brien and 
colleagues) 
Oct 1997 - Mar 2000 
U47 Buenos Aires, Argentina (Gentile and colleagues) 2001 - 2013 
U62 Berlin, Germany (Rath and colleagues) 
1st Apr 2010 - 31st Mar 
2014 
U63 Amman, Jordan (Khuri and colleagues) Mar 2010 - Mar 2013 
U65 Rabat, Morocco (Bassat and colleagues) Nov 2010 - Dec 2011 
U68 Basse, Gambia (PERCH) 
3rd Nov 2011 - 2nd Nov 
2013 
U69 Kilifi, Kenya (PERCH) 
15th Aug 2011 - 15th Nov 
2013 
U70 Bamako, Mali (PERCH) 3rd Jan 2012 - 14th Jan 2014 
U71 Nakhon Phanom and Sa Kaeo, Thailand (PERCH) 1st Jan 2012 - 31st Jan 2014 
U72 Lusaka, Zambia (PERCH) 
10th Oct 2011 - 31st Oct 
2013 
U73 Dhaka, Bangladesh (PERCH) 1st Jan 2012 - 31st Dec 2013 
U74 Matlab, Bangladesh (PERCH) 1st Jan 2012 - 31st Dec 2013 
U75 Tacloban, Philippines (Lupisan and colleagues) May 2008 - Jul 2012 
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Table 56: List of 18 studies with hypoxemia data which were excluded 
Location (reference) Study Period Reason for exclusion 
Banjul, Fajara and Sibanor, Gambia 
(Weber et al., 2002) 
Jan 1994 - Dec 
1996 
unclear or unknown definitions for 
hypoxemia 
Freiburg, Germany (Berner et al., 
2001) 
Apr 1997 - Mar 
1999 
unclear or unknown definitions for 
hypoxemia 
Hong Kong, China (Chan et al., 2007) 
1st Jan 2004 - 31st 
Dec 2004 
unclear or unknown definitions for 
hypoxemia 
Athens, Greece (Vagia et al., 2010) 2008 - 2009 
unclear or unknown definitions for 
hypoxemia 
Palma, Spain (Hervas et al., 2012) 
Jan 1995 - Dec 
2006 
unclear or unknown definitions for 
hypoxemia 
Dallas, Texas, USA (Garcia et al., 
2010) 
Jan 2002 - Dec 
2007 
unclear or unknown definitions for 
hypoxemia 
Manhiça, Mozambique (Bassat and 
colleagues) 
1st Jan 2011 - 30th 
Jun 2014 
study design: children with oxygen 
saturation <85% were excluded 
Nha Trang, Vietnam (Yoshida and 
colleagues) 
Feb 2007 - Dec 
2012 
study design: the onset of illness to 
hospitalisation was short - threshold 
of hospitalisation is low 
Athens, Greece (Tsolia et al., 2003) 
Feb 1997 - Jun 
2000 
different definition: SpO2 <95% 
Amman, Jordan (Al-Toum et al., 
2006) 
Sep 2002 - Mar 
2004 
different definition: SpO2 <95% 
Madrid, Spain (Garcia-Garcia et al., 
2006) 
Oct 2000 - Jun 
2005 
different definition: SpO2 <95% 
Madrid, Spain (Calvo et al., 2010) 
Sep 2005 - Aug 
2008 
different definition: SpO2 <95% 
Buenos Aires, Argentina (Echavarria 
and colleagues) 
1st Jun 2008 - 31st 
Dec 2010 
different definition: SpO2 <92% 
Milan, Italy (Canducci et al., 2008) 
Oct 2004 - Sep 
2006 
different definition: SpO2 <92% 
Quetzaltenango, Guatemala 
(McCracken and colleagues) 
Feb 2009 - Dec 
2013 
different definition: SpO2 <87% for 
1-59 months and <85% for neonates 
at altitude >2500 m 
CEMIC, Buenos Aires, Argentina 
(Echavarria and colleagues) 
1st Jun 2008 - 31st 
Dec 2010 
different definition: SpO2 <94% 
Gambia Western Region, Gambia 
(Howie and colleagues) 
Jul 2007 - Jun 
2008 
small number of RSV cases (16) 
Tone district, Togo (Gessner and 
colleagues) 
Aug 2011 - Dec 
2013 
small number of RSV cases (15) 
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Table 57: List of 28 studies reporting proportion of RSV associated hospitalised ALRI cases with hypoxemia 
Location (reference) 




Definition of hypoxemia 
Proportion of RSV positive cases with hypoxemia 
(%) 
0-11m 12-23m 0-23m 24-59m 0-59m 
Matlab, Bangladesh (PERCH) 100.00 
SpO2 <90% or based on supplemental oxygen 
at altitude ≤2500 m 
2.2 0.0 1.9 0.0 1.8 
Basse, Gambia (PERCH) 100.00 
SpO2 <90% or based on supplemental oxygen 
at altitude ≤2500 m 
7.4 7.1 7.3 0.0 7.0 
Santa Rosa, Guatemala 
(McCracken and colleagues) 
93.00 
SpO2 <90% for 1-59 months and <88% for 
neonates at altitude ≤2500 m 
7.5 5.0 7.1 11.1 7.4 
Dhaka, Bangladesh (PERCH) 100.00 
SpO2 <90% or based on supplemental oxygen 
at altitude ≤2500 m 
10.5 0.0 5.9 33.3 8.1 
Tacloban, Philippines (Lupisan 
and colleagues) 
100.00 
SpO2 <90% (at altitude ≤2500 m) in children 
aged 1-59 months and <88% for neonates 
9.2 12.7 9.8 12.1 10.1 
Kilifi hospital study, Kenya 
(Nokes and colleagues) 
99.93 SpO2 <90% for all at altitude ≤2500 m 11.1 5.4 10.2 8.7 10.1 
Bondo district, Kenya (Feikin and 
colleagues) 
100.00 
SpO2 <90% for 1-59 months and <88% for 
neonates at altitude ≤2500 m (at sea level) 
15.8 5.9 12.7 0.0 10.6 
Rabat, Morocco (Bassat and 
colleagues) 
93.38 SpO2 <90% for all at altitude ≤2500 m 12.9 14.8 13.4 6.7 11.8 
Nakhon Phanom and Sa Kaeo, 
Thailand (PERCH) 
100.00 
SpO2 <90% or based on supplemental oxygen 
at altitude ≤2500 m 
15.8 6.7 11.8 12.5 12.0 
David City, Panama (Jara and 
colleagues) 
71.86 
SpO2 <90% for 1-59 months and <88% for 
neonates at altitude ≤2500 m (at sea level) 
17.1 10.3 15.3 33.3 16.7 
Berlin, Germany (Rath and 
colleagues) 
78.11 
SpO2 <90% for 1-59 months and <88% for 
neonates at altitude ≤0.942500 m 








Definition of hypoxemia 
Proportion of RSV positive cases with hypoxemia 
(%) 
0-11m 12-23m 0-23m 24-59m 0-59m 
Soweto, South Africa (Madhi and 
colleagues) 
99.65 SpO2 <90% for 1-59 months 27.2 15.3 25.0 5.7 23.8 
Kilifi, Kenya (PERCH) 100.00 
SpO2 <90% or based on supplemental oxygen 
at altitude ≤2500 m 
26.3 17.4 24.8 15.4 24.0 
Lusaka, Zambia (PERCH) 97.09 
SpO2 <90% or based on supplemental oxygen 
at altitude ≤2500 m 
42.5 40.0 36.1 66.7 37.0 
Bamako, Mali (PERCH) 100.00 
SpO2 <90% or based on supplemental oxygen 
at altitude ≤2500 m 
37.8 393.3 39.3 0.0 37.8 
Manhiça, Mozambique (Bassat 
and colleagues) 
100.00 SpO2 <90% for all at altitude ≤2500 m 55.9 22.2 48.8 0.0 42.9 
Damanhour, Egypt (Rowlinson et 
al., 2013) 
27.41 SpO2 <90% for all at altitude ≤2500 m     46.9 
Sa Kaeo and Nakhon Phanom, 
Thailand (Thamthitiwat and 
colleagues) 
51.95 
SpO2 <90% for 1-59 months and <88% for 
neonates at altitude ≤2500 m (at sea level) 
61.6 8.1 54.6 3.9 51.9 
Buenos Aires, Argentina (Gentile 
and colleagues) 
99.94 
SpO2 <90% for 1-59 months and <88% for 
neonates at altitude ≤2500 m (at sea level) 
60.6 60.7 60.6 62.5 60.8 
Colorado, USA (Simoes and 
colleagues) 
100.00 ICD-9 codes 64.2 71.6 66.0 67.8 66.3 
Maela Camp, Tak Province, 
Thailand (Turner and colleagues) 
93.02 
SpO2 <90% for 1-59 months and <88% for 
neonates at altitude ≤2500 m (at sea level) 
11.3 2.5 8.3  
 
Tagbilaran and 6 rural sites, 
Philippines (Lucero and 
colleagues) 
NA 
SpO2 <90% for 1-59 months and <88% for 
neonates at altitude ≤2500 m (at sea level) 









Definition of hypoxemia 
Proportion of RSV positive cases with hypoxemia 
(%) 
0-11m 12-23m 0-23m 24-59m 0-59m 
Alaska, USA (Singleton and 
colleagues)# 
100.00 SpO2 <90% for all at altitude ≤2500 m 16.4 36.4 21.1  
 
Lombok, Indonesia (Gessner and 
colleagues) 
99.19 
SpO2 <90% for 1-59 months and <88% for 
neonates at altitude ≤2500 m (at sea level) 
33.0 36.6 33.6  
 
Amman, Jordan (Khuri and 
colleagues) 
100.00 SpO2 <90% for all at altitude ≤2500 m 9.4 7.3 9.1  
 
Paarl, South Africa (Zar and 
colleagues) 
92.86 
SpO2 <90% for 1-59 months and <88% for 
neonates at altitude ≤2500 m 
36.0 0.0 34.6  
 
Buenos Aires, Argentina (Polack 
and colleagues) 
98.71 
SpO2 <90% for 1-59 months and <88% for 
neonates at altitude ≤2500 m 
41.5 41.6 41.5  
 
Navajo and WMA, USA - EPI 
(O'Brien and colleagues)# 
92.05 
SpO2 <90% for 1-59 months and <88% for 
neonates at altitude ≤2500 m (at sea level) 
82.0 84.4 82.7  
 
RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. ICD=international classification of diseases. NA=not applicable. #Studies 
reporting hypoxemia data in an aboriginal population from a high-income country.   
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Table 58: Meta-estimate of proportion of RSV associated hospitalised ALRI cases with hypoxemia 
Region 
0-11m 12-23m 0-23m 24-59m 0-59m 
No. Prop (%) No. Prop (%) No. Prop (%) No. Prop (%) No. Prop (%) 
Low income 8 16.4 (9.1-29.6) 8 18.9 (2.2-162.7) 8 14.4 (7.8-26.5) 8 10.7 (6.1-18.8) 8 13.9 (7.7-24.9) 
Lower middle income 6 16.5 (9.1-30.0) 6 17.7 (9.9-31.8) 6 16.3 (9.2-29.1) 4 14.7 (6.5-33.3) 5 17.3 (7.8-38.6) 
Upper middle income 9 26.9 (18.3-39.5) 9 23.0 (14.9-35.3) 9 24.3 (16.7-35.5) 5 36.6 (23.7-56.5) 5 30.5 (20.1-46.1) 
High income 2 32.4 (8.3-127.3) 2 53.8 (28.1-103.0) 2 37.0 (11.7-117.4) 2 53.2 (29.9-94.9) 2 39.6 (14.2-110.5) 





Developing 23 20.2 (15.1-26.9) 23 19.7 (12.8-30.4) 23 18.6 (14.0-24.8) 17 20.6 (13.3-31.9) 18 18.4(12.8-26.4) 
Industrialised 2 32.4 (8.3-127.3) 2 53.8 (28.1-103.0) 2 37.0 (11.7-117.4) 2 53.2 (29.9-94.9) 2 39.6 (14.2-110.5) 





Global 25 21.6 (17.1-27.2) 25 23.8 (17.4-32.6) 25 20.3 (16.1-25.5) 19 27.8 (20.4-37.8) 20 21.2 (16.7-27.0) 




Table 59: List of 13 studies reporting hospitalisation rate of RSV associated ALRI cases with hypoxemia 
Location (reference) 
Hospitalisation rate of RSV associated ALRI cases with hypoxaemia 
(per 1000 children per year) 
0-5m 6-11m 0-11m 12-23m 24-59m 0-59m 
Kilifi hospital study, Kenya (Nokes and colleagues) 3.5 0.7 2.1 0.2 0.1 0.5 
Bondo district, Kenya (Feikin and colleagues) 10.5 4.4 6.9 1.3 0.0 3.0 
Manhiça, Mozambique (Bassat and colleagues) 7.9 3.9 6.0 0.6 0.0 1.3 
David City, Panama (Jara and colleagues) 
  
12.5 4.5 0.5 3.8 
Soweto, South Africa (Madhi and colleagues) 10.4 1.7 5.4 0.6 0.0 1.1 
Sa Kaeo and Nakhon Phanom, Thailand (Thamthitiwat and colleagues) 1.7 1.3 1.5 0.6 0.1 0.5 
Lombok, Indonesia (Gessner and colleagues) 4.4 4.2 4.3 1.0 
 
 
Tagbilaran and 6 rural sites, Philippines (Lucero and colleagues) 11.5 8.1 9.5 4.2 
 
 
Paarl, South Africa (Zar and colleagues) 53.3 7.5 31.7 0.0 
 
 
Maela Camp, Tak Province, Thailand (Turner and colleagues) 9.4 12.2 10.7 1.5 
 
 
Navajo and WMA, USA (O'Brien and colleagues)# 170.3 123.8 147.0 63.3 
 
 
Buenos Aires, Argentina (Polack and colleagues) 27.9 12.1 20.0 3.8 
 
 
Colorado, USA (Simoes and colleagues) 
  
11.6 4.1 1.1 3.8 





Table 60: Meta-estimate of hospitalisation rate of RSV associated ALRI cases with hypoxemia 
Region 












(per 1000 children per year) 
Low income 3 6.1 (3.0-12.6) 3 2.1 (0.5-8.7) 3 0.1 (0.1-0.3) 
Lower middle income 2 7.1 (2.8-18.1) 2 5.8 (3.1-11.0) 0 NA 
Upper middle income 5 11.9 (4.3-33.3) 5 4.6 (1.3-16.1) 3 0.4 (0.1-1.5) 
High income 0 NA 0 NA 1 1.8 (1.8-1.9) 
       
Developing 10 8.9 (4.4-18.0) 10 3.8 (1.9-7.6) 6 0.3 (0.1-0.8) 
Industrialised 0 NA 0 NA 1 1.8 (1.8-1.9) 




Table 61: Number of new cases of RSV associated hospitalised ALRI with hypoxemia 
Region 
0-5m 6-11m 12-59m 0-59m* 
Hospitalised cases  
(*10³) 
Hospitalised cases  
(*10³) 
Hospitalised cases  
(*10³) 
Hospitalised cases  
(*10³) 
Low income 65 (32-134) 23 (6-93) 11 (5-27) 99 (42-254) 
Lower middle income 227 (88-581) 186 (98-355) NA NA 
Upper middle income 210 (75-589) 81 (23-285) 55 (14-211) 347 (112-1084) 
High income NA NA 118 (113-121) NA 
     
Developing 548 (272-1107) 234 (118-469) 129 (48-363) 912 (437-1939) 
Industrialised NA NA 103 (99-106) NA 
RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. NA=not applicable. *number of hospitalised cases in 0-59m is sum of estimates 





Table 62: List of 25 studies reporting in-hospital CFR among RSV cases with hypoxemia 
Location (reference) 
RSV with hypoxemia All RSV cases 
Deaths Cases CFR (%) Deaths Cases CFR (%) 
Damanhour, Egypt (Rowlinson et al., 2013) 0 60 0.0 0 467 0.0 
Berlin, Germany (Rath and colleagues) 0 54 0.0 0 297 0.0 
Rabat, Morocco (Bassat and colleagues) 1 15 6.7 4 136 2.9 
Basse, Gambia (PERCH) 0 8 0.0 0 114 0.0 
Kilifi, Kenya (PERCH) 3 36 8.3 6 150 4.0 
Bamako, Mali (PERCH) 4 59 6.8 4 156 2.6 
Nakhon Phanom and Sa Kaeo, Thailand (PERCH) 0 6 0.0 0 50 0.0 
Lusaka, Zambia (PERCH) 4 37 10.8 6 103 5.8 
Dhaka, Bangladesh (PERCH) 0 3 0.0 0 37 0.0 
Tacloban, Philippines (Lupisan and colleagues) 1 36 2.8 6 358 1.7 
Santa Rosa, Guatemala (McCracken and colleagues) 4 47 8.5 15 505 3.0 
Kilifi hospital study, Kenya (Nokes and colleagues) 31 144 21.5 31 1428 2.2 
Bondo district, Kenya (Feikin and colleagues) 0 7 0.0 1 66 1.5 
Manhiça, Mozambique (Bassat and colleagues) 1 21 4.8 1 49 2.0 
David City, Panama (Jara and colleagues) 0 20 0.0 0 167 0.0 
Soweto, South Africa (Madhi and colleagues) 12 205 5.9 14 863 1.6 
Sa Kaeo and Nakhon Phanom, Thailand (Thamthitiwat and colleagues) 0 37 0.0 0 795 0.0 
Lombok, Indonesia (Gessner and colleagues) 4 247 1.6 13 741 1.8 




RSV with hypoxemia All RSV cases 
Deaths Cases CFR (%) Deaths Cases CFR (%) 
Paarl, South Africa (Zar and colleagues) 0 9 0.0 0 28 0.0 
Amman, Jordan (Khuri and colleagues) 5 123 4.1 6 1352 0.4 
Buenos Aires, Argentina (Polack and colleagues) 24 888 2.7 24 2167 1.1 
Buenos Aires, Argentina (Gentile and colleagues) 63 2180 2.9 65 3590 1.8 
Matlab, Bangladesh (PERCH) 0 2 0.0 0 109 0.0 
Colorado, USA (Simoes and colleagues) 0 7686 0.0 6 11592 0.1 




5.2.9 Year by year variation in individual study site  
Several studies reported incidence rate or hospitalisation rate for several years. Therefore, 
when studies reported data in infants for at least three years and provided the data by year, 
these studies were selected to display year to year variation of incidence rate or 
hospitalisation rate for this study site. Two studiesU3, U5 reporting incidence rate of infants for 
at least three years were selected. Incidence rate in Bangladesh was highest in 2006 while 
there was little variation in the other three years under investigation (from 13.1 to 84.6 per 
1000 children per year). In Indonesia, the incidence rate was highest in 2001 and it was 
almost the same in years 1999 and 2000 (from 151.7 to 364.4 per 1000 children per year). 
The figures showing incidence rate year by year from these two sites were available in 
Appendices - A22. Regarding studies reporting hospitalisation rate, stricter selection criteria 
were applied. Seven studiesU19, U21-22, U26, U33, U35, U42 reporting hospitalisation rate for at least 
five years and recording more than 100 RSV associated hospitalised ALRI cases in infants 
were chosen. There were substantial variations in hospitalisation rate across different study 
years in several sites, such as El Salvador, Guatemala (2 sites), and South Africa. In Kenya, 
Philippines and Colorado, however, the hospitalisation rate was similar in each study year 
with slight variations. The figures displaying their hospitalisation rates by year were 




 Discussion  
5.3.1 Main results  
In 2015, 30.5 (95% CI 19.5-47.9) million episodes of RSV associated ALRI were estimated 
to occur in children younger than 5 years in developing countries (30.0 (95% CI 19.1-47.0) 
million in low and middle income countries). A substantial proportion of RSV associated 
ALRI - 10.9 (95% CI 7.2-16.4) million occurred in the first year of life, with incidence rate 
in infants 1.7 times greater than what was reported for children younger than 5 years. The 
global estimate in children under five was around 33.0 (95% CI 20.6-53.2) million RSV 
associated ALRI. Also, in 2015, 3.0 (95% CI 2.2-4.0) million young children worldwide 
were estimated to develop RSV associated ALRI necessitating hospital admission, and 
around 60,000 (95% CI 48,000-75,000) children younger than 5 years died from RSV 
associated hospitalised ALRI, with 99% of these deaths occurring in developing countries. 
An inflation factor was calculated based on three community-based studies from developing 
countries, considering that access to healthcare in developing countries is limited. This 
inflation factor was estimated as 2.2. Overall, the global number of RSV associated ALRI 
deaths if active community based case ascertainment was applied in the developing country 
settings, was around 131,000 (95% CI 106,000-163,000). 
Two independent approaches with differing data sources and assumptions were adopted to 
obtain a data-derived estimate of the plausible number of RSV associated hospitalised ALRI: 
hospitalisation rate approach which used meta-estimate of hospitalisation rate and 
corresponding demographic data of population of interest; proportion approach which 
combined the proportion of hospitalised ALRI cases that are RSV positive with 
corresponding number of hospitalised ALRI cases. The two approaches generated estimates 
of the global number of new episodes of RSV associated hospitalised ALRI with overlapping 
95% confidence intervals: 3.0 (95% CI 2.2-4.0) million and 2.8 (95% CI 2.3-3.4) million 
respectively. This was considered to represent a broad replication of the estimate, which 
supports the general validity of the estimate.  
5.3.2 Variation of estimates  
Estimates of RSV associated ALRI are highly variable within countries or regions and across 
regions. It is impossible to deduce how much of this variation is due to methodological 
differences and how much is due to variation in RSV epidemiology between study 
populations or region-specific differences. Thus, the true uncertainty is wider than that 
expressed in a standard 95% CI. Four methodological factors might have affected the 
estimates: method of case ascertainment; case definition used in included studies 
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(community-based and hospital-based); accuracy of diagnostic assays to identify RSV 
infection, and the fact that a proportion of eligible ALRI cases were not tested.  
5.3.2.1 Case ascertainment  
All studies reporting incidence rate of RSV associated ALRI used active community-based 
case ascertainment, which means health-care workers visit house-to-house to identify cases. 
Even though active case ascertainment was used to identify cases, the RSV associated ALRI 
incidence estimate in developing countries is still likely to be underestimated because there 
will be an unknown proportion of cases missed. For studies reporting hospitalisation rate of 
RSV associated ALRI, in-hospital CFR as well as proportion data, they all used passive case 
ascertainment including only inpatients. The estimates generated from these hospital-based 
studies can only indicate the morbidity and mortality of RSV associated ALRI in hospital 
settings. This is because the health-care access in some developing countries, especially in 
rural areas, is poor and not all infected children manage to visit clinics or hospitals and 
receive required treatments (Macfarlane, 2000). Delays in transferring children to health 
facilities from presentation can affect the disease progression, increase morbidity and 
mortality of the illness, and also affect RSV titres and test sensitivity. There were 41 studies 
conducted in rural populations and 38 were in a mixture of urban and rural areas across the 
included studies. An emergency room based study from a Nigerian tertiary hospital showed 
that most children received care within homes and after 24 hours of onset of illness (Tinuade, 
2010). The duration between onset of illness and presentation at hospital was long, with the 
majority being after 48 hours. Therefore, an inflation factor was calculated and used to 
extrapolate the overall mortality from RSV associated ALRI if active community-based 
ascertainment was applied. Since mothers were involved in most decisions where health-care 
seeking was approached for their ill children (Tinuade, 2010), empowerment of women and 
improvement of maternal education is important. This is not only to increase their awareness 
of prompt health-care seeking behaviour, but also to help them recognise the danger signs or 
symptoms young children might have. Improving accessibility to health facilities in terms of 
distance and expenditures will also encourage carers to take sick children to hospitals. The 
association of parental education and RSV associated ALRI was investigated in Chapter 4.  
5.3.2.2 Case definition 
Case definitions used among included studies varied from the WHO definition to physician-
diagnosed ALRI (with or without chest radiographic confirmation) and unspecified acute 
respiratory illness that was severe enough to necessitate hospital admission. For community-
based studies, healthcare workers used WHO definition to define the cases (cough or 
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difficulty in breathing with fast breathing for age, with or without chest wall indrawing and 
general danger signs). For hospital-based studies, the majority of studies defined the cases 
based on physician’s assessment (with or without chest wall indrawing, hypoxemia, general 
danger signs, mechanical ventilation and intensive care unit admission). Several studies used 
other case definitions, such as SARI, which was defined as an acute respiratory infection 
with history of fever or measured fever ≥38°C and cough, with onset within the last ten days 
and requires hospitalisation. Some studies excluded cases with wheeze or included fever as 
part of the case definitions. Therefore, these studies were excluded to run a sensitivity 
analysis. The result did not differ substantially to the estimate where these studies were 
included. It was slightly lower and the underlying mechanism required further investigation. 
In Table 48, codes corresponding to different definitions or clinical features used to define 
ALRI were compared between studies reporting hospitalisation rate and studies providing in-
hospital CFR data. A variety of case definition codes was observed. The percentage of each 
code used in included studies differed from each other but was consistently similar between 
these two groups of studies.  
Ability to recognise and diagnose clinical symptoms and signs accurately is important. For 
example, fast breathing is diagnosed at different thresholds for children at different ages 
(WHO IMCI cut-offs). It is best to count the respiratory rate using a timing device when the 
child is in a quiet but in an alert state. Chest wall indrawing refers to lower chest wall 
indrawing (subcostal indrawing or subcostal retraction) when the child breaths in, which 
occurs below the costal margin and indicates that more effort is needed to breath in since the 
lung becomes stiff due to infection. This must be present clearly and visible all the time.  
Despite there being a large number of clinical symptoms and signs that could be assessed in 
children, none of the clinical features mentioned above has sufficient validity to diagnose 
pneumonia on its own. The WHO definition of clinical pneumonia has high sensitivity but 
was claimed to have low specificity (Cardoso et al., 2011). A prospective study involving 
390 children aged 2-59 months from Sao Paulo (Brazil) showed that WHO criteria to 
identify children with pneumonia had a high sensitivity of 84% and a low specificity of 19% 
(Cardoso et al., 2011). The sensitivity was higher in younger age group (94% in children <24 
months compared to 62% in children ≥24 months). A pragmatic perspective led to the WHO 
clinical case definition emphasising sensitivity over specificity. This is of public health 
significance because the WHO case definition is aimed to capture the majority of children 
with pneumonia for timely management, mitigating the progress of illness and decreasing the 
severity and mortality of the disease. Nevertheless, low specificity may lead to over-use of 
antibiotics, incur multiple clinic or hospital visits and unnecessary medical expenditure 
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which increases family financial burden, and also impose more burden on paediatric 
healthcare system.  
5.3.2.3 Clinical specimen and diagnostic test 
The 304 included studies also differed in the method of nasal sampling and in the specific 
diagnostic assays applied, which will also have contributed to some of the variations in 
reported estimates. Most studies took nasopharyngeal aspirate (NPA), nasopharyngeal wash 
(NPW), nasopharyngeal swab (NPS), or oropharyngeal swab (OPS) clinical specimens. 
Children have a higher concentration of RSV secretion compared to adults. The 
concentration is also lower in elderly people and immune-compromised persons.  
A timely diagnosis of respiratory infections which are RSV positive is important for 
infection control measures, which can limit the transmission and progress of the virus. It can 
also limit unnecessary antibiotic utilisation and allow early implementation of antiviral 
treatment. The main diagnostic techniques used in included studies were polymerase chain 
reaction (PCR), immunofluorescence (IF), direct immunofluorescence (DFA), indirect 
immunofluorescence (IFA), and enzyme-linked immunosorbent assay (ELISA). Among 304 
studies, 117 studies used PCR-based assays; the remaining studies used IF (28 studies), DFA 
(66 studies), IFA (18 studies), ELISA (12 studies) and a mixture of diagnosis tests (46 
studies). Another 17 studies did not provide clear information about diagnosis test.  
The effect of these diagnostic methods on the estimates depends on their sensitivity and 
specificity and factors which affect their performance: quality of specimen (collection and 
handling), transport conditions of specimen, adequacy of specimen (virus load), 
manufacturer, quality of reagent, laboratory technician skills and features of population 
under diagnosis.  
As described in the Chapter 1 - Introduction, antigen-based assays (IF, DFA, IFA, ELISA 
and rapid antigen-detection tests) are widely available, easy to perform, inexpensive and 
provide results rapidly while they have a relatively low sensitivity and specificity (compared 
to nucleic acid amplification), especially outside the disease season (low prevalence of virus) 
and among special populations (immunocompromised individuals and elderly people) 
(Henrickson and Hall, 2007). They also lack adequate sensitivity in testing adults with RSV 
infection due to small virus load. They require a high level of laboratory microscope 
handling experience and a rich sample with cells. The immunofluorescence assays have 
variable and lower sensitivity (69.4%) and specificity (99.7%) compared to RT-PCR 
according to a prospective cohort study consisting of 173 healthy new-borns who were 
followed up until two years old (Reis et al., 2008). During the high season of RSV, rapid 
206 
 
antigen tests could be applied to facilitate viral diagnosis because of their availability and 
practicality. They have relatively good sensitivity and specificity when the test is carried out 
during peak season of virus among healthy children (not immunocompromised).  
Molecular assays have fulfilled the requirements of rapid diagnosis and high sensitivity and 
specificity for respiratory viruses testing. However, they are expensive and are not available 
in most clinical laboratories. They also have the potential to detect viruses for a longer time 
due to their high sensitivity. During this extended shedding period being detected by PCR, it 
is possible that the child gets another viral infection. It is difficult to decide which pathogen 
is the cause of illness. Real time PCR involves fewer steps and decreases risk of 
contamination. However, its costs are higher and the reagent is unstable and more expensive 
(Henrickson, 2004). Multiplex virus testing is available and makes it efficient to have several 
viruses tested at the same time. There are several important issues of molecular diagnostic 
test remaining to be considered, such as expense of reagents, the requirement for reliable 
commercial reagents, and the necessity for building up capability and providing platforms 
that are able to respond to new emerging and “re-emerging” agents (Henrickson, 2004).  
Cell culture, which was previously considered as the gold standard to diagnose respiratory 
viruses, has been replaced by molecular assays (PCR) in many settings due to its long 
processing time, special requirement of specimen handling procedure, large financial cost 
and lower sensitivity in comparison to PCR (Henrickson and Hall, 2007, Reis et al., 2008). 
There were 27 studies using cell culture as part of the diagnostic tests (all of them were 
combined with other methods). Studies using serology as the only diagnostic test were 
excluded (listed in Table 19) because it is not useful for diagnosing ALRI and the rate of 
false negative results is high (Henrickson, 2004).  
A prospective study including 378 children aged 2-35 months proposed point-of-care 
ultrasound for the diagnosis of childhood pneumonia as an alternative imaging approach in 
resource-limited settings (Chavez et al., 2015). It takes around 6.4 minutes to perform one. A 
systematic review was carried out to investigate the performance of the lung ultrasound 
(Pereda et al., 2015). It has a pooled sensitivity of 96% (94%-97%) and a pooled specificity 
of 93% (90%-96%) using chest radiographs and/or clinical criteria as the reference standard. 
Also, considering that it is quick to perform and it does not involve ionizing radiation, it is 
recommended as an alternative approach to diagnose pneumonia, especially when chest 
radiographs are not available. However, the number of included studies is small (only 8 
studies), the sample size from each study is small, and there is a possibility of missing small 
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consolidations (< 1 cam) that do not reach the pleura. Lung ultrasound, therefore, still needs 
further research and assessment.  
All these diagnosis tests need trained laboratory technicians (except for rapid antigen-
detection test) and specialised equipment. With the emergence of these various diagnostic 
methodologies, it is necessary to develop guidelines to direct their appropriate use in the 
laboratory. Clinicians should also recognise the benefits and limitations of these diagnostic 
tests while making clinical decisions about their use. 
5.3.2.4 ALRI cases which were not tested 
In some studies, a substantial proportion of children with ALRI were not tested for RSV for 
various reasons: samples were selected randomly and tested; patients were very ill; no 
informed consent from parents; patients died or got discharged before samples were taken; 
samples were lost; and poor quality of samples. During the process of extracting data from 
included studies, the number of RSV associated ALRI cases was scaled up accordingly (if 
possible) to account for ALRI cases which were not tested, on the assumption that the 
proportion of ALRI cases which were RSV positive in untested ALRI was the same as in 
tested ALRI. However, for hospital-based studies reporting CFR, this such adjustment for 
those untested ALRI cases was not available. Table 63 shows 30 unpublished studies with 
complete information about proportion of hospitalised ALRI cases not tested for RSV, 
reasons for not being tested, in-hospital CFR among hospitalised ALRI tested for RSV and 
untested ALRI cases respectively in their overall age groups. Accordingly, 0.3-75.0% of all 
eligible ALRI cases were not tested for RSV for various reasons. In most cases, the in-
hospital mortality was higher among hospitalised ALRI cases which were not tested for RSV 
compared to those cases which were tested. This is possible because children who were not 
tested with RSV probably had a severe illness and clinical specimen was not taken while the 
children were receiving urgent treatment. Among all deaths due to ALRI, the proportion of 
these deaths being untested (with unknown pathogen) ranged from 0 to 100% (in this case, 
there were two deaths of ALRI and both of them were not tested for pathogen). A sensitivity 
analysis was carried out to estimate in-hospital CFR taking into account of untested ALRI, 
on the assumptions that the proportion of RSV detection in untested ALRI was the same as 
in the tested ALRI and the in-hospital CFR of these RSV cases (from untested ALRI) was 
the same as the CFR of the overall untested ALRI. Under these assumptions, the adjusted in-
hospital CFR in children aged 0-59m from the developing countries was 1.57 (95% CI 0.99-
2.49). It was slightly higher than the estimate 1.47 (95% CI 0.94-2.30) when no adjustment 
was made. This result is consistent with the previous observation that in-hospital CFR was 
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higher among untested ALRI cases than ALRI which were tested for RSV. Therefore, the 
adjustment factor was 1.07 (1.57/1.47) and if it was applied to the in-hospital deaths 
estimated above - 59578 (47750-74325), the adjusted in-hospital deaths was 63748 (51093-
79528) in children under five from developing countries. More details of calculation process 
are available in Appendices – A24. 
Furthermore, 13 unpublished studies with more than 2 deaths of untested ALRI in infants 
and with available data regarding seasonality of RSV and number of deaths from untested 
ALRI in infants by month were selected. They were used to explore whether these deaths of 
untested ALRI occurred within RSV season or outside RSV season. Seasonality of RSV 
(proportion of hospitalised ALRI cases which are RSV positive) and number of deaths of 
untested ALRI in infants by each study month were plotted for each study site. In Figure 18, 
there were several deaths of untested ALRI occurring during RSV season (overlapped of two 
lines). This might result in an underestimation of in-hospital deaths of RSV cases. 
5.3.3 Mortality estimate  
In-hospital mortality estimates were generated by using Monte Carlos simulation on the 
assumption that meta-estimates of hospitalisation rate and in-hospital CFR followed log-
normal distributions. Repeatedly every 10,000 sample from each age band and region 
specific group were drawn. Output data for each outcome were produced independently from 
run to run. The median value of the resultant calculation was reported as the point estimate, 
while the 2.5th and 97.5th percentiles from the resultant calculation were reported as the 95% 
confidence interval. This Monte Carlos simulation method took the point estimate and its 
bounding confidence intervals from both variables (hospitalisation rate and in-hospital CFR) 
into account to create samples of the in-hospital deaths (compound effect measure). Since it 
considered the uncertainty from both parameters, the confidence intervals for the compound 
effect measure were wide (Greenland, 2004). The difference between global point estimate 
and the sum of respective regional point estimates is a result of the sampling from the 
simulation process. 
In-hospital CFR decreased with age. Studies with more than 10 deaths due to RSV 
associated hospitalised ALRI in the age group of 0-23m were selected considering that most 
deaths happen within first two years of life. Six studies were included and displayed in the 
spaghetti plot demonstrating in-hospital CFR by narrower age bands (Figure 19). Each 
colour represents a different study. Clearly, in each study, the in-hospital CFR is higher in 
infants compared to the older age group.   
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The estimate of RSV mortality in the community was generated based on the assumption 
that all excess ALRI mortality during RSV season is due to RSV, which is unlikely to be true 
considering that other respiratory pathogens may circulate during RSV season and the 
likelihood of RSV deaths occurring outside the defined RSV season. 
210 
 
Table 63: List of 30 studies reporting eligible ALRI cases not tested for RSV as well as CFR among tested ALRI and untested ALRI cases 
Location (reference) 
% of eligible 
cases not 
tested for RSV 




for RSV (%) 
CFR among 
hospitalised 
ALRI not tested 





Kilifi, Kenya (PERCH, unpublished) 0.3 (2/634) specimen not collected 4.9 100.0 6.1 
Iquique, Chile (Fasce, unpublished) 0.6 (4/683) 
cases were not notified in time so as to collect 
sample 
0.4 0.0 0.0 
Buenos Aires, Argentina (Polack, 
unpublished) 
0.9 (30/3371) sample inadequate 1.3 43.3 23.6 
Gauteng province, South Africa (Cohen, 
unpublished) 
2.0 (122/6016) 
child too ill to take sample from; specimens 
not reaching laboratory within 72 hours 
0.8 2.5 5.7 
Manhiça, Mozambique (Bassat, 
unpublished) 
3.1 (15/491) 
NPA not collected or processed without 
results 
2.5 13.3 14.3 
Klerksdorp site, South Africa (Cohen, 
unpublished) 
3.2 (30/932) 
patient very ill; parents refuse consent, 
specimen not at lab within 72 hours 
2.1 0.0 0.0 
Tone District, Togo (Gessner, 
unpublished) 
3.2 (4/124) testing just started 0.0 66.7 100.0 
Concepcion, Chile (Fasce, unpublished) 3.3 (16/481) 
cases were not notified in time so as to collect 
sample 
0.4 0.0 0.0 
Manhiça, Mozambique (Bassat, 
unpublished) 
3.4 (28/835) 
NPA not collected or processed without 
results 
9.3 25.0 8.5 
Mpumalanga, South Africa (Cohen, 
unpublished) 
4.0 (52/1310) 
patient very ill; parents refuse consent; 
specimen not at lab within 72 hours 
6.1 21.2 12.5 
Western Gambia (Howie, unpublished) 4.2 (4/95) technical problem with specimen 3.3 0.0 0.0 
KwaZulu-Natal province, South Africa 
(Cohen, unpublished) 
4.5 (72/1607) 
patient very ill; parents refuse consent, 
specimen not at lab within 72 hours 




% of eligible 
cases not 
tested for RSV 




for RSV (%) 
CFR among 
hospitalised 
ALRI not tested 





Soweto, South Africa (Madhi, 
unpublished) 
4.6 (240/5231) missed as part of surveillance 5.5 22.5 16.3 
CEMIC, Buenos Aires, Argentina 
(Echavarria, unpublished) 
5.3 (3/57) insufficient sample 0.0 0.0 NA 
Santa Rosa, Guatemala (McCracken, 
unpublished) 
5.8 (104/1810) no consent or no specimen 5.2 1.9 2.2 
Basse Santa Su, Gambia (PERCH, 
unpublished) 
7.2 (46/638) quality control not yet complete 2.9 10.9 22.7 
Bamako, Mali (PERCH, unpublished) 9.1 (61/674) quality control not yet complete 14.5 21.3 12.7 
41 sites in Netherlands (Bont, 
unpublished) 
10.0 (24/241) 
reasons for not testing are unknown, as the 
decisions for testing are made by independent 
physicians at hospital of presentation 
0.0 0.0 NA 
Lusaka, Zambia (PERCH, unpublished) 10.5 (65/617) quality control not yet complete 18.1 26.2 14.5 




no consent or no specimen 2.7 0.0 0.0 




NA 2.0 1.6 10.8 
Paarl, South Africa (Zar, unpublished) 16.4 (21/128) specimens were not obtained 0.9 4.8 50.0 
Nakhon Phanom and Sa Kaeo, Thailand 
(PERCH, unpublished) 
18.3 (41/224) quality control not yet complete 1.1 2.4 33.3 




died; discharged; refusal 5.2 32.7 67.0 




% of eligible 
cases not 
tested for RSV 




for RSV (%) 
CFR among 
hospitalised 
ALRI not tested 










primarily age <3 months and critical illness on 
presentation; specimens collected 4 days a 
week so if patients who had rapid admission, 
would not have been done 
2.2 33.1 86.1 




no specimen collected for those cases not 
tested for RSV 
0.5 2.2 70.6 




frozen samples at weekends; laboratory 
refused 
1.2 1.3 62.5 




refusal to consent; unavailability of transport 
from field site to lab; high patient volumes; 
inadequate staffing levels 
3.4 2.5 66.0 




patients refused to take part in it 0.0 0.0 NA 

























































































































Buenos Aires, Argentina (Gentile and colleagues)




























































Buenos Aires, Argentina (Fernando and colleagues)




























































Belo Horizonte, Brazil (Oliveira and colleagues)


























































Lombok, Indonesia (Gessner and colleagues) 




























































Bondo, Kenya (Feikin and colleagues)   















































































































Kilifi, Kenya (Nokes and colleagues)






























































Lwak, Kenya (Montgomery and colleagues) 



























































































































Manhiça, Mozambique (Bassat and colleagues)





























































































































Philippines (Lucero and colleagues)
























































Agincourt, South Africa (Cohen and colleagues)




Figure 18: RSV seasonality and number of deaths of ALRI cases which were not 




























































Gauteng, South Africa (Cohen and colleagues)




Figure 19: Spaghetti plot of in-hospital CFR by narrower age bands 
Black line – Buenos Aires, Argentina (Gentile and colleagues); light green line – Buenos 
Aires, Argentina (Polack and colleagues); red line – Santa Rosa, Guatemala (McCracken 
and colleagues); rose line – Lombok, Indonesia (Gessner and colleagues); green line – Kilifi 
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 Discussion   
This thesis provides a comprehensive review of the aetiological roles, risk factors, morbidity 
and mortality of RSV associated ALRI. It assembles epidemiological data on RSV through 
systematic review of literatures, national or large scale surveillance sites and cohort studies.  
Aetiological role of RSV in ALRI 
There were 23 studies in total identified through the literature search to investigate the viral 
aetiology of ALRI in young children. Strong evidence was observed for RSV in support of 
its causal contribution in children presenting with ALRI and the association was significant 
measured in the odds ratio: 9.79 (4.98-19.27). Thus, the corresponding attributable fraction 
among the exposed was estimated as 90% (80%-95%), which means 90% of RSV associated 
ALRI cases were in fact attributed to RSV in a causal path. This review has been published 
in Journal of Global Health (Shi et al., 2015b). This was presented in an expanded 
description of methods, results and critical discussion in Chapter 3. 
Risk factors for RSV associated ALRI 
In order to assess the roles of various risk factors for RSV associated ALRI, 27 studies 
(including 4 unpublished studies) were identified and contributed to the analysis. In total 18 
risk factors were described and 8 were observed to have significant associations with RSV 
infection: prematurity - gestational age <37 weeks, low birth weight (<2.5 kg), being male, 
having siblings, maternal smoking, history of atopy, no breastfeeding and crowding - >7 
persons in household. This review has been published in Journal of Global Health (Shi et al., 
2015a). This was presented in a detailed and critical description of methods and results in 
Chapter 4. 
Burden of RSV associated ALRI 
Overall, 304 studies were included to estimate the global and regional burden of RSV 
associated ALRI in young children. Among them, 76 were unpublished studies provided by 
the RSV GEN working group, mainly from developing countries. It is estimated that in 2015, 
there were 33.0 (95% CI 20.6-53.2) million episodes of RSV associated ALRI occurring in 
children younger than 5 years old across the world. Among them, 30.5 (95% CI 19.5-47.9) 
million were in developing countries. 3.0 (95% CI 2.2-4.0) million cases were severe enough 
and warranted hospitalisation. Around 60,000 children died in hospital settings with 99% of 
these deaths occurring in developing countries. The overall mortality from RSV associated 
ALRI was estimated to be about 131,000. More details were presented in Chapter 5. 
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This thesis aims not only to enhance the epidemiological understanding of RSV in young 
children, but also to provide important information for public health decision makers. It 
incorporates both data through systematic reviews of published articles in the past 20 years 
and more than 70 unpublished data sets shared by RSV GEN working group. The population 
based incidence, hospitalisation, mortality and risk factor data give a good basis from which 
to assess the various severity of illness in a specific age group and region and inform local 
public health professionals regarding appropriate and prompt cases management, treatment 
and prevention strategies. The disproportionate age distribution in disease burden requires a 
long-term planning according to the change in population composition.  
 Strengths  
6.1.1 Incorporation of unpublished data 
The RSV GEN research group was formed and data from developing countries were 
collected, which supplemented the lack of published data in developing region. This research 
group involves 45 leading researchers on paediatric pneumonia from worldwide. Within the 
RSV GEN research group, common case definitions were formulated and a standard 
approach for data collection, analysis and interpretation was agreed on before data collection 
and the process was consistently carried out. This facilitated comparison across studies to be 
made. Data were verified and cross checked before being included in the analysis. 
Substantial data in finer age bands (neonates, children in their first six months of life, infants) 
were provided which made estimates in these age bands available. Most data obtained from 
RSV GEN had been fully or partially published recently, or related data within the same 
context had been previously published. This peer review process helped assure the quality of 
data from unpublished studies. The meta-estimate generated from unpublished studies was 
similar to the result from published studies: e.g. incidence rate in children aged 0-59m from 
developing countries is 51.2 (26.9-97.3) per 1000 children per year based on 8 unpublished 
studies vs. 51.2 (28.7-91.2) from 6 published studies. 
6.1.2 Comprehensive approach to global and regional estimates of RSV 
infection in young children was adopted 
This thesis represents a comprehensive study to estimate the global and regional burden of 
RSV associated ALRI in children younger than five years old. The following estimates are 
presented: the incidence rate and number of RSV associated ALRI cases in community-
based settings (where active case ascertainment was applied); the rate of children admitted to 
hospitals and corresponding number of hospitalised cases, the proportion of deaths among 
hospitalised RSV associated ALRI cases, the proportion of hospitalised ALRI cases which 
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are RSV positive; and the community-based mortality due to RSV associated ALRI. Global 
burden of disease was generated from regional estimates and estimates across the full age 
range was summed from estimates in narrower age bands. The aetiological role of RSV (as 
well as several other common respiratory viruses) in ALRI was explored and its attributable 
fraction was reported, and this could be used to adjust estimates of ALRI cases truly 
attributable to RSV. According to the result, RSV was significantly more identified in young 
children presenting with ALRI compared to children without any respiratory symptoms (or 
healthy children). The meta-estimate of odds ratios was 9.8 (5.0-19.3). This means 90% of 
children infected with RSV associated ALRI were attributed to RSV in a causal pathway. 
Thus, the likely true burden of RSV associated ALRI in young children in 2015 would be 
about 29.7 (95% CI 18.5-47.9) million (adjusted from 33.0 (95% CI 20.6-53.2)). Risk factors 
of RSV associated ALRI were reported and this could be used to inform prevention 
strategies if the risk factors were modifiable and select interventions targeting at children 
who are at high risk of developing illness. While the main focus was on children under five 
years old, analyses limited to children in younger age groups (neonates, infants, children 
aged 0-5m, children aged 6-11m, and children aged 12-59m) were also presented where 
possible. The analysis was also carried out in different regions, such as by World Bank 
income level, WHO region, developing or industrialised countries.  
 Limitations 
6.2.1 Variable quality of RSV epidemiology data 
RSV GEN collaborators either reanalysed data from their already published work with 
standardised case definitions or shared hitherto unpublished data from ongoing studies. 
Therefore, a proportion of the unpublished studies were not previously subject to the peer 
review, which cannot ensure the quality of these unpublished data. Even though the same 
case definition was required during the data collection process, some variations based on 
specific study designs or enrolment criteria still occurred, which to some extent 
compromised the comparison across studies. This concern also applies to data from 
published articles identified through the literature search. There were several other issues 
which limited the quality of reported data: quality of surveillance system, scarcity of 
surveillance outside the hospital setting, insufficiency of diagnostic confirmation of RSV 
infection (not all ALRI cases were tested for RSV), and a lack of a universal definition used 
to define the ALRI cases. Therefore, sensitivity analyses were carried out whenever there 
were studies using substantially different case definitions. This was performed consistently 
and discussed in Chapter 5. Moreover, for study sites with pulse oximeter data reported 
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appropriate equipment and standardised methods to obtain pulse oximetry readings are 
crucial to their proper interpretation. It is also important that healthcare professionals are 
well trained to conduct the pulse oximetry, especially in infants and young children. Details 
of these aspects were not always available from studies included in this thesis. In addition, 
although studies reporting data for nosocomial infection (hospital acquired illness) were 
excluded consistently across all systematic reviews, there is still an unknown proportion of 
hospital associated pneumonia involved in studies to the extent that our estimates may 
overestimate the burden of community acquired pneumonia associated with RSV. The issues 
discussed above resulted in variable quality of RSV epidemiology data. Most of them existed 
in both unpublished studies and published articles. A standard and comprehensive quality 
assessment tool is needed to assess and compare the quality of data from these two sources 
and measure the direction and strength of the effect. However, this is expected to be very 
difficult since many clinical/laboratory/technical details are not always available, even in the 
unpublished studies. Even though the inclusion of unpublished studies and articles in other 
languages (Chinese and Spanish) might decrease the possibility of publication bias, there is 
still an unknown proportion of publication bias which might affect the representativeness 
and validity of this study. 
6.2.2 Variation in RSV disease severity 
In some developing countries, especially in rural areas, due to long distance (in length or 
time) from the children’s home to the healthcare facility, the threshold for admission to 
hospitals is lower. Thus, although some of these children present with a non-severe infection, 
they may be hospitalised. This may mean that the severity of RSV associated ALRI admitted 
to hospital varies across settings and so are not completely comparable. In some settings, 
accessibility to healthcare facilities may be poor leading to a delay in seeking care: e.g. due 
to financial burden to the family, long distance and long travel time to hospital, due to poor 
road condition, or other cultural and social issues (Tinuade, 2010). In these settings, children 
may be in a more severe condition when presenting to the clinics/hospitals. Moreover, in 
some underprivileged areas, sometimes caregivers seek care from a non-medical provider. In 
these cases, there is an unknown proportion of children with severe infection which are not 
identified in hospitals and do not receive prompt treatment. This will tend to underestimate 
the burden of RSV associated ALRI cases in hospital settings.  
In addition, hospitals or clinics (or even different personnel) may have different criteria to 
admit children which leads to a variety of severity of illness among children hospitalised 
with RSV. This might limit the validity of comparison between different study sites.  
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Variations in risk factors in the underlying population might affect the severity of RSV 
disease. A prospective surveillance study was carried out among children less than 2 years 
old admitted to hospital with respiratory infection in Amman (Halasa et al., 2015). In this 
study, risk factors for oxygen requirement in children with RSV positive were identified as 
underlying medical conditions, lack of breastfeeding, younger age, and higher viral load via 
a multivariable analysis. Younger age was also associated with ICU admission. Mechanical 
ventilation was related to younger age and higher vitamin D level. Children having 
underlying medical condition, lack of breastfeeding, at younger age, with lower virus load, 
or having a low birth weight were associated with longer length of stay in the hospital based 
on a multivariable analysis.  
6.2.3 Variable levels of co-infection among RSV cases  
Co-infection with other viruses or bacteria were mentioned in several studies reporting 
epidemiological data on RSV. This might tend to overestimate the individual role of RSV in 
ALRI. Around 6% to 30% of young children hospitalised with pneumonia or bronchiolitis 
with RSV positive were identified with multiple pathogens (Sparremberger et al., 2011, Jain 
et al., 2015, Canducci et al., 2008, Harada et al., 2013). Respiratory virus could interact with 
other viruses directly or indirectly, affecting the clinical presentation or the disease outcome. 
Children with RSV disease co-infected with other respiratory viruses might increase the risk 
of developing a more severe disease (Harada et al., 2013). An adjusted odds ratio of 1.3 (1.0-
1.7) was detected for longer stay in hospital (3 or more days) in young children infected with 
both RSV and RV, compared to children only infected with RSV (Mansbach et al., 2012). 
Infants hospitalised with bronchiolitis with RSV and BoV positive had a higher clinical 
severity score and more days of hospital stay than infants infected with RSV only (Midulla et 
al., 2010). However, both studies were carried out for less than one year, the co-infection 
rate from which might be affected by seasonal variations in circulating respiratory viruses. 
Moreover, greater disease severity in RSV cases with multiple pathogens was not observed 
in other studies (Peng et al., 2009a, Martin et al., 2012). The rate of co-infection with RSV 
associated ALRI should be monitored and the severity of RSV disease in these cases should 
be evaluated in order to elucidate the association between co-infection and severity of 
outcome. RSV was reported to be significantly associated with an increase of hospitalisation 
due to pneumococcal pneumonia in infants. After the implementation of pneumococcal 
conjugate vaccine (PCV7), RSV hospitalisation rate has been reported to decline 
substantially (Weinberger et al., 2015). Further investigation is needed to clarify the role of 
bacterial-viral and viral-viral interactions in the pathogenesis of RSV infection. 
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 RSV illness in adults and elderly 
RSV also causes a substantial disease burden in adults and the elderly. Advances in 
molecular assays using nucleic acid amplification, which has high sensitivity and specificity, 
makes it possible to detect viruses in adults and elderly people with relatively low titres of 
virus load more accurately. A 15-year population based study in United Kingdom indicated 
that during each RSV season, there were around 500,000 general practice visits, 18,000 
episodes of hospitalisation and 8,000 deaths attributable to RSV in adults aged more than 18 
years (Fleming et al., 2015). Among them, 36% of GP visits, 79% of hospitalisation episodes 
and 93% of deaths occurred in elderly people aged more than 65 years old. This suggests that 
RSV also represents a substantial disease burden in adults, especially among the elderly. 
Another surveillance study in Tennessee also reported a substantial RSV disease in adults in 
terms of emergency department visits and hospital stays (Widmer et al., 2014). Both of these 
were higher in adults more than 50 years old, compared to adults aged 18-49 years. 
Moreover, adults hospitalised with RSV disease can develop severe respiratory 
complications, such as respiratory failure, requirement of supplemental oxygen and 
mechanical ventilation, prolonged hospitalisation and high mortality, similar to adults 
infected with influenza (Lee et al., 2013). This evidence basis requires that RSV prevention 
and management strategies as well as clinical trials of antivirals and vaccines should take 
this underlying population into consideration.  
 Issues in conducting meta-analysis of data 
Conducting meta-analysis based on a fixed effect model at first and then moving to a random 
effects model if statistically significant heterogeneity is identified across the included studies 
is technically incorrect. The selection of a computational model should not be based on the 
statistical test for heterogeneity, but it should focus on the nature of underlying data. If these 
studies are not functionally identical and differ in several aspects that might have an 
influence on the results, the effect size is likely to vary from one study to another (within the 
full set of studies, within subgroups, or for studies with a common set of covariate values), 
then the random effects model which takes study level variance into consideration should be 
used even if the test for heterogeneity fails to yield a significant p-value. This lack of 
significance means only that a certain threshold of proof is failed to meet. It is possibly 
because of low statistical power and does not prove that the studies share a common effect 
size. 
In the previous three Chapters where systematic reviews were carried out to identify relevant 
published articles reporting data of interest, differences in methodology and population at 
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risk were expected and found. Thus, different effect sizes were assumed across these studies 
and so, random effects model was applied consistently in these three systematic reviews to 
synthesise results from different studies. The meta-analyses results based on random effects 
model can then in principle be generalised to a wider population.  
When there is a small number of studies included in a meta-analysis and the underlying 
effects differ across studies, the random effects model is still the proper model to use but the 
estimate of between-study variance will have poor precision (Borenstein et al., 2009). In this 
case, there are several other approaches available: an individual effect from each study can 
be reported instead; a fixed-effect analysis can be used to generate a descriptive result of 
included studies but it cannot be generalisable to other populations; or a Bayesian approach 
to estimate the between-study variation from outside data can be used. The third option is in 
theory the best approach but it is a complex statistical method requiring a special expertise in 
Bayesian meta-analysis. Therefore, it was decided meta-analyses were conducted only if 
there were at least three studies and this approach was applied consistently throughout this 
thesis.  
 Implications for the management of RSV disease in young 
children 
Protecting infants from RSV infections is a high public health priority based on the evidence 
generated from this thesis. Understanding RSV incidence and mortality across different 
regions and children at different age bands could place a rational basis for health care 
providers to implement prompt and proper prevention strategies in order to minimise 
transmission, and also to introduce prophylactic options or supportive treatments (hydration 
and oxygenation) to high-risk patients as early as possible. There is no effective specific 
antiviral treatment available to manage RSV infection at present. Therefore, RSV prevention 
strategy remains the only option.  
A few antivirals for RSV are being investigated in clinical trials. Passive immune-
prophylaxis with RSV specific monoclonal antibody can be administered to high-risk infants 
to prevent severe disease outcome during RSV season. Palivizumab, a humanised 
monoclonal antibody targeting at the RSV fusion F protein, was licensed in 1998 by Food 
and Drug Administration (FDA) for immune-prophylaxis in high-risk infants. A phase 3 
clinical trial involving multiple centres and countries was conducted to evaluate the safety 
and effectiveness of palivizumab to prevent RSV infection in children at high risk. This RSV 
trial indicated that a reduction of 55% hospitalisation with confirmed RSV infection was 
observed in children with prematurity (≤35 weeks) or bronchopulmonary dysplasia (BPD) 
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after receiving palivizumab prophylaxis, in comparison to children in the placebo arm (The 
IMpact-RSV Study Group, 1998). It was well tolerated without any significantly different 
adverse events compared to the placebo group. Since then, the guidance to use palivizumab 
has been updated periodically based on the emerging new evidence. However, it is expensive 
and limited in a few high-resource country settings. Another variant of palivizumab, 
motavizumab, has been discontinued in spite of its higher neutralising activity, possibly 
because the incidence of cutaneous adverse events was observed higher in the recipients and 
RSV viral load or severity of illness were not decreased in the previously healthy term 
infants with motavizumab treatment (Carbonell-Estrany et al., 2010, Ramilo et al., 2014). 
However, another randomised double-blind phase 3 study in healthy term Native American 
infants showed a relative 87% of reduction in the proportion of infants admitted to hospital 
with RSV positive who received motavizumab, compared to the participants in the placebo 
group (O'Brien et al., 2015). Serious adverse events were also reduced. The safety and 
efficacy of motavizumab need to be confirmed with further investigations.  
The UK National Institute for Health and Care Excellence (NICE) recommends a few new 
guidelines to manage bronchiolitis in children based on the best available evidence (Ricci et 
al., 2015). Since RSV is the most common virus associated with bronchiolitis (Meissner, 
2016), these guidelines also apply in managing RSV cases. When children present with 
apnoea, severe respiratory distress, central cyanosis, are hypoxemic (SaO2 <92%), or appear 
seriously unwell to a healthcare professional, they should be referred for emergency hospital 
care immediately; if children have tachypnea (respiratory rate >60 breaths/min), difficulty in 
breastfeeding, <75% of usual volume of oral fluid intake, or clinical dehydration, they 
should be referred to secondary care (Ricci et al., 2015). Apart from these clinical features, a 
few issues should be taken into account for more severe bronchiolitis: children with 
underlying risk factors (such as chronic lung disease, young age, prematurity, 
immunodeficiency etc.) and the ability of care-givers to look after the children (such as 
social economic situation, capability to recognise key symptoms showing disease 
deterioration, distance from home to nearest health facility etc.). Chest radiography should 
not be conducted as a routine. Oxygen supplementation should be provided if the children 
presents with hypoxemia consistently (SaO2 <92%). Fluids via nasogastric or orogastric tube 
should be supplied to children if taking fluid orally is not enough for them. Upper airway 
suctioning might be needed if there are signs of upper airway secretions or if children present 
with apnoea. There are slight variations in the guidelines to manage bronchiolitis developed 
in different institution bodies. The differences were summarised in an article and presented 
in Table 64 (Mazur et al., 2015).  
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According to the result of this thesis, RSV disease burden is substantial in children in their 
early months of life, such as infants aged 0-5 months, therefore, a considerable attention 
should be given to this age group to identify key features indicating varied disease severity 
and refer them to relevant settings for appropriate treatment. Proper and prompt management 
of RSV disease in young children could mitigate the progress of RSV associated ALRI in 
children, and decrease the childhood morbidity and mortality related to this illness. They also 
enable current available medical resources to be used efficiently, especially in resource-
limited areas.  
Table 64: Evidence-based global guidelines for bronchiolitis management in children 
(Mazur et al., 2015) 
 







Supplemental oxygen optional if SpO2 is 
greater than 90%, nebulised hypertonic 
saline optional for hospitalised children with 
expected length of stay longer than 72 h, 
nasogastric or intravenous fluids if oral 
hydration cannot be maintained 
Albuterol, epinephrine, nebulised 
hypertonic saline in emergency 
department, systemic corticosteroids, 
antibacterial medicine (unless 
concomitant bacterial infection), 










Supplemental oxygen, saline nasal drops, 
nasal suctioning, comfortable positioning 
(prone or supine if unable to position self), 
continuous pulse oximetry monitoring if in 
prone position, oral feeding can continue 
unless respiratory distress increases, trial of 
β2 agonist bronchodilators for children older 
than 9 months (discontinue if no response), 
antibiotics if clinical signs or symptoms of 
bacterial infection, paracetamol or ibuprofen 
can be used if pyrexia is present 
Chest physiotherapy, routine mist, 
routine steam, routine nebulised 
saline, routine nebulised adrenaline, 
routine β2 agonist bronchodilators, 
routine ipratropium bromide, routine 
antibiotics, routine corticosteroids, 
routine ribavirin, routine 
immunoglobulin, routine oral 














Supplemental oxygen if SpO2 is less than 
92% or if severe respiratory distress or 
cyanosis, nasogastric feeding if child cannot 
maintain hydration or oral intake, nasal 
suction for hospitalised infants showing 
respiratory distress, pulse oximetry 8 to 12 h 
after supplementary oxygen is discontinued 
Nebulised ribavirin, antibiotic 
therapy, inhaled β2 agonist 
bronchodilators, nebulised 
ipratropium or epinephrine, inhaled 









Supplemental oxygen if SpO2 is less than 
92%, continuous positive airway pressure if 
impending respiratory failure, upper airway 
suctioning in children who have respiratory 
distress or feeding difficulties because of 
upper airway secretions or children who 
present with apnoea, fluids by nasogastric or 
orogastric tube if children cannot take fluid 
Chest physiotherapy for children who 
do not have relevant comorbidities, 
antibiotics, hypertonic saline, 
nebulised adrenaline, salbutamol, 
montelukast, ipratropium bromide, 
systemic or inhaled corticosteroids 
and nebulised adrenaline, routine 
upper airway suctioning, routine 
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orally, intravenous isotonic fluids to children 
who do not tolerate nasogastric or orogastric 
fluids or have impending respiratory failure, 
consider capillary blood case testing in 
children with severe worsening respiratory 
distress or impending respiratory failure 
blood gas testing gas testing 
Footnote: Peripheral capillary oxygen saturation=SpO2. Guidelines included are either 
accepted on a national level (not hospital based) and apply a clearly defined evidence-based 
framework to recommendations.  
 Implications for vaccination policies and allocation strategies 
Despite the high disease burden of RSV among young children, currently there is no licensed 
RSV vaccine available. This leaves children at risk of getting infected and causes a huge 
burden to caregivers and healthcare systems, especially in developing areas where there are 
limited resources and a disproportionately high burden of disease. Prophylactic treatment 
with RSV specific monoclonal antibody is effective in reducing RSV infection in children at 
high-risk, such as premature children, children with congenital heart illness or chronic lung 
disease. However, this is only available in selected populations in a few countries due to its 
high expense and challenges in delivery. Developing a vaccine against RSV becomes critical 
to mitigate this situation. A disproportionately high burden of RSV disease in young infants 
has been reported in this thesis: around 5.5 million infants aged 0-5 months of RSV 
associated ALRI were estimated in the worldwide in 2015 (about 17% of all under five 
cases). Among them, nearly 1.4 million were severe enough requiring hospital admission 
(about 48% of all under five cases admitted to hospital), and around 27,000 of them died in 
hospital (46% of all under five deaths due to RSV associated ALRI). Since RSV incidence is 
highest in children in the earliest months of life, the development of RSV vaccine has been 
advanced to focus on this age group, aiming to prevent serious outcome after RSV infection 
as early as possible in childhood. 
Laboratory experiments are instrumental in discovering new potential vaccines. They are 
helpful in interpreting the immune response in recipients and mechanisms of how new 
vaccine candidates function as well as identifying their potential adverse events. However, 
the in vitro and animal models cannot fully mimic the reaction in humans.  
There are a variety of vaccine constructs in development currently, such as live-attenuated 
vaccines, whole-inactivated, particle-based, subunit-based, gene-based vectors and nuclei 
acid-based vaccines (Figure 20). Several vaccine candidates are being tested in humans at 
different phases. Different types of vaccine have their specific advantages and target on 
different populations (infants less than 6 months, older children older than 6 months, 
pregnant women and elderly people aged 65 years or more). Live vaccines could be used in 
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older siblings to protect them from RSV infection and to reduce the transmission of RSV to 
the youngest and most vulnerable infants. This approach is supported by an individual-based 
transmission model carried out in rural Kenya. This study indicates that 39% of infant 
infections was attributed to household transmission and children at school-age were the main 
agents in introducing the infection into the family units and led to around 55% of cases 
within household (Poletti et al., 2015). Moreover, the decreased level of maternally derived 
antibodies and the more mature immune system make older children more likely to respond 
well to the vaccine.  
Active immunisation of young infants would be an ideal option to prevent RSV infection in 
young children but it poses a few challenges to implement. This is because the youngest age 
groups have the highest susceptibility to RSV infection. However, there is a history of 
vaccine-enhanced illness with RSV infection leading to more severe outcomes including two 
deaths in infants after receiving a formalin-inactivated RSV (FI-RSV) vaccine in the 1966-
1969 (Kim et al., 1969). This tragedy slowed down efforts to produce RSV vaccines over the 
past 5 decades. Directly vaccinating infants requires RSV vaccine constructs with an optimal 
balance of safety and efficacy. Live-attenuated vaccines are mainly targeted to the paediatric 
population with the aim of safely attenuating RSV virus and inducing maximum 
immunogenicity. A number of such vaccines are in early clinical testing. Subunit vaccines 
are an alternative option without possibility of reversing to wild-type but they result in lower 
immunogenicity in young children. They are more widely designed for maternal 
immunisation. Paediatric immunisation has several limitations: potential risk of enhanced 
illness; poor immunogenicity due to immature infant immune system; reduced 
immunogenicity induced by subunit vaccines; and decreased effectiveness due to interfered 
by maternally derived antibodies (Mazur et al., 2015, Anderson et al., 2013).  
Maternal immunization is an alternative approach which can provide immediate protection 
for infants at the early stage, approximately for the first six months. This is a promising 
approach to protect those vulnerable children promptly from birth. RSV specific neutralising 
monoclonal antibody delivered prophylactically to children has been observed to reduce the 
incidence of severe RSV disease. The preventive impact of antibody to RSV infection has 
been confirmed. It has been reported that administering vaccines to pregnant women and 
boosting the RSV antibody concentrations to a sufficiently protective level facilitates 
mother-to-child transmission of antibodies, which is critical for newborns since they are 
unlikely to benefit from active immunization. In a mother-infant pairs study in Bangladesh, 
RSV-specific IgG placental transfer from pregnant women to infants was shown to be an 
efficient process resulting in lower risk of serologic infection (Chu et al., 2014). A hospital-
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based case-control study among Navajo and White Mountain Apache infants has shown a 30% 
reduction of hospitalisation with RSV infection with an increase of 1 log2 in the 
concentration of cord blood maternally derived RSV neutralising antibodies (Eick et al., 
2008), but no association was observed for the severity of illness. Moreover, prevention of 
RSV infection in the pregnant women also reduces the chance of transmitting the infection 
from mothers to vulnerable young children. Maternal vaccine should meet high standards of 
tolerability and safety. Such vaccines that are currently in late stages of clinical trials are 
particle-based or subunit-based (Neuzil, 2016). One candidate is going through phase 3 
testing in third-trimester pregnant women: a RSV recombinant fusion (F) nanoparticle 
vaccine (National Institutes of Health, 2016). It was previously tested in phase 2 for safety 
and immunogenicity in healthy women of childbearing age (18-35 years) (Glenn et al., 2016). 
The result showed that this vaccine was well and immunogenic, and no vaccine-related 
adverse events were observed. Therefore, it is anticipated that immunogenicity will be 
reproduced in third trimester pregnant women after receiving this vaccine and these women 
can confer protective high levels of antibodies to their infants through placental transfer. 
Furthermore, platform to deliver a maternal tolerated vaccine has been established 
worldwide. In the majority of countries including those underprivileged areas, women have 
access to some antenatal health care. Maternal immunisation to protect infants has been 
successful in the cases of tetanus, pertussis and influenza, which suggests that maternal 
vaccine in against of RSV infection in infants might be a feasible approach. However, there 
also remains a few challenges: limitation of placental transfer, need of high titre of 
neutralising antibody level, limited half-life of antibody, safety in pregnant women, and the 
fact that having previously experienced several episodes of infection might compromise the 
response to vaccines (Mazur et al., 2015).  
The first WHO RSV vaccine consultation agreed on two strategic goals for developing 
global-use RSV preventive vaccines: maternal immunisation (passive) to prevent RSV 
infection in infants in their first 6 months of life; and paediatric immunisation to prevent 
RSV illness in infants and young children after the maternal immunisation stops protecting 
them (Modjarrad et al., 2016). Some data from this thesis (global and regional burden of 
RSV associated ALRI) were made available to WHO at this meeting and helped inform 
discussions. In order to guarantee the quality, safety and efficacy of vaccines, several other 
issues need to be taken into account in the clinical trials: a well-defined targeted population; 
agreement on the most relevant clinical outcomes; standard and precise measures of disease 
severity; applicable and relevant endpoints of vaccine efficacy depending on the culture 
context; and objective case definition. In addition, the following aspects are also important: 
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paediatric vaccine testing first in healthy adults for safety and immunogenicity; phase 1 trials 
which involve RSV-seronegative infants in settings with good resources and facilities in case 
of any adverse events; monitoring of safety and immunogenicity when the novel vaccine is 
administered with routine vaccines in infants; follow up of infants for the first 6 months as 
long as the antibody persists or to an extended period (second RSV season) to detect 
unexpected adverse events occurred in later life or assess long-term wheezing; post-trial 
availability of vaccines is required before the onset of the trial; clinical vaccine development 
should consider the context of low and middle income countries where there is a 
disproportionately high burden of RSV disease (Modjarrad et al., 2016).  
There are many pharmaceutical companies and academic institutions working on developing 
and testing RSV vaccine candidates. Local governments should work with them in 
improving safety, efficacy and feasibility of vaccines based on population specific 
information. The WHO Product Development for Vaccines Advisory Committee (PDVAC) 
has reported that it expects that safe and effective RSV vaccine will be available for global 
use in the short to medium term. The data presented in this thesis should be evidence basis 




Figure 20: RSV vaccine snapshot (PATH, 2016) 
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 Proposals for improving future RSV disease estimates in young 
children 
National sentinel systems of RSV surveillance gathering structured and reasonably 
representative data is needed, especially in some developing countries where there is still a 
lack of population based data (e.g. Eastern Mediterranean). These data are essential for 
clinical workers to optimise the management and prevention of RSV disease. They also 
provide principles for national policy makers and immunisation advisory groups to guide 
future priority setting of immunisation. There are several approaches available to establish an 
ongoing surveillance system for RSV (Campbell et al., 2015). Global Influenza Surveillance 
and Reporting System (GISRS) has been established to collect complete data on influenza 
from over 140 National Influenza Centres (NICs) worldwide with quality and timeliness, in 
order to inform the composition of the annual influenza vaccine and prepare for pandemics. 
More than 1 million respiratory samples each year are shared within GISRS to detect 
influenza. This system might be adapted to conduct RSV surveillance without compromising 
its original purpose. However, considering the different seasonal pattern of RSV, different 
age structure of illness (mainly in the first two years of life) and different clinical features of 
RSV cases, separate case definitions and sampling procedures should be modified to identify 
episodes of ALRI cases due to RSV. These pose challenges to set up RSV surveillance 
within GISRS in parallel to influenza surveillance. Therefore, it is better to assess the 
validity and feasibility of this approach in a few pilot projects in each global region. The Flu 
Informed Decisions (FLuID) is a global web-based platform for national focal points to share 
the epidemiological data of influenza (World Health Organization, 2016a). It combines these 
data into one single global database and keeps tracking data on the evolution and trend of 
influenza in order to make informed decisions. A related tool, FluNet, is used to collect 
influenza virological data globally and monitors the movement of influenza (World Health 
Organization, 2016b). These two platforms could in principle be used as a basis to build the 
RSV surveillance system. It will need support from RSV reference laboratories to assure the 
quality of the data from participating laboratories. In high-resource countries, a new 
surveillance system can be set up. However, it requires very substantial additional financial 
and technical support which would need to be introduced in a stepwise manner. An RSV 
Task Force conducted a five-season surveillance of RSV in 6 countries within European 
Influenza Surveillance Scheme (EISS) and concluded that a comprehensive RSV 
surveillance scheme within the EISS framework was feasible (Meerhoff et al., 2009a). All of 
the approaches mentioned above need to be accompanied by further new large-scale cohort 
studies which could help to better understand the epidemiology of RSV.    
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There were several limitations of current studies estimating RSV disease burden as discussed 
previously: a lack of universal case definition, various diagnostic tests with varied sensitivity 
and specificity, differed quality of surveillance system, a shortage of surveillance outside 
hospitals etc. Therefore, establishing an active surveillance or facilitated passive surveillance 
of RSV activity and its long-term consequences are essential to understand the trend, 
magnitude and impact of RSV. Within the surveillance system, a universal definition 
regarding various settings and disease severity should be developed, and diagnostic methods 
with higher sensitivity and specificity should be applied. This is instrumental for defining 





 Conclusion  
This thesis presents an overall picture of epidemiology of RSV associated ALRI in young 
children from the following aspects: aetiological roles of RSV and other common viruses in 
ALRI, risk factors of RSV associated ALRI, incidence and mortality of RSV associated 
ALRI in community and hospital settings. It incorporates data from systematic literature 
search of publications in the last 20 years and 76 unpublished datasets from RSV GEN 
working group.  
It supports RSV (as well as IFV, PIV, MPV and RV) as important causes of ALRI in young 
children, and provides quantitative estimates of the absolute proportion of virus-associated 
ALRI cases to which a viral cause can be attributed. This is used to adjust for global and 
regional burden of RSV associated ALRI in young children. 
It also assesses the role of putative socio-demographic risk factors for RSV associated ALRI. 
Many of these risk factors are similar to those that have been identified for (all cause) ALRI 
and thus, in addition to the potential future impact of novel RSV vaccines currently under 
development and evaluation, national action against ALRI risk factors as part of national 
control programmes can be expected to reduce burden of disease from RSV. Since some risk 
factors are preventable, policy makers and public health practitioners could develop targeted 
interventions to decrease the prevalence of these risk factors in order to reduce RSV 
associated ALRI disease burden. However, this evidence base is limited by paucity of data. 
Therefore, large scale, high quality studies using multivariable analysis should be conducted 
on a priority basis to better understand the role of each individual risk factor for RSV 
associated ALRI in diverse settings. 
Moreover, this thesis provides comprehensive revised global and regional estimates of RSV 
associated ALRI in both community and hospital settings. More studies than in previous 
published estimates were identified for younger age group, especially in infants and neonates. 
It reports that RSV is a major cause of childhood ALRI, resulting in substantial hospital 
admission and mortality among young children, especially in developing countries and in 
children’s early months of life. This study will provide important baseline estimates to 
inform RSV prevention and treatment strategies as well as future vaccine priorities and plans. 
Objective and clear clinical and laboratory endpoints should be well-defined, established and 
applied consistently. More active and facilitated passive RSV surveillance sites with good 
quality data informing RSV incidence and mortality are required to obtain a more accurate 
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A1. RSV data collection template 
Sheet 1 – site description  
S. No 
Location of study site (including district, state, and country) 
Site characteristics (rural, urban etc.) 
Study period 
Age group under study 
Case ascertainment (Active community based / Passive Hospital based) 
Case definition used for ALRI 
Case definition used for SEVERE ALRI 
Case definition used for VERY SEVERE ALRI 






Diagnostic testing done onsite or off site? 
Average time lag between specimen collection and diagnostic testing 
Population denominator - midyear 
catchment population / child years at risk 
Source of data 
Year 
0-27 days 















If yes, what is the scaling factor used. Please provide 
detailed calculations separately 
Malaria 
Is the location endemic for malaria 
Which months of the year are malaria season 
Paediatric HIV prevalence (0-4 years) 
Any special groups excluded (premature babies / those with co-morbidities) 
Month and year when HiB vaccine introduced 
Hib coverage 
Month and year when PCV introduced 
PCV coverage 
Results from reported study previously published? Please provide reference 
 
Sheet 2 – RSV incidence  
Year 
Number & % of cases not tested for RSV 





RSV associated ALRI 
RSV A 
0-27 days 


























All RSV (including un-
subtyped RSV) 
0-27 days 









































All RSV (including un-
subtyped RSV) 
0-<27 days 









































All RSV (including un-
subtyped RSV) 
0-<27 days 










































































































































hs             
 
0-11 


































Sheet 4 – RSV proportion 
Year 
Number & % of cases not tested for RSV 
Reason for not testing (please provide in text below table if space is inadequate) 
Number of hospitalised ALRI cases that were tested for 
RSV 
0-27 days 










Number of hospitalised ALRI cases that are positive for 
RSV A 
0-27 days 










Number of hospitalised ALRI cases that are positive for 
RSV B 
0-27 days 












Number of hospitalised ALRI cases that are positive for all 
RSV (including un-subtyped RSV) 
0-27 days 











Sheet 5 – RSV morbidity and mortality by month for children with all 
gestational ages 
S. No Characteristic Age group Month n 
1 Total hospitalised ALRI cases 
0-27 days 
 










































































Total cases of hospitalised ALRI positive for 
all RSV / un-subtyped RSV 
0-27 days 
 















Number of RSV positive ALRI cases where 
SpO2 was recorded 
0-27 days 
 















Number of RSV positive ALRI cases with 
hypoxemia (SpO2<90% for 1-59 months and 
88% for neonates at altitude<=2500 m; and 
<87% and 85% for post-neonatal age groups 
and neonates at altitude above 2500 m) 
0-27 days 
 















Number of RSV positive ALRI cases 
requiring admission into Intensive Care Units 
0-27 days 
 

















Number of RSV positive ALRI cases 
requiring mechanical ventilation 
0-27 days 
 















No. of RSV positive ALRI cases with co-
morbidities (congenital heart disease, renal 
disease, cancer, on immunosuppressant, 
chronic lung disease etc.) 
0-27 days 
 









































































9a Number of ALRI deaths in hospital 
0-27 days 
 















Number of ALRI cases tested for RSV and 
who died in-hospital  
0-27 days 
 















Number of ALRI cases NOT tested for RSV 
and who died in-hospital  
0-27 days 
 










































































No. of in-hospital deaths in RSV positive 
ALRI cases with co-morbidities (congenital 
heart disease, renal disease, cancer, on 



















Number of in-hospital deaths in RSV positive 
ALRI cases with hypoxemia (SpO2<90% for 
1-59 months and 88% for neonates at altitude 
<= 2500 m; and <87% and 85% for post-
neonatal age groups and neonates at altitude 
above 2500 m) 
0-27 days 
 

















Sheet 6 – RSV morbidity and mortality by month for children with gestational 
age 32-36 weeks 
Same table as above 
 
Sheet 7 – RSV morbidity and mortality by month for children with gestational 
age <32 weeks 
Same table as above 
 































No. of hospitalised ALRI 
cases         
2 
No. of hospitalised ALRI 
cases positive for RSV         
3 
No. of in-hospital deaths in 
RSV positive ALRI cases         
3 Prematurity                 
a 
No. of RSV positive 
hospitalised ALRI cases 
where gestational age has 
been recorded 
        
b 
No. of RSV positive 
hospitalised ALRI with 
history of prematurity         
c 
No. of in-hospital deaths in 
RSV positive ALRI cases 
with history of prematurity         
d 
No. of RSV positive 
hospitalised ALRI with 
gestational age 32-36 
weeks at birth 
        
e 
No. of in-hospital deaths in 
RSV positive ALRI cases 
with gestational age 32-36 
weeks at birth 
        
f 
No. of RSV positive 
hospitalised ALRI with 
gestational age <32 weeks 
at birth 




No. of in-hospital deaths in 
RSV positive ALRI cases 
with gestational age <32 
weeks at birth 
        
4 Malnutrition                 
a 
No. of RSV positive 
hospitalised ALRI cases 
where nutritional status 
(W/A) has been recorded 
        
b 
No. of RSV positive 
hospitalised ALRI cases 
with z-score between (-)1 
and (-) 1.99 SD 
        
c 
No. of RSV positive 
hospitalised ALRI cases 
with z-score between (-)2 
and (-)2.99 SD 
        
d 
No. of RSV positive 
hospitalised ALRI cases 
with z-score > (-) 3SD         
e 
No. of in-hospital deaths in 
RSV positive ALRI cases 
with z-score between (-)1 
and (-) 1.99 SD 
        
f 
No. of in-hospital deaths in 
RSV positive ALRI cases 
with z-score between (-)2 
and (-)2.99 SD 
        
g 
No. of in-hospital deaths in 
RSV positive ALRI cases 
with z-score > (-) 3SD         
5 Low birth weight                 
a 
No. of RSV positive 
hospitalised ALRI cases 
where birth weight has 
been recorded 
        
b 
No. of RSV positive 
hospitalised ALRI cases 
with birth weight <2500 g         
c 
No. of in-hospital deaths in 
RSV positive ALRI cases 
with birth weight <2500g         
6 Breast feeding                 
a 
No. of RSV positive 
hospitalised ALRI cases 
where breast feeding 
history has been recorded 
        
b No. of RSV positive 
hospitalised ALRI cases         
284 
 
with exclusive breast 
feeding (only breast milk 
in first 4 months of life) 
c 
No. of RSV positive 
hospitalised ALRI cases 
with partial breast feeding 
(less than 4 months’ 
exclusive breast feeding) 
        
d 
No. of RSV positive 
hospitalised ALRI cases 
not breast fed         
e 
No. of in-hospital deaths in 
RSV positive ALRI cases 
with exclusive breast 
feeding 
        
f 
No. of in-hospital deaths in 
RSV positive ALRI cases 
with partial breast feeding         
g 
No. of in-hospital deaths in 
RSV positive ALRI cases 
who were not breast fed         
7 HIV                 
a 
No. of RSV positive 
hospitalised ALRI cases 
with HIV test conducted         
b 
No. of RSV positive 
hospitalised ALRI cases 
who are HIV positive         
c 
No. of in-hospital deaths in 
RSV positive ALRI cases 
who are HIV positive         
8 Crowding                 
a 
No. of RSV positive 
hospitalised ALRI cases 
where history of crowding 
has been recorded 
        
b 
No. of RSV positive 
hospitalised ALRI cases in 
households with crowding 
(> 7 people per household) 
        
c 
No. of RSV positive 
hospitalised ALRI cases in 
households with crowding 
(>2 people sharing child's 
bedroom) 
        
d 
No. of in-hospital deaths in 
RSV positive ALRI cases 
in households with 
crowding (> 7 people per 





No. of in-hospital deaths in 
RSV positive ALRI cases 
in households with 
crowding (>2 people 
sharing child's bedroom) 
        
 











Study design (case-control, prospective cohort, retrospective cohort, RCT) 
 
Cases (hospital or community based) 
 
Controls (hospital or community based) 
 
Main outcome measure 
 
Confounding factors  
 
Confounders adjusted for 
 




Total number of laboratory confirmed RSV cases 
 








RSV cases with risk factor 
 
RSV cases without risk factor 
 
Controls / reference group with risk factor 
 







A2. Verbal autopsy and RSV seasonality data collection template 
Sheet 1 – site description 
S. 
No 
Location of study 
site (including 










Method to interpret 





      
 
Sheet 2 – VA mortality data 
Year Month 
VA confirmed pneumonia deaths in children 
28 days- 11 months 12-59 months 
    
 
Sheet 3 – RSV and flu seasonality 
Year Month 





(all types and sub-
types) 





A3. Search strategy of aetiological roles of common respiratory 
viruses in ALRI  
Medline   
1. Prospective study.mp. or exp Prospective Studies/ 
2. control*.mp. 
3. exp Case-Control Studies/ or case control.mp. 
4. (case* adj2 control*).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
5. virus.mp. or exp Viruses/ 
6. exp Virus Diseases/ or virus disease*.mp. 
7. pneumonia.mp. or exp Pneumonia/ or exp Pneumonia, Viral/ 
8. bronchiolitis.mp. or exp Bronchiolitis/ or exp Bronchiolitis, Viral/ 
9. exp Respiratory Tract Infections/ or respiratory infection*.mp. 
10. exp Respiratory Tract Diseases/ or respiratory disease*.mp. 
11. 1 and 2 
12. 3 or 4 or 11 
13. 5 or 6 
14. 7 or 8 or 9 or 10 
15. 12 and 13 and 14 
16. limit 15 to (yr="1990 -Current" and ("all infant (birth to 23 months)" or "newborn infant (birth to 




1. virus*.mp. or exp virus/ 
2. exp virus infection/ or virus disease*.mp. 
3. exp community acquired pneumonia/ or exp pneumonia/ or exp virus pneumonia/ or exp infectious 
pneumonia/ or pneumonia.mp. 
4. bronchiolitis.mp. or exp bronchiolitis/ or exp viral bronchiolitis/ 
5. exp respiratory tract infection/ or exp lower respiratory tract infection/ or respiratory infection*.mp. 
6. exp respiratory tract disease/ or respiratory disease*.mp. 
7. exp case control study/ or case control.mp. 
8. (case* adj2 control*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
9. prospective study.mp. or exp prospective study/ 
10. control*.mp. or exp control group/ or exp control/ 
11. 1 or 2 
12. 3 or 4 or 5 or 6 
288 
 
13. 9 and 10 
14. 7 or 8 or 13 
15. 11 and 12 and 14 
16. limit 15 to (yr="1990 -Current" and (infant or child or preschool child <1 to 6 years>)) 
 
Global Health  
1. virus.mp. or exp viruses/ 
2. viral disease*.mp. or viral diseases.sh. 
3. exp community acquired pneumonia/ or pneumonia.mp. or exp pneumonia/ 
4. bronchiolitis.mp. or exp bronchiolitis/ 
5. respiratory infection*.mp. 
6. respiratory disease*.mp. or respiratory diseases.sh. 
7. case control.mp. 
8. exp case-control studies/ 
9. (case* adj2 control*).mp. [mp=abstract, title, original title, broad terms, heading words] 
10. prospective study.mp. 
11. exp control/ or control*.mp. 
12. 1 or 2 
13. 3 or 4 or 5 or 6 
14. 10 and 11 
15. 7 or 8 or 9 or 14 
16. 12 and 13 and 15 
17. limit 16 to yr="1990 -Current" 
 
LILACS (AMRO/PAHO)  
tw:(virus OR viral) AND tw:(pneumonia OR bronchiolitis OR alri OR lrti OR "lower respiratory" OR 
"respiratory infection") AND tw:(control) 
 
CNKI 
        Topic: respiratory infection or pneumonia (vague)  
Or    Topic: bronchiolitis (vague) 
And Topic: virus (vague) 
And Topic: case control (vague) 
And Topic: child (vague)  





All (vague): respiratory infection or 
All (vague): pneumonia or 
All (vague): bronchiolitis and 
All (vague): virus and 
All (vague): case control and 
All (vague): child  
Time: 1990 – 2014 
 
Chongqing VIP 
Title/key word: respiratory infection 
Or    Title/key word: pneumonia 
And Title/key word: virus  
And Title/key word: case control 
And Title/key word: child 
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A5. Forest plots for meta-analysis results of the aetiological roles of 
common respiratory viruses in ALRI 
Hospitalised cases vs. asymptomatic controls
NOTE: Weights are from random effects analysis
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NOTE: Weights are from random effects analysis
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NOTE: Weights are from random effects analysis
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NOTE: Weights are from random effects analysis
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NOTE: Weights are from random effects analysis
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NOTE: Weights are from random effects analysis
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NOTE: Weights are from random effects analysis
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NOTE: Weights are from random effects analysis
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A6. Search strategy of risk factors for RSV associated ALRI  
Medline   
1. exp Respiratory Syncytial Viruses/ or exp Respiratory Syncytial Virus Infections/ or RSV.mp. or 
exp Respiratory Syncytial Virus, Human/ 
2. respiratory syncytial virus*.mp. 
3. 1 or 2 
4. pneumonia.mp. or exp Pneumonia/ or exp Pneumonia, Viral/ 
5. bronchiolitis.mp. or exp Bronchiolitis/ or exp Bronchiolitis, Viral/ 
6. exp Respiratory Tract Infections/ or respiratory infection*.mp. 
7. exp Respiratory Tract Diseases/ or respiratory disease*.mp. 
8. 4 or 5 or 6 or 7 
9. risk factor*.mp. or exp Risk Factors/ 
10. low birth weight.mp. or exp Infant, Low Birth Weight/ 
11. breast feeding.mp. or exp Breast Feeding/ 
12. exp Crowding/ or crowd*.mp. 
13. indoor air pollution.mp. or exp Air Pollution, Indoor/ 
14. exp Malnutrition/ or malnutrition.mp. 
15. exp Measles Vaccine/ or measles vaccin*.mp. 
16. exp HIV/ or HIV.mp. 
17. exp Infant, Premature/ or prematur*.mp. 
18. asthma.mp. or exp Asthma/ 
19. exp Education/ or education.mp. 
20. exp Altitude/ or altitude.mp. 
21. child care.mp. or exp Child Care/ 
22. day care.mp. or exp Day Care/ 
23. atop*.mp. 
24. exp Tobacco Smoke Pollution/ or tobacco smok*.mp. 
25. hygiene.mp. or Hygiene/ 
26. water.mp. or Water/ or Water Supply/ 
27. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 
26 
28. 3 and 8 
29. 27 and 28 
30. limit 29 to (humans and yr="1995 -Current" and ("all infant (birth to 23 months)" or "newborn 
infant (birth to 1 month)" or "infant (1 to 23 months)" or "preschool child (2 to 5 years)")) 
 
Embase  
1. exp respiratory syncytial virus infection/ or RSV.mp. or exp Respiratory syncytial pneumovirus/ 
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2. respiratory syncytial virus*.mp. 
3. exp community acquired pneumonia/ or exp pneumonia/ or exp virus pneumonia/ or exp infectious 
pneumonia/ or pneumonia.mp. 
4. bronchiolitis.mp. or exp bronchiolitis/ or exp viral bronchiolitis/ 
5. exp lower respiratory tract infection/ or exp respiratory tract infection/ or respiratory infection*.mp. 
6. exp respiratory tract disease/ or respiratory disease*.mp. 
7. 1 or 2 
8. 3 or 4 or 5 or 6 
9. exp risk factor/ or risk factor*.mp. 
10. low birth weight.mp. or exp low birth weight/ 
11. breast feeding.mp. or exp breast feeding/ 
12. exp crowding/ or crowd*.mp. 
13. indoor air pollution.mp. or exp indoor air pollution/ 
14. exp malnutrition/ or malnutrition.mp. 
15. exp measles vaccine/ or measles vaccin*.mp. 
16. HIV.mp. or exp Human immunodeficiency virus/ 
17. exp prematurity/ or prematur*.mp. 
18. exp asthma/ or asthma.mp. 
19. education.mp. or exp education/ 
20. altitude.mp. or exp altitude/ 
21. child care.mp. or exp child care/ 
22. day care.mp. or exp day care/ 
23. atop*.mp. 
24. exp smoking/ or exp tobacco smoke/ or exp passive smoking/ or tobacco smok*.mp. 
25. water.mp. or water/ or water supply/ 
26. hygiene/ or hygiene.mp. 
27. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 
26 
28. 7 and 8 and 27 
29. limit 28 to (human and yr="1995 -Current" and (infant or preschool child <1 to 6 years>)) 
 
Global Health  
1. exp human respiratory syncytial virus/ or rsv.mp. 
2. respiratory syncytial virus*.mp. 
3. 1 or 2 
4. exp community acquired pneumonia/ or pneumonia*.mp. or exp pneumonia/ 
5. bronchiolitis.mp. or exp bronchiolitis/ 
6. respiratory infection*.mp. 
7. exp respiratory diseases/ or respiratory disease*.mp. 
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8. 4 or 5 or 6 or 7 
9. exp risk factors/ or risk factor*.mp. 
10. low birth weight.mp. or exp low birth weight infants/ 
11. exp premature infants/ or exp prematurity/ or prematur*.mp. 
12. exp asthma/ or asthma.mp. 
13. exp atopy/ or atop*.mp. 
14. exp education/ or education.mp. 
15. exp breast feeding/ or breast feeding.mp. 
16. exp altitude/ or altitude.mp. 
17. exp malnutrition/ or malnutrition.mp. 
18. exp child care/ or child care.mp. 
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A8. Forest plots for meta-analysis results of 12 risk factors  
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NOTE: Weights are from random effects analysis
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A9. Search strategy of global burden of RSV associated ALRI  
Medline  
1. exp Respiratory Syncytial Viruses/ or exp Respiratory Syncytial Virus, Human/ or exp Respiratory 
Syncytial Virus Infections/ or RSV.mp. 
2. respiratory syncytial virus*.mp. 
3. pneumonia.mp. or exp Pneumonia/ or exp Pneumonia, Viral/ 
4. bronchiolitis.mp. or exp Bronchiolitis/ or exp Bronchiolitis, Viral/ 
5. exp Respiratory Tract Infections/ or respiratory infection*.mp. 
6. exp Respiratory Tract Diseases/ or respiratory disease*.mp. 
7. incidence.mp. or exp Incidence/ 
8. prevalence.mp. or exp Prevalence/ 
9. exp Child Mortality/ or exp Infant Mortality/ or mortality.mp. or exp Hospital Mortality/ or exp 
Mortality/ 
10. death*.mp. or exp Death/ or exp "Cause of Death"/ 
11. morbidity.mp. or exp Morbidity/ 
12. burden.mp. 
13. epidemiology.mp. or exp Epidemiology/ 
14. 1 or 2 
15. 3 or 4 or 5 or 6 
16. 7 or 8 or 9 or 10 or 11 or 12 or 13 
17. 15 or 16 
18. 14 and 17 
19. limit 18 to (yr="1995 -Current" and ("all infant (birth to 23 months)" or "newborn infant (birth to 




1. RSV.mp. or exp Respiratory syncytial pneumovirus/ or exp respiratory syncytial virus infection/ 
2. respiratory syncytial virus*.mp. 
3. exp community acquired pneumonia/ or exp pneumonia/ or exp virus pneumonia/ or exp infectious 
pneumonia/ or pneumonia.mp. 
4. bronchiolitis.mp. or exp bronchiolitis/ or exp viral bronchiolitis/ 
5. exp respiratory tract infection/ or exp lower respiratory tract infection/ or respiratory infection*.mp. 
6. exp respiratory tract disease/ or respiratory disease*.mp. 
7. exp incidence/ or incidence.mp. 
8. prevalence.mp. or exp prevalence/ 
9. exp newborn mortality/ or exp mortality/ or exp childhood mortality/ or mortality.mp. or exp infant 
mortality/ 
10. exp death/ or death*.mp. or exp "cause of death"/ or exp child death/ 
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11. morbidity.mp. or exp morbidity/ or exp newborn morbidity/ 
12. burden.mp. 
13. exp epidemiology/ or epidemiology.mp. 
14. 1 or 2 
15. 3 or 4 or 5 or 6 
16. 7 or 8 or 9 or 10 or 11 or 12 or 13 
17. 15 or 16 
18. 14 and 17 




2. exp human respiratory syncytial virus/ 
3. respiratory syncytial virus*.mp. 
4. exp community acquired pneumonia/ or pneumonia*.mp. or exp pneumonia/ 
5. bronchiolitis.mp. or exp bronchiolitis/ 
6. respiratory infection*.mp. 
7. exp respiratory diseases/ 
8. respiratory disease*.mp. 
9. incidence.mp. or exp disease incidence/ or exp incidence/ 
10. prevalence*.mp. or exp disease prevalence/ 
11. mortality.mp. or exp infant mortality/ or exp neonatal mortality/ or exp mortality/ 
12. death*.mp. or exp death/ or exp "causes of death"/ 
13. morbidity.mp. or exp morbidity/ 
14. exp epidemiology/ or epidemiology.mp. 
15. burden.mp. 
16. 1 or 2 or 3 
17. 4 or 5 or 6 or 7 or 8 
18. 9 or 10 or 11 or 12 or 13 or 14 or 15 
19. 17 or 18 
20. 16 and 19 
21. limit 20 to yr="1995 -Current" 
 
CINAHL  
S1= (MH “respiratory syncytial virus infections”) OR (MH “respiratory syncytial viruses”) OR 




S3= (MH “pneumonia+”) OR “pneumonia” OR (MH “pneumonia, viral”) OR (MH “community-
acquired pneumonia”) 
S4= (MH “bronchiolitis+”) OR “bronchiolitis” 
S5= (MH “respiratory tract infections+”) OR “respiratory infection” 
S6= (MH “respiratory tract diseases+”) OR “respiratory disease” 
S7= (MH “incidence”) OR “incidence” 
S8= (MH “prevalence”) OR “prevalence” 
S9= (MH “mortality+”) OR “mortality” OR (MH “infant mortality”) OR (MH “child mortality”) OR 
(MH “hospital mortality”) 
S10= (MH “death+”) OR “death” OR (MH “cause of death”) OR (MH “infant death+”) 
S11= (MH “morbidity+”) OR “morbidity” 
S12= “burden” 
S13= (MH “epidemiology+”) OR “epidemiology” 
S14= S1 OR S2 
S15= S3 OR S4 OR S5 OR S6 
S16= S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 
S17= S15 OR S16 
S18= S14 AND S17 
Limiters: Published date: 19950101 – 20150804; Age groups: infant, newborn: birth-1 month, infant: 
1-23 months, child, preschool: 2-5 years 
 
Web of Science  
Topic= (respiratory syncytial virus) AND Topic= (epidemiology) AND Topic= (children) 
From 1995 to 2015 
 
WHOLIS (KMS)  
Respiratory syncytial virus in All Indexes 
 
LILACS (AMRO/PAHO) 
Respiratory syncytial virus in All Indexes 
 
IndMed  
RSV in anywhere 
 
SIGLE   





Topic: respiratory infection or pneumonia (vague)  
Or    Topic: bronchiolitis (vague) 
And Topic: respiratory syncytial virus (vague) 
And Topic: children (vague)  
Publication time: 1st Jan 1995 – 30th Aug 2015 
 
Wanfang Data 
All (vague): respiratory infection or 
All (vague): pneumonia or 
All (vague): bronchiolitis and 
All (vague): respiratory syncytial virus and 
All (vague): children  
Time: 1995 – 2015 
 
ChongQing VIP 
Title/key word: respiratory tract infection 
Or    Title/key word: pneumonia 
Or    Title/key word: bronchiolitis 
And Title/key word: respiratory syncytial virus  
And Title/key word: children 




A10. R codes to estimate in-hospital mortality from RSV associated 
ALRI 
In-hospital deaths from RSV associated ALRI in developing countries 
#Developing in 0-5m 
# The population 
pop0to5 <- 61545050 
 
# The hospitalisation rate 
# Log transform and calculate standard deviation 
de0to5 <- c(est = 20.20, lci = 16.66, uci = 24.50) 
de0to5_log <- log(de0to5) 
de0to5_se <- (de0to5_log["uci"] - de0to5_log["lci"]) / (2*1.96) 
 
# Sample 10,000 from a normal distribution 
de0to5_sample <- rnorm(10000, de0to5_log["est"], de0to5_se) 
de0to5_sample <- exp(de0to5_sample) 
 
# Summarise and plot the hospitalisation rate 
hist(de0to5_sample) 
mean(de0to5_sample) 
quantile(de0to5_sample, probs = c(0.025, 0.975)) 
 
# Case fatality 
# Log transform and calculate standard deviation 
de0to5_cfr <- c(est = 2.18, lci = 1.80, uci = 2.65) 
de0to5_cfr_log <- log(de0to5_cfr) 
de0to5_se_cfr <- (de0to5_cfr_log["uci"] - de0to5_cfr_log["lci"]) / (2*1.96) 
 
# sample 10,000 from a normal distribution 
de0to5_cfr_sample <-  rnorm(10000, de0to5_cfr_log["est"], de0to5_se_cfr) 
de0to5_cfr_sample <- exp(de0to5_cfr_sample) 
 
# Summarise and plot cfr 
plot(density((de0to5_cfr_sample)), xlim = c(0,10)) 
median((de0to5_cfr_sample)) 




## Combine two samples to make estimate for number of deaths 
de0to5_num_deaths_sample <-(de0to5_sample) * 0.001 * pop0to5 * 0.01 * (de0to5_cfr_sample) 
 
## Examine combined results 
plot(density((de0to5_num_deaths_sample)), xlim= c(0,40000)) 
quantile((de0to5_num_deaths_sample), probs = c(0.025, 0.975)) 
median(de0to5_num_deaths_sample) 
 
####### Developing 0-5m deaths 
 
 
#Developing in 6-11m 
# The population 
pop6to11 <- 61545050 
 
# The hospitalisation rate 
# Log transform and calculate standard deviation 
de6to11 <- c(est = 10.95, lci = 7.66, uci = 15.65) 
de6to11_log <- log(de6to11) 
de6to11_se <- (de6to11_log["uci"] - de6to11_log["lci"]) / (2*1.96) 
 
# Sample 10,000 from a normal distribution 
de6to11_sample <- rnorm(10000, de6to11_log["est"], de6to11_se) 
de6to11_sample <- exp(de6to11_sample) 
 
# Summarise and plot the hospitalisation rate 
hist(de6to11_sample) 
mean(de6to11_sample) 
quantile(de6to11_sample, probs = c(0.025, 0.975)) 
 
# Case fatality 
# Log transform and calculate standard deviation 
de6to11_cfr <- c(est = 2.44, lci = 1.85, uci = 3.23) 
de6to11_cfr_log <- log(de6to11_cfr) 
de6to11_se_cfr <- (de6to11_cfr_log["uci"] - de6to11_cfr_log["lci"]) / (2*1.96) 
 
# sample 10,000 from a normal distribution 
de6to11_cfr_sample <-  rnorm(10000, de6to11_cfr_log["est"], de6to11_se_cfr) 
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de6to11_cfr_sample <- exp(de6to11_cfr_sample) 
 
# Summarise and plot cfr 
plot(density((de6to11_cfr_sample)), xlim = c(0,10)) 
median((de6to11_cfr_sample)) 
quantile((de6to11_cfr_sample), probs = c(0.025, 0.975)) 
 
## Combine two samples to make estimate for number of deaths 
de6to11_num_deaths_sample <-(de6to11_sample) * 0.001 * pop6to11 * 0.01 * (de6to11_cfr_sample) 
 
## Examine combined results 
plot(density((de6to11_num_deaths_sample)), xlim= c(0,25000)) 
quantile((de6to11_num_deaths_sample), probs = c(0.025, 0.975)) 
median(de6to11_num_deaths_sample) 
 
####### Developing 6-11m deaths 
 
 
#Developing in 12-59m 
# The population 
pop12to59 <- 477627786 
 
# The hospitalisation rate 
# Log transform and calculate standard deviation 
de12to59 <- c(est = 1.45, lci = 1.01, uci = 2.10) 
de12to59_log <- log(de12to59) 
de12to59_se <- (de12to59_log["uci"] - de12to59_log["lci"]) / (2*1.96) 
 
# Sample 10,000 from a normal distribution 
de12to59_sample <- rnorm(10000, de12to59_log["est"], de12to59_se) 
de12to59_sample <- exp(de12to59_sample) 
 
# Summarise and plot the hospitalisation rate 
hist(de12to59_sample) 
mean(de12to59_sample) 
quantile(de12to59_sample, probs = c(0.025, 0.975)) 
 
# Case fatality 
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# Log transform and calculate standard deviation 
de12to59_cfr <- c(est = 2.20, lci = 1.60, uci = 3.02) 
de12to59_cfr_log <- log(de12to59_cfr) 
de12to59_se_cfr <- (de12to59_cfr_log["uci"] - de12to59_cfr_log["lci"]) / (2*1.96) 
 
# sample 10,000 from a normal distribution 
de12to59_cfr_sample <-  rnorm(10000, de12to59_cfr_log["est"], de12to59_se_cfr) 
de12to59_cfr_sample <- exp(de12to59_cfr_sample) 
 
# Summarise and plot cfr 
plot(density((de12to59_cfr_sample)), xlim = c(0,10)) 
median((de12to59_cfr_sample)) 
quantile((de12to59_cfr_sample), probs = c(0.025, 0.975)) 
 
## Combine samples to make estimate for number of deaths 
de12to59_num_deaths_sample <-(de12to59_sample) * 0.001 * pop12to59 * 0.01 * 
(de12to59_cfr_sample) 
 
## Examine combined results 
plot(density((de12to59_num_deaths_sample)), xlim= c(0,30000)) 
quantile((de12to59_num_deaths_sample), probs = c(0.025, 0.975)) 
median(de12to59_num_deaths_sample) 
 
####### Developing 12-59m deaths 
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#Industrialised in 0-5m 
# The population 




# The hospitalisation rate 
# Log transform and calculate standard deviation 
ind0to5 <- c(est = 27.26, lci = 23.14, uci = 32.11) 
ind0to5_log <- log(ind0to5) 
ind0to5_se <- (ind0to5_log["uci"] - ind0to5_log["lci"]) / (2*1.96) 
 
# Sample 10,000 from a normal distribution 
ind0to5_sample <- rnorm(10000, ind0to5_log["est"], ind0to5_se) 
ind0to5_sample <- exp(ind0to5_sample) 
 
# Summarise and plot the hospitalisation rate 
hist(ind0to5_sample) 
mean(ind0to5_sample) 
quantile(ind0to5_sample, probs = c(0.025, 0.975)) 
 
# Case fatality 
# Log transform and calculate standard deviation 
ind0to5_cfr <- c(est = 0.02, lci = 0+0.00005, uci = 0.13) 
ind0to5_cfr_log <- log(ind0to5_cfr) 
ind0to5_se_cfr <- (ind0to5_cfr_log["uci"] - ind0to5_cfr_log["lci"]) / (2*1.96) 
 
# sample 10,000 from a normal distribution 
ind0to5_cfr_sample <-  rnorm(10000, ind0to5_cfr_log["est"], ind0to5_se_cfr) 
ind0to5_cfr_sample <- exp(ind0to5_cfr_sample) 
 
# Summarise and plot cfr 
plot(density((ind0to5_cfr_sample)), xlim = c(0,10)) 
median((ind0to5_cfr_sample)) 
quantile((ind0to5_cfr_sample), probs = c(0.025, 0.975)) 
 
## Combine two samples to make estimate for number of deaths 
ind0to5_num_deaths_sample <-(ind0to5_sample) * 0.001 * pop0to5 * 0.01 * (ind0to5_cfr_sample) 
 
## Examine combined results 
plot(density((ind0to5_num_deaths_sample)), xlim= c(0,40000)) 





####### Industrialised 0-5m deaths 
 
 
#Industrialised in 6-11m 
# The population 
pop6to11 <- 6778914 
 
# The hospitalisation rate 
# Log transform and calculate standard deviation 
ind6to11 <- c(est = 11.53, lci = 5.49, uci = 24.23) 
ind6to11_log <- log(ind6to11) 
ind6to11_se <- (ind6to11_log["uci"] - ind6to11_log["lci"]) / (2*1.96) 
 
# Sample 10,000 from a normal distribution 
ind6to11_sample <- rnorm(10000, ind6to11_log["est"], ind6to11_se) 
ind6to11_sample <- exp(ind6to11_sample) 
 
# Summarise and plot the hospitalisation rate 
hist(ind6to11_sample) 
mean(ind6to11_sample) 
quantile(ind6to11_sample, probs = c(0.025, 0.975)) 
 
# Case fatality 
# Log transform and calculate standard deviation 
ind6to11_cfr <- c(est = 0.05, lci = 0.01, uci = 0.38) 
ind6to11_cfr_log <- log(ind6to11_cfr) 
ind6to11_se_cfr <- (ind6to11_cfr_log["uci"] - ind6to11_cfr_log["lci"]) / (2*1.96) 
 
# sample 10,000 from a normal distribution 
ind6to11_cfr_sample <-  rnorm(10000, ind6to11_cfr_log["est"], ind6to11_se_cfr) 
ind6to11_cfr_sample <- exp(ind6to11_cfr_sample) 
 
# Summarise and plot cfr 
plot(density((ind6to11_cfr_sample)), xlim = c(0,10)) 
median((ind6to11_cfr_sample)) 




## Combine two samples to make estimate for number of deaths 
ind6to11_num_deaths_sample <-(ind6to11_sample) * 0.001 * pop6to11 * 0.01 * 
(ind6to11_cfr_sample) 
 
## Examine combined results 
plot(density((ind6to11_num_deaths_sample)), xlim= c(0,25000)) 
quantile((ind6to11_num_deaths_sample), probs = c(0.025, 0.975)) 
median(ind6to11_num_deaths_sample) 
 
####### Industrialised 6-11m deaths 
 
 
#Industrialised in 12-59m 
# The population 
pop12to59 <- 56260723 
 
# The hospitalisation rate 
# Log transform and calculate standard deviation 
ind12to59 <- c(est = 2.01, lci = 1.30, uci = 3.12) 
ind12to59_log <- log(ind12to59) 
ind12to59_se <- (ind12to59_log["uci"] - ind12to59_log["lci"]) / (2*1.96) 
 
# Sample 10,000 from a normal distribution 
ind12to59_sample <- rnorm(10000, ind12to59_log["est"], ind12to59_se) 
ind12to59_sample <- exp(ind12to59_sample) 
 
# Summarise and plot the hospitalisation rate 
hist(ind12to59_sample) 
mean(ind12to59_sample) 
quantile(ind12to59_sample, probs = c(0.025, 0.975)) 
 
# Case fatality 
# Log transform and calculate standard deviation 
ind12to59_cfr <- c(est = 0.09, lci = 0.03, uci = 0.25) 
ind12to59_cfr_log <- log(ind12to59_cfr) 
ind12to59_se_cfr <- (ind12to59_cfr_log["uci"] - ind12to59_cfr_log["lci"]) / (2*1.96) 
 
# sample 10,000 from a normal distribution 
ind12to59_cfr_sample <-  rnorm(10000, ind12to59_cfr_log["est"], ind12to59_se_cfr) 
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ind12to59_cfr_sample <- exp(ind12to59_cfr_sample) 
 
# Summarise and plot cfr 
plot(density((ind12to59_cfr_sample)), xlim = c(0,10)) 
median((ind12to59_cfr_sample)) 
quantile((ind12to59_cfr_sample), probs = c(0.025, 0.975)) 
 
## Combine samples to make estimate for number of deaths 
ind12to59_num_deaths_sample <-(ind12to59_sample) * 0.001 * pop12to59 * 0.01 * 
(ind12to59_cfr_sample) 
 
## Examine combined results 
plot(density((ind12to59_num_deaths_sample)), xlim= c(0,30000)) 
quantile((ind12to59_num_deaths_sample), probs = c(0.025, 0.975)) 
median(ind12to59_num_deaths_sample) 
 
####### Developing 12-59m deaths 
 
 








In-hospital deaths from RSV associated ALRI in children aged 0-59m 
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A12. List of studies reporting untested ALRI and corresponding 
reasons 
Reference 
% of eligible 
cases not tested 
for RSV 
Reasons for not testing 
Dhaka, Bangladesh (Jan 
2005 - Feb 2008) (Brooks, 
unpublished) 
19.3 (290/1500) NA 
Bandung, Indonesia (1st 




subjects did not meet case definition (LRI) 
Gilgit, Pakistan (1st Apr 
2012 - 31st Mar 2014) 
(Rasmussen, unpublished) 
14.3 (34/238) 
child absent when collecting samples, samples 
were not valid by the time it reached the testing 
center, mother refusal 
Paarl, South Africa (Mar 
2012 - Dec 2014) (Zar, 
unpublished) 
36.1 (116/321) specimen not collected, PCR results not available 
Sa Kaeo and Nakhom 
Phanom, Thailand (1st 
Jan 2004 - 31st Dec 2007) 




Damanhour, Egypt (Jun 
2009 - Jun 2012) 
(Rowlinson et al., 2013) 
12.4 (659/5324) no informed consent or samples 
Multicentric, Germany 
(Nov 1999 - Oct 2001) 
(Forster et al., 2004) 
36.9 
(1078/2924) 
no informed consent, unavailable clinical 
specimens or specimens were not tested 
Banjul, Fajara and 
Sibanor, Gambia (Jan 




no village of origin documented, from outside the 
western region, no sex documented, samples not 
being taken because children admitted during 
weekends/holidays, absence of the patient from the 
ward for investigations and lack of documentation 
of an admission diagnosis on the patient's chart 
Nashville, Rochester and 
Cincinnati, USA (Oct 2000 




a lack of parental consent or unavailability of 
parents 
CEMIC, Buenos Aires, 
Argentina (1st Jun 2008 - 
31st Dec 2010) 
(Echavarria, unpublished) 
5.3 (3/57) insufficient sample 
Buenos Aires, Argentina 
(2011 - 2013) (Polack, 
unpublished) 
0.9 (30/3371) sample inadequate 
Belo Horizonte, Brazil 
(2011 - 2013) (Oliveira, 
unpublished) 
59.4 (757/1275) frozen samples at weekends; laboratory refused 




% of eligible 
cases not tested 
for RSV 
Reasons for not testing 
2012 - Dec 2013) (Fasce, 
unpublished) 
sample 
Iquique, Chile (Jan 2012 - 
Dec 2013) (Fasce, 
unpublished) 
0.6 (4/683) 
cases were not notified in time so as to collect 
sample 
Jingzhou, China (Jan 2010 





Santa Ana, El Salvador 





Gambia Western Region, 
Gambia (Jul 2007 - Jun 
2008) (Howie, 
unpublished) 
4.2 (4/95) technical problem with specimen 
Santa Rosa, Guatemala 
(2008 - 2013) (McCracken, 
unpublished) 
5.7 (104/1810) no consent or no specimen 
Quetzaltenango, 
Guatemala (2009 - 2013) 
(McCracken, unpublished) 
10.9 (207/1893) no consent or no specimen 
Pune, India (May 2009 - 
Apr 2013) (Chadha, 
unpublished) 
12.7 (78/612) 
poor quality swab; inadequate specimen; sample 
lost 





primarily age <3 months and critical illness on 
presentation; specimens collected 4 days a week so 
if patients who had rapid admission, would not 
have been done 
Kilifi hospital study, 





died; discharged; refusal 
Bondo district, Kenya (Jan 
2007 - Jun 2009) (Feikin, 
unpublished) 
28.7 (208/726) low swab quality 
Manhiça, Mozambique 
(20th Sep 2006 - 19th Sep 
2007) (Bassat, 
unpublished) 
3.4 (28/835) NPA not collected or processed without results 
Manhiça, Mozambique 
(1st Jan 2011 - 30th Jun 
2014) (Bassat, 
unpublished) 
3.1 (15/491) NPA not collected or processed without results 
41 sites in Netherlands 
(2008 - 2013) (Bont, 
unpublished) 
10.0 (24/241) 
reasons for not testing are unknown, as the 
decisions for testing are made by independent 




% of eligible 
cases not tested 
for RSV 
Reasons for not testing 
David City, Panama (Jan 




lack of resources at the lab to test 
Tagbilaran and 6 rural 
sites, Philippines (5th Jul 
2000 - 31st Dec 2004) 
(Lucero, unpublished) 
36.0 (537/1491) 
no specimen collected for those cases not tested for 
RSV 
Gauteng province, South 
Africa (2009 - 2012) 
(Cohen, unpublished) 
2.0 (122/6016) 
child too ill to take sample from; specimens not 
reaching laboratory within 72 hours 
KwaZulu-Natal province, 
South Africa (2010 - 2014) 
(Cohen, unpublished) 
4.5 (72/1607) 
patient very ill; parents refuse consent, specimen 
not at lab within 72 hours 
Klerksdorp site, South 




patient very ill; parents refuse consent, specimen 
not at lab within 72 hours 
Soweto, South Africa (Mar 
1998 - Oct 2005) (Madhi, 
unpublished) 
4.6 (240/5231) missed as part of surveillance 
Male Camp, Tak Province, 
Thailand (Nov 2007 - Oct 
2010) (Turner, 
unpublished) 
2.3 (8/354) parents refused NPA taken 
Sa Kaeo and Nakhon 
Phanom, Thailand (Jan 






Tone district, Togo (Aug 
2011 - Dec 2013) (Gessner, 
unpublished) 
3.2 (4/124) testing just started 
Alaska, USA (Jul 1994 - 




at provider discretion 
Navajo and WMA, USA - 




specimen not collected, most probably due to short 
hospitalisation stay (<2 days) 
Nha Trang, Vietnam (Feb 
2007 - Dec 2012) (Yoshida, 
unpublished) 
3.1 (25/795) some sample being lost 
Subiaco, Australia (Jan 





Lanzhou, China (Oct 2004 
- Oct 2005) (Zhang et al., 




% of eligible 
cases not tested 
for RSV 
Reasons for not testing 
2011) was not obtained 
Hong Kong, China (Nov 
2005 - Oct 2006) (Sung et 
al., 2009) 
80 sampling 
Nagasaki, Japan (Apr 
2009 - Mar 2010) (Harada 
et al., 2013) 
3.0 (13/433) NA 
Seoul, Korea (Jan - Dec 
2004) (Yoo et al., 2007) 71.8 (509/709) 
excluded during sampling process and small 
quantities not enough for RNA extraction 
Khon Kaen, Thailand 
(Apr 2002 - Aug 2004) 
(Teeratakulpisarn et al., 
2007) 
35.0 (91/260) 
parents didn't give consent for collection of NPA 
from their children; inappropriately stored for viral 
detection 
Tak Province, Thailand 
(Apr 2009 - Sep 2011) 
(Turner et al., 2013)  
14.0 (117/836) 
failure to meet the case definition; presented twice 
within 14 days; inadequate specimens 
Turku, Finland (Jan 1993 
- Dec 1995) (Juven et al., 
2000) 
14.2 (42/296) 
a convalescent serum sample was not obtained, 
chest radiographs did not have infiltrates 
compatible with pneumonia at the reevaluation 
done by 3 pediatric radiologists, or the radiographs 
were not available for the reevaluation 
Kiel, Germany (Jul 1996 - 





Pisa, Italy (Jan 2000 - May 
2006) (Maggi et al., 2007) 19.5 (39/200) 
some specimens were frozen immediately after 
collection and unsuitable for virus detection by 
DFA or rapid culture in shell vials 
Milan, Italy (1st Dec 2008 
- 31st Dec 2009) (Zuccotti 
et al., 2011) 
4.0 (24/600) no guardian consent 
Palma, Spain (Jan 1995 - 
Dec 2006) (Hervas et al., 
2012) 
17.5 (505/2889) 
no info about RSV microbiology; erroneously 
codified; >2y; had a previous episode of 
obstructive lower airway infection 
Madrid, Spain (Sep 2005 - 
Aug 2008) (Calvo et al., 
2010) 
14.1 (52/370) lack of NPA samples or they refused to participate 
Lausanne and Geneva, 
Switzerland (Mar 2003 - 
Dec 2005) (Cevey-
Macherel et al., 2009) 
10.8 (12/111) 
impossibility to obtain samples or interrupt the 
study 
Pelotas, Brazil  (1st Aug 
1997 - 31st Jul 1998) 
(Macedo et al., 2002) 
30.4 (266/874) 
refusals and losses; insufficient available data to 
generate adequate diagnostic by the judge or the 
judge did not give a diagnostic of ARD; 
readmission; not tested for RSV 
Sao Paulo, Brazil (Jan 
2006 - Dec 2007) 
17.7 (53/299) 





% of eligible 
cases not tested 
for RSV 
Reasons for not testing 
(Ferronato et al., 2012) 
Sao Paulo, Brazil (May 
2004 - Sep 2005) (Salomao 
Jr et al., 2011) 
4.3 (13/303) loss of specimen 
Sao Paulo, Brazil (Mar 
2008 - Aug 2011) (Ferone 
et al., 2014) 
27.5 (308/1121) repeated or inadequate samples 
Belem, Brazil (Nov 2006 - 
Oct 2007) (Lamarao et al., 
2012) 
13.5 (164/1214) no consent from parents or legal guardians 
Porto Alegre, Brazil (Sep 
2009 - Sep 2010) 
(Sparremberger et al., 
2011) 
3.0 (2/67) no samples collected 
Iqaluit, Canada (28th Jan 
2002 - 27th Mar 2003) 
(Banerji et al., 2009) 
7.3 (9/124) NA 
San Luis Potosi, Mexico 
(1st May 2003 - 30th Apr 
2005) (Noyola et al., 2007) 
16.1 (118/734) no respiratory samples 
California, USA (1996 - 
2004) (Flaherman et al., 
2010) 
15.0 (309/2060) NA 
Dallas, Texas, USA (Jan 
2002 - Dec 2007) (Garcia 
et al., 2010) 
4.4 (211/4800) not tested 
Rarieda, Kenya (1st Mar 
2007 - 28th Feb 2010) 




Kilifi, Kenya (Jan - Dec 
2010) (Hammitt et al., 
2012a) 
16.0 (154/963) 
refused; died during the admission process; failure 
of the computerized flagging system; other reasons 
Bondo district, Kenya 
(Aug 2008 - Dec 2010) 
(Fuller et al., 2013) 
58.9 (974/1654) not tested 
Santiago, Chile (Jan 1989 - 
Dec 2000) (Avendano et 
al., 2003) 
NA poor sample quality or quantity 
Cape Town, South Africa 
(Jun 1995 - Aug 1996) 





Mozambique (Oct 1998 - 
May 2000) (Loscertales et 
al., 2002) 
44.2 (793/1794) 





% of eligible 
cases not tested 
for RSV 
Reasons for not testing 
Athens, Greece (Feb 1997 - 
Jun 2000) (Tsolia et al., 
2003) 
25.6 (163/636) NA 
Buenos Aires, Argentina 










refusal to consent; unavailability of transport from 
field site to lab; high patient volumes; inadequate 
staffing levels 
Kathmandu, Nepal (Jan 




other severe illness, history of documented TB, 
severe malnutrition, heart disease, diarrhoea with 
dehydration, disappearance of indrawing after 
salbutamol, recurrent wheezing, 
effusion/pneumothorax on chest X-ray, Hb% < 7 
gm/dl, chronic cough, already enrolled in study 
once 
Basse, Gambia (3rd Nov 
2011 - 2nd Nov 2013) 
(PERCH, unpublished) 
7.2 (46/638) quality control not yet complete 
Kilifi, Kenya (15th Aug 
2011 - 15th Nov 2013) 
(PERCH, unpublished) 
0.3 (2/634) specimen not collected 
Bamako, Mali (3rd Jan 
2012 - 14th Jan 2014) 
(PERCH, unpublished) 
9.1 (61/674) quality control not yet complete 
Nakhon Phanom and Sa 
Kaeo, Thailand (1st Jan 
2012 - 31st Jan 2014) 
(PERCH, unpublished) 
18.3 (41/224) quality control not yet complete 
Lusaka, Zambia (10th Oct 
2011 - 31st Oct 2013) 
(PERCH, unpublished) 
10.5 (65/617) quality control not yet complete 
Mpumalanga, South 




patient very ill; parents refuse consent; specimen 
not at lab within 72 hours 
Beirut, Lebanon (Oct 2012 
- Mar 2014) (Assaf-Casals 
et al., 2015) 
18.3 (99/542) 
no specimens collected or had onset of respiratory 
symptoms for more than 7 days 
Buenos Aires, Argentina 
(Apr 1993 - Dec 1994) 
(Carballal et al., 2001) 
3.4 (44/1278) NA 
Beer-Sheva, Israel (Nov to 
Mar, 2004 - 2011) 
(Greenberg et al., 2014) 
52.8 
(1182/2240) 
specimens were not obtained 
Jingzhou, China (Jan - 
Dec 2011) (Huo et al., 




% of eligible 
cases not tested 
for RSV 
Reasons for not testing 
2013) (6803/7314) 
Amman, Jordan (18th Jan 
- 29th Mar 2007) (Khuri-
Bulos et al., 2010) 
2.0 (15/743) clinical or laboratory data were not available 
RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. 




A13. List of studies reporting the incidence rate of RSV associated 
ALRI in narrower age bands 
Location (reference) 





3-5m 6-8m 9-11m 12-59m 
San Marcos, Guatemala (rural, 
Dec 2002 - Dec 2004) (Bruce and 
colleagues) 
97.2 67.8 127.6 149.8 195.4 
 
Dhaka, Bangladesh (urban, Jan 
2005 - Feb 2008) (Brooks and 
colleagues) 
2.1 8.7 54.3 31.6 42.4 12.6 
Ballabhgarh, India (rural, Aug 
2012 - Aug 2013) (Krishnan and 
colleagues)  
55.0 123.5 77.2 76.6 21.7 
Bandung, Indonesia (periurban 
and rural, 1st Feb 1999 - 26th Apr 
2001) (Simoes and colleagues)  
11.8 44.7 189.7 96.7 55.5 
Managua, Nicaragua (urban, Sep 
2011 - Sep 2012) (Gordon and 
colleagues)   
47.5 142.9 
  
Gilgit, Pakistan (rural, 1st Apr 
2012 - 31st Mar 2014) (Rasmussen 
and colleagues)   
69.8 107.1 95.9 27.3 
Paarl, South Africa (periurban, 
Mar 2012 - Dec 2014) (Zar and 
colleagues) 
235.3 471.4 619.0 144.7 137.9 
 




A14. Forest plots for meta-analysis results of incidence rate of RSV 
associated ALRI 
By regions (world bank income level and developing/industrialised)





Overall  (I-squared = 97.1%, p = 0.000)
Krishnan et al
Wright et al
Subtotal  (I-squared = 95.0%, p = 0.000)
Forster et al
Subtotal  (I-squared = 91.4%, p = 0.000)
High income
Subtotal  (I-squared = 97.7%, p = 0.000)
Author
Wu, A. et al
Sutmoller et al
Brooks et al































Aug 2012 - Aug 2013
Jan 1973 - Dec 1993
Nov 1999 - Oct 2001
period
Mar 2009 - Sep 2011
Jan 1987 - Dec 1989
Jan 2005 - Feb 2008
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Oct 2001 - Mar 2005
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1st Feb 1999 - 26th Apr 2001
1st Apr 2012 - 31st Mar 2014
Sep 2011 - Sep 2012
Jan 2002 - May 2005
Mar 2012 - Dec 2014
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Incidence rate of RSV associated ALRI in 0-5m (per 1000 per year)
384 
 
NOTE: Weights are from random effects analysis
.
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Subtotal  (I-squared = 95.0%, p = 0.000)
Homaira, N. et al
Nokes et al
Krishnan et al






























Oct 1993 - Aug 1996
Oct 2001 - Mar 2005
1st Feb 1999 - 26th Apr 2001
Apr 2009 - Mar 2011
Jan 2002 - May 2005
Aug 2012 - Aug 2013
Mar 2009 - Sep 2011
Jan 1973 - Dec 1993
1st Apr 2012 - 31st Mar 2014
Sep 2011 - Sep 2012
Jan 1987 - Dec 1989
Nov 1999 - Oct 2001
Study
Jan 2005 - Feb 2008
Mar 2012 - Dec 2014
Jun 1999 - May 2001
Dec 2002 - Dec 2004
80.65 (54.44, 119.49)
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Subtotal  (I-squared = 94.3%, p = 0.000)
Subtotal  (I-squared = 95.0%, p = 0.000)
Sutmoller et al
Subtotal  (I-squared = 97.2%, p = 0.000)
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Robertson et al
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Sep 2011 - Sep 2012
Jan 2002 - May 2005
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Study
Apr 2009 - Mar 2011
85.14 (60.01, 120.80)























Incidence rate of RSV associated ALRI in 0-11m (per 1000 per year)
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NOTE: Weights are from random effects analysis
.
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A15. Comparison of meta-estimate after excluding imputed data 
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14 5.3 (4.0-7.0) 31 5.5 (4.7-6.3) 
















9 5.8 (4.1-8.2) 25 5.5 (4.7-6.5) 




A16. List of studies reporting hospitalisation rate of RSV associated 
hospitalised ALRI in narrower age bands 
Location (reference) 
Hospitalisation rate of RSV associated ALRI 
(per 1000 children per year) 




Sa Kaeo and Nakhom Phanom, 
Thailand (rural, 1st Jan 2004 - 31st 
Dec 2007) (Fry et al., 2010)      
4.1 
Damanhour, Egypt (urban and 
rural, Jun 2009 - Jun 2012) 
(Rowlinson et al., 2013)      
0.7 
USA (urban and rural, 1997 - 2006) 
(Stockman et al., 2012)   
28.4 
   
Dadaab and Kakuma, Kenya 
(rural, Sep 2007 - Aug 2010)§ 
(Ahmed et al., 2012)      
5.2 
Gipuzoka, Spain (urban, Jul 1996 - 
Jun 2000) (Vicente et al., 2003) 
31.0 54.6 26.9 
  
1.3 
England, United Kingdom (urban, 
Apr 1995 - Mar 1998) (Muller-
Pebody et al., 2002)      
1.3 
Buenos Aires, Argentina (urban 
and rural, 2011 - 2013) (Polack and 
colleagues) 
32.1 82.0 63.5 40.8 25.9 
 
Belo Horizonte, Brazil (urban, 2011 
- 2013) (Oliveira and colleagues)      
0.7 
Concepcion, Chile (urban and 
rural, Jan 2012 - Dec 2013) (Fasce 
and colleagues)      
0.7 
Iquique, Chile (urban and rural, 
Jan 2012 - Dec 2013) (Fasce and 
colleagues)      
1.1 
Jingzhou, China (urban and rural, 
Jan 2010 - Dec 2012) (Yu and 
colleagues)   
6.1 6.5 6.7 2.5 
Gambia Western Region, Gambia 
(urban and rural, Jul 2007 - Jun 
2008) (Howie and colleagues)      
1.6 
Santa Rosa, Guatemala (urban and 
rural, 2008 - 2013) (McCracken 
and colleagues)      
2.0 
Quetzaltenango, Guatemala (urban 
and rural, 2009 - 2013) 





Hospitalisation rate of RSV associated ALRI 
(per 1000 children per year) 




Ballabhgarh, India (rural, Jan 2010 
- Dec 2012) (Broor and colleagues) 
4.5 10.5 4.5 2.9 1.1 0.3 
Pune, India (rural, May 2009 - Apr 
2013) (Chadha and colleagues) 
12.6 5.1 17.5 20.5 23.4 3.9 
Lombok, Indonesia (urban and 
rural, 2000 - 2002) (Gessner and 
colleagues) 
2.0 12.6 18.9 14.6 10.0 
 
Kilifi hospital study, Kenya (urban 
and rural, Jan 2002 - Dec 2010) 
(Nokes and colleagues)§ 
23.9 25.5 31.7 14.8 7.9 1.3 
Bondo district, Kenya (rural, Jan 
2007 - Jun 2009) (Feikin and 
colleagues)§ 
32.3 108.5 31.7 16.8 15.5 19.3 
Manhiça, Mozambique (rural, 20th 
Sep 2006 - 19th Sep 2007) (Bassat 
and colleagues)§ 
16.7 13.7 14.0 10.9 2.5 1.3 
Manhiça, Mozambique (rural, 1st 
Jan 2011 - 30th Jun 2014) (Bassat 
and colleagues)§ 
1.1 8.1 3.3 2.3 1.6 0.6 
Tagbilaran and 6 rural sites, 
Philippines (urban and rural, 5th 
Jul 2000 - 31st Dec 2004) (Lucero 
and colleagues) 
 
65.5 76.1 56.2 53.5 
 
Gauteng province, South Africa 
(urban, 2009 - 2012) (Cohen and 
colleagues)§      
2.6 
Klerksdorp site, South Africa 
(periurban, Jan 2011 - Dec 2014) 
(Cohen and colleagues)§      
1.1 
Soweto, South Africa (urban, Mar 
1998 - Oct 2005) (Madhi and 
colleagues)§  
45.6 26.9 10.1 10.4 1.4 
Paarl, South Africa (periurban, 
Mar 2012 - Dec 2014) (Zar and 
colleagues)§ 
176.5 171.4 111.1 26.3 34.5 
 
Maela Camp, Tak Province, 
Thailand (rural, Nov 2007 - Oct 
2010) (Turner and colleagues) 
117.5 246.0 77.0 71.5 74.7 
 
Sa Kaeo and Nakhon Phanom, 
Thailand (rural, Jan 2008 - Dec 
2011) (Thamthitiwat and 
colleagues) 
5.3 17.6 10.5 17.1 20.1 8.5 
Tone district, Togo (rural, Aug 









Hospitalisation rate of RSV associated ALRI 
(per 1000 children per year) 





Alaska, USA (rural, Jul 1994 - Jun 
2012) (Singleton and colleagues)# 
264.8 240.7 156.2 138.1 104.2 
 
Colorado, USA (urban and rural, 
Jan 2008 - Jun 2013) (Simoes and 
colleagues)      
2.6 
Navajo and WMA, USA - MEDI 
(rural, Oct 2004 - Dec 2010) 
(O'Brien and colleagues)# 
65.9 601.6 199.6 278.7 
  
Navajo and WMA, USA - EPI 
(rural, Oct 1997 - Mar 2000) 
(O'Brien and colleagues)# 
209.5 284.5 198.6 162.4 155.4 
 
Nha Trang, Vietnam (urban and 
rural, Feb 2007 - Dec 2012) 
(Yoshida and colleagues)  
12.6 9.0 6.2 2.1 1.8 
Spain (urban, Jan 1997 - Dec 2011) 
(Gil-Prieto et al., 2015)      
3.6 
RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. #Studies reporting 
hospitalisation rate in an aboriginal population from a high-income country. §Studies sites in 
sub-Saharan Africa which had high-HIV burden.  
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A17. Forest plots for meta-analysis results of hospitalisation rate of 
RSV associated hospitalised ALRI 
By regions (world bank income level and developing/industrialised)





Overall  (I-squared = 99.9%, p = 0.000)
Robertson et al
Jain, S. et al











Subtotal  (I-squared = 100.0%, p = 0.000)
Cilla, G. et al
Howie et al
Resch et al,
Leader, S. et al
Fjaerli, H. O. et al
Feikin et al







Subtotal  (I-squared = 98.9%, p = 0.000)
Hall









Stockman, L. J. et al
Madhi and Cohen et al
Madhi et al
Muller-Pebody et al
Anders, K. L. et al
Polack
Subtotal  (I-squared = 97.9%, p = 0.000)
Paramore, L. C.
Broor et al
Hacimustafaoglu, M. et al
Nokes et al
Madhi and Cohen et al
Echavarria
Forster et al
Fry, A. M. et al








Dede, A. et al
McCracken







Gil-Prieto, R. et al











































































Apr 2000 - Mar 2001
Jul 2010 - Jun 2012
Sep 2007 - Aug 2010
Jul 1989 - Jun 1993
1997 - 2003
Jan 2012 - Dec 2013
2008 to 2013
Jul 2009 - Dec 2013
2008 - 2013
2011 - 2013
Jan 2012 - Dec 2013
Jan 2000 - Dec 2001
Jul 1996  - Jun 2000
Jul 2004 - Jun 2007




Jan 2007 - Jun 2009
2003-2006
Jan 2008 - Jun 2013
Nov 1996 - Oct 1998
Oct 2000 - Sep 2001
1987 - 1998
May 2009 - Apr 2013
Study
Oct 2000 - Sep 2004
2010 to 2014
Jan 2002 - Dec 2010
1993 - 1997
period
Aug 2009 - Jul 2012
2001 - 2010




Mar 1998 - Oct 2005
Apr 1995 - Mar 1998
Aug 2009 - Dec 2012
2011 - 2013
2000
Jan 2010 - Dec 2012
1st Mar 2010 - 28th Feb 2011
Jan 2002 - May 2005
Jan 2011 - Dec 2014
1st Jun 2008 - 31st Dec 2010
Nov 1999 - Oct 2001
1st Jan 2004 - 31st Dec 2007
Jun 2009 - Jun 2012
Feb 2007 - Dec 2012
Mar 2012 - Dec 2014
1996 - 1999
Jan 2007 - Dec 2008
2008 - 2013
Nov 2007 - Oct 2010
Jan 2010 - Dec 2012
1st Jan 2000 - 31st Dec 2004
2009 to 2013
2001 - 2002
1996 - 97 to 2000 -2001
2010 - 2013
5th Jul 2000 - 31st Dec 2004
1999-2000
Jan 2011 - Dec 2013
Jan 1997 - Dec 2011
Jan 1994 - Dec 1996
Jan 2008 - Dec 2011
1st Jan 2011 - 30th Jun 2014
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NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 99.9%, p = 0.000)












Stockman, L. J. et al
Vicente et al








Subtotal  (I-squared = 100.0%, p = 0.000)







Jain, S. et al
Hernando and Wifrido





Fjaerli, H. O. et al







Subtotal  (I-squared = 99.4%, p = 0.000)
Diez Domingo, J. et al
Rowlinson, E. et al
Homaira et al.
Fasce et al






Fry, A. M. et al
Madhi and Cohen et al
Gil-Prieto, R. et al
Hall
Bont et al
Madhi and Cohen et al
Anders, K. L. et al




Chiu, S. S. et al
Yu et al
Forster et al








































































1st Jan 2000 - 31st Dec 2004
Nov 1996 - Oct 1998
1987 - 1998




5th Jul 2000 - 31st Dec 2004
1996 - 1999
Oct 2000 - Sep 2001
Jan 2012 - Dec 2013
1st Jun 2008 - 31st Dec 2010
1997 - 2006
Jul 1996  - Jun 2000
1st Mar 2010 - 28th Feb 2011
Jan 2002 - May 2005
Nov 2007 - Oct 2010




Mar 1998 - Oct 2005
1997 - 2003
May 2009 - Apr 2013
Jan 1994 - Dec 1996
1996 - 97 to 2000 -2001
Jan 2010 - Dec 2012
Jul 2010 - Jun 2012
2008 - 2013
Aug 2009 - Dec 2012
Aug 2011 - Dec 2013
Mar 2012 - Dec 2014
Jan 2007 - Jun 2009
2011 - 2013
1993-2000
Jan 2007 - Dec 2008
1st Jan 2011 - 30th Jun 2014
2000 - 2002
Jul 2007 - Jun 2008
2009 to 2013




Jun 2009 - Jun 2012
2010 - 2013
Jan 2012 - Dec 2013
Aug 2009 - Jul 2012
Apr 2000 - Mar 2001
Jan 2011 - Dec 2013
Jan 2008 - Jun 2013
20th Sep 2006 - 19th Sep 2007
2000
1st Jan 2004 - 31st Dec 2007
2010 to 2014
Jan 1997 - Dec 2011
Oct 2000 - Sep 2004
2001 - 2010
Jan 2011 - Dec 2014
Jul 2009 - Dec 2013
Jul 2004 - Jun 2007
2008 to 2013
Jan 2002 - Dec 2010
Feb 2007 - Dec 2012
2003-2006
Jan 2010 - Dec 2012
Nov 1999 - Oct 2001
Sep 2007 - Aug 2010
1999 - 2000
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Chiu, S. S. et al
Lucero et al
Subtotal  (I-squared = 96.5%, p = 0.000)
Iwane et al,
Feikin et al
Subtotal  (I-squared = 98.8%, p = 0.000)
Vicente et al
Hirve and Chadha








Subtotal  (I-squared = 99.1%, p = 0.000)
Subtotal  (I-squared = 99.4%, p = 0.000)
Yoshida et al
Zar et al






































Jan 2002 - May 2005
Jan 2010 - Dec 2012
Jul 1989 - Jun 1993
2003-2006
5th Jul 2000 - 31st Dec 2004
Oct 2000 - Sep 2001
Jan 2007 - Jun 2009
Jul 1996  - Jun 2000
May 2009 - Apr 2013
Aug 2009 - Jul 2012
Oct 2000 - Sep 2004
Mar 1998 - Oct 2005
2000 - 2002
Jul 2004 - Jun 2007
20th Sep 2006 - 19th Sep 2007
Nov 2007 - Oct 2010
2011 - 2013
Feb 2007 - Dec 2012
Mar 2012 - Dec 2014
1997 - 2006
1st Jan 2011 - 30th Jun 2014
Jan 2008 - Dec 2011
Jan 2002 - Dec 2010
Jul 2007 - Jun 2008
Jan 2010 - Dec 2012
period




































Hospitalisation rate of RSV-ALRI in 6-11m (per 1000 per year)
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NOTE: Weights are from random effects analysis
.
.










Chiu, S. S. et al
Thamthitiwat
Emukule, G. O. et al
Broor et al
Subtotal  (I-squared = 99.0%, p = 0.000)
Bassat
Nokes











































Mar 2012 - Dec 2014
2000 - 2002
20th Sep 2006 - 19th Sep 2007
Jan 2002 - May 2005
May 2009 - Apr 2013
Aug 2011 - Dec 2013
Oct 2000 - Sep 2004
2003-2006
Jan 2008 - Dec 2011
Aug 2009 - Jul 2012
Jan 2010 - Dec 2012
1st Jan 2011 - 30th Jun 2014
Jan 2002 - Dec 2010
1997 - 2006
Jul 2007 - Jun 2008
Oct 2000 - Sep 2001
2011 - 2013
Nov 2007 - Oct 2010
Jan 2010 - Dec 2012
Jul 1989 - Jun 1993
Jul 2004 - Jun 2007
5th Jul 2000 - 31st Dec 2004
Mar 1998 - Oct 2005
Jul 1996  - Jun 2000
Feb 2007 - Dec 2012
Jan 2007 - Jun 2009
Study
11.09 (8.10, 15.17)
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Gil-Prieto, R. et al
Oliveira et al
Feikin et al
Subtotal  (I-squared = 99.8%, p = 0.000)
Bassat
Subtotal  (I-squared = 96.5%, p = 0.000)
Low income








Fry, A. M. et al
Hirve and Chadha
Ahmed, J. A. et al
Muller-Pebody et al
Lower middle income
Subtotal  (I-squared = 98.1%, p = 0.000)






























Jul 1996  - Jun 2000
Feb 2007 - Dec 2012
period
Jan 2012 - Dec 2013
2009 to 2013
Jan 2008 - Dec 2011
Jan 2010 - Dec 2012
Jan 2002 - Dec 2010
Jan 1997 - Dec 2011
2011 - 2013
Jan 2007 - Jun 2009
20th Sep 2006 - 19th Sep 2007
2009 to 2012
Jan 2010 - Dec 2012
Jan 2012 - Dec 2013
Mar 1998 - Oct 2005
Jun 2009 - Jun 2012
1st Jan 2011 - 30th Jun 2014
Jan 2008 - Jun 2013
1st Jan 2004 - 31st Dec 2007
May 2009 - Apr 2013
Sep 2007 - Aug 2010
Apr 1995 - Mar 1998
Jan 2011 - Dec 2014
2008 to 2013








































NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 99.6%, p = 0.000)





Ahmed, J. A. et al
McCracken
Gessner et al
Gil-Prieto, R. et al
Thamthitiwat














Rowlinson, E. et al
Subtotal  (I-squared = 99.9%, p = 0.000)
McCracken
Oliveira et al
Madhi and Cohen et al




























Jan 2012 - Dec 2013
Jan 2012 - Dec 2013
Jul 1996  - Jun 2000
Jan 2010 - Dec 2012
Sep 2007 - Aug 2010
2009 to 2013
Aug 2011 - Dec 2013
Jan 1997 - Dec 2011
Jan 2008 - Dec 2011
1st Jan 2004 - 31st Dec 2007
Apr 1995 - Mar 1998
Jan 2010 - Dec 2012
1st Jan 2011 - 30th Jun 2014
period
Study
May 2009 - Apr 2013
Jan 2002 - Dec 2010
20th Sep 2006 - 19th Sep 2007
Jan 2007 - Jun 2009
Mar 1998 - Oct 2005
Jan 2008 - Jun 2013
Feb 2007 - Dec 2012
Jun 2009 - Jun 2012
2008 to 2013
2011 - 2013
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A18. Forest plots for meta-analysis results of proportion of 
hospitalised ALRI cases which are RSV positive 
By WHO regions 
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Overall  (I-squared = 98.3%, p = 0.000)
Baccala et al
Bedoya, V. I. et al
Baccala et al
Lin, Z. B. et al
Lu, X.M. et al
Foulongne, V. et al
Sparremberger, Dionéia A. H. et al
Cao, L. et al
Mazumdar, J. et al
Pecchini, R. et al
Santibanez, P. et al
Fasce et al
Ding. X.F. et al
Fan, M. et al
Fasce et al
Chan, P. W. et al
Salomao Jr, J. B. et al
Huang, L. et al
Chang, J. et al
Wang, F.M. et al
Xiang, Q.W. et al
O'Brien et al-PERCH
Sun, L.X. et al
Tang, L. F. et al
Baccala et al
Ye, L.F. et al
Xue, H. F. et al
Mlinaric-Galinovic, G. et al
Yeolekar, L. R. et al
Ru, G.P. et al
Xie, Y.P. et al
Moore, H. C. et al
Subtotal  (I-squared = 97.5%, p = 0.000)
Al-Toum, R. et al
O'Brien et al-PERCH
Pineros, J. G. et al
Mlinaric-Galinovic, G. et al
Singh, A. K. et al
Fasce et al
Weigl, J. A. et al
Subtotal  (I-squared = 97.4%, p = 0.000)
Zhang, B. et al
Fasce et al
Subtotal  (I-squared = 93.0%, p = 0.000)
Jiang. M. et al
Author
Yin, F. et al
Okada, T. et al
Madhi and Cohen et al
Turner, P. et al
Zhao, G.C. et al





Zhi, L. (Master dissertation)
Murray, J. et al
Fasce et al
Wang, S.M.
Do, A. H. et al
Liu, X.T. et al
Che, D.D. et al
Zhang, Q. et al
Du, L.N. (Master dissertation)
Chen, C. J. et al
Wang, D. et al
O'Brien et al-PERCH




Ferronato, A. E. et al
Sheng, K. H. et al
Bukhari, E. E. et al
Yang, W.M. et al
Baccala et al
Jiang, Z.M. et al
Liu, Q. et al
Europe
Zhao, B.H. et al
Cao, S.Y. et al
Xie, H. et al
Ding, P. B. et al
Lei, X.Y. (Master dissertation)
Zhang, Y.M. et al
Baccala et al
Loscertales, M. P. et al
Liu, C. Y. et al
Peng, D.H. et al
Shi, W.Y. et al
Americas
O'Brien et al-PERCH
Zhang, Y. L. et al
Chen, Q. et al
Baccala et al
Subtotal  (I-squared = 97.1%, p = 0.000)
Ye, Y. Y. et al
Noyola, D. E. et al
Tan, Z. T. et al
Tsolia, M. N. et a;
Cheng, L.F. et al
Zheng, W.J. (Master dissertation)
Subtotal  (I-squared = 98.6%, p = 0.000)
Qin, M. et al
Liang, L. et al
Ju, H.X. et al
Khuri et al
South-East Asia
Chen, J. (Master dissertation)
Zhang, G. Y. et al
Xiao, N. G. et al
Jansson, L. et al
Macedo, S.E.C. et al
Malekshahi
Basnet et al
Wasem, S. et al






Xu, L. et al
Zeng, M. et al
He, Y. et al
Hu, X. W. et al
Zuccotti, G. et al
Huang, G. et al
Eastern Mediterranean
Vieira, S. E. et al
Zhang, A.L. et al
Yao, J. et al
Goyet et al
Miao, Z.Y. et al
Zhang, Q. L. et al
Li, L.P. et al





Wang, W. et al
Chen, X. et al
He, Y.
Lu, M. et al








































































































































Jan 2011 - Dec 2012
Apr 1994 - Apr 1995
Jul 2011 - Nov 2012
Jan 2012 - Jan 2013
Mar 2011 - May 2012
1st Nov 2003 - 31st  Oct 2004
Sep 2009 - Sep 2010
Feb 2001 - Mar 2003
Apr 2010 - Mar 2011
Feb 2005 - Sep 2006
Apr 2008 - Mar 2010
2010 - 2013
Sep 2007 - Aug 2008
Oct 2005 - Oct 2007
2010 - 2013
Jan 1982 - Dec 1997
May 2004 - Sep 2005
Jun 2006 - Apr 2011
Jan 2007 - Dec 2008
Feb 2009 - Jan 2010
Jan 2003 - Jan 2005
3rd Nov 2011 - 2nd Nov 2013
Jan 2002 - Mar 2004
Jan 2001 - Dec 2006
Oct 2010 - Jan 2013
2000 - 2001
Dec 2012 - Nov 2013
1994 - 2005
Feb 2002 - Dec 2004
May 2011 - May 2012
Oct 2009 - Sep 2010
Jan 2000 - Dec 2005
Sep 2002 - Mar 2004
3rd Jan 2012 - 14th Jan 2014
Apr 2005 - Apr 2006
Aug 2006 - Aug 2007
Jun 2011 - May 2012
2010 - 2013
Jul 1996 - Jun 2001
Jan 2006 - Dec 2010
2010 - 2013
Jan 2009 - Dec 2011
Period
Jan 2009 - Dec 2013
Apr 2008 - Apr 2009
Jan 2010 - Dec 2014
Apr 2009 - Sep 2011
May 2001 - Apr 2002
Study
Sep 2005 - Oct 2011
1st Apr 2010 - 31st Mar 2014
Nov 2007 - Apr 2013
Jan - Dec 2007
Apr 2007 - Mar 2008
2010 - 2013
Jan 2007 - Dec 2009
Nov 2004 - Jan 2008
Apr 2011 - Mar 2012
Jan - Dec 2000
Oct 2004 - Oct 2005
Apr 2008 - Mar 2009
Jan 2001 - Dec 2003
Feb 2013 - Apr 2014
1st Jan 2012 - 31st Dec 2013
Aug 2012 - Apr 2014
10th Oct 2011 - 31st Oct 2013
Apr 2002 - Aug 2004
2001 - 2013
Jan 2006 - Dec 2007
Jan 2012 - Mar 2013
Jan 2005 - Dec 2010
Nov 2007 - Nov 2008
Jun 2012 - Dec 2013
Jan - Dec 2011
Apr 2013 - Mar 2014
Jan 2009 - Mar 2010
Nov 2004 - Nov 2006
Jun 2011 - Oct 2012
Jan 2010 - Dec 2013
Jan 2009 - Dec 2011
1994 - 1997
Sep 2011 - Oct 2012
Oct 1998 - May 2000
Mar 2010 - Feb 2012
Apr 2003 - Oct 2007
Jan - Dec 2010
1st Jan 2012 - 31st Dec 2013
Jan 2010 - Mar 2013
Sep 2008 - Aug 2009
Dec 2010 - Feb 2013
Jan 2013 - Dec 2013
1st May 2003 - 30th Apr 2005
Jan 2007 - Oct 2008
Feb 1997 - Jun 2000
Oct 2007 - Oct 2008
Sep 2009 - Sep 2010
Apri 2006 - Mar 2007
Jan 2012 - Dec 2013
Jun 2011 - Jul 2012
Mar 2010 - Mar 2013
Dec 2010 - Dec 2011
Jan 2013 - Dec 2013
Sep 2007 - Aug 2008
1998 - 1999
1st Aug 1997 - 31st Jul 1998
Mar 2008 - May 2009
Jan 2006 - Jun 2008
Nov 1999 - Oct 2001 and Oct 2002 - Jun 2005
Jan 2003 - Dec 2006
2007 - 2011
1st Jun 2008 - 31st Dec 2010
Nov 2010 - Dec 2011
15th Aug 2011 - 15th Nov 2013
Jan 2009 - Sep 2013
Jul 2010 - Jul 2012
2003 - 2006
Jul 2007 - Jun 2010
Jan 2011 - Dec 2012
1st Dec 2008 - 31st Dec 2009
1st Jan - 31st Dec 2011
Mar 1999 - Jun 2000
Aug 2010 - Aug 2012
Jan 2011 - Dec 2013
Apr 2007 - Feb 2010
Dec 2008 - Dec 2009
Feb 2012 - Jan 2014
Jun 2011 - Jun 2012
Jan 2013 - Dec 2013
May 2008 - Jul 2012
Aug 2009 - Jul 2012
1st Jan 2012 - 31st Jan 2014
Jul 2010 - May 2013
Jan 2010 - Jun 2011
Jun 2012 - Jun 2013
Jan 2011 - Dec 2012






























































































































































Overall  (I-squared = 98.5%, p = 0.000)
Fuller, J.A. et al
Ji, W. et al
Ou, S. Y. et al
O'Brien et al-PERCH
Al-Shehri, M. A. et al
Hammitt, L. L. et al




Xie, Y.P. et al
Wolf, D. G. et al
Baccala et al
Ding. X.F. et al
Sutmoller et al
Wolf, D. G. et al
Che, D.D. et al
Mlinaric-Galinovic, G. et al
Author
Li, L.P. et al
O'Brien et al-PERCH
Sheng, K. H. et al
Tallo, V. L. et al
Africa
Harada, Y. et al
Chen, X. et al
Feikin, D. R. et al
Oliveira, D. B. et al
O'Brien et al-PERCH
Subtotal  (I-squared = 66.6%, p = 0.001)
Subtotal  (I-squared = 77.2%, p = 0.000)
Singh, A. K. et al




Weigl, J. A. et al
Fasce et al





Pecchini, R. et al
Mlinaric-Galinovic, G. et al
Liu, Q. et al
Zheng, W.J. (Master dissertation)
Wang, D. et al
O'Brien et al-PERCH
Xiao, N. G. et al
Subtotal  (I-squared = 98.7%, p = 0.000)
O'Brien et al-PERCH
Zuccotti, G. et al
Cevey-Macherel, M. et al
Yoo, S. J. et al
Sung, R. Y. et al
Ru, G.P. et al
Zhang, Q. et al
Lin, Z. B. et al
Bassat
Fasce et al
Mazumdar, J. et al
Zhang, B. et al





Moura, F. E. A. et al
Ye, Y. Y. et al
O'Brien et al-PERCH
Lu, M. et al
Xue, H. F. et al
Baccala et al
Okada, T. et al
Zeng, M. et al
He, Y.
Ekalaksananan, T. et al
Xu, L. et al
Chung, J. Y. et al
Western Pacific
Zhang, H. Q. et al
Bakir, T. M. et al
Goyet et al
Qin, M. et al
South-East Asia
Subtotal  (I-squared = 96.3%, p = 0.000)
Siritantikorn, S. et al
Yao, J. et al
Yin, F. et al
Kwofie, T. B. et al
Yu et al
Wang, F.M. et al
Subtotal  (I-squared = 98.6%, p = 0.000)
Do, A. H. et al
Subtotal  (I-squared = 95.6%, p = 0.000)
O'Brien et al-PERCH
Fasce et al
Zhang, Q. L. et al
Baccala et al
Gentile et al
Jiang, Z.M. et al
Fasce et al
Chen, C. J. et al
Vagia, F. et al
Europe
Liu, C. Y. et al
Bukhari, E. E. et al


































































































Aug 2008 - Dec 2010
Sep 2005 - Oct 2011
Jan 2007 - Dec 2007
3rd Nov 2011 - 2nd Nov 2013
Oct 1997 - Sep 2001
Jan - Dec 2010
Sep 2003 - May 2005
Aug 2009 - Jul 2012
Mar 2008 - May 2009
Study
Oct 2009 - Sep 2010
Nov 2001 - Oct 2002
Jul 2011 - Nov 2012
Sep 2007 - Aug 2008
Jan 1987 - Dec 1989
Nov 2001 - Oct 2005
Jan - Dec 2000
Aug 2006 - Aug 2007
Period
Jun 2011 - Jun 2012
15th Aug 2011 - 15th Nov 2013
Jan 2012 - Mar 2013
Apr 2009 - Dec 2011
Apr 2009 - Mar 2010
Jun 2012 - Jun 2013
1st Mar 2007 - 28th Feb 2010
Jan 2003 - Dec 2006
1st Jan 2012 - 31st Dec 2013
Jun 2011 - May 2012
Jan 2010 - Dec 2014
Dec 2010 - Feb 2013
1st Jun 2008 - 31st Dec 2010
1st Apr 2010 - 31st Mar 2014
Jul 1996 - Jun 2001
2010 - 2013
Dec 2007 - Dec 2008
Jul 2010 - May 2013
1999 - 2004
2007 - 2011
Feb 2005 - Sep 2006
1994 - 2005
Apr 2013 - Mar 2014
Sep 2009 - Sep 2010
Feb 2013 - Apr 2014
1st Jan 2012 - 31st Jan 2014
Sep 2007 - Aug 2008
1st Jan 2012 - 31st Dec 2013
1st Dec 2008 - 31st Dec 2009
Mar 2003 - Dec 2005
Jan - Dec 2004
Nov 2005 - Oct 2006
May 2011 - May 2012
Oct 2004 - Oct 2005
Jan 2012 - Jan 2013
Nov 2010 - Dec 2011
2010 - 2013
Apr 2010 - Mar 2011
Jan 2006 - Dec 2010
Feb 2001 - Mar 2003
Jan 2011 - Dec 2012
2010 - 2013
Jun 2012 - Dec 2013
May 2008 - Jul 2012
Jan - Dec 1998
Jan 2013 - Dec 2013
3rd Jan 2012 - 14th Jan 2014
Oct 2002 - Apr 2004
Dec 2012 - Nov 2013
Oct 2010 - Jan 2013
Apr 2008 - Apr 2009
2003 - 2006
Jan 2011 - Dec 2012
Aug 1992 - Nov 1994
Jul 2010 - Jul 2012
Jul 2004 - Jan 2006
Jan 2013 - Dec 2013
Apr 1993 - Mar 1996
Apr 2007 - Feb 2010
Apri 2006 - Mar 2007
Nov 1998 - Feb 2001
Jan 2011 - Dec 2013
Jan 2009 - Dec 2013
Jan 2008 - Dec 2008
Jan 2009 - Sep 2013
Feb 2009 - Jan 2010
Nov 2004 - Jan 2008
10th Oct 2011 - 31st Oct 2013
2010 - 2013
Feb 2012 - Jan 2014
Sep 2011 - Oct 2012
2001 - 2013
Jan - Dec 2011
2010 - 2013
Jan 2001 - Dec 2003
2008 - 2009
Mar 2010 - Feb 2012
Jan 2005 - Dec 2010











































































































Proportion of hospitalised ALRI positive with RSV in 0-59m (%)
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A19. List of studies reporting in-hospital CFR for RSV associated 
hospitalised ALRI in narrower age bands 
Location (reference) 
In-hospital CFR of RSV associated hospitalised ALRI (%) 
0-27 days 28 days-<3m 3-5m 6-8m 9-11m 12-59m 
Buenos Aires, Argentina (urban, 
2001 - 2013) (Gentile and 
colleagues)* 
0.0 2.1 1.8 2.1 1.1 1.8 
Takeo ad Kampong Cham, 
Cambodia (urban, Apr 2007 - Feb 
2010) (Goyet and colleagues)*  
0.0 0.0 0.0 0.0 0.0 
Beijing, China (urban, Jan 2011 - 
Dec 2012) (GABRIEL and 
colleagues)*  
0.0 0.0 0.0 0.0 0.0 
Ulaanbaatar, Mongolia (urban, 
Sep 2011 - Oct 2012) (GABRIEL 
and colleagues)*   
0.0 0.0 0.0 0.0 
Phnom Penh, Cambodia (urban, 
Oct 2010 - Jan 2013) (GABRIEL 
and colleagues)*   
0.0 0.0 0.0 0.0 
Lucknow, India (urban and rural, 
Jun 2012 - Dec 2013) (GABRIEL 





(urban and rural, Dec 2010 - Feb 






Asuncion, Paraguay (urban, Jul 
2010 - May 2013) (GABRIEL and 
colleagues)*  
0.0 0.0 0.0 0.0 0.0 
Bamako, Mali (urban, Jul 2011 - 
Nov 2012) (GABRIEL and 
colleagues)*  
0.0 0.0 33.3 0.0 0.0 
Berlin, Germany (urban, 1st Apr 
2010 - 31st Mar 2014) (Rath and 
colleagues)* 
0.0 0.0 0.0 0.0 0.0 0.0 
Amman, Jordan (urban, Mar 
2010 - Mar 2013) (Khuri and 
colleagues) 
0.0 0.8 0.0 0.5 0.0 
 
Lwak, Kenya (rural, 2007 - 2011) 
(Montgomery and colleagues)*§ 
33.3 0.0 12.5 0.0 0.0 3.8 
Rabat, Morocco (urban, Nov 2010 
- Dec 2011) (Bassat and 
colleagues)* 
0.0 0.0 6.5 0.0 11.8 0.0 
Karachi, Pakistan (urban, Aug 
2009 - Jul 2012) (Ali and 
colleagues)* 




In-hospital CFR of RSV associated hospitalised ALRI (%) 
0-27 days 28 days-<3m 3-5m 6-8m 9-11m 12-59m 
Basse Santa Su, Gambia (rural, 
3rd Nov 2011 - 2nd Nov 2013) 
(PERCH and colleagues)*  
0.0 0.0 0.0 0.0 0.0 
Kilifi, Kenya (urban, 15th Aug 
2011 - 15th Nov 2013) (PERCH 
and colleagues)*§  
4.3 2.4 0.0 14.3 5.6 
Bamako, Mali (urban, 3rd Jan 
2012 - 14th Jan 2014) (PERCH 
and colleagues)*  
0.0 3.8 10.0 0.0 4.8 
Nakhon Phanom and Sa Kaeo, 
Thailand (rural, 1st Jan 2012 - 
31st Jan 2014) (PERCH and 
colleagues)* 
 
0.0 0.0 0.0 0.0 0.0 
Lusaka, Zambia (urban, 10th Oct 
2011 - 31st Oct 2013) (PERCH 
and colleagues)*§  
0.0 10.0 0.0 16.7 6.7 
Dhaka, Bangladesh (urban, 1st 
Jan 2012 - 31st Dec 2013) 
(PERCH and colleagues)*  
0.0 0.0 0.0 0.0 0.0 
Matlab, Bangladesh (rural, 1st 
Jan 2012 - 31st Dec 2013) 
(PERCH and colleagues)*  
0.0 0.0 0.0 0.0 0.0 
Tacloban City, Philippines (rural, 
May 2008 - Jul 2012) (Lupisan 
and colleagues)* 
5.3 2.5 1.6 3.0 0.0 0.0 
Mpumalanga, South Africa 
(rural, Jan 2010 - Dec 2014) 
(Cohen and colleagues)*§ 
0.0 1.6 3.9 4.7 4.5 0.0 
CEMIC, Buenos Aires, Argentina 
(urban, 1st Jun 2008 - 31st Dec 






Buenos Aires, Argentina (urban 
and rural, 2011 - 2013) (Polack 
and colleagues) 
0.0 1.4 1.7 1.0 1.2 
 
Belo Horizonte, Brazil (urban, 
2011 - 2013) (Oliveira and 
colleagues)* 
0.0 0.0 4.3 3.8 0.0 0.0 
Concepcion, Chile (urban and 
rural, Jan 2012 - Dec 2013) (Fasce 
and colleagues)* 
0.0 0.0 0.0 0.0 0.0 2.0 
Iquique, Chile (urban and rural, 
Jan 2012 - Dec 2013) (Fasce and 
colleagues)* 
0.0 0.0 0.0 4.7 0.0 0.0 
Western Gambia (urban and 
rural, Jul 2007 - Jun 2008) (Howie    




In-hospital CFR of RSV associated hospitalised ALRI (%) 
0-27 days 28 days-<3m 3-5m 6-8m 9-11m 12-59m 
and colleagues) 
Santa Rosa, Guatemala (urban 
and rural, 2008 - 2013) 
(McCracken and colleagues)* 
6.3 4.5 1.1 0.0 4.5 2.6 
Quetzaltenango, Guatemala 
(urban and rural, 2009 - 2013) 
(McCracken and colleagues)* 
0.0 1.7 0.0 2.4 0.0 2.1 
Ballabhgarh, India (rural, 2010 - 
2012) (Broor and colleagues)* 
0.0 0.0 0.0 0.0 0.0 0.0 
Pune, India (rural, May 2009 - 
Apr 2013) (Chadha and 
colleagues)* 
0.0 0.0 0.0 0.0 0.0 0.0 
Lombok, Indonesia (urban and 
rural, 2000 - 2002) (Gessner and 
colleagues) 
0.0 6.1 2.3 0.6 0.9 
 
Kilifi hospital study, Kenya 
(urban and rural, Jan 2002 - Dec 
2010) (Nokes and colleagues)*§ 
2.5 1.8 2.4 1.0 4.2 2.3 
Bondo district, Kenya (rural, Jan 
2007 - Jun 2009) (Feikin and 
colleagues)*§ 
0.0 0.0 0.0 14.3 0.0 0.0 
Manhiça, Mozambique (rural, 
20th Sep 2006 - 19th Sep 2007) 
(Bassat and colleagues)*§ 
0.0 0.0 0.0 12.5 0.0 0.0 
Manhiça, Mozambique (rural, 1st 
Jan 2011 - 30th Jun 2014) (Bassat 
and colleagues)*§ 
0.0 0.0 0.0 0.0 0.0 0.0 
Utrecht, Netherlands (urban, 
2001 - 2010) (Bont and colleagues)  
0.0 0.0 0.0 0.0 
 
41 sites in Netherlands (urban 
and rural, 2008 - 2013) (Bont and 
colleagues) 
0.0 0.0 0.0 0.0 0.0 
 
David City, Panama (urban, Jan 
2011 - Dec 2013) (Jara and 
colleagues)* 
0.0 0.0 0.0 0.0 0.0 0.0 
Tagbilaran and 6 rural sites, 
Philippines (urban and rural, 5th 
Jul 2000 - 31st Dec 2004) (Lucero 
and colleagues) 
 
0.0 1.1 1.5 0.0 
 
Gauteng province, South Africa 
(urban, 2009 - 2012) (Cohen and 
colleagues)*§ 
1.0 0.7 1.1 0.0 0.0 0.0 
KwaZulu-Natal province, South 
Africa (periurban, 2010 - 2014) 
(Cohen and colleagues)*§ 




In-hospital CFR of RSV associated hospitalised ALRI (%) 
0-27 days 28 days-<3m 3-5m 6-8m 9-11m 12-59m 
Klerksdorp site, South Africa 
(periurban, Jan 2011 - Dec 2014) 
(Cohen and colleagues)*§ 
0.0 3.1 2.0 
  
0.0 
Soweto, South Africa (urban, Mar 
1998 - Oct 2005) (Madhi and 
colleagues)*§  
2.8 2.0 1.0 1.0 0.5 
Paarl, South Africa (periurban, 
Mar 2012 - Dec 2014) (Zar and 
colleagues) 
0.0 0.0 0.0 0.0 0.0 
 
Sa Kaeo and Nakhon Phanom, 
Thailand (rural, Jan 2008 - Dec 
2011) (Thamthitiwat and 
colleagues)* 
0.0 0.0 0.0 0.0 0.0 0.0 
Tone District, Togo (rural, Aug 







Colorado, USA (urban and rural, 
Jan 2008 - Jun 2013) (Simoes and 
colleagues)* 
0.0 0.0 0.1 0.1 0.0 0.1 
Navajo and WMA, USA - MEDI 
(rural, Oct 2004 - Dec 2010) 
(O'Brien and colleagues)# 
0.0 0.0 0.0 0.0 
  
Navajo and WMA, USA - EPI 
(rural, Oct 1997 - Mar 2000) 
(O'Brien and colleagues)# 
0.0 0.6 0.0 0.0 0.0 
 
Nha Trang, Vietnam (urban and 
rural, Feb 2007 - Dec 2012) 
(Yoshida and colleagues)*  
0.0 0.0 0.0 0.0 0.0 
Spain (urban, Jan 1997 - Dec 
2011) (Gil-Prieto et al., 2015)      
0.1 
RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. CFR=case fatality 
ratio. *Studies providing in-hospital CFR for full age range (0-5m, 6-11m and 12-59m). 
#Studies reporting in-hospital CFR in an aboriginal population from a high-income country. 
§Studies sites in sub-Saharan Africa which had high-HIV burden and reported data in 0-59m.  
406 
 
A20. Forest plots for meta-analysis results of in-hospital CFR of RSV 
associated hospitalised ALRI 
43 studies reporting data in full age range – stratified by regions (world bank 
income level and developing/industrialised)
































Subtotal  (I-squared = 0.0%, p = 1.000)




Subtotal  (I-squared = 76.2%, p = 0.001)
Hirve and Chadha































































Apr 2007 - Feb 2010
period
Jan 2012 - Dec 2013




Jan 2010 - Dec 2014
15th Aug 2011 - 15th Nov 2013
Jan 2008 - Dec 2011
1st Apr 2010 - 31st Mar 2014
Jan 2011 - Dec 2012
Mar 1998 - Oct 2005
Jun 2012 - Dec 2013
Nov 2010 - Dec 2011
20th Sep 2006 - 19th Sep 2007
Oct 2010 - Jan 2013
Aug 2009 - Jul 2012
Sep 2011 - Oct 2012
Jan 2011 - Dec 2014
Jan 2011 - Dec 2013
Jan 2007 - Jun 2009
2009 - 2013
Aug 2011 - Dec 2013
2007 - 2011
Jan 2012 - Dec 2013
Jan 2002 - Dec 2010
1st Jan 2012 - 31st Jan 2014
May 2009 - Apr 2013
2009 - 2012
1st Jan 2012 - 31st Dec 2013
1st Jun 2008 - 31st Dec 2010
1st Jan 2012 - 31st Dec 2013
1st Jan 2011 - 30th Jun 2014
Jan 2008 - Jun 2013
Jul 2011 - Nov 2012
3rd Jan 2012 - 14th Jan 2014
10th Oct 2011 - 31st Oct 2013
2010 - 2012
2011 - 2013
Feb 2007 - Dec 2012
2010 - 2014
3rd Nov 2011 - 2nd Nov 2013
Dec 2010 - Feb 2013





















































In-hospital CFR of RSV-hospitalised ALRI in 0-5m (%)
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NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 1.5%, p = 0.443)
Developing
Echavarria
Madhi and Cohen et al
Industrialised
McCracken























Madhi and Cohen et al
Fasce et al



































































Jan 2002 - Dec 2010
Jan 2007 - Jun 2009
Jan 2012 - Dec 2013
Jun 2012 - Dec 2013
1st Jan 2012 - 31st Dec 2013
3rd Nov 2011 - 2nd Nov 2013
Jul 2010 - May 2013
2008 - 2013
2001 - 2013
Apr 2007 - Feb 2010
3rd Jan 2012 - 14th Jan 2014
Aug 2009 - Jul 2012
Jan 2008 - Dec 2011
15th Aug 2011 - 15th Nov 2013
Jan 2011 - Dec 2014
May 2009 - Apr 2013
Jan 2008 - Jun 2013
10th Oct 2011 - 31st Oct 2013
Mar 1998 - Oct 2005
2009 - 2012
Jan 2012 - Dec 2013




Jul 2011 - Nov 2012
1st Jan 2012 - 31st Jan 2014
20th Sep 2006 - 19th Sep 2007
Jan 2011 - Dec 2012
1st Jan 2011 - 30th Jun 2014
Feb 2007 - Dec 2012
1st Jan 2012 - 31st Dec 2013
Oct 2010 - Jan 2013
Dec 2010 - Feb 2013
Sep 2011 - Oct 2012
Nov 2010 - Dec 2011
Jan 2011 - Dec 2013
1st Apr 2010 - 31st Mar 2014
May 2008 - Jul 2012



















































In-hospital CFR of RSV-hospitalised ALRI in 0-5m (%)
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Subtotal  (I-squared = 60.2%, p = 0.028)





























































































Aug 2009 - Jul 2012
Jan 2011 - Dec 2013
Apr 2007 - Feb 2010
1st Jun 2008 - 31st Dec 2010
3rd Jan 2012 - 14th Jan 2014
1st Jan 2012 - 31st Dec 2013
Jul 2010 - May 2013
Jan 2008 - Dec 2011
May 2008 - Jul 2012
2009 - 2012
Dec 2010 - Feb 2013
Jun 2012 - Dec 2013
2010 - 2012
Jan 2011 - Dec 2014
2001 - 2013
2009 - 2013
Jan 2012 - Dec 2013
1st Jan 2012 - 31st Dec 2013
2010 - 2014
15th Aug 2011 - 15th Nov 2013
3rd Nov 2011 - 2nd Nov 2013
Nov 2010 - Dec 2011
Mar 1998 - Oct 2005
1st Jan 2012 - 31st Jan 2014
10th Oct 2011 - 31st Oct 2013
1st Apr 2010 - 31st Mar 2014
2007 - 2011
Aug 2011 - Dec 2013
Sep 2011 - Oct 2012
2008 - 2013
Feb 2007 - Dec 2012
May 2009 - Apr 2013
Jan 2007 - Jun 2009
Jan 2010 - Dec 2014
Jul 2011 - Nov 2012
Jan 2011 - Dec 2012
Jan 2002 - Dec 2010
2011 - 2013
20th Sep 2006 - 19th Sep 2007
1st Jan 2011 - 30th Jun 2014
Study
Oct 2010 - Jan 2013
Jan 2012 - Dec 2013





















































In-hospital CFR of RSV-hospitalised ALRI in 6-11m (%)
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NOTE: Weights are from random effects analysis
.
.













Madhi and Cohen et al















































































Jan 2002 - Dec 2010
Study
Aug 2009 - Jul 2012
1st Jan 2012 - 31st Jan 2014
1st Jun 2008 - 31st Dec 2010
1st Jan 2012 - 31st Dec 2013
Jan 2008 - Dec 2011
Dec 2010 - Feb 2013
1st Apr 2010 - 31st Mar 2014
10th Oct 2011 - 31st Oct 2013
Oct 2010 - Jan 2013
Nov 2010 - Dec 2011
Apr 2007 - Feb 2010
Jan 2010 - Dec 2014
2010 - 2014
Jan 2008 - Jun 2013
period
2001 - 2013
1st Jan 2011 - 30th Jun 2014
2009 - 2012
20th Sep 2006 - 19th Sep 2007
Sep 2011 - Oct 2012
Mar 1998 - Oct 2005
Jul 2011 - Nov 2012
3rd Nov 2011 - 2nd Nov 2013
Jan 2011 - Dec 2014
May 2008 - Jul 2012
Jun 2012 - Dec 2013
2010 - 2012
Aug 2011 - Dec 2013
Jan 2011 - Dec 2012
2008 - 2013
Feb 2007 - Dec 2012




1st Jan 2012 - 31st Dec 2013
Jan 2007 - Jun 2009
May 2009 - Apr 2013
Jan 2012 - Dec 2013
Jan 2011 - Dec 2013
Jul 2010 - May 2013
3rd Jan 2012 - 14th Jan 2014



















































In-hospital CFR of RSV-hospitalised ALRI in 6-11m (%)
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Overall  (I-squared = 4.1%, p = 0.395)
Feikin et al
Echavarria













Subtotal  (I-squared = 82.4%, p = 0.000)
Rath et al
Fasce et al
Madhi and Cohen et al
Madhi et al
Subtotal  (I-squared = 0.0%, p = 1.000)







Madhi and Cohen et al



































































Jan 2007 - Jun 2009
1st Jun 2008 - 31st Dec 2010
Jan 2011 - Dec 2014
Aug 2009 - Jul 2012
Jan 2011 - Dec 2012
1st Jan 2012 - 31st Jan 2014
Oct 2010 - Jan 2013
May 2009 - Apr 2013
2007 - 2011
Jan 2011 - Dec 2013
Jan 2008 - Jun 2013
1st Jan 2012 - 31st Dec 2013
Jun 2012 - Dec 2013
1st Apr 2010 - 31st Mar 2014
Jan 2012 - Dec 2013
2009 - 2012
Mar 1998 - Oct 2005
Dec 2010 - Feb 2013
15th Aug 2011 - 15th Nov 2013
1st Jan 2011 - 30th Jun 2014
2001 - 2013
2009 - 2013
Jul 2011 - Nov 2012
2010 - 2014
Jan 2010 - Dec 2014
10th Oct 2011 - 31st Oct 2013
Nov 2010 - Dec 2011
2011 - 2013
1st Jan 2012 - 31st Dec 2013
Jan 2008 - Dec 2011
Jan 2002 - Dec 2010
Jul 2010 - May 2013
May 2008 - Jul 2012
Aug 2011 - Dec 2013
2008 - 2013
Apr 2007 - Feb 2010
3rd Jan 2012 - 14th Jan 2014
Feb 2007 - Dec 2012
2010 - 2012
20th Sep 2006 - 19th Sep 2007
3rd Nov 2011 - 2nd Nov 2013
period
Sep 2011 - Oct 2012




































































NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 4.1%, p = 0.395)
O'Brien et al-PERCH
































Madhi and Cohen et al
O'Brien et al-PERCH
Yoshida et al
























































3rd Jan 2012 - 14th Jan 2014
Oct 2010 - Jan 2013
Apr 2007 - Feb 2010
2001 - 2013
May 2008 - Jul 2012
1st Apr 2010 - 31st Mar 2014




Dec 2010 - Feb 2013
2010 - 2014
2008 - 2013
Jan 2012 - Dec 2013
1st Jan 2012 - 31st Dec 2013
1st Jun 2008 - 31st Dec 2010
Jul 2010 - May 2013
1st Jan 2011 - 30th Jun 2014
2007 - 2011
period
Jul 2011 - Nov 2012
Mar 1998 - Oct 2005
15th Aug 2011 - 15th Nov 2013
20th Sep 2006 - 19th Sep 2007
Jan 2012 - Dec 2013
Nov 2010 - Dec 2011
3rd Nov 2011 - 2nd Nov 2013
May 2009 - Apr 2013
Jan 2011 - Dec 2012
Jan 2007 - Jun 2009
2009 - 2012
1st Jan 2012 - 31st Jan 2014
Feb 2007 - Dec 2012
Jan 2011 - Dec 2014
Jan 2008 - Jun 2013
Jan 2011 - Dec 2013
Aug 2009 - Jul 2012
Jan 2008 - Dec 2011
Jan 2002 - Dec 2010
Sep 2011 - Oct 2012
Jun 2012 - Dec 2013
1st Jan 2012 - 31st Dec 2013
10th Oct 2011 - 31st Oct 2013




















































In-hospital CFR of RSV-hospitalised ALRI in 12-59m (%)
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A21. Sensitivity analyses to compute inflation factors for RSV in community mortality from developing countries 
Use “at least 4 (5%) of the submitted specimen were RSV positive” to define RSV seasonality – same result 
Site Study year 
Months of 
















due to RSV 
(%) (e)* 
ALRI deaths 
overall in this 
country (f) 
(Liu et al., 
2015a) 
RSV deaths 




2011 4 6.3 1.8 39 46.2 887 409 
2012 4 8.5 0.9 41 74.4 878 653 
2013 11 3.3 0.9 20 47.5 844 401 
Mean       488 
Multicentre, 
Bangladesh 
2010 9 3.0 2.7 35 8.6 21917 1879 
2011 4 8.8 5.4 78 17.3 20028 3466 
2012 6 9.5 6.3 95 20.0 18759 3752 
Mean       3032 
Lombok, 
Indonesia 
2000 6 73.3 62.3 814 8.1 39257 3183 
2001 6 84.8 48.8 802 26.9 37584 10122 
2002 7 45.0 36.8 499 11.5 36020 4143 
Mean       5816 





Meta-estimate of hospitalisation 
rate (per 1000 per year) (h)§ 
Meta-estimate of in-
hospital CFR (%) 
(i)§ 
Population in mean 
study period (j) 
RSV deaths in 
hospital overall 
(k)* 





Argentina 4.9 1.9 3407649 320 488 1.5 
Bangladesh 4.9 1.9 15197631 1426 3032 2.1 
Indonesia 4.9 1.9 21639000 2030 5816 2.9 
Mean      2.2 





Add one more month as RSV season (based on “at least 10 specimens were analysed and 5% of the submitted specimens were 
RSV positive”) – increase inflation factor 
Site Study year 
Months of 
















due to RSV 
(%) (e)* 
ALRI deaths 
overall in this 
country (f) 
(Liu et al., 
2015a) 
RSV deaths 




2011 5 5.6 1.6 39 51.6 887 458 
2012 5 7.4 0.6 41 83.3 878 731 
2013 5 3.0 0.7 20 57.1 844 482 
Mean       557 
Multicentre, 
Bangladesh 
2010 11 3.0 2.0 35 31.4 21917 6888 
2011 4 8.8 5.4 78 17.3 20028 3466 
2012 8 9.5 4.8 95 40.0 18759 7504 
Mean       5953 
Lombok, 
Indonesia 
2000 7 78.7 52.6 814 22.5 39257 8816 
2001 7 86.3 39.6 802 40.7 37584 15315 
2002 9 43.2 36.7 499 11.8 36020 4259 
Mean       9463 




Meta-estimate of hospitalisation 
rate (per 1000 per year) (h)§ 
Meta-estimate of in-
hospital CFR (%) 
(i)§ 
Population in mean 
study period (j) 
RSV deaths in 
hospital overall 
(k)* 





Argentina 4.9 1.9 3407649 320 557 1.7 
Bangladesh 4.9 1.9 15197631 1426 5953 4.2 
Indonesia 4.9 1.9 21639000 2030 9463 4.7 
Mean      3.5 




A22. Incidence rate of RSV associated ALRI in infants by year 





























































Bandung, Indonesia (Simoes and colleagues)
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A23. Hospitalisation rate of RSV associated ALRI in infants by year  












































































































































































































































































Colorado, USA (Simoes and colleagues)
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0.0 30 0.22 6.72 0.00 3 202 1.49 1.44 
Tone District, 
Togo (Gessner, 










































































































1.9 104 0.41 34.10 0.66 15 505 2.97 2.90 








21.3 61 0.25 15.52 3.31 4 156 2.56 4.26 
























































4.8 21 0.26 5.50 0.26 0 28 0.00 0.78 
Nakhon Phanom 


















33.1 1500 0.20 300.57 99.59 13 741 1.75 10.81 















































2.5 1231 0.21 264.53 6.66 4 101 3.96 2.92 





0.0 14334 0.17 2389.50 0.00 0 795 0.00 0.00 
§d=b*c. *e=d*a*0.01. #h=f/g*100. $i=(f+e)/(g+d)*100. 
 
 
